MET 10-Q Quarterly Report Sept. 30, 2022

METLIFE INC

10-Ks and 10-Qs

10-Q	Quarter ended Sept. 30, 2025
10-Q	Quarter ended June 30, 2025
10-Q	Quarter ended March 31, 2025
10-K	Fiscal year ended Dec. 31, 2024
10-Q	Quarter ended Sept. 30, 2024
10-Q	Quarter ended June 30, 2024
10-Q	Quarter ended March 31, 2024
10-K	Fiscal year ended Dec. 31, 2023
10-Q	Quarter ended Sept. 30, 2023
10-Q	Quarter ended June 30, 2023
10-Q	Quarter ended March 31, 2023
10-K	Fiscal year ended Dec. 31, 2022
10-Q	Quarter ended Sept. 30, 2022
10-Q	Quarter ended June 30, 2022
10-Q	Quarter ended March 31, 2022
10-K	Fiscal year ended Dec. 31, 2021
10-Q	Quarter ended Sept. 30, 2021
10-Q	Quarter ended June 30, 2021
10-Q	Quarter ended March 31, 2021
10-K	Fiscal year ended Dec. 31, 2020
10-Q	Quarter ended Sept. 30, 2020
10-Q	Quarter ended June 30, 2020
10-Q	Quarter ended March 31, 2020
10-K	Fiscal year ended Dec. 31, 2019
10-Q	Quarter ended Sept. 30, 2019
10-Q	Quarter ended June 30, 2019
10-Q	Quarter ended March 31, 2019
10-K	Fiscal year ended Dec. 31, 2018
10-Q	Quarter ended Sept. 30, 2018
10-Q	Quarter ended June 30, 2018
10-Q	Quarter ended March 31, 2018
10-K	Fiscal year ended Dec. 31, 2017
10-Q	Quarter ended Sept. 30, 2017
10-Q	Quarter ended June 30, 2017
10-Q	Quarter ended March 31, 2017
10-K	Fiscal year ended Dec. 31, 2016
10-Q	Quarter ended Sept. 30, 2016
10-Q	Quarter ended June 30, 2016
10-Q	Quarter ended March 31, 2016
10-K	Fiscal year ended Dec. 31, 2015
10-Q	Quarter ended Sept. 30, 2015
10-Q	Quarter ended June 30, 2015
10-Q	Quarter ended March 31, 2015
10-K	Fiscal year ended Dec. 31, 2014
10-Q	Quarter ended Sept. 30, 2014
10-Q	Quarter ended June 30, 2014
10-Q	Quarter ended March 31, 2014
10-K	Fiscal year ended Dec. 31, 2013
10-Q	Quarter ended Sept. 30, 2013
10-Q	Quarter ended June 30, 2013
10-Q	Quarter ended March 31, 2013
10-K	Fiscal year ended Dec. 31, 2012
10-Q	Quarter ended Sept. 30, 2012
10-Q	Quarter ended June 30, 2012
10-Q	Quarter ended March 31, 2012
10-K	Fiscal year ended Dec. 31, 2011
10-Q	Quarter ended Sept. 30, 2011
10-Q	Quarter ended June 30, 2011
10-Q	Quarter ended March 31, 2011
10-K	Fiscal year ended Dec. 31, 2010
10-Q	Quarter ended Sept. 30, 2010
10-Q	Quarter ended June 30, 2010
10-Q	Quarter ended March 31, 2010
10-K	Fiscal year ended Dec. 31, 2009

PROXIES

DEF 14A	Filed on June 17, 2025
DEF 14A	Filed on April 29, 2025
DEF 14A	Filed on June 18, 2024
DEF 14A	Filed on April 26, 2024
DEF 14A	Filed on April 28, 2023
DEF 14A	Filed on June 21, 2022
DEF 14A	Filed on April 29, 2022
DEF 14A	Filed on April 29, 2021
DEF 14A	Filed on April 29, 2020
DEF 14A	Filed on April 25, 2019
DEF 14A	Filed on April 26, 2018
DEF 14A	Filed on Sept. 14, 2017
DEF 14A	Filed on April 27, 2017
DEF 14A	Filed on April 26, 2016
DEF 14A	Filed on March 23, 2015
DEF 14A	Filed on March 25, 2014
DEF 14A	Filed on March 22, 2013
DEF 14A	Filed on March 26, 2012
DEF 14A	Filed on March 28, 2011
DEF 14A	Filed on March 23, 2010

met-20220930

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________________________

Form 10-Q

(Mark One)


☑			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM TO

Commission file number: 001-15787

_____________________________________

MetLife, Inc.

(Exact name of registrant as specified in its charter)

Delaware

13-4075851

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

200 Park Avenue,

New York,

10166-0188

(Address of principal executive offices)

(Zip Code)

( 212 ) 578-9500

( Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01	MET	New York Stock Exchange
Floating Rate Non-Cumulative Preferred Stock, Series A, par value $0.01	MET PRA	New York Stock Exchange
Depositary Shares, each representing a 1/1,000th interest in a share of 5.625% Non-Cumulative Preferred Stock, Series E	MET PRE	New York Stock Exchange
Depositary Shares, each representing a 1/1,000th interest in a share of 4.75% Non-Cumulative Preferred Stock, Series F	MET PRF	New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☑	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

At October 31, 2022, 784,606,205 shares of the registrant’s common stock were outstanding.

Table of Contents


		Page
Part I — Financial Information
Item 1.	Financial Statements (Unaudited) (at September 30, 2022 and December 31, 2021 and for the Three Months and Nine Months Ended September 30, 2022 and 2021)
	Interim Condensed Consolidated Balance Sheets	4
	Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)	5
	Interim Condensed Consolidated Statements of Equity	6
	Interim Condensed Consolidated Statements of Cash Flows	7
	Notes to the Interim Condensed Consolidated Financial Statements:
	Note 1 — Business, Basis of Presentation and Summary of Significant Accounting Policies	8
	Note 2 — Segment Information	12
	Note 3 — Dispositions	19
	Note 4 — Insurance	20
	Note 5 — Closed Block	22
	Note 6 — Investments	25
	Note 7 — Derivatives	42
	Note 8 — Fair Value	54
	Note 9 — Long-Term Debt	71
	Note 10 — Equity	71
	Note 11 — Other Revenues and Other Expenses	76
	Note 12 — Employee Benefit Plans	77
	Note 13 — Income Tax	77
	Note 14 — Earnings Per Common Share	78
	Note 15 — Contingencies, Commitments and Guarantees	78
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	82
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	150
Item 4.	Controls and Procedures	151

Part II — Other Information
Item 1.	Legal Proceedings	152
Item 1A.	Risk Factors	152
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	152
Item 6.	Exhibits	153

Signatures		154

Table of Contents

As used in this Form 10 ‑ Q, “MetLife,” the “Company,” “we,” “our” and “us” refer to MetLife, Inc., a Delaware corporation incorporated in 1999, its subsidiaries and affiliates.

Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10‑Q, including Management’s Discussion and Analysis of Financial Condition and Results of Operations, may contain or incorporate by reference information that includes or is based upon forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give expectations or forecasts of future events and do not relate strictly to historical or current facts. They use words and terms such as “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “if,” “intend,” “likely,” “may,” “plan,” “potential,” “project,” “should,” “will,” “would” and other words and terms of similar meaning or that are otherwise tied to future periods or future performance, in each case in all derivative forms. They include statements relating to future actions, prospective services or products, future performance or results of current and anticipated services or products, future sales efforts, future expenses, the outcome of contingencies such as legal proceedings, and future trends in operations and financial results.

Many factors determine Company results, and they involve unpredictable risks and uncertainties. Our forward-looking statements depend on our assumptions, our expectations, and our understanding of the economic environment, but they may be inaccurate and may change. We do not guarantee any future performance. Our results could differ materially from those we express or imply in forward-looking statements. The risks, uncertainties and other factors, including those relating to the COVID-19 pandemic, identified in MetLife, Inc.’s filings with the U.S. Securities and Exchange Commission, and others, may cause such differences. These factors include:

(1) economic condition difficulties, including risks relating to public health, interest rates, credit spreads, equity, real estate, obligors and counterparties, currency exchange rates, derivatives, and terrorism and security;

(2) global capital and credit market adversity;

(3) credit facility inaccessibility;

(4) financial strength or credit ratings downgrades;

(5) unavailability, unaffordability, or inadequate reinsurance;

(6) statutory life insurance reserve financing costs or limited market capacity;

(7) legal, regulatory, and supervisory and enforcement policy changes;

(8) changes in tax rates, tax laws or interpretations;

(9) litigation and regulatory investigations;

(10) London Interbank Offered Rate discontinuation and transition to alternative reference rates;

(11) unsuccessful efforts to meet all environmental, social, and governance standards or to enhance our sustainability;

(12) MetLife, Inc.’s inability to pay dividends and repurchase common stock;

(13) MetLife, Inc.’s subsidiaries’ inability to pay it dividends;

(14) investment defaults, downgrades, or volatility;

(15) investment sales or lending difficulties;

(16) collateral or derivative-related payments;

(17) investment valuations, allowances, or impairments changes;

(18) claims or other results that differ from our estimates, assumptions, or models;

(19) global political, legal, or operational risks;

(20) business competition;

(21) technological changes;

(22) catastrophes;

(23) climate changes or responses to it;

(24) deficiencies in our closed block;

(25) goodwill or other asset impairment, or deferred income tax asset allowance;

(26) acceleration of amortization of deferred policy acquisition costs, deferred sales inducements, value of business acquired, value of distribution agreements acquired or value of customer relationships acquired;

(27) product guarantee volatility, costs, and counterparty risks;

(28) risk management failures;

(29) insufficient protection from operational risks;

(30) failure to protect confidentiality and integrity of data or other cybersecurity or disaster recovery failures;

(31) accounting standards changes;

(32) excessive risk-taking;

(33) marketing and distribution difficulties;

(34) pension and other postretirement benefit assumption changes;

(35) inability to protect our intellectual property or avoid infringement claims;

(36) acquisition, integration, growth, disposition, or reorganization difficulties;

(37) Brighthouse Financial, Inc. separation risks;

(38) MetLife, Inc.’s Board of Directors influence over the outcome of stockholder votes through the voting provisions of the MetLife Policyholder Trust; and

(39) legal- and corporate governance-related effects on business combinations.

MetLife, Inc. does not undertake any obligation to publicly correct or update any forward-looking statement if MetLife, Inc. later becomes aware that such statement is not likely to be achieved. Please consult any further disclosures MetLife, Inc. makes on related subjects in subsequent reports to the U.S. Securities and Exchange Commission.

Table of Contents

Corporate Information

We encourage investors and others to frequently visit our website (www.metlife.com), including our Investor Relations web pages (https://investor.metlife.com). We announce significant financial and other information to our investors and the public on the Investor Relations web pages, as well as in U.S. Securities and Exchange Commission filings, in news releases, public conference calls and webcasts, fact sheets and other documents and media. The information found on our website, including MetLife’s Sustainability Report, is not incorporated by reference into this Quarterly Report on Form 10-Q or in any other report or document we submit to the U.S. Securities and Exchange Commission, and any references to our website are intended to be inactive textual references only.

Note Regarding Reliance on Statements in Our Contracts

See “Exhibits — Note Regarding Reliance on Statements in Our Contracts” for information regarding agreements included as exhibits to this Quarterly Report on Form 10-Q.

Table of Contents

Part I — Financial Information

Item 1. Financial Statements

MetLife, Inc.

Interim Condensed Consolidated Balance Sheets

September 30, 2022 and December 31, 2021 (Unaudited)

(In millions, except share and per share data)


	September 30, 2022		December 31, 2021
Assets
Investments:
Fixed maturity securities available-for-sale, at estimated fair value (amortized cost: $ 302,457 and $ 310,884 , respectively; allowance for credit loss of $ 198 and $ 91 , respectively)	$	270,765	$	340,274
Equity securities, at estimated fair value	973		1,269
Contractholder-directed equity securities and fair value option securities, at estimated fair value	8,954		12,142
Mortgage loans (net of allowance for credit loss of $ 467 and $ 634 , respectively; includes $ 0 and $ 127 , respectively, under the fair value option)	82,437		79,353
Policy loans	8,783		9,111
Real estate and real estate joint ventures (includes $ 315 and $ 240 , respectively, under the fair value option and $ 204 and $ 175 , respectively, of real estate held-for-sale)	12,532		12,216
Other limited partnership interests	14,387		14,625
Short-term investments, principally at estimated fair value	5,266		7,176
Other invested assets (includes $ 1,801 and $ 1,930 , respectively, of leveraged and direct financing leases; $ 323 and $ 351 , respectively, relating to variable interest entities and allowance for credit loss of $ 33 and $ 40 , respectively)	22,299		18,655
Total investments	426,396		494,821
Cash and cash equivalents, principally at estimated fair value	22,200		20,047
Accrued investment income	3,355		3,185
Premiums, reinsurance and other receivables	17,666		17,149
Deferred policy acquisition costs and value of business acquired	21,523		16,061
Current income tax recoverable	194		184
Deferred income tax asset	2,700		189
Goodwill	9,005		9,535

Assets held-for-sale	—		7,238
Other assets	11,294		11,426
Separate account assets	135,771		179,873
Total assets	$	650,104	$	759,708
Liabilities and Equity
Liabilities
Future policy benefits	$	199,671	$	199,721
Policyholder account balances	198,251		203,473
Other policy-related balances	19,491		17,751
Policyholder dividends payable	429		478
Policyholder dividend obligation	—		1,682
Payables for collateral under securities loaned and other transactions	24,890		31,920
Short-term debt	183		341
Long-term debt	14,520		13,933
Collateral financing arrangement	729		766
Junior subordinated debt securities	3,158		3,156


Deferred income tax liability	172		9,693
Liabilities held-for-sale	—		6,634
Other liabilities	27,509		22,538
Separate account liabilities	135,771		179,873
Total liabilities	624,774		691,959
Contingencies, Commitments and Guarantees (Note 15)
Equity
MetLife, Inc.’s stockholders’ equity:
Preferred stock, par value $ 0.01 per share; $ 3,905 and $ 3,905 aggregate liquidation preference, respectively	—		—
Common stock, par value $ 0.01 per share; 3,000,000,000 shares authorized; 1,189,607,908 and 1,186,540,473 shares issued, respectively; 787,340,553 and 825,540,267 shares outstanding, respectively	12		12
Additional paid-in capital	33,589		33,511
Retained earnings	41,032		41,197
Treasury stock, at cost; 402,267,355 and 361,000,206 shares, respectively	( 20,862 )		( 18,157 )
Accumulated other comprehensive income (loss)	( 28,695 )		10,919
Total MetLife, Inc.’s stockholders’ equity	25,076		67,482
Noncontrolling interests	254		267
Total equity	25,330		67,749
Total liabilities and equity	$	650,104	$	759,708

See accompanying notes to the interim condensed consolidated financial statements.

Table of Contents

MetLife, Inc.

Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

For the Three Months and Nine Months Ended September 30, 2022 and 2021 (Unaudited)

(In millions, except per share data)


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Revenues
Premiums	$	17,547	$	9,455	$	40,039	$	28,914
Universal life and investment-type product policy fees	1,302		1,521		4,236		4,334
Net investment income	3,585		5,568		11,452		16,162
Other revenues	730		663		2,006		1,958
Net investment gains (losses)	( 414 )		( 84 )		( 1,617 )		1,655
Net derivative gains (losses)	( 480 )		( 218 )		( 2,534 )		( 2,032 )
Total revenues	22,270		16,905		53,582		50,991
Expenses
Policyholder benefits and claims	17,993		10,103		40,976		30,031
Interest credited to policyholder account balances	980		1,287		2,102		4,153
Policyholder dividends	155		189		546		672
Other expenses	2,723		3,284		8,826		9,315
Total expenses	21,851		14,863		52,450		44,171
Income (loss) before provision for income tax	419		2,042		1,132		6,820
Provision for income tax expense (benefit)	19		453		( 80 )		1,456
Net income (loss)	400		1,589		1,212		5,364
Less: Net income (loss) attributable to noncontrolling interests	5		5		16		15
Net income (loss) attributable to MetLife, Inc.	395		1,584		1,196		5,349
Less: Preferred stock dividends	64		63		156		166
Preferred stock redemption premium	—		—		—		6
Net income (loss) available to MetLife, Inc.’s common shareholders	$	331	$	1,521	$	1,040	$	5,177
Comprehensive income (loss)	$	( 10,923 )	$	1,392	$	( 38,405 )	$	( 595 )
Less: Comprehensive income (loss) attributable to noncontrolling interests, net of income tax	5		6		13		17
Comprehensive income (loss) attributable to MetLife, Inc.	$	( 10,928 )	$	1,386	$	( 38,418 )	$	( 612 )





Net income (loss) available to MetLife, Inc.’s common shareholders per common share:
Basic	$	0.42	$	1.78	$	1.28	$	5.94
Diluted	$	0.41	$	1.77	$	1.28	$	5.90

See accompanying notes to the interim condensed consolidated financial statements.

Table of Contents

MetLife, Inc.

Interim Condensed Consolidated Statements of Equity

For the Nine Months Ended September 30, 2022 and 2021 (Unaudited)

(In millions)


	Preferred Stock		Common Stock		Additional Paid-in Capital		Retained Earnings		Treasury Stock at Cost		Accumulated Other Comprehensive Income (Loss)		Total MetLife, Inc.’s Stockholders’ Equity		Noncontrolling Interests		Total Equity
Balance at December 31, 2021	$	—	$	12	$	33,511	$	41,197	$	( 18,157 )	$	10,919	$	67,482	$	267	$	67,749
Treasury stock acquired in connection with share repurchases									( 2,031 )				( 2,031 )				( 2,031 )
Stock-based compensation					37								37				37
Dividends on preferred stock							( 92 )						( 92 )				( 92 )
Dividends on common stock (declared per share of $ 0.980 )							( 805 )						( 805 )				( 805 )
Change in equity of noncontrolling interests													—		( 9 )		( 9 )
Net income (loss)							801						801		11		812
Other comprehensive income (loss), net of income tax											( 28,291 )		( 28,291 )		( 3 )		( 28,294 )
Balance at June 30, 2022	—		12		33,548		41,101		( 20,188 )		( 17,372 )		37,101		266		37,367
Treasury stock acquired in connection with share repurchases									( 674 )				( 674 )				( 674 )
Stock-based compensation					41								41				41
Dividends on preferred stock							( 64 )						( 64 )				( 64 )
Dividends on common stock (declared per share of $ 0.500 )							( 400 )						( 400 )				( 400 )
Change in equity of noncontrolling interests													—		( 17 )		( 17 )
Net income (loss)							395						395		5		400
Other comprehensive income (loss), net of income tax											( 11,323 )		( 11,323 )		—		( 11,323 )
Balance at September 30, 2022	$	—	$	12	$	33,589	$	41,032	$	( 20,862 )	$	( 28,695 )	$	25,076	$	254	$	25,330


	Preferred Stock		Common Stock		Additional Paid-in Capital		Retained Earnings		Treasury Stock at Cost		Accumulated Other Comprehensive Income (Loss)		Total MetLife, Inc.’s Stockholders’ Equity		Noncontrolling Interests		Total Equity
Balance at December 31, 2020	$	—	$	12	$	33,812	$	36,491	$	( 13,829 )	$	18,072	$	74,558	$	259	$	74,817
Redemption of preferred stock					( 494 )								( 494 )				( 494 )
Preferred stock redemption premium							( 6 )						( 6 )				( 6 )
Treasury stock acquired in connection with share repurchases									( 2,112 )				( 2,112 )				( 2,112 )
Stock-based compensation					122								122				122
Dividends on preferred stock							( 103 )						( 103 )				( 103 )
Dividends on common stock (declared per share of $ 0.940 )							( 829 )						( 829 )				( 829 )
Change in equity of noncontrolling interests													—		15		15
Net income (loss)							3,765						3,765		10		3,775
Other comprehensive income (loss), net of income tax											( 5,763 )		( 5,763 )		1		( 5,762 )
Balance at June 30, 2021	—		12		33,440		39,318		( 15,941 )		12,309		69,138		285		69,423
Treasury stock acquired in connection with share repurchases									( 1,015 )				( 1,015 )				( 1,015 )
Stock-based compensation					17								17				17
Dividends on preferred stock							( 63 )						( 63 )				( 63 )
Dividends on common stock (declared per share of $ 0.480 )							( 413 )						( 413 )				( 413 )
Change in equity of noncontrolling interests													—		( 8 )		( 8 )
Net income (loss)							1,584						1,584		5		1,589
Other comprehensive income (loss), net of income tax											( 198 )		( 198 )		1		( 197 )
Balance at September 30, 2021	$	—	$	12	$	33,457	$	40,426	$	( 16,956 )	$	12,111	$	69,050	$	283	$	69,333

See accompanying notes to the interim condensed consolidated financial statements.

Table of Contents

MetLife, Inc.

Interim Condensed Consolidated Statements of Cash Flows

For the Nine Months Ended September 30, 2022 and 2021 (Unaudited)

(In millions)


	Nine Months Ended September 30,
	2022		2021
Net cash provided by (used in) operating activities	$	10,670	$	7,256
Cash flows from investing activities
Sales, maturities and repayments of:
Fixed maturity securities available-for-sale	66,380		63,778
Equity securities	621		476
Mortgage loans	8,983		12,692
Real estate and real estate joint ventures	466		1,160
Other limited partnership interests	1,306		512
Purchases and originations of:
Fixed maturity securities available-for-sale	( 62,085 )		( 69,525 )
Equity securities	( 419 )		( 57 )
Mortgage loans	( 13,277 )		( 9,909 )
Real estate and real estate joint ventures	( 957 )		( 1,174 )
Other limited partnership interests	( 1,965 )		( 2,092 )
Cash received in connection with freestanding derivatives	3,175		2,574
Cash paid in connection with freestanding derivatives	( 6,068 )		( 6,794 )

Sales of businesses, net of cash and cash equivalents disposed of $ 67 and $ 611 , respectively	590		3,329

Purchases of investments in operating joint ventures	( 240 )		—
Net change in policy loans	88		179
Net change in short-term investments	1,832		( 3,165 )
Net change in other invested assets	( 824 )		( 267 )
Other, net	( 29 )		( 42 )
Net cash provided by (used in) investing activities	( 2,423 )		( 8,325 )
Cash flows from financing activities
Policyholder account balances:
Deposits	83,707		75,536
Withdrawals	( 79,114 )		( 71,495 )
Payables for collateral under securities loaned and other transactions:
Net change in payables for collateral under securities loaned and other transactions	( 6,602 )		1,279

Cash paid for other transactions with tenors greater than three months	—		( 100 )
Long-term debt issued	1,013		29
Long-term debt repaid	( 77 )		( 540 )
Collateral financing arrangement repaid	( 37 )		( 39 )

Financing element on certain derivative instruments and other derivative related transactions, net	—		305
Treasury stock acquired in connection with share repurchases	( 2,730 )		( 3,127 )

Redemption of preferred stock	—		( 494 )
Preferred stock redemption premium	—		( 6 )
Dividends on preferred stock	( 156 )		( 166 )
Dividends on common stock	( 1,205 )		( 1,242 )
Other, net	( 206 )		20
Net cash provided by (used in) financing activities	( 5,407 )		( 40 )
Effect of change in foreign currency exchange rates on cash and cash equivalents balances	( 756 )		( 392 )
Change in cash and cash equivalents	2,084		( 1,501 )
Cash and cash equivalents, including subsidiaries held-for-sale, beginning of period	20,116		20,560
Cash and cash equivalents, including subsidiaries held-for-sale, end of period	$	22,200	$	19,059
Cash and cash equivalents, subsidiaries held-for-sale, beginning of period	$	69	$	765
Cash and cash equivalents, subsidiaries held-for-sale, end of period	$	—	$	103
Cash and cash equivalents, beginning of period	$	20,047	$	19,795
Cash and cash equivalents, end of period	$	22,200	$	18,956


Supplemental disclosures of cash flow information
Net cash paid (received) for:
Interest	$	591	$	606
Income tax	$	612	$	861
Non-cash transactions:
Fixed maturity securities available-for-sale received in connection with pension risk transfer transactions	$	8,707	$	—
Real estate and real estate joint ventures acquired in satisfaction of debt	$	210	$	172
Increase in equity securities due to in-kind distributions received from other limited partnership interests	$	86	$	273
Reclassification of certain other invested assets to contractholder-directed equity securities and fair value option securities	$	—	$	309

See accompanying notes to the interim condensed consolidated financial statements .

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)

1. Business, Basis of Presentation and Summary of Significant Accounting Policies

Business

“MetLife” and the “Company” refer to MetLife, Inc., a Delaware corporation incorporated in 1999, its subsidiaries and affiliates. MetLife is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management. MetLife is organized into five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa (“EMEA”); and MetLife Holdings.

Basis of Presentation

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to adopt accounting policies and make estimates and assumptions that affect amounts reported on the interim condensed consolidated financial statements. In applying these policies and estimates, management makes subjective and complex judgments that frequently require assumptions about matters that are inherently uncertain, including uncertainties associated with the COVID-19 pandemic. Many of these policies, estimates and related judgments are common in the insurance and financial services industries; others are specific to the Company’s business and operations. Actual results could differ from these estimates.

The accompanying interim condensed consolidated financial statements are unaudited and reflect all adjustments (including normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in conformity with GAAP. Interim results are not necessarily indicative of full year performance. The December 31, 2021 consolidated balance sheet data was derived from audited consolidated financial statements included in MetLife, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Annual Report”), which include all disclosures required by GAAP. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company included in the 2021 Annual Report.

Consolidation

The accompanying interim condensed consolidated financial statements include the accounts of MetLife, Inc. and its subsidiaries, as well as partnerships and joint ventures in which the Company has a controlling financial interest, and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. Intercompany accounts and transactions have been eliminated.

The Company uses the equity method of accounting or the fair value option (“FVO”) for real estate joint ventures and other limited partnership interests (“investee”) when it has more than a minor ownership interest or more than a minor influence over the investee’s operations. The Company generally recognizes its share of the investee’s earnings in net investment income on a three-month lag in instances where the investee’s financial information is not sufficiently timely or when the investee’s reporting period differs from the Company’s reporting period.

Held-for-Sale

The Company classifies a business as held-for-sale when management has approved or received approval to sell the business, the sale is probable to occur during the next 12 months at a price that is reasonable in relation to its current estimated fair value and certain other specified criteria are met. The business classified as held-for-sale is recorded at the lower of the carrying value and estimated fair value, less cost to sell. If the carrying value of the business exceeds its estimated fair value, less cost to sell, a loss is recognized and reported in net investment gains (losses). Assets and liabilities related to the business classified as held-for-sale are separately reported in the Company's consolidated balance sheets in the period in which the business is classified as held-for-sale. See Note 3. If a component of the Company has either been disposed of or is classified as held-for-sale and represents a strategic shift that has or will have a major effect on the Company’s operations and financial results, the results of the component are reported in discontinued operations.

Reclassifications

Certain amounts in the prior year periods’ interim condensed consolidated financial statements and related footnotes thereto have been reclassified to conform to the 2022 presentation as discussed throughout the Notes to the Interim Condensed Consolidated Financial Statements.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued )

1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)

Recent Accounting Pronouncements

Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASUs”) to the FASB Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. The following tables provide a description of ASUs recently issued by the FASB and the impact of their adoption on the Company’s interim condensed consolidated financial statements.

Adopted Accounting Pronouncements

The table below describes the impacts of the ASUs recently adopted by the Company.


Standard	Description	Effective Date and Method of Adoption	Impact on Financial Statements
ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting ; as clarified and amended by ASU 2021-01, Reference Rate Reform (Topic 848): Scope	The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The expedients and exceptions provided by the amendments do not apply to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022, with certain exceptions. ASU 2021-01 amends the scope of the recent reference rate reform guidance. New optional expedients allow derivative instruments impacted by changes in the interest rate used for margining, discounting, or contract price alignment to qualify for certain optional relief.	Effective for contract modifications made between March 12, 2020 and December 31, 2022.	The guidance has reduced the operational and financial impacts of contract modifications that replace a reference rate, such as London Interbank Offered Rate (“LIBOR”), affected by reference rate reform. Contract modifications for invested assets and derivative instruments occurred during 2021 and have continued into 2022. Based on actions taken to date, the adoption of the guidance has not had a material impact on the Company’s interim condensed consolidated financial statements. The Company does not expect the adoption of this guidance to have a material ongoing impact and will continue to evaluate the impacts of reference rate reform on contract modifications and hedging relationships through December 31, 2022.
ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance	The guidance requires entities to provide annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy and can include tax credits and other forms of government assistance. Entities are required to disclose information about (i) the nature of the transactions and the related accounting policy used to account for the transactions; (ii) the line items on the balance sheet and income statement that are affected by the transactions, including the associated amounts; and (iii) the significant terms and conditions of the transactions, including commitments and contingencies.	Effective for annual periods beginning January 1, 2022, to be applied prospectively.	The adoption of the guidance will not have a material impact on the Company’s annual consolidated financial statements.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued )

1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)

Future Adoption of Accounting Pronouncements

ASUs not listed below were assessed and either determined to be not applicable or are not expected to have a material impact on the Company’s interim condensed consolidated financial statements or disclosures. ASUs issued but not yet adopted as of September 30, 2022 that are currently being assessed and may or may not have a material impact on the Company’s interim condensed consolidated financial statements or disclosures are summarized in the table below.


Standard	Description	Effective Date and Method of Adoption	Impact on Financial Statements
ASU 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts, as amended by ASU 2019-09, Financial Services—Insurance (Topic 944): Effective Date, as amended by ASU 2020-11 , Financial Services—Insurance (Topic 944): Effective Date and Early Application	The guidance (i) prescribes the discount rate to be used in measuring the liability for future policy benefits for traditional and limited payment long-duration contracts, and requires assumptions for those liability valuations to be updated after contract inception, (ii) requires more market-based product guarantees (“market risk benefits”) on certain separate account and other account balance long-duration contracts to be accounted for at fair value, (iii) simplifies the amortization of deferred policy acquisition costs (“DAC”) for virtually all long-duration contracts, and (iv) introduces certain financial statement presentation requirements, as well as significant additional quantitative and qualitative disclosures. The amendments in ASU 2019-09 defer the effective date of ASU 2018-12 to January 1, 2022 for all entities, and the amendments in ASU 2020-11 further defer the effective date of ASU 2018-12 for an additional year to January 1, 2023 for all entities.	January 1, 2023, to be applied retrospectively to January 1, 2021 (with early adoption permitted). Estimated impacts from adoption as of the transition date of January 1, 2021 are measured using market assumptions appropriate as of that date. Such estimates do not reflect changes in market assumptions subsequent to January 1, 2021.	The Company’s implementation efforts and the evaluation of the impacts of the guidance on its consolidated financial statements, as well as its systems, processes, and controls, continue to progress. Given the nature and extent of the required changes to a significant portion of the Company’s operations, the adoption of this guidance is expected to have a material impact on its financial position, results of operations, and disclosures. The Company will adopt the guidance effective January 1, 2023. The modified retrospective approach will be used, except in regard to market risk benefits where the Company will use the full retrospective approach. Based upon these transition methods, the Company currently estimates that the January 1, 2021 transition date impact from adoption is expected to result in a decrease to total equity in a range of approximately $ 21.5 billion to $ 24.0 billion, net of income tax. The expected decrease in total equity includes the estimated impact to Accumulated other comprehensive income (loss) (“AOCI”) which, as of the transition date, is expected to result in a decrease in a range of approximately $ 17.0 billion to $ 18.5 billion, net of income tax. The most significant drivers of the expected decrease in AOCI are the anticipated impacts of the changes in the discount rates as of the transition date to be used in measuring the liability for future policy benefits for traditional and limited payment contracts and the non-performance risk in the valuation of the Company’s market risk benefits. The expected decrease in AOCI is expected to be partially offset by the removal of loss recognition balances recorded in AOCI related to unrealized investment gains associated with certain long-duration products. The expected decrease in total equity also includes the estimated impact to retained earnings which, from adoption, is expected to result in a decrease in a range of approximately $ 4.5 billion to $ 5.5 billion, net of income tax. This decrease results from the requirement to account for variable annuity guarantees as market risk benefits measured at fair value (except for the changes in fair value already recognized under an existing accounting model) and other valuation impacts to the liability for future policy benefits. The changes in market conditions from January 1, 2021 to September 30, 2022 are estimated to cause the initial transition date reduction in total equity (as discussed in the preceding paragraphs) to largely reverse as of September 30, 2022.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued )

1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)


Standard	Description	Effective Date and Method of Adoption	Impact on Financial Statements
ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions	The amendments in this update clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. In addition, the amendments clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The amendments also require entities that hold equity securities subject to contractual sale restrictions to make disclosures about the fair value of such equity securities, the nature and remaining duration of the restriction(s) and the circumstances that could cause a lapse in the restriction(s).	January 1, 2024, to be applied prospectively with any adjustments from the adoption of the amendments recognized in earnings and disclosed on the date of adoption (with early adoption permitted).	The Company is continuing to evaluate the impact of the guidance, and it does not expect the adoption of the guidance to have a material impact on its interim condensed consolidated financial statements.
ASU 2022-02, Financial Instruments—Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures	The amendments in the new ASU eliminate the accounting guidance for troubled debt restructurings (“TDRs”) by creditors that have adopted the current expected credit loss guidance while enhancing disclosure requirements for certain loan refinancings and restructurings by creditors when a borrower is experiencing financial difficulty. In addition, the amendments require that a public business entity disclose current-period gross write-offs by year of origination for financing receivables and net investment in leases.	January 1, 2023, to be applied prospectively; however, for the transition method related to the recognition and measurement of TDRs, an entity can apply a modified retrospective transition method, resulting in a cumulative-effect adjustment to retained earnings in the period of adoption. Entities are permitted to early adopt these amendments, including adoption in any interim period, provided that the amendments are adopted as of the beginning of the annual reporting period that includes the interim period of adoption. In addition, entities are permitted to elect to early adopt the amendments related to TDRs accounting and related disclosure enhancements separately from the amendments related to certain vintage disclosures.	The Company is continuing to evaluate the impact of the guidance and the alternative methods of adoption. Also, the Company is in the process of finalizing the updates to its loan administration systems, as well as updating its accounting policies and controls to comply with the new disclosure requirements. The Company does not expect the adoption of the guidance to have a material impact on its interim condensed consolidated financial statements.
ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers	The guidance indicates how to determine whether a contract liability is recognized by the acquirer in a business combination and provides specific guidance on how to recognize and measure acquired contract assets and contract liabilities from revenue contracts in a business combination.	January 1, 2023, to be applied prospectively (with early adoption permitted).	The Company is currently evaluating the impact of the guidance on its interim condensed consolidated financial statements.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

2. Segment Information

MetLife is organized into five segments: U.S.; Asia; Latin America; EMEA; and MetLife Holdings. In addition, the Company reports certain of its results of operations in Corporate & Other.

U.S.

The U.S. segment offers a broad range of protection products and services aimed at serving the financial needs of customers throughout their lives. These products are sold to corporations and their respective employees, other institutions and their respective members, as well as individuals. The U.S. segment is organized into two businesses: Group Benefits and Retirement and Income Solutions (“RIS”).

• The Group Benefits business offers products such as term, variable and universal life insurance, dental, group and individual disability, vision and accident & health insurance.

• The RIS business offers a broad range of life and annuity-based insurance and investment products, including stable value and pension risk transfer products, institutional income annuities, structured settlements, longevity reinsurance solutions, benefit funding solutions and capital markets investment products.

Asia

The Asia segment offers a broad range of products and services to both individuals and corporations, as well as to other institutions, and their respective employees, which include life insurance, accident & health insurance and retirement and savings.

Latin America

The Latin America segment offers a broad range of products to both individuals and corporations, as well as to other institutions, and their respective employees, which include life insurance, retirement and savings, accident & health insurance and credit insurance.

EMEA

The EMEA segment offers products to individuals, corporations, other institutions, and their respective employees, which include life insurance, accident & health insurance, retirement and savings and credit insurance.

MetLife Holdings

The MetLife Holdings segment consists of operations relating to products and businesses that the Company no longer actively markets in the United States. These include variable, universal, term and whole life insurance, variable, fixed and index-linked annuities and long-term care insurance.

Corporate & Other

Corporate & Other contains various start-up, developing and run-off businesses. Also included in Corporate & Other are: the excess capital, as well as certain charges and activities, not allocated to the segments (including external integration and disposition costs, internal resource costs for associates committed to acquisitions and dispositions and enterprise-wide strategic initiative restructuring charges), interest expense related to the majority of the Company’s outstanding debt, expenses associated with certain legal proceedings and income tax audit issues, the elimination of intersegment amounts (which generally relate to affiliated reinsurance, investment expenses and intersegment loans bearing interest rates commensurate with related borrowings), and the Company’s investment management business (through which the Company provides public fixed income, private capital and real estate investment solutions to institutional investors worldwide).

Financial Measures and Segment Accounting Policies

Adjusted earnings is used by management to evaluate performance and allocate resources. Consistent with GAAP guidance for segment reporting, adjusted earnings is also the Company’s GAAP measure of segment performance and is reported below. Adjusted earnings should not be viewed as a substitute for net income (loss). The Company believes the presentation of adjusted earnings, as the Company measures it for management purposes, enhances the understanding of its performance by highlighting the results of operations and the underlying profitability drivers of the business.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

2. Segment Information (continued)

Adjusted earnings is defined as adjusted revenues less adjusted expenses, net of income tax.

The financial measures of adjusted revenues and adjusted expenses focus on the Company’s primary businesses principally by excluding the impact of market volatility, which could distort trends, and revenues and costs related to non-core products and certain entities required to be consolidated under GAAP. Also, these measures exclude results of discontinued operations under GAAP and other businesses that have been or will be sold or exited by MetLife but do not meet the discontinued operations criteria under GAAP and are referred to as divested businesses. Divested businesses also include the net impact of transactions with exited businesses that have been eliminated in consolidation under GAAP and costs relating to businesses that have been or will be sold or exited by MetLife that do not meet the criteria to be included in results of discontinued operations under GAAP. Adjusted revenues also excludes net investment gains (losses) and net derivative gains (losses). Adjusted expenses also excludes goodwill impairments.

The following additional adjustments are made to revenues, in the line items indicated, in calculating adjusted revenues:

• Universal life and investment-type product policy fees excludes the amortization of unearned revenue related to net investment gains (losses) and net derivative gains (losses) and certain variable annuity guaranteed minimum income benefits (“GMIBs”) fees (“GMIB fees”);

• Net investment income: (i) includes adjustments for earned income on derivatives and amortization of premium on derivatives that are hedges of investments or that are used to replicate certain investments, but do not qualify for hedge accounting treatment, (ii) excludes post-tax adjusted earnings adjustments relating to insurance joint ventures accounted for under the equity method, (iii) excludes certain amounts related to contractholder-directed equity securities, (iv) excludes certain amounts related to securitization entities that are VIEs consolidated under GAAP and (v) includes distributions of profits from certain other limited partnership interests that were previously accounted for under the cost method, but are now accounted for at estimated fair value, where the change in estimated fair value is recognized in net investment gains (losses) under GAAP; and

• Other revenues is adjusted for settlements of foreign currency earnings hedges and excludes fees received in association with services provided under transition service agreements (“TSA fees”).

The following additional adjustments are made to expenses, in the line items indicated, in calculating adjusted expenses:

• Policyholder benefits and claims and policyholder dividends excludes: (i) amortization of basis adjustments associated with de-designated fair value hedges of future policy benefits, (ii) changes in the policyholder dividend obligation related to net investment gains (losses) and net derivative gains (losses), (iii) inflation-indexed benefit adjustments associated with contracts backed by inflation-indexed investments and amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass through adjustments, (iv) benefits and hedging costs related to GMIBs (“GMIB costs”) and (v) market value adjustments associated with surrenders or terminations of contracts (“Market value adjustments”);

• Interest credited to policyholder account balances includes adjustments for earned income on derivatives and amortization of premium on derivatives that are hedges of policyholder account balances but do not qualify for hedge accounting treatment and excludes certain amounts related to net investment income earned on contractholder-directed equity securities;

• Amortization of DAC and value of business acquired (“VOBA”) excludes amounts related to: (i) net investment gains (losses) and net derivative gains (losses), (ii) GMIB fees and GMIB costs and (iii) Market value adjustments;

• Amortization of negative VOBA excludes amounts related to Market value adjustments;

• Interest expense on debt excludes certain amounts related to securitization entities that are VIEs consolidated under GAAP; and

• Other expenses excludes: (i) noncontrolling interests, (ii) implementation of new insurance regulatory requirements costs, and (iii) acquisition, integration and other costs. Other expenses includes TSA fees.

Adjusted earnings also excludes the recognition of certain contingent assets and liabilities that could not be recognized at acquisition or adjusted for during the measurement period under GAAP business combination accounting guidance.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

2. Segment Information (continued)

The tax impact of the adjustments mentioned above are calculated net of the U.S. or foreign statutory tax rate, which could differ from the Company’s effective tax rate. Additionally, the provision for income tax (expense) benefit also includes the impact related to the timing of certain tax credits, as well as certain tax reforms.

Set forth in the tables below is certain financial information with respect to the Company’s segments, as well as Corporate & Other, for the three months and nine months ended September 30, 2022 and 2021. The segment accounting policies are the same as those used to prepare the Company’s interim condensed consolidated financial statements, except for adjusted earnings adjustments as defined above. In addition, segment accounting policies include the method of capital allocation described below.

Economic capital is an internally developed risk capital model, the purpose of which is to measure the risk in the business and to provide a basis upon which capital is deployed. The economic capital model accounts for the unique and specific nature of the risks inherent in the Company’s business.

The Company’s economic capital model, coupled with considerations of local capital requirements, aligns segment allocated equity with emerging standards and consistent risk principles. The model applies statistics-based risk evaluation principles to the material risks to which the Company is exposed. These consistent risk principles include calibrating required economic capital shock factors to a specific confidence level and time horizon while applying an industry standard method for the inclusion of diversification benefits among risk types. The Company’s management is responsible for the ongoing production and enhancement of the economic capital model and reviews its approach periodically to ensure that it remains consistent with emerging industry practice standards.

Segment net investment income is credited or charged based on the level of allocated equity; however, changes in allocated equity do not impact the Company’s consolidated net investment income, net income (loss) or adjusted earnings.

Net investment income is based upon the actual results of each segment’s specifically identifiable investment portfolios adjusted for allocated equity. Other costs are allocated to each of the segments based upon: (i) a review of the nature of such costs; (ii) time studies analyzing the amount of employee compensation costs incurred by each segment; and (iii) cost estimates included in the Company’s product pricing.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

2. Segment Information (continued)



Three Months Ended September 30, 2022	U.S.		Asia		Latin America		EMEA		MetLife Holdings		Corporate & Other		Total		Adjustments		Total Consolidated
	(In millions)
Revenues
Premiums	$	14,164	$	1,347	$	823	$	475	$	745	$	( 7 )	$	17,547	$	—	$	17,547
Universal life and investment-type product policy fees	286		421		290		62		232		( 1 )		1,290		12		1,302
Net investment income	1,716		827		399		40		1,118		63		4,163		( 578 )		3,585
Other revenues	516		21		10		8		39		96		690		40		730
Net investment gains (losses)	—		—		—		—		—		—		—		( 414 )		( 414 )
Net derivative gains (losses)	—		—		—		—		—		—		—		( 480 )		( 480 )
Total revenues	16,682		2,616		1,522		585		2,134		151		23,690		( 1,420 )		22,270
Expenses
Policyholder benefits and claims and policyholder dividends	14,265		1,257		874		239		1,659		( 3 )		18,291		( 143 )		18,148
Interest credited to policyholder account balances	478		497		89		16		202		—		1,282		( 302 )		980
Capitalization of DAC	( 23 )		( 358 )		( 130 )		( 96 )		( 6 )		( 2 )		( 615 )		—		( 615 )
Amortization of DAC and VOBA	15		190		68		79		( 20 )		3		335		( 117 )		218
Amortization of negative VOBA	—		( 11 )		—		( 1 )		—		—		( 12 )		—		( 12 )
Interest expense on debt	3		—		3		—		2		231		239		—		239
Other expenses	1,003		749		398		269		228		186		2,833		60		2,893
Total expenses	15,741		2,324		1,302		506		2,065		415		22,353		( 502 )		21,851
Provision for income tax expense (benefit)	197		95		49		19		10		( 63 )		307		( 288 )		19
Adjusted earnings	$	744	$	197	$	171	$	60	$	59	$	( 201 )	1,030
Adjustments to:
Total revenues													( 1,420 )
Total expenses													502
Provision for income tax (expense) benefit													288
Net income (loss)													$	400			$	400

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

2. Segment Information (continued)



Three Months Ended September 30, 2021	U.S.		Asia		Latin America		EMEA		MetLife Holdings		Corporate & Other		Total		Adjustments		Total Consolidated
	(In millions)
Revenues
Premiums	$	5,746	$	1,594	$	705	$	532	$	805	$	16	$	9,398	$	57	$	9,455
Universal life and investment-type product policy fees	279		477		274		128		279		—		1,437		84		1,521
Net investment income	2,098		1,354		306		46		1,771		93		5,668		( 100 )		5,568
Other revenues	383		17		9		10		57		108		584		79		663
Net investment gains (losses)	—		—		—		—		—		—		—		( 84 )		( 84 )
Net derivative gains (losses)	—		—		—		—		—		—		—		( 218 )		( 218 )
Total revenues	8,506		3,442		1,294		716		2,912		217		17,087		( 182 )		16,905
Expenses
Policyholder benefits and claims and policyholder dividends	6,118		1,220		885		268		1,611		9		10,111		181		10,292
Interest credited to policyholder account balances	362		513		63		17		212		—		1,167		120		1,287
Capitalization of DAC	( 17 )		( 373 )		( 109 )		( 110 )		( 8 )		( 3 )		( 620 )		( 15 )		( 635 )
Amortization of DAC and VOBA	26		470		62		118		80		2		758		58		816
Amortization of negative VOBA	—		( 5 )		—		( 1 )		—		—		( 6 )		—		( 6 )
Interest expense on debt	1		—		2		—		1		236		240		—		240
Other expenses	886		811		363		308		255		137		2,760		109		2,869
Total expenses	7,376		2,636		1,266		600		2,151		381		14,410		453		14,863
Provision for income tax expense (benefit)	235		237		( 1 )		22		155		( 96 )		552		( 99 )		453
Adjusted earnings	$	895	$	569	$	29	$	94	$	606	$	( 68 )	2,125
Adjustments to:
Total revenues													( 182 )
Total expenses													( 453 )
Provision for income tax (expense) benefit													99
Net income (loss)													$	1,589			$	1,589

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

2. Segment Information (continued)



Nine Months Ended September 30, 2022	U.S.		Asia		Latin America		EMEA		MetLife Holdings		Corporate & Other		Total		Adjustments		Total Consolidated
	(In millions)
Revenues
Premiums	$	29,582	$	4,295	$	2,381	$	1,476	$	2,281	$	( 17 )	$	39,998	$	41	$	40,039
Universal life and investment-type product policy fees	867		1,367		876		236		840		1		4,187		49		4,236
Net investment income	5,300		3,081		1,180		119		3,807		172		13,659		( 2,207 )		11,452
Other revenues	1,347		66		29		25		106		295		1,868		138		2,006
Net investment gains (losses)	—		—		—		—		—		—		—		( 1,617 )		( 1,617 )
Net derivative gains (losses)	—		—		—		—		—		—		—		( 2,534 )		( 2,534 )
Total revenues	37,096		8,809		4,466		1,856		7,034		451		59,712		( 6,130 )		53,582
Expenses
Policyholder benefits and claims and policyholder dividends	30,151		3,670		2,454		758		4,610		( 12 )		41,631		( 109 )		41,522
Interest credited to policyholder account balances	1,212		1,488		241		53		607		—		3,601		( 1,499 )		2,102
Capitalization of DAC	( 60 )		( 1,120 )		( 363 )		( 305 )		( 21 )		( 7 )		( 1,876 )		( 11 )		( 1,887 )
Amortization of DAC and VOBA	43		799		238		260		130		7		1,477		( 106 )		1,371
Amortization of negative VOBA	—		( 27 )		—		( 4 )		—		—		( 31 )		—		( 31 )
Interest expense on debt	6		—		10		—		5		669		690		—		690
Other expenses	2,931		2,349		1,122		863		706		506		8,477		206		8,683
Total expenses	34,283		7,159		3,702		1,625		6,037		1,163		53,969		( 1,519 )		52,450
Provision for income tax expense (benefit)	588		487		184		55		197		( 243 )		1,268		( 1,348 )		( 80 )
Adjusted earnings	$	2,225	$	1,163	$	580	$	176	$	800	$	( 469 )	4,475
Adjustments to:
Total revenues													( 6,130 )
Total expenses													1,519
Provision for income tax (expense) benefit													1,348
Net income (loss)													$	1,212			$	1,212

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

2. Segment Information (continued)



Nine Months Ended September 30, 2021	U.S.		Asia		Latin America		EMEA		MetLife Holdings		Corporate & Other		Total		Adjustments		Total Consolidated
	(In millions)
Revenues
Premiums	$	16,919	$	4,861	$	1,936	$	1,751	$	2,471	$	54	$	27,992	$	922	$	28,914
Universal life and investment-type product policy fees	858		1,371		831		302		826		1		4,189		145		4,334
Net investment income	6,106		3,776		913		171		4,960		153		16,079		83		16,162
Other revenues	1,159		54		30		39		188		303		1,773		185		1,958
Net investment gains (losses)	—		—		—		—		—		—		—		1,655		1,655
Net derivative gains (losses)	—		—		—		—		—		—		—		( 2,032 )		( 2,032 )
Total revenues	25,042		10,062		3,710		2,263		8,445		511		50,033		958		50,991
Expenses
Policyholder benefits and claims and policyholder dividends	17,999		3,750		2,370		944		4,683		36		29,782		921		30,703
Interest credited to policyholder account balances	1,080		1,498		182		66		632		—		3,458		695		4,153
Capitalization of DAC	( 48 )		( 1,203 )		( 304 )		( 359 )		( 25 )		( 9 )		( 1,948 )		( 104 )		( 2,052 )
Amortization of DAC and VOBA	50		1,080		205		274		190		7		1,806		137		1,943
Amortization of negative VOBA	—		( 20 )		—		( 5 )		—		—		( 25 )		—		( 25 )
Interest expense on debt	4		—		4		—		4		683		695		1		696
Other expenses	2,695		2,542		1,041		1,006		752		278		8,314		439		8,753
Total expenses	21,780		7,647		3,498		1,926		6,236		995		42,082		2,089		44,171
Provision for income tax expense (benefit)	681		703		46		78		449		( 288 )		1,669		( 213 )		1,456
Adjusted earnings	$	2,581	$	1,712	$	166	$	259	$	1,760	$	( 196 )	6,282
Adjustments to:
Total revenues													958
Total expenses													( 2,089 )
Provision for income tax (expense) benefit													213
Net income (loss)													$	5,364			$	5,364

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

2. Segment Information (continued)

The following table presents total assets with respect to the Company’s segments, as well as Corporate & Other, at:


	September 30, 2022		December 31, 2021
	(In millions)
U.S.	$	253,280	$	282,741
Asia	141,750		169,291
Latin America	54,991		59,763
EMEA	15,673		27,038
MetLife Holdings	149,134		179,551
Corporate & Other	35,276		41,324
Total	$	650,104	$	759,708

Revenues derived from one U.S. segment customer were $ 8.1 billion for both the three months and nine months ended September 30, 2022, which represented 42 % and 18 %, respectively, of consolidated premiums, universal life and investment-type product policy fees and other revenues. The revenue was from a single premium received for a pension risk transfer. Revenues derived from any other customer did not exceed 10 % of consolidated premiums, universal life and investment-type product policy fees and other revenues for the three months and nine months ended September 30, 2022 and 2021.

3. Dispositions

Disposition of MetLife Poland and Greece

In July 2021, the Company entered into definitive agreements to sell its wholly-owned subsidiaries in Poland and Greece (collectively, “MetLife Poland and Greece”) to NN Group N.V. for $ 738 million in total consideration, including a pre-closing dividend of $ 43 million. In January 2022 and April 2022, the Company completed the sales of its wholly-owned subsidiaries in Greece and Poland, respectively. In connection with the sales, a loss of $ 25 million, net of income tax, was recorded for the nine months ended September 30, 2022, which was reflected in net investment gains (losses) and resulted in a total loss on the sales of $ 239 million, net of income tax. MetLife Poland and Greece results of operations are reported in the EMEA segment adjusted earnings through June 30, 2021. See Note 2 for information on accounting for divested business.

MetLife Poland and Greece met the criteria in the second quarter of 2021 to be classified as held-for-sale but did not meet the criteria to be classified as discontinued operations. As a result, the related assets and liabilities are included in the separate held-for-sale line items of the asset and liability sections of the interim condensed consolidated balance sheet until the quarter in which the disposition is completed.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

3. Dispositions (continued)

The following table summarizes the assets and liabilities held-for-sale:


	December 31, 2021
	(In millions)
Assets:
Fixed maturity securities available-for-sale	$	2,043
Contractholder-directed equity securities	1,114
Other investments	118
Total investments	3,275
Cash and cash equivalents	69
Deferred policy acquisition costs and value of business acquired	138
Other	259
Separate account assets	3,497
Total assets held-for-sale	$	7,238

Liabilities:
Future policy benefits	$	916
Policyholder account balances	2,005
Other policy-related balances	103
Other	113
Separate account liabilities	3,497
Total liabilities held-for-sale	$	6,634

MetLife Poland and Greece income (loss) before provision for income tax as reflected in the interim condensed consolidated statements of operations was $ 19 million for the nine months ended September 30, 2022, and $ 12 million and $ 40 million for the three months and nine months ended September 30, 2021, respectively.

4. Insurance

Guarantees

As discussed in Notes 1 and 4 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report, the Company issues directly and assumes through reinsurance variable annuity products with guaranteed minimum benefits. Guaranteed minimum accumulation benefits (“GMABs”), the non-life contingent portion of guaranteed minimum withdrawal benefits (“GMWBs”) and certain non-life contingent portions of GMIBs are accounted for as embedded derivatives in policyholder account balances and are further discussed in Note 7.

The Company also issues other annuity contracts that apply a lower rate on funds deposited if the contractholder elects to surrender the contract for cash and a higher rate if the contractholder elects to annuitize. These guarantees include benefits that are payable in the event of death, maturity or at annuitization. Certain other annuity contracts contain guaranteed annuitization benefits that may be above what would be provided by the current account value of the contract. Additionally, the Company issues universal and variable life contracts where the Company contractually guarantees to the contractholder a secondary guarantee or a guaranteed paid-up benefit.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

4. Insurance (continued)

Information regarding the Company’s guarantee exposure, which includes direct and assumed business, but excludes offsets from hedging or ceded reinsurance, if any, was as follows at:


	September 30, 2022						December 31, 2021
	In the Event of Death			At Annuitization			In the Event of Death			At Annuitization
	(Dollars in millions)
Annuity Contracts:
Variable Annuity Guarantees:
Total account value (1), (2), (3)	$	45,246		$	16,413		$	62,281		$	23,121
Separate account value (1)	$	29,096		$	15,059		$	42,043		$	21,508
Net amount at risk (2)	$	6,091	(4)	$	685	(5)	$	1,490	(4)	$	500	(5)
Average attained age of contractholders	69 years			68 years			68 years			66 years
Other Annuity Guarantees:
Total account value (1), (3)	N/A			$	3,686		N/A			$	5,002
Net amount at risk	N/A			$	180	(6)	N/A			$	196	(6)
Average attained age of contractholders	N/A			57 years			N/A			56 years


	September 30, 2022				December 31, 2021
	Secondary Guarantees		Paid-Up Guarantees		Secondary Guarantees		Paid-Up Guarantees
	(Dollars in millions)
Universal and Variable Life Contracts:
Total account value (1), (3)	$	11,370	$	2,603	$	13,678	$	2,694
Net amount at risk (7)	$	76,358	$	12,008	$	78,762	$	12,657
Average attained age of policyholders	55 years		67 years		55 years		66 years

__________________

(1) The Company’s annuity and life contracts with guarantees may offer more than one type of guarantee in each contract. Therefore, the amounts listed above may not be mutually exclusive.

(2) Includes amounts, which are not reported on the interim condensed consolidated balance sheets, from assumed variable annuity guarantees from the Company’s former operating joint venture in Japan.

(3) Includes the contractholders’ investments in the general account and separate account, if applicable.

(4) Defined as the death benefit less the total account value, as of the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts on the balance sheet date and includes any additional contractual claims associated with riders purchased to assist with covering income taxes payable upon death.

(5) Defined as the amount (if any) that would be required to be added to the total account value to purchase a lifetime income stream, based on current annuity rates, equal to the minimum amount provided under the guaranteed benefit. This amount represents the Company’s potential economic exposure to such guarantees in the event all contractholders were to annuitize on the balance sheet date, even though the contracts contain terms that allow annuitization of the guaranteed amount only after the 10th anniversary of the contract, which not all contractholders have achieved.

(6) Defined as either the excess of the upper tier, adjusted for a profit margin, less the lower tier, as of the balance sheet date or the amount (if any) that would be required to be added to the total account value to purchase a lifetime income stream, based on current annuity rates, equal to the minimum amount provided under the guaranteed benefit. These amounts represent the Company’s potential economic exposure to such guarantees in the event all contractholders were to annuitize on the balance sheet date.

(7) Defined as the guarantee amount less the account value, as of the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts on the balance sheet date.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

4. Insurance (continued)

Liabilities for Unpaid Claims and Claim Expenses

Rollforward of Claims and Claim Adjustment Expenses

Information regarding the liabilities for unpaid claims and claim adjustment expenses was as follows:


	Nine Months Ended September 30,
	2022		2021
	(In millions)
Balance, beginning of period	$	20,013	$	18,591
Less: Reinsurance recoverables	3,121		2,417
Net balance, beginning of period	16,892		16,174
Incurred related to:
Current period	19,826		20,667
Prior periods (1)	765		960
Total incurred	20,591		21,627
Paid related to:
Current period	( 13,738 )		( 14,426 )
Prior periods	( 6,203 )		( 6,416 )
Total paid	( 19,941 )		( 20,842 )
Reclassified to liabilities held-for-sale (2)	—		( 55 )
Dispositions	—		( 64 )
Net balance, end of period	17,542		16,840
Add: Reinsurance recoverables	2,867		2,910
Balance, end of period (included in future policy benefits and other policy-related balances)	$	20,409	$	19,750

__________________

(1) The nine months ended September 30, 2022 and 2021 include incurred claim activity and claim adjustment expenses associated with prior periods but reported in the respective current period, which contain impacts related to the COVID-19 pandemic, partially offset by additional premiums recorded for experience-rated contracts that are not reflected in the table above.

(2) See Note 3 for information on the Company’s business dispositions.

5. Closed Block

On April 7, 2000 (the “Demutualization Date”), Metropolitan Life Insurance Company (“MLIC”) converted from a mutual life insurance company to a stock life insurance company and became a wholly-owned subsidiary of MetLife, Inc. The conversion was pursuant to an order by the New York Superintendent of Insurance approving MLIC’s plan of reorganization, as amended (the “Plan of Reorganization”). On the Demutualization Date, MLIC established a closed block for the benefit of holders of certain individual life insurance policies of MLIC.

Experience within the closed block, in particular mortality and investment yields, as well as realized and unrealized gains and losses, directly impact the policyholder dividend obligation. Amortization of the closed block DAC, which resides outside of the closed block, is based upon cumulative actual and expected earnings within the closed block. Accordingly, the Company’s net income continues to be sensitive to the actual performance of the closed block.

Closed block assets, liabilities, revenues and expenses are combined on a line-by-line basis with the assets, liabilities, revenues and expenses outside the closed block based on the nature of the particular item.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

5. Closed Block (continued)

Information regarding the closed block liabilities and assets designated to the closed block was as follows at:


	September 30, 2022		December 31, 2021
	(In millions)
Closed Block Liabilities
Future policy benefits	$	37,385	$	38,046
Other policy-related balances	257		290
Policyholder dividends payable	219		253
Policyholder dividend obligation	—		1,682
Deferred income tax liability	—		210
Other liabilities	444		263
Total closed block liabilities	38,305		40,744
Assets Designated to the Closed Block
Investments:
Fixed maturity securities available-for-sale, at estimated fair value	19,515		25,669
Equity securities, at estimated fair value	14		21
Mortgage loans	6,624		6,417
Policy loans	4,096		4,191
Real estate and real estate joint ventures	604		565
Other invested assets	910		535
Total investments	31,763		37,398
Cash and cash equivalents	344		126
Accrued investment income	386		384
Premiums, reinsurance and other receivables	38		50
Current income tax recoverable	82		81
Deferred income tax asset	460		—
Total assets designated to the closed block	33,073		38,039
Excess of closed block liabilities over assets designated to the closed block	5,232		2,705
AOCI:
Unrealized investment gains (losses), net of income tax	( 1,609 )		2,562
Unrealized gains (losses) on derivatives, net of income tax	408		107
Allocated to policyholder dividend obligation, net of income tax	—		( 1,329 )
Total amounts included in AOCI	( 1,201 )		1,340
Maximum future earnings to be recognized from closed block assets and liabilities	$	4,031	$	4,045

Information regarding the closed block policyholder dividend obligation was as follows:


	Nine Months Ended September 30, 2022		Year Ended December 31, 2021
	(In millions)
Balance, beginning of period	$	1,682	$	2,969
Change in unrealized investment and derivative gains (losses)	( 1,682 )		( 1,287 )
Balance, end of period	$	—	$	1,682

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

5. Closed Block (continued)

Information regarding the closed block revenues and expenses was as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
	(In millions)
Revenues
Premiums	$	267	$	310	$	816	$	955
Net investment income	326		390		1,039		1,165
Net investment gains (losses)	( 4 )		( 7 )		( 52 )		( 12 )
Net derivative gains (losses)	28		12		39		19
Total revenues	617		705		1,842		2,127
Expenses
Policyholder benefits and claims	459		522		1,404		1,588
Policyholder dividends	91		127		352		478
Other expenses	22		24		68		73
Total expenses	572		673		1,824		2,139
Revenues, net of expenses before provision for income tax expense (benefit)	45		32		18		( 12 )
Provision for income tax expense (benefit)	10		6		4		( 3 )
Revenues, net of expenses and provision for income tax expense (benefit)	$	35	$	26	$	14	$	( 9 )

MLIC charges the closed block with federal income taxes, state and local premium taxes and other state or local taxes, as well as investment management expenses relating to the closed block as provided in the Plan of Reorganization. MLIC also charges the closed block for expenses of maintaining the policies included in the closed block.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments

Fixed Maturity Securities Available-for-Sale

Fixed Maturity Securities Available-for-Sale by Sector

The following table presents fixed maturity securities available-for-sale (“AFS”) by sector. U.S. corporate and foreign corporate sectors include redeemable preferred stock. Residential mortgage-backed securities (“RMBS”) includes agency, prime, alternative and sub-prime mortgage-backed securities. Asset-backed securities and collateralized loan obligations (“ABS & CLO”), previously disclosed as ABS in the 2021 Annual Report, includes securities collateralized by consumer loans, corporate loans and broadly syndicated bank loans. Municipals includes taxable and tax-exempt revenue bonds and, to a much lesser extent, general obligations of states, municipalities and political subdivisions. Commercial mortgage-backed securities (“CMBS”) primarily includes securities collateralized by multiple commercial mortgage loans. RMBS, ABS & CLO and CMBS are, collectively, “Structured Products.”


	September 30, 2022										December 31, 2021
	Amortized Cost				Gross Unrealized				Estimated Fair Value		Amortized Cost				Gross Unrealized (1)				Estimated Fair Value
Sector			Allowance for Credit Loss		Gains		Losses						Allowance for Credit Loss		Gains		Losses
	(In millions)
U.S. corporate	$	88,539	$	( 30 )	$	1,121	$	10,806	$	78,824	$	82,694	$	( 30 )	$	10,651	$	281	$	93,034
Foreign corporate	59,259		( 13 )		1,010		10,329		49,927		59,124		( 28 )		5,275		731		63,640
Foreign government	46,819		( 136 )		1,918		4,551		44,050		56,848		( 19 )		5,603		823		61,609
U.S. government and agency	34,572		—		705		3,715		31,562		41,068		—		5,807		276		46,599
RMBS	30,417		—		241		3,513		27,145		29,152		—		1,440		188		30,404
ABS & CLO	18,007		—		43		1,284		16,766		18,443		—		185		59		18,569
Municipals	13,464		—		302		1,752		12,014		11,761		—		2,464		13		14,212
CMBS	11,380		( 19 )		148		1,032		10,477		11,794		( 14 )		476		49		12,207
Total fixed maturity securities AFS	$	302,457	$	( 198 )	$	5,488	$	36,982	$	270,765	$	310,884	$	( 91 )	$	31,901	$	2,420	$	340,274

_________________

(1) Excludes gross unrealized gains (losses) related to assets held-for-sale; these unrealized gains (losses) are included in AOCI as no component of equity is held-for-sale. See Note 3 for information on the Company’s business dispositions.

The Company held non-income producing fixed maturity securities AFS with an estimated fair value of $ 133 million and $ 22 million at September 30, 2022 and December 31, 2021, respectively, with unrealized gains (losses) of ($ 29 ) million and $ 8 million at September 30, 2022 and December 31, 2021, respectively.

Maturities of Fixed Maturity Securities AFS

The amortized cost, net of allowance for credit loss (“ACL”) and estimated fair value of fixed maturity securities AFS, by contractual maturity date, were as follows at September 30, 2022:


	Due in One Year or Less		Due After One Year Through Five Years		Due After Five Years Through Ten Years		Due After Ten Years		Structured Products		Total Fixed Maturity Securities AFS
	(In millions)
Amortized cost, net of ACL	$	7,503	$	50,362	$	54,206	$	130,403	$	59,785	$	302,259
Estimated fair value	$	7,346	$	48,275	$	49,497	$	111,259	$	54,388	$	270,765

Actual maturities may differ from contractual maturities due to the exercise of call or prepayment options. Fixed maturity securities AFS not due at a single maturity date have been presented in the year of final contractual maturity. Structured Products are shown separately, as they are not due at a single maturity.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

Continuous Gross Unrealized Losses for Fixed Maturity Securities AFS by Sector

The following table presents the estimated fair value and gross unrealized losses of fixed maturity securities AFS in an unrealized loss position without an ACL by sector and aggregated by length of time that the securities have been in a continuous unrealized loss position.


	September 30, 2022								December 31, 2021
	Less than 12 Months				Equal to or Greater than 12 Months				Less than 12 Months				Equal to or Greater than 12 Months
Sector & Credit Quality	Estimated Fair Value		Gross Unrealized Losses		Estimated Fair Value		Gross Unrealized Losses		Estimated Fair Value		Gross Unrealized Losses (1)		Estimated Fair Value		Gross Unrealized Losses (1)
	(Dollars in millions)
U.S. corporate	$	58,850	$	9,547	$	3,721	$	1,259	$	8,076	$	165	$	1,499	$	116
Foreign corporate	33,828		8,238		6,209		2,090		10,011		404		2,834		327
Foreign government	16,696		2,290		6,598		2,260		7,812		319		5,377		502
U.S. government and agency	19,728		2,739		3,078		976		14,419		138		1,571		138
RMBS	20,502		2,629		3,404		884		10,363		158		417		30
ABS & CLO	13,681		1,065		1,858		219		8,150		39		804		20
Municipals	7,907		1,690		157		62		524		10		65		3
CMBS	7,981		823		1,339		208		2,664		31		657		18
Total fixed maturity securities AFS	$	179,173	$	29,021	$	26,364	$	7,958	$	62,019	$	1,264	$	13,224	$	1,154
Investment grade	$	170,622	$	27,906	$	24,394	$	7,376	$	58,358	$	1,123	$	12,022	$	1,025
Below investment grade	8,551		1,115		1,970		582		3,661		141		1,202		129
Total fixed maturity securities AFS	$	179,173	$	29,021	$	26,364	$	7,958	$	62,019	$	1,264	$	13,224	$	1,154
Total number of securities in an unrealized loss position	17,320				2,796				4,774				979

________________

(1) Excludes gross unrealized losses related to assets held-for-sale; these unrealized losses are included in AOCI as no component of equity is held-for-sale. See Note 3 for information on the Company’s business dispositions.

Evaluation of Fixed Maturity Securities AFS for Credit Loss

Evaluation and Measurement Methodologies

Management considers a wide range of factors about the security issuer and uses its best judgment in evaluating the cause of the decline in the estimated fair value of the security and in assessing the prospects for near-term recovery. Inherent in management’s evaluation of the security are assumptions and estimates about the operations of the issuer and its future earnings potential. Considerations used in the credit loss evaluation process include, but are not limited to: (i) the extent to which the estimated fair value has been below amortized cost, (ii) adverse conditions specifically related to a security, an industry sector or sub-sector, or an economically depressed geographic area, adverse change in the financial condition of the issuer of the security, changes in technology, discontinuance of a segment of the business that may affect future earnings, and changes in the quality of credit enhancement, (iii) payment structure of the security and likelihood of the issuer being able to make payments, (iv) failure of the issuer to make scheduled interest and principal payments, (v) whether the issuer, or series of issuers or an industry has suffered a catastrophic loss or has exhausted natural resources, (vi) whether the Company has the intent to sell or will more likely than not be required to sell a particular security before the decline in estimated fair value below amortized cost recovers, (vii) with respect to Structured Products, changes in forecasted cash flows after considering the changes in the financial condition of the underlying loan obligors and quality of underlying collateral, expected prepayment speeds, current and forecasted loss severity, consideration of the payment terms of the underlying assets backing a particular security, and the payment priority within the tranche structure of the security, (viii) changes in the rating of the security by a rating agency, and (ix) other subjective factors, including concentrations and information obtained from regulators.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

The methodology and significant inputs used to determine the amount of credit loss are as follows:

• The Company calculates the recovery value by performing a discounted cash flow analysis based on the present value of future cash flows. The discount rate is generally the effective interest rate of the security at the time of purchase for fixed-rate securities and the spot rate at the date of evaluation of credit loss for floating-rate securities.

• When determining collectability and the period over which value is expected to recover, the Company applies considerations utilized in its overall credit loss evaluation process which incorporates information regarding the specific security, fundamentals of the industry and geographic area in which the security issuer operates, and overall macroeconomic conditions. Projected future cash flows are estimated using assumptions derived from management’s single best estimate, the most likely outcome in a range of possible outcomes, after giving consideration to a variety of variables that include, but are not limited to: payment terms of the security; the likelihood that the issuer can service the interest and principal payments; the quality and amount of any credit enhancements; the security’s position within the capital structure of the issuer; possible corporate restructurings or asset sales by the issuer; any private and public sector programs to restructure foreign government securities and municipals; and changes to the rating of the security or the issuer by rating agencies.

• Additional considerations are made when assessing the unique features that apply to certain Structured Products including, but not limited to: the quality of underlying collateral, historical performance of the underlying loan obligors, historical rent and vacancy levels, changes in the financial condition of the underlying loan obligors, expected prepayment speeds, current and forecasted loss severity, consideration of the payment terms of the underlying loans or assets backing a particular security, changes in the quality of credit enhancement and the payment priority within the tranche structure of the security.

With respect to securities that have attributes of debt and equity (“perpetual hybrid securities”), consideration is given in the credit loss analysis as to whether there has been any deterioration in the credit of the issuer and the likelihood of recovery in value of the securities that are in a severe unrealized loss position. Consideration is also given as to whether any perpetual hybrid securities with an unrealized loss, regardless of credit rating, have deferred any dividend payments.

In periods subsequent to the recognition of an initial ACL on a security, the Company reassesses credit loss quarterly. Subsequent increases or decreases in the expected cash flow from the security result in corresponding decreases or increases in the ACL which are recognized in earnings and reported within net investment gains (losses); however, the previously recorded ACL is not reduced to an amount below zero. Full or partial write-offs are deducted from the ACL in the period the security, or a portion thereof, is considered uncollectible. Recoveries of amounts previously written off are recorded to the ACL in the period received. When the Company has the intent-to-sell the security or it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost, any ACL is written off and the amortized cost is written down to estimated fair value through a charge within net investment gains (losses), which becomes the new amortized cost of the security.

Evaluation of Fixed Maturity Securities AFS in an Unrealized Loss Position

Gross unrealized losses on securities without an ACL increased $ 34.6 billion for the nine months ended September 30, 2022 to $ 37.0 billion primarily due to increases in interest rates, widening credit spreads, and the impact of weakening foreign currencies on certain non-functional currency denominated fixed maturity securities.

Gross unrealized losses on securities without an ACL that have been in a continuous gross unrealized loss position for 12 months or greater were $ 8.0 billion at September 30, 2022, or 22 % of the total gross unrealized losses on securities without an ACL.

Investment Grade Fixed Maturity Securities AFS

Of the $ 8.0 billion of gross unrealized losses on securities without an ACL that have been in a continuous gross unrealized loss position for 12 months or greater, $ 7.4 billion, or 93 %, were related to 2,477 investment grade securities. Unrealized losses on investment grade securities are principally related to widening credit spreads since purchase and, with respect to fixed-rate securities, rising interest rates since purchase.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

Below Investment Grade Fixed Maturity Securities AFS

Of the $ 8.0 billion of gross unrealized losses on securities without an ACL that have been in a continuous gross unrealized loss position for 12 months or greater, $ 582 million, or 7 %, were related to 319 below investment grade securities. Unrealized losses on below investment grade securities are principally related to U.S. corporate and foreign corporate securities (primarily industrial and consumer) and foreign government securities. These unrealized losses are the result of significantly wider credit spreads resulting from higher risk premiums since purchase, largely due to economic and market uncertainty, as well as, with respect to fixed-rate securities, rising interest rates since purchase. Management evaluates U.S. corporate and foreign corporate securities based on several factors such as expected cash flows, financial condition and near-term and long-term prospects of the issuers. Management evaluates foreign government securities based on factors impacting the issuers such as expected cash flows, financial condition of the issuers and any country specific economic conditions or public sector programs to restructure foreign government securities.

Current Period Evaluation

At September 30, 2022, with respect to securities in an unrealized loss position without an ACL, the Company did not intend to sell these securities, and it was not more likely than not that the Company would be required to sell these securities before the anticipated recovery of the remaining amortized cost. Based on the Company’s current evaluation of its securities in an unrealized loss position without an ACL, the Company concluded that these securities had not incurred a credit loss and should not have an ACL at September 30, 2022.

Future provisions for credit loss will depend primarily on economic fundamentals, issuer performance (including changes in the present value of future cash flows expected to be collected), changes in credit ratings and collateral valuation.

Rollforward of Allowance for Credit Loss for Fixed Maturity Securities AFS by Sector

The rollforward of ACL for fixed maturity securities AFS by sector is as follows:


	U.S. Corporate		Foreign Corporate		Foreign Government		CMBS		Total
Three Months Ended September 30, 2022	(In millions)

Balance, at beginning of period	$	28	$	53	$	166	$	14	$	261
Additions:
ACL not previously recorded	—		—		—		5		5


Reductions:
Changes for securities with previously recorded ACL	2		( 1 )		( 19 )		—		( 18 )
Securities sold or exchanged	—		( 39 )		—		—		( 39 )

Disposition	—		—		—		—		—
Effect of foreign currency translation	—		—		( 11 )		—		( 11 )
Write-offs	—		—		—		—		—

Balance, at end of period	$	30	$	13	$	136	$	19	$	198
Three Months Ended September 30, 2021
Balance, at beginning of period	$	39	$	32	$	21	$	7	$	99
Additions:
ACL not previously recorded	18		—		—		—		18

Reductions:
Changes for securities with previously recorded ACL	—		( 2 )		—		—		( 2 )
Securities sold or exchanged	( 26 )		( 6 )		—		—		( 32 )

Disposition	—		—		( 2 )		—		( 2 )
Effect of foreign currency translation	—		—		—		—		—
Write-offs	( 13 )		—		—		—		( 13 )

Balance, at end of period	$	18	$	24	$	19	$	7	$	68

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)


	U.S. Corporate		Foreign Corporate		Foreign Government		CMBS		Total
Nine Months Ended September 30, 2022	(In millions)

Balance, at beginning of period	$	30	$	28	$	19	$	14	$	91
Additions:
ACL not previously recorded	13		67		207		5		292


Reductions:
Changes for securities with previously recorded ACL	17		1		( 42 )		—		( 24 )
Securities sold or exchanged	( 8 )		( 83 )		( 37 )		—		( 128 )

Disposition	—		—		—		—		—
Effect of foreign currency translation	—		—		( 11 )		—		( 11 )
Write-offs	( 22 )		—		—		—		( 22 )

Balance, at end of period	$	30	$	13	$	136	$	19	$	198
Nine Months Ended September 30, 2021
Balance, at beginning of period	$	44	$	16	$	21	$	—	$	81
Additions:
ACL not previously recorded	18		25		—		11		54

Reductions:
Changes for securities with previously recorded ACL	3		( 7 )		—		( 4 )		( 8 )
Securities sold or exchanged	( 34 )		( 10 )		—		—		( 44 )

Disposition	—		—		( 2 )		—		( 2 )
Effect of foreign currency translation	—		—		—		—		—
Write-offs	( 13 )		—		—		—		( 13 )

Balance, at end of period	$	18	$	24	$	19	$	7	$	68

Equity Securities

The following table presents equity securities by security type. Common stock includes common stock, exchange traded funds, mutual funds and real estate investment trusts.



	September 30, 2022						December 31, 2021
	Cost		Net Unrealized Gains (Losses) (1)		Estimated Fair Value		Cost		Net Unrealized Gains (Losses) (1)		Estimated Fair Value
Security Type
			(In millions)
Common stock	$	610	$	183	$	793	$	784	$	295	$	1,079
Non-redeemable preferred stock	188		( 8 )		180		189		1		190
Total	$	798	$	175	$	973	$	973	$	296	$	1,269

________________

(1) Represents cumulative changes in estimated fair value, recognized in earnings, and not in Other Comprehensive Income (Loss) (“OCI”).

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

Contractholder-Directed Equity Securities and FVO Securities

The following table presents these investments by asset type. Contractholder-directed investments supporting unit-linked variable annuity type liabilities (“Unit-linked investments”) are primarily equity securities (including mutual funds) and, to a lesser extent, fixed income investments and cash and cash equivalents.


	September 30, 2022						December 31, 2021
	Cost or Amortized Cost		Net Unrealized Gains (Losses) (1)		Estimated Fair Value		Cost or Amortized Cost		Net Unrealized Gains (Losses) (1)		Estimated Fair Value
Asset Type
	(In millions)
Unit-linked investments	$	7,566	$	74	$	7,640	$	8,643	$	1,897	$	10,540
FVO Securities	1,111		203		1,314		1,243		359		1,602
Total	$	8,677	$	277	$	8,954	$	9,886	$	2,256	$	12,142

________________

(1) Represents cumulative changes in estimated fair value, recognized in earnings, and not in OCI.

Mortgage Loans

Mortgage Loans by Portfolio Segment

Mortgage loans are summarized as follows at:


	September 30, 2022				December 31, 2021
Portfolio Segment	Carrying Value		% of Total		Carrying Value		% of Total
	(Dollars in millions)
Commercial	$	52,273	63.4	%	$	50,553	63.7	%
Agricultural	18,923		23.0		18,111		22.8
Residential	11,708		14.2		11,196		14.1
Total amortized cost	82,904		100.6		79,860		100.6
Allowance for credit loss	( 467 )		( 0.6 )		( 634 )		( 0.8 )
Subtotal mortgage loans, net	82,437		100.0		79,226		99.8
Residential — FVO	—		—		127		0.2
Total mortgage loans held-for-investment, net	82,437		100.0		79,353		100.0

Total mortgage loans, net	$	82,437	100.0	%	$	79,353	100.0	%

The Company elects the FVO for certain residential mortgage loans that are managed on a total return basis, with changes in estimated fair value included in net investment income. See Note 8 for further information.

The amount of net (discounts) premiums and deferred (fees) expenses, included within total amortized cost, primarily attributable to residential mortgage loans was ($ 687 ) million and ($ 759 ) million at September 30, 2022 and December 31, 2021, respectively. The accrued interest income excluded from total amortized cost for commercial, agricultural and residential mortgage loans at September 30, 2022 was $ 205 million, $ 152 million and $ 80 million, respectively. The accrued interest income excluded from total amortized cost for commercial, agricultural and residential mortgage loans at December 31, 2021 was $ 180 million, $ 161 million and $ 86 million, respectively.

Purchases of mortgage loans, consisting primarily of residential mortgage loans, were $ 462 million and $ 2.2 billion for the three months and nine months ended September 30, 2022, respectively, and $ 499 million and $ 1.5 billion for the three months and nine months ended September 30, 2021, respectively.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

Rollforward of Allowance for Credit Loss for Mortgage Loans by Portfolio Segment

The rollforward of ACL for mortgage loans, by portfolio segment, is as follows:


	Nine Months Ended September 30,
	2022								2021
	Commercial		Agricultural		Residential		Total		Commercial		Agricultural		Residential		Total
	(In millions)
Balance, beginning of period	$	340	$	88	$	206	$	634	$	252	$	106	$	232	$	590

Provision (release)	( 11 )		52		( 64 )		( 23 )		22		—		( 37 )		( 15 )
Initial credit losses on PCD loans (1)	—		—		—		—		—		—		3		3
Charge-offs, net of recoveries	( 120 )		( 22 )		( 2 )		( 144 )		—		( 13 )		( 2 )		( 15 )

Balance, end of period	$	209	$	118	$	140	$	467	$	274	$	93	$	196	$	563

________________

(1) Represents the initial credit losses on purchased mortgage loans accounted for as purchased financial assets with credit deterioration (“PCD”).

Allowance for Credit Loss Methodology

The Company records an allowance for expected lifetime credit loss in earnings within net investment gains (losses) in an amount that represents the portion of the amortized cost basis of mortgage loans that the Company does not expect to collect, resulting in mortgage loans being presented at the net amount expected to be collected. In determining the Company’s ACL, management applies significant judgment to estimate expected lifetime credit loss, including: (i) pooling mortgage loans that share similar risk characteristics, (ii) considering expected lifetime credit loss over the contractual term of its mortgage loans adjusted for expected prepayments and any extensions, and (iii) considering past events and current and forecasted economic conditions. Each of the Company’s commercial, agricultural and residential mortgage loan portfolio segments are evaluated separately. The ACL is calculated for each mortgage loan portfolio segment based on inputs unique to each loan portfolio segment. On a quarterly basis, mortgage loans within a portfolio segment that share similar risk characteristics, such as internal risk ratings or consumer credit scores, are pooled for calculation of ACL. On an ongoing basis, mortgage loans with dissimilar risk characteristics (i.e., loans with significant declines in credit quality), collateral dependent mortgage loans (i.e., when the borrower is experiencing financial difficulty, including when foreclosure is reasonably possible or probable) and reasonably expected TDRs (i.e., the Company grants concessions to borrower that is experiencing financial difficulties) are evaluated individually for credit loss. The ACL for loans evaluated individually are established using the same methodologies for all three portfolio segments. For example, the ACL for a collateral dependent loan is established as the excess of amortized cost over the estimated fair value of the loan’s underlying collateral, less selling cost when foreclosure is probable. Accordingly, the change in the estimated fair value of collateral dependent loans, which are evaluated individually for credit loss, is recorded as a change in the ACL which is recorded on a quarterly basis as a charge or credit to earnings in net investment gains (losses).

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

Commercial and Agricultural Mortgage Loan Portfolio Segments

Commercial and agricultural mortgage loan ACL are calculated in a similar manner. Within each loan portfolio segment, commercial and agricultural, loans are pooled by internal risk rating. Estimated lifetime loss rates, which vary by internal risk rating, are applied to the amortized cost of each loan, excluding accrued investment income, on a quarterly basis to develop the ACL. Internal risk ratings are based on an assessment of the loan’s credit quality, which can change over time. The estimated lifetime loss rates are based on several loan portfolio segment-specific factors, including (i) the Company’s experience with defaults and loss severity, (ii) expected default and loss severity over the forecast period, (iii) current and forecasted economic conditions including growth, inflation, interest rates and unemployment levels, (iv) loan specific characteristics including loan-to-value (“LTV”) ratios, and (v) internal risk ratings. These evaluations are revised as conditions change and new information becomes available. The Company uses its several decades of historical default and loss severity experience which capture multiple economic cycles. The Company uses a forecast of economic assumptions for a two-year period for most of its commercial and agricultural mortgage loans, while a one-year period is used for loans originated in certain markets. After the applicable forecast period, the Company reverts to its historical loss experience using a straight-line basis over two years. For evaluations of commercial mortgage loans, in addition to historical experience, management considers factors that include the impact of a rapid change to the economy, which may not be reflected in the loan portfolio, recent loss and recovery trend experience as compared to historical loss and recovery experience, and loan specific characteristics including debt service coverage ratios (“DSCR”). In estimating expected lifetime credit loss over the term of its commercial mortgage loans, the Company adjusts for expected prepayment and extension experience during the forecast period using historical prepayment and extension experience considering the expected position in the economic cycle and the loan profile (i.e., floating rate, shorter-term fixed rate and longer-term fixed rate) and after the forecast period using long-term historical prepayment experience. For evaluations of agricultural mortgage loans, in addition to historical experience, management considers factors that include increased stress in certain sectors, which may be evidenced by higher delinquency rates, or a change in the number of higher risk loans. In estimating expected lifetime credit loss over the term of its agricultural mortgage loans, the Company’s experience is much less sensitive to the position in the economic cycle and by loan profile; accordingly, historical prepayment experience is used, while extension terms are not prevalent with the Company’s agricultural mortgage loans.

Commercial mortgage loans are reviewed on an ongoing basis, which review includes, but is not limited to, an analysis of the property financial statements and rent roll, lease rollover analysis, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios, DSCR and tenant creditworthiness. The monitoring process focuses on higher risk loans, which include those that are classified as restructured, delinquent or in foreclosure, as well as loans with higher LTV ratios and lower DSCR. Agricultural mortgage loans are reviewed on an ongoing basis, which review includes, but is not limited to, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios and borrower creditworthiness, as well as reviews on a geographic and property-type basis. The monitoring process for agricultural mortgage loans also focuses on higher risk loans.

For commercial mortgage loans, the primary credit quality indicator is the DSCR, which compares a property’s net operating income to amounts needed to service the principal and interest due under the loan. Generally, the lower the DSCR, the higher the risk of experiencing a credit loss. The Company also reviews the LTV ratio of its commercial mortgage loan portfolio. LTV ratios compare the unpaid principal balance of the loan to the estimated fair value of the underlying collateral. Generally, the higher the LTV ratio, the higher the risk of experiencing a credit loss. The DSCR and the values utilized in calculating the ratio are updated routinely. In addition, the LTV ratio is routinely updated for all but the lowest risk loans as part of the Company’s ongoing review of its commercial mortgage loan portfolio.

For agricultural mortgage loans, the Company’s primary credit quality indicator is the LTV ratio. The values utilized in calculating this ratio are developed in connection with the ongoing review of the agricultural mortgage loan portfolio and are routinely updated.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

Commitments to lend: After loans are approved, the Company makes commitments to lend and, typically, borrowers draw down on some or all of the commitments. The timing of mortgage loan funding is based on the commitment expiration dates. A liability for credit loss for unfunded commercial and agricultural mortgage loan commitments that are not unconditionally cancellable is recognized in earnings and is reported within net investment gains (losses). The liability is based on estimated lifetime loss rates as described above and the amount of the outstanding commitments, which for lines of credit, considers estimated utilization rates. When the commitment is funded or expires, the liability is adjusted accordingly.

Residential Mortgage Loan Portfolio Segment

The Company’s residential mortgage loan portfolio is comprised primarily of purchased closed end, amortizing residential mortgage loans, including both performing loans purchased within 12 months of origination and reperforming loans purchased after they have been performing for at least 12 months post-modification. Residential mortgage loans are pooled by loan type (i.e., new origination and reperforming) and pooled by similar risk profiles (including consumer credit score and LTV ratios). Estimated lifetime loss rates, which vary by loan type and risk profile, are applied to the amortized cost of each loan excluding accrued investment income on a quarterly basis to develop the ACL. The estimated lifetime loss rates are based on several factors, including (i) industry historical experience and expected results over the forecast period for defaults, (ii) loss severity, (iii) prepayment rates, (iv) current and forecasted economic conditions including growth, inflation, interest rates and unemployment levels, and (v) loan pool specific characteristics including consumer credit scores, LTV ratios, payment history and home prices. These evaluations are revised as conditions change and new information becomes available. The Company uses industry historical experience which captures multiple economic cycles as the Company has purchased most of its residential mortgage loans in the last five years. The Company uses a forecast of economic assumptions for a two-year period for most of its residential mortgage loans. After the applicable forecast period, the Company immediately reverts to industry historical loss experience.

For residential mortgage loans, the Company’s primary credit quality indicator is whether the loan is performing or nonperforming. The Company generally defines nonperforming residential mortgage loans as those that are 60 or more days past due and/or in nonaccrual status which is assessed monthly. Generally, nonperforming residential mortgage loans have a higher risk of experiencing a credit loss.

Troubled Debt Restructuring

The Company may grant concessions to borrowers experiencing financial difficulties and if significant, these concessions are classified as TDRs. Generally, the types of concessions include: reduction of contractual interest rates, extension of the maturity date at an interest rate lower than current market interest rates, and/or a reduction of accrued interest. The amount, timing and extent of the concessions granted are considered in determining any ACL recorded.

For the three months and nine months ended September 30, 2022, the Company had one and two commercial mortgage loans modified in a TDR, respectively with both pre-modification and post-modification carrying value, after ACL, of $ 64 million and $ 162 million, respectively.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

Credit Quality of Mortgage Loans by Portfolio Segment

The amortized cost of commercial mortgage loans by credit quality indicator and vintage year was as follows at September 30, 2022:


Credit Quality Indicator	2022		2021		2020		2019		2018		Prior		Revolving Loans		Total		% of Total
	(Dollars in millions)
LTV ratios:
Less than 65%	$	4,602	$	5,684	$	3,677	$	5,588	$	5,167	$	13,630	$	2,756	$	41,104	78.6	%
65% to 75%	1,831		1,188		929		1,389		1,340		1,767		—		8,444		16.2
76% to 80%	17		7		32		559		225		211		—		1,051		2.0
Greater than 80%	144		39		—		144		151		1,196		—		1,674		3.2
Total	$	6,594	$	6,918	$	4,638	$	7,680	$	6,883	$	16,804	$	2,756	$	52,273	100.0	%
DSCR:
> 1.20x	$	6,239	$	6,176	$	4,414	$	7,354	$	6,148	$	14,591	$	2,756	$	47,678	91.2	%
1.00x - 1.20x	286		366		18		50		275		950		—		1,945		3.7
<1.00x	69		376		206		276		460		1,263		—		2,650		5.1
Total	$	6,594	$	6,918	$	4,638	$	7,680	$	6,883	$	16,804	$	2,756	$	52,273	100.0	%

The amortized cost of agricultural mortgage loans by credit quality indicator and vintage year was as follows at September 30, 2022:


Credit Quality Indicator	2022		2021		2020		2019		2018		Prior		Revolving Loans		Total		% of Total
	(Dollars in millions)
LTV ratios:
Less than 65%	$	2,147	$	2,646	$	2,644	$	1,707	$	2,389	$	4,413	$	1,175	$	17,121	90.4	%
65% to 75%	152		319		343		184		100		495		44		1,637		8.7
76% to 80%	—		—		—		—		—		12		—		12		0.1
Greater than 80%	—		—		29		76		—		44		4		153		0.8
Total	$	2,299	$	2,965	$	3,016	$	1,967	$	2,489	$	4,964	$	1,223	$	18,923	100.0	%

The amortized cost of residential mortgage loans by credit quality indicator and vintage year was as follows at September 30, 2022:


Credit Quality Indicator	2022		2021		2020		2019		2018		Prior		Revolving Loans		Total		% of Total
	(Dollars in millions)
Performance indicators:
Performing	$	1,476	$	1,268	$	372	$	987	$	437	$	6,684	$	—	$	11,224	95.9	%
Nonperforming (1)	6		6		8		46		16		402		—		484		4.1
Total	$	1,482	$	1,274	$	380	$	1,033	$	453	$	7,086	$	—	$	11,708	100.0	%

__________________

(1) Includes residential mortgage loans in process of foreclosure of $ 145 million and $ 70 million at September 30, 2022 and December 31, 2021, respectively.

LTV ratios compare the unpaid principal balance of the loan to the estimated fair value of the underlying collateral. The amortized cost of commercial and agricultural mortgage loans with an LTV ratio in excess of 100% was $ 599 million, or 1 % of total commercial and agricultural mortgage loans, at September 30, 2022.

Past Due and Nonaccrual Mortgage Loans

The Company has a high quality, well performing mortgage loan portfolio, with 99 % of all mortgage loans classified as performing at both September 30, 2022 and December 31, 2021. The Company defines delinquency consistent with

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

industry practice, when mortgage loans are past due more than two or more months, as applicable, by portfolio segment. The past due and nonaccrual mortgage loans at amortized cost, prior to ACL, by portfolio segment, were as follows:


	Past Due				Greater than 90 Days Past Due and Still Accruing Interest				Nonaccrual
Portfolio Segment	September 30, 2022		December 31, 2021		September 30, 2022		December 31, 2021		September 30, 2022		December 31, 2021
	(In millions)
Commercial	$	5	$	13	$	5	$	13	$	151	$	155
Agricultural	118		124		31		16		207		225
Residential	484		450		10		8		478		442
Total	$	607	$	587	$	46	$	37	$	836	$	822

The amortized cost for nonaccrual commercial, agricultural and residential mortgage loans at beginning of year 2021 was $ 317 million, $ 266 million and $ 534 million, respectively. The amortized cost for nonaccrual agricultural mortgage loans with no ACL was $ 88 million and $ 134 million at September 30, 2022 and December 31, 2021, respectively. There were no nonaccrual commercial or residential mortgage loans without an ACL at either September 30, 2022 or December 31, 2021.

Real Estate and Real Estate Joint Ventures

The Company’s real estate investment portfolio is diversified by property type, geography and income stream, including income from operating leases, operating income and equity in earnings from equity method real estate joint ventures. Real estate investments, by income type, as well as income earned, were as follows at and for the periods indicated:


	September 30, 2022		December 31, 2021		Three Months Ended September 30,				Nine Months Ended September 30,
					2022		2021		2022		2021
Income Type	Carrying Value				Income
	(In millions)
Wholly-owned real estate:
Leased real estate	$	4,416	$	5,146	$	95	$	108	$	299	$	327
Other real estate	479		474		89		58		189		144
Real estate joint ventures	7,637		6,596		100		113		503		189
Total real estate and real estate joint ventures	$	12,532	$	12,216	$	284	$	279	$	991	$	660

The carrying value of wholly-owned real estate acquired through foreclosure was $ 175 million and $ 181 million at September 30, 2022 and December 31, 2021, respectively. Depreciation expense on real estate investments was $ 29 million and $ 88 million for the three months and nine months ended September 30, 2022, respectively, and $ 31 million and $ 92 million for the three months and nine months ended September 30, 2021, respectively. Real estate investments were net of accumulated depreciation of $ 903 million and $ 883 million at September 30, 2022 and December 31, 2021, respectively.

Leases

Leased Real Estate Investments - Operating Leases

The Company, as lessor, leases investment real estate, principally commercial real estate for office and retail use, through a variety of operating lease arrangements, which typically include tenant reimbursement for property operating costs and options to renew or extend the lease. In some circumstances, leases may include an option for the lessee to purchase the property. In addition, certain leases of retail space may stipulate that a portion of the income earned is contingent upon the level of the tenants’ revenues. The Company has elected a practical expedient of not separating non-lease components related to reimbursement of property operating costs from associated lease components. These property operating costs have the same timing and pattern of transfer as the related lease component, because they are incurred over the same period of time as the operating lease. Therefore, the combined component is accounted for as a single operating lease. Risk is managed through lessee credit analysis, property type diversification, and geographic diversification.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

See Note 8 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report for a summary of leased real estate investments and income earned, by property type.

Leveraged and Direct Financing Leases

The Company has diversified leveraged and direct financing lease portfolios. Its leveraged leases principally include renewable energy generation facilities, rail cars, commercial real estate and commercial aircraft, and its direct financing leases principally include commercial real estate. These assets are leased through a variety of lease arrangements, which may include options to renew or extend the lease and options for the lessee to purchase the property. Residual values are estimated using available third-party data at inception of the lease. Risk is managed through lessee credit analysis, asset allocation, geographic diversification, and ongoing reviews of estimated residual values, using available third-party data and, in certain leases, linking the amount of future rental receipts to changes in inflation rates. Generally, estimated residual values are not guaranteed by the lessee or a third party.

Lease receivables are generally due in periodic installments. The payment periods for leveraged leases generally range from one to 10 years, but in certain circumstances can be over 10 years, while the payment periods for direct financing leases generally range from one to 25 years but in certain circumstances can be over 25 years.

The Company records an allowance for expected lifetime credit loss in earnings within net investment gains (losses) in an amount that represents the portion of the investment in leases that the Company does not expect to collect, resulting in the investment in leases being presented at the net amount expected to be collected. In determining the ACL, management applies significant judgment to estimate expected lifetime credit loss, including: (i) pooling leases that share similar risk characteristics, (ii) considering expected lifetime credit loss over the contractual term of the lease, and (iii) considering past events and current and forecasted economic conditions. Leases with dissimilar risk characteristics are evaluated individually for credit loss. Expected lifetime credit loss on leveraged lease receivables is estimated using a probability of default and loss given default model, where the probability of default incorporates third party credit ratings of the lessee and the related historical default data. Direct financing leases principally relate to leases of commercial real estate; accordingly, expected lifetime credit loss is estimated on such lease receivables consistent with the methodology for commercial mortgage loans (see “— Mortgage Loans — Allowance for Credit Loss Methodology”). The Company also assesses the non-guaranteed residual values for recoverability by comparison to the current estimated fair value of the leased asset and considers other relevant market information such as independent third-party forecasts, consulting, asset brokerage and investment banking reports and data, comparable market transactions, and factors such as the competitive dynamics impacting specific industries, technological change and obsolescence, government and regulatory rules, tax policy, potential environmental liabilities and litigation.

The investment in leveraged and direct financing leases, net of ACL, was $ 795 million and $ 1.0 billion, respectively, at September 30, 2022 and $ 787 million and $ 1.1 billion, respectively, at December 31, 2021. The ACL for leveraged and direct financing leases was $ 33 million and $ 40 million at September 30, 2022 and December 31, 2021, respectively.

Cash Equivalents

Cash equivalents, which includes securities and other investments with an original or remaining maturity of three months or less at the time of purchase, wa s $ 9.4 billion and $ 9.0 billion, principally at estimated fair value, at September 30, 2022 and December 31, 2021, respectively.

Net Unrealized Investment Gains (Losses)

Unrealized investment gains (losses) on fixed maturity securities AFS and derivatives and the effect on policyholder liabilities, DAC, VOBA and deferred sales inducements (“DSI”) that would result from the realization of the unrealized gains (losses), are included in net unrealized investment gains (losses) in AOCI.

The components of net unrealized investment gains (losses), included in AOCI, were as follows:


	September 30, 2022		December 31, 2021
	(In millions)
Fixed maturity securities AFS	$	( 31,771 )	$	29,461
Derivatives	3,877		2,061
Other	471		389
Subtotal	( 27,423 )		31,911
Amounts allocated from:
Policyholder liabilities (1)	( 1,174 )		( 4,978 )
DAC, VOBA and DSI	3,499		( 3,208 )
Subtotal	2,325		( 8,186 )
Deferred income tax benefit (expense)	5,111		( 6,031 )
Net unrealized investment gains (losses)	( 19,987 )		17,694
Net unrealized investment gains (losses) attributable to noncontrolling interests	( 21 )		( 23 )
Net unrealized investment gains (losses) attributable to MetLife, Inc.	$	( 20,008 )	$	17,671

__________________

(1) Includes unearned revenue liabilities.

The changes in net unrealized investment gains (losses) were as follows:


	Nine Months Ended September 30, 2022
	(In millions)
Balance, beginning of period	$	17,671
Unrealized investment gains (losses) during the period	( 59,334 )
Unrealized investment gains (losses) relating to:
Policyholder liabilities	3,804
DAC, VOBA and DSI	6,707
Deferred income tax benefit (expense)	11,142
Net unrealized investment gains (losses)	( 20,010 )
Net unrealized investment gains (losses) attributable to noncontrolling interests	2
Balance, end of period	$	( 20,008 )
Change in net unrealized investment gains (losses)	$	( 37,681 )
Change in net unrealized investment gains (losses) attributable to noncontrolling interests	2
Change in net unrealized investment gains (losses) attributable to MetLife, Inc.	$	( 37,679 )

Concentrations of Credit Risk

Investments in any counterparty that were greater than 10% of the Company’s equity, other than the U.S. government and its agencies, at estimated fair value at September 30, 2022 and December 31, 2021, were in fixed income securities of the Japanese government and its agencies of $ 22.9 billion and $ 32.7 billion, respectively, in fixed income securities of the South Korean government and its agencies of $ 5.0 billion and $ 7.1 billion, respectively, and in fixed income securities of the Mexican government and its agencies of $ 3.1 billion at September 30, 2022.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

Securities Lending Transactions and Repurchase Agreements

Securities, Collateral and Reinvestment Portfolio

A summary of these transactions and agreements accounted for as secured borrowings was as follows:


		September 30, 2022						December 31, 2021
		Securities (1)						Securities (1)
Agreement Type		Estimated Fair Value		Cash Collateral Received from Counterparties (2)		Reinvestment Portfolio at Estimated Fair Value		Estimated Fair Value		Cash Collateral Received from Counterparties (2)		Reinvestment Portfolio at Estimated Fair Value
	(In millions)
Securities lending		$	13,117	$	13,471	$	13,091	$	20,654	$	21,055	$	21,319
Repurchase agreements		$	3,160	$	3,125	$	3,043	$	3,416	$	3,325	$	3,357

__________________

(1) These securities were included within fixed maturity securities AFS and short-term investments at September 30, 2022 and within fixed maturity securities AFS at December 31, 2021.

(2) The liability for cash collateral is included within payables for collateral under securities loaned and other transactions.

Contractual Maturities

Contractual maturities of these transactions and agreements accounted for as secured borrowings were as follows:


	September 30, 2022										December 31, 2021
	Remaining Maturities										Remaining Maturities
Security Type	Open (1)		1 Month or Less		Over 1 Month to 6 Months		Over 6 Months to 1 Year		Total		Open (1)		1 Month or Less		Over 1 Month to 6 Months		Over 6 Months to 1 Year		Total
	(In millions)
Cash collateral liability by security type:
Securities lending:
U.S. government and agency	$	2,468	$	5,901	$	3,654	$	—	$	12,023	$	5,900	$	7,052	$	7,055	$	—	$	20,007
Foreign government	—		243		887		47		1,177		—		285		762		—		1,047
Agency RMBS	—		251		20		—		271		—		—		—		—		—
U.S. corporate	—		—		—		—		—		1		—		—		—		1

Total	$	2,468	$	6,395	$	4,561	$	47	$	13,471	$	5,901	$	7,337	$	7,817	$	—	$	21,055

Repurchase agreements:
U.S. government and agency	$	—	$	3,125	$	—	$	—	$	3,125	$	—	$	3,325	$	—	$	—	$	3,325

__________________

(1) The related security could be returned to the Company on the next business day, which would require the Company to immediately return the cash collateral.

If the Company is required to return significant amounts of cash collateral on short notice and is forced to sell investments to meet the return obligation, it may have difficulty selling such collateral that is invested in a timely manner, be forced to sell investments in a volatile or illiquid market for less than what otherwise would have been realized under normal market conditions, or both.

The securities lending and repurchase agreements reinvestment portfolios consist principally of high quality, liquid, publicly-traded fixed maturity securities AFS, short-term investments, cash equivalents or cash. If the securities, or the reinvestment portfolio become less liquid, liquidity resources within the general account are available to meet any potential cash demands when securities are put back by the counterparty.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

Invested Assets on Deposit, Held in Trust and Pledged as Collateral

Invested assets on deposit, held in trust and pledged as collateral are presented below at estimated fair value for all asset classes, except mortgage loans, which are presented at carrying value and were as follows at:


	September 30, 2022		December 31, 2021
	(In millions)
Invested assets on deposit (regulatory deposits)	$	1,540	$	1,872
Invested assets held in trust (external reinsurance agreements) (1)	845		1,114
Invested assets pledged as collateral (2)	26,746		24,261
Total invested assets on deposit, held in trust and pledged as collateral	$	29,131	$	27,247

__________________

(1) Represents assets held in trust related to third-party reinsur ance agreements. Excludes assets held in trust related to reinsurance agreements between wholly-owned subsidiaries of $ 1.9 billion and $ 2.1 billion at September 30, 2022 and December 31, 2021, respectively.

(2) The Company has pledged invested assets in connection with various agreements and transactions, including funding agreements, secured debt and short-term debt related to repurchase agreements and a collateral financing arrangement (see Notes 4, 13 and 14 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report) and derivative transactions (see Note 7).

See “— Securities Lending Transactions and Repurchase Agreements” for information regarding securities supporting securities lending transactions and repurchase agreements an d Note 5 f or information regarding investments designated to the closed block. In addition, the Company’s investment in Federal Home Loan Bank common stock, included within other invested assets, which is considered restricted until redeemed by the issuer, was $ 768 million and $ 769 million, at redemption value, at September 30, 2022 and December 31, 2021, respectively.

Variable Interest Entities

The Company has invested in legal entities that are VIEs. In certain instances, the Company holds both the power to direct the most significant activities of the entity, as well as an economic interest in the entity and, as such, is deemed to be the primary beneficiary or consolidator of the entity. The determination of the VIE’s primary beneficiary requires an evaluation of the contractual and implied rights and obligations associated with each party’s relationship with or involvement in the entity.

Consolidated VIEs

Creditors or beneficial interest holders of VIEs where the Company is the primary beneficiary have no recourse to the general credit of the Company, as the Company’s obligation to the VIEs is limited to the amount of its committed investment.

The following table presents the total assets and total liabilities relating to investment related VIEs for which the Company has concluded that it is the primary beneficiary and which are consolidated at:


	September 30, 2022				December 31, 2021
Asset Type	Total Assets		Total Liabilities		Total Assets		Total Liabilities
	(In millions)
Investment funds (primarily other invested assets)	$	265	$	1	$	292	$	1
Renewable energy partnership (primarily other invested assets)	77		—		79		—
Other investments (primarily other assets)	1		—		1		—
Total	$	343	$	1	$	372	$	1

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

Unconsolidated VIEs

The carrying amount and maximum exposure to loss relating to VIEs in which the Company holds a significant variable interest but is not the primary beneficiary and which have not been consolidated were as follows at:


	September 30, 2022				December 31, 2021
Asset Type	Carrying Amount		Maximum Exposure to Loss (1)		Carrying Amount		Maximum Exposure to Loss (1)
	(In millions)
Fixed maturity securities AFS (2)	$	52,391	$	52,391	$	62,654	$	62,654



Other limited partnership interests	13,232		18,978		13,287		20,720
Other invested assets	1,354		1,439		1,257		1,314
Other investments	923		925		776		926
Total	$	67,900	$	73,733	$	77,974	$	85,614

__________________

(1) The maximum exposure to loss relating to fixed maturity securities AFS is equal to their carrying amounts or the carrying amounts of retained interests. The maximum exposure to loss relating to other limited partnership interests is equal to the carrying amounts plus any unfunded commitments. For certain of its investments in other invested assets, the Company’s return is in the form of income tax credits which are guaranteed by creditworthy third parties. For such investments, the maximum exposure to loss is equal to the carrying amounts plus any unfunded commitments, reduced by income tax credits guaranteed by third parties of $ 6 million and $ 5 million at September 30, 2022 and December 31, 2021, respectively. Such a maximum loss would be expected to occur only upon bankruptcy of the issuer or investee.

(2) For variable interests in Structured Products included within fixed maturity securities AFS, the Company’s involvement is limited to that of a passive investor in mortgage-backed or asset-backed securities issued by trusts that do not have substantial equity.

As described in Note 15, the Company makes commitments to fund partnership investments in the normal course of business. Excluding these commitments, the Company did not provide financial or other support to investees designated as VIEs for either the nine months ended September 30, 2022 or 2021.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

Net Investment Income

The composition of net investment income by asset type was as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
Asset Type	2022		2021		2022		2021
	(In millions)
Fixed maturity securities AFS	$	2,903	$	2,759	$	8,449	$	8,251
Equity securities	14		8		26		28
FVO Securities	( 43 )		6		( 197 )		92
Mortgage loans	899		838		2,556		2,586
Policy loans	115		118		345		359
Real estate and real estate joint ventures	284		279		991		660
Other limited partnership interests	( 194 )		1,541		900		3,870
Cash, cash equivalents and short-term investments	103		25		183		74
Operating joint ventures	12		17		61		55
Other	156		95		503		189
Subtotal investment income	4,249		5,686		13,817		16,164
Less: Investment expenses	343		232		858		701
Subtotal, net	3,906		5,454		12,959		15,463
Unit-linked investments	( 321 )		114		( 1,507 )		699


Net investment income	$	3,585	$	5,568	$	11,452	$	16,162

Net investment income included realized and unrealized gains (losses) recognized in earnings of ($ 373 ) million and ($ 1.7 ) billion for the three months and nine months ended September 30, 2022, respectively, and $ 137 million and $ 811 million for the three months and nine months ended September 30, 2021, respectively. The amount includes realized gains (losses) on sales and disposals, primarily related to FVO securities (“FVO Securities”) and Unit-linked investments, of $ 30 million and $ 139 million for the three months and nine months ended September 30, 2022, respectively, and $ 146 million and $ 407 million for the three months and nine months ended September 30, 2021, respectively. The amount also includes unrealized gains (losses), representing changes in estimated fair value, recognized in earnings, primarily related to FVO Securities and Unit-linked investments, of ($ 403 ) million and ($ 1.8 ) billion for the three months and nine months ended September 30, 2022, respectively, and ($ 9 ) million and $ 404 million for the three months and nine months ended September 30, 2021, respectively.

Changes in estimated fair value subsequent to purchase of FVO Securities and Unit-linked investments still held at the end of the respective periods and included in net investment income were ($ 304 ) million and ($ 1.5 ) billion for the three months and nine months ended September 30, 2022, respectively, and $ 55 million and $ 577 million for the three months and nine months ended September 30, 2021, respectively.

Net investment income from equity method investments, comprised primarily of real estate joint ventures, other limited partnership interests, tax credit and renewable energy partnerships and operating joint ventures, was ($ 135 ) million and $ 1.3 billion for the three months and nine months ended September 30, 2022, respectively, and $ 1.7 billion and $ 4.0 billion for the three months and nine months ended September 30, 2021, respectively.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

Net Investment Gains (Losses)

Net Investment Gains (Losses) by Asset Type and Transaction Type

The composition of net investment gains (losses) by asset type and transaction type was as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
Asset Type	2022		2021		2022		2021
	(In millions)
Fixed maturity securities AFS	$	( 286 )	$	129	$	( 1,555 )	$	67



Equity securities	( 23 )		( 33 )		( 115 )		97



Mortgage loans	47		43		139		101
Real estate and real estate joint ventures (excluding changes in estimated fair value)	—		66		163		482
Other limited partnership interests (excluding changes in estimated fair value)	( 1 )		( 4 )		15		( 17 )
Other gains (losses)	54		20		230		66
Subtotal	( 209 )		221		( 1,123 )		796




Change in estimated fair value of other limited partnership interests and real estate joint ventures	( 18 )		9		( 12 )		23
Non-investment portfolio gains (losses)	( 187 )		( 314 )		( 482 )		836
Subtotal	( 205 )		( 305 )		( 494 )		859
Net investment gains (losses)	$	( 414 )	$	( 84 )	$	( 1,617 )	$	1,655

Transaction Type
Realized gains (losses) on investments sold or disposed	$	( 252 )	$	202	$	( 908 )	$	639
Impairments	( 3 )		( 11 )		( 38 )		( 24 )
Recognized gains (losses):
Change in allowance for credit loss recognized in earnings	72		35		( 87 )		18
Unrealized net gains (losses) recognized in earnings	( 44 )		4		( 102 )		186
Total recognized gains (losses)	28		39		( 189 )		204
Non-investment portfolio gains (losses)	( 187 )		( 314 )		( 482 )		836
Net investment gains (losses)	$	( 414 )	$	( 84 )	$	( 1,617 )	$	1,655

Net realized investment gains (losses) of ($ 222 ) million and ($ 769 ) million for the three months and nine months ended September 30, 2022, respectively, and $ 348 million and $ 1.0 billion for the three months and nine months ended September 30, 2021, respectively, represent realized gains (losses) on sales and disposals from all invested asset classes, including realized gains (losses) on sales and disposals recognized in net investment income, primarily related to FVO Securities and Unit-linked investments.

Changes in estimated fair value subsequent to purchase of equity securities still held as of the end of the period included in net investment gains (losses) were ($ 25 ) million and ($ 87 ) million for the three months and nine months ended September 30, 2022, respectively, and ($ 16 ) million and $ 86 million for the three months and nine months ended September 30, 2021, respectively.

Other gains (losses) included ($ 15 ) million and $ 45 million reclassified from AOCI to earnings due to the sale of certain investments that were hedged in qualifying cash flow hedges for the three months and nine months ended September 30, 2022, respectively, and $ 6 million and $ 54 million for the three months and nine months ended September 30, 2021, respectively.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Investments (continued)

Net investment gains (losses) includes gains (losses) from foreign currency transactions of ($ 67 ) million and ($ 81 ) million for the three months and nine months ended September 30, 2022, respectively, and ($ 23 ) million and ($ 4 ) million for the three months and nine months ended September 30, 2021, respectively.

Non-investment portfolio gains (losses) for the nine months ended September 30, 2021, include a gain of $ 1.4 billion on the disposition of Metropolitan Property and Casualty Insurance Company and certain of its wholly-owned subsidiaries (collectively, “MetLife P&C”). See Note 3 for information on non-investment portfolio losses relating to the disposition of MetLife Poland and Greece.

Fixed Maturity Securities AFS and Equity Securities – Composition of Net Investment Gains (Losses)

The composition of net investment gains (losses) for these securities is as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
Fixed Maturity Securities AFS	2022		2021		2022		2021
	(In millions)
Proceeds	$	15,484	$	10,743	$	50,218	$	37,306
Gross investment gains	$	124	$	217	$	464	$	580
Gross investment (losses)	( 457 )		( 106 )		( 1,861 )		( 497 )
Realized gains (losses) on sales and disposals	( 333 )		111		( 1,397 )		83
Net credit loss (provision) release (change in ACL recognized in earnings)	50		29		( 120 )		8
Impairment (loss)	( 3 )		( 11 )		( 38 )		( 24 )
Net credit loss (provision) release and impairment (loss)	47		18		( 158 )		( 16 )
Net investment gains (losses)	$	( 286 )	$	129	$	( 1,555 )	$	67

Equity Securities
Realized gains (losses) on sales and disposals	$	3	$	( 27 )	$	( 27 )	$	( 61 )
Unrealized net gains (losses) recognized in earnings	( 26 )		( 6 )		( 88 )		158
Net investment gains (losses)	$	( 23 )	$	( 33 )	$	( 115 )	$	97

7. Derivatives

Accounting for Derivatives

See Note 1 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report for a description of the Company’s accounting policies for derivatives and Note 8 for information about the fair value hierarchy for derivatives.

Derivative Strategies

Types of Derivative Instruments and Derivative Strategies

The Company is exposed to various risks relating to its ongoing business operations, including interest rate, foreign currency exchange rate, credit and equity market. The Company uses a variety of strategies to manage these risks, including the use of derivatives. Commonly used derivative instruments include, but are not limited to:

• Interest rate derivatives: swaps, total return swaps, caps, floors, futures, swaptions, forwards and synthetic guaranteed interest contracts (“GICs”);

• Foreign currency exchange rate derivatives: swaps, forwards, options and exchange-traded futures;

• Credit derivatives: purchased or written single name or index credit default swaps, and forwards; and

• Equity derivatives: index options, variance swaps, exchange-traded futures and total return swaps.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Derivat ives (continued)

For detailed information on these contracts and the related strategies, see Note 9 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report.

Primary Risks Managed by Derivatives

The following table presents the primary underlying risk exposure, gross notional amount and estimated fair value of the Company’s derivatives, excluding embedded derivatives, held at:


		September 30, 2022						December 31, 2021
	Primary Underlying Risk Exposure	Gross Notional Amount		Estimated Fair Value				Gross Notional Amount		Estimated Fair Value
				Assets		Liabilities				Assets		Liabilities
		(In millions)
Derivatives Designated as Hedging Instruments:
Fair value hedges:
Interest rate swaps	Interest rate	$	4,222	$	1,435	$	447	$	3,550	$	2,164	$	6
Foreign currency swaps	Foreign currency exchange rate	630		133		—		801		11		23
Foreign currency forwards	Foreign currency exchange rate	1,536		—		180		1,636		—		58
Subtotal		6,388		1,568		627		5,987		2,175		87
Cash flow hedges:
Interest rate swaps	Interest rate	4,107		6		43		4,117		6		1
Interest rate forwards	Interest rate	8,241		—		1,221		6,889		89		119
Foreign currency swaps	Foreign currency exchange rate	42,518		5,156		2,545		41,095		1,600		1,557
Subtotal		54,866		5,162		3,809		52,101		1,695		1,677
Net investment in a foreign operation (“NIFO”) hedges:
Foreign currency forwards	Foreign currency exchange rate	245		33		—		—		—		—
Currency options	Foreign currency exchange rate	3,000		338		—		3,000		139		—
Subtotal		3,245		371		—		3,000		139		—
Total qualifying hedges		64,499		7,101		4,436		61,088		4,009		1,764
Derivatives Not Designated or Not Qualifying as Hedging Instruments:
Interest rate swaps	Interest rate	32,464		1,712		1,116		38,860		3,644		115
Interest rate floors	Interest rate	17,071		60		—		7,701		145		—
Interest rate caps	Interest rate	65,409		1,063		—		65,559		124		—
Interest rate futures	Interest rate	1,394		2		6		1,615		4		—
Interest rate options	Interest rate	23,885		641		45		11,754		493		10
Interest rate forwards	Interest rate	647		—		139		374		—		26
Interest rate total return swaps	Interest rate	1,048		—		99		1,048		9		4
Synthetic GICs	Interest rate	45,066		—		—		40,121		—		—
Foreign currency swaps	Foreign currency exchange rate	13,002		1,974		509		12,787		768		614
Foreign currency forwards	Foreign currency exchange rate	16,565		217		1,346		16,230		36		666
Currency futures	Foreign currency exchange rate	665		—		4		839		—		2
Currency options	Foreign currency exchange rate	—		—		—		900		—		—
Credit default swaps — purchased	Credit	2,993		32		79		3,042		13		113
Credit default swaps — written	Credit	13,059		78		89		8,626		177		12
Equity futures	Equity market	2,966		29		5		4,204		12		5
Equity index options	Equity market	23,431		1,076		299		29,743		1,004		458
Equity variance swaps	Equity market	692		18		13		699		17		13
Equity total return swaps	Equity market	2,985		190		—		3,025		11		50
Total non-designated or nonqualifying derivatives		263,342		7,092		3,749		247,127		6,457		2,088
Total		$	327,841	$	14,193	$	8,185	$	308,215	$	10,466	$	3,852

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Derivat ives (continued)

Based on gross notional amounts, a substantial portion of the Company’s derivatives was not designated or did not qualify as part of a hedging relationship a t both September 30, 2022 and December 31, 2021. The Company’s use of derivatives includes (i) derivatives that serve as macro hedges of the Company’s exposure to various risks and that generally do not qualify for hedge accounting due to the criteria required under the portfolio hedging rules, (ii) derivatives that economically hedge insurance liabilities that contain mortality or morbidity risk and that generally do not qualify for hedge accounting because the lack of these risks in the derivatives cannot support an expectation of a highly effective hedging relationship, (iii) derivatives that economically hedge embedded derivatives that do not qualify for hedge accounting because the changes in estimated fair value of the embedded derivatives are already recorded in net income, and (iv) written credit default swaps and interest rate swaps that are used to synthetically create investments and that do not qualify for hedge accounting because they do not involve a hedging relationship. For these nonqualified derivatives, changes in market factors can lead to the recognition of fair value changes on the statement of operations without an offsetting gain or loss recognized in earnings for the item being hedged.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Derivat ives (continued)

The Effects of Derivatives on the Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

The following table presents the interim condensed consolidated financial statement location and amount of gain (loss) recognized on fair value, cash flow, NIFO, nonqualifying hedging relationships and embedded derivatives:


	Three Months Ended September 30, 2022
	Net Investment Income		Net Investment Gains (Losses)		Net Derivative Gains (Losses)		Policyholder Benefits and Claims		Interest Credited to Policyholder Account Balances		Other Expenses		OCI
	(In millions)
Gain (Loss) on Fair Value Hedges:
Interest rate derivatives:
Derivatives designated as hedging instruments (1)	$	2	$	—	$	—	$	( 299 )	$	( 16 )	$	—	N/A
Hedged items	( 1 )		—		—		271		15		—		N/A
Foreign currency exchange rate derivatives:
Derivatives designated as hedging instruments (1)	67		( 97 )		—		—		—		—		N/A
Hedged items	( 68 )		94		—		—		—		—		N/A
Amount excluded from the assessment of hedge effectiveness	—		20		—		—		—		—		N/A
Subtotal	—		17		—		( 28 )		( 1 )		—		N/A
Gain (Loss) on Cash Flow Hedges:
Interest rate derivatives: (1)
Amount of gains (losses) deferred in AOCI	N/A		N/A		N/A		N/A		N/A		N/A		$	( 500 )
Amount of gains (losses) reclassified from AOCI into income	15		( 16 )		—		—		—		1		—
Foreign currency exchange rate derivatives: (1)
Amount of gains (losses) deferred in AOCI	N/A		N/A		N/A		N/A		N/A		N/A		1,475
Amount of gains (losses) reclassified from AOCI into income	1		( 567 )		—		—		—		—		566
Foreign currency transaction gains (losses) on hedged items	—		558		—		—		—		—		—
Credit derivatives: (1)
Amount of gains (losses) deferred in AOCI	N/A		N/A		N/A		N/A		N/A		N/A		—
Amount of gains (losses) reclassified from AOCI into income	—		—		—		—		—		—		—
Subtotal	16		( 25 )		—		—		—		1		1,541
Gain (Loss) on NIFO Hedges:
Foreign currency exchange rate derivatives (1)	N/A		N/A		N/A		N/A		N/A		N/A		29
Non-derivative hedging instruments	N/A		N/A		N/A		N/A		N/A		N/A		19
Subtotal	N/A		N/A		N/A		N/A		N/A		N/A		48
Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments:
Interest rate derivatives (1)	—		—		( 649 )		( 40 )		—		—		N/A
Foreign currency exchange rate derivatives (1)	—		—		( 53 )		( 2 )		—		—		N/A
Credit derivatives — purchased (1)	—		—		7		—		—		—		N/A
Credit derivatives — written (1)	—		—		1		—		—		—		N/A
Equity derivatives (1)	8		—		215		64		—		—		N/A
Foreign currency transaction gains (losses) on hedged items	—		—		( 19 )		—		—		—		N/A
Subtotal	8		—		( 498 )		22		—		—		N/A
Earned income on derivatives	107		—		254		33		( 41 )		—		—
Embedded derivatives (2)	N/A		N/A		( 236 )		—		N/A		N/A		N/A
Total	$	131	$	( 8 )	$	( 480 )	$	27	$	( 42 )	$	1	$	1,589

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Derivat ives (continued)


	Three Months Ended September 30, 2021
	Net Investment Income		Net Investment Gains (Losses)		Net Derivative Gains (Losses)		Policyholder Benefits and Claims		Interest Credited to Policyholder Account Balances		Other Expenses		OCI
	(In millions)
Gain (Loss) on Fair Value Hedges:
Interest rate derivatives:
Derivatives designated as hedging instruments (1)	$	1	$	—	$	—	$	( 53 )	$	—	$	—	N/A
Hedged items	( 2 )		—		—		48		—		—		N/A
Foreign currency exchange rate derivatives:
Derivatives designated as hedging instruments (1)	28		( 9 )		—		—		—		—		N/A
Hedged items	( 22 )		9		—		—		—		—		N/A
Amount excluded from the assessment of hedge effectiveness	—		( 2 )		—		—		—		—		N/A
Subtotal	5		( 2 )		—		( 5 )		—		—		N/A
Gain (Loss) on Cash Flow Hedges:
Interest rate derivatives: (1)
Amount of gains (losses) deferred in AOCI	N/A		N/A		N/A		N/A		N/A		N/A		$	24
Amount of gains (losses) reclassified from AOCI into income	14		6		—		—		—		1		( 21 )
Foreign currency exchange rate derivatives: (1)
Amount of gains (losses) deferred in AOCI	N/A		N/A		N/A		N/A		N/A		N/A		398
Amount of gains (losses) reclassified from AOCI into income	2		( 259 )		—		—		—		—		257
Foreign currency transaction gains (losses) on hedged items	—		256		—		—		—		—		—
Credit derivatives: (1)
Amount of gains (losses) deferred in AOCI	N/A		N/A		N/A		N/A		N/A		N/A		20
Amount of gains (losses) reclassified from AOCI into income	—		—		—		—		—		—		—
Subtotal	16		3		—		—		—		1		678
Gain (Loss) on NIFO Hedges:
Foreign currency exchange rate derivatives (1)	N/A		N/A		N/A		N/A		N/A		N/A		12
Non-derivative hedging instruments	N/A		N/A		N/A		N/A		N/A		N/A		2
Subtotal	N/A		N/A		N/A		N/A		N/A		N/A		14
Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments:
Interest rate derivatives (1)	( 1 )		—		( 379 )		( 12 )		—		—		N/A
Foreign currency exchange rate derivatives (1)	—		—		( 128 )		( 2 )		—		—		N/A
Credit derivatives — purchased (1)	—		—		4		—		—		—		N/A
Credit derivatives — written (1)	—		—		( 2 )		—		—		—		N/A
Equity derivatives (1)	( 1 )		—		47		5		—		—		N/A
Foreign currency transaction gains (losses) on hedged items	—		—		( 65 )		—		—		—		N/A
Subtotal	( 2 )		—		( 523 )		( 9 )		—		—		N/A
Earned income on derivatives	62		—		258		55		( 43 )		—		—
Embedded derivatives (2)	N/A		N/A		47		—		N/A		N/A		N/A
Total	$	81	$	1	$	( 218 )	$	41	$	( 43 )	$	1	$	692

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Derivat ives (continued)


	Nine Months Ended September 30, 2022
	Net Investment Income		Net Investment Gains (Losses)		Net Derivative Gains (Losses)		Policyholder Benefits and Claims		Interest Credited to Policyholder Account Balances		Other Expenses		OCI
	(In millions)
Gain (Loss) on Fair Value Hedges:
Interest rate derivatives:
Derivatives designated as hedging instruments (1)	$	9	$	—	$	—	$	( 1,159 )	$	( 26 )	$	—	N/A
Hedged items	( 9 )		—		—		1,094		24		—		N/A
Foreign currency exchange rate derivatives:
Derivatives designated as hedging instruments (1)	160		( 348 )		—		—		—		—		N/A
Hedged items	( 159 )		339		—		—		—		—		N/A
Amount excluded from the assessment of hedge effectiveness	—		81		—		—		—		—		N/A
Subtotal	1		72		—		( 65 )		( 2 )		—		N/A
Gain (Loss) on Cash Flow Hedges:
Interest rate derivatives: (1)
Amount of gains (losses) deferred in AOCI	N/A		N/A		N/A		N/A		N/A		N/A		$	( 2,167 )
Amount of gains (losses) reclassified from AOCI into income	46		44		—		—		—		3		( 93 )
Foreign currency exchange rate derivatives: (1)
Amount of gains (losses) deferred in AOCI	N/A		N/A		N/A		N/A		N/A		N/A		2,676
Amount of gains (losses) reclassified from AOCI into income	4		( 1,405 )		—		—		—		1		1,400
Foreign currency transaction gains (losses) on hedged items	—		1,386		—		—		—		—		—
Credit derivatives: (1)
Amount of gains (losses) deferred in AOCI	N/A		N/A		N/A		N/A		N/A		N/A		—
Amount of gains (losses) reclassified from AOCI into income	—		—		—		—		—		—		—
Subtotal	50		25		—		—		—		4		1,816
Gain (Loss) on NIFO Hedges:
Foreign currency exchange rate derivatives (1)	N/A		N/A		N/A		N/A		N/A		N/A		240
Non-derivative hedging instruments	N/A		N/A		N/A		N/A		N/A		N/A		75
Subtotal	N/A		N/A		N/A		N/A		N/A		N/A		315
Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments:
Interest rate derivatives (1)	3		—		( 3,480 )		( 96 )		—		—		N/A
Foreign currency exchange rate derivatives (1)	2		—		( 791 )		( 4 )		—		—		N/A
Credit derivatives — purchased (1)	—		—		99		—		—		—		N/A
Credit derivatives — written (1)	—		—		( 244 )		—		—		—		N/A
Equity derivatives (1)	53		—		966		333		—		—		N/A
Foreign currency transaction gains (losses) on hedged items	—		—		275		—		—		—		N/A
Subtotal	58		—		( 3,175 )		233		—		—		N/A
Earned income on derivatives	330		—		738		131		( 113 )		—		—
Embedded derivatives (2)	N/A		N/A		( 97 )		—		N/A		N/A		N/A
Total	$	439	$	97	$	( 2,534 )	$	299	$	( 115 )	$	4	$	2,131

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Derivat ives (continued)


	Nine Months Ended September 30, 2021
	Net Investment Income		Net Investment Gains (Losses)		Net Derivative Gains (Losses)		Policyholder Benefits and Claims		Interest Credited to Policyholder Account Balances		Other Expenses		OCI
	(In millions)
Gain (Loss) on Fair Value Hedges:
Interest rate derivatives:
Derivatives designated as hedging instruments (1)	$	4	$	—	$	—	$	( 418 )	$	—	$	—	N/A
Hedged items	( 4 )		—		—		379		—		—		N/A
Foreign currency exchange rate derivatives:
Derivatives designated as hedging instruments (1)	40		( 144 )		—		—		—		—		N/A
Hedged items	( 33 )		139		—		—		—		—		N/A
Amount excluded from the assessment of hedge effectiveness	—		( 6 )		—		—		—		—		N/A
Subtotal	7		( 11 )		—		( 39 )		—		—		N/A
Gain (Loss) on Cash Flow Hedges:
Interest rate derivatives: (1)
Amount of gains (losses) deferred in AOCI	N/A		N/A		N/A		N/A		N/A		N/A		$	( 687 )
Amount of gains (losses) reclassified from AOCI into income	41		54		—		—		—		2		( 97 )
Foreign currency exchange rate derivatives: (1)
Amount of gains (losses) deferred in AOCI	N/A		N/A		N/A		N/A		N/A		N/A		567
Amount of gains (losses) reclassified from AOCI into income	6		( 383 )		—		—		—		1		376
Foreign currency transaction gains (losses) on hedged items	—		372		—		—		—		—		—
Credit derivatives: (1)
Amount of gains (losses) deferred in AOCI	N/A		N/A		N/A		N/A		N/A		N/A		( 52 )
Amount of gains (losses) reclassified from AOCI into income	—		—		—		—		—		—		—
Subtotal	47		43		—		—		—		3		107
Gain (Loss) on NIFO Hedges:
Foreign currency exchange rate derivatives (1)	N/A		N/A		N/A		N/A		N/A		N/A		58
Non-derivative hedging instruments	N/A		N/A		N/A		N/A		N/A		N/A		31
Subtotal	N/A		N/A		N/A		N/A		N/A		N/A		89
Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments:
Interest rate derivatives (1)	1		—		( 1,993 )		( 51 )		—		—		N/A
Foreign currency exchange rate derivatives (1)	—		—		( 734 )		1		—		—		N/A
Credit derivatives — purchased (1)	—		—		16		—		—		—		N/A
Credit derivatives — written (1)	—		—		33		—		—		—		N/A
Equity derivatives (1)	( 33 )		—		( 992 )		( 202 )		—		—		N/A
Foreign currency transaction gains (losses) on hedged items	—		—		167		—		—		—		N/A
Subtotal	( 32 )		—		( 3,503 )		( 252 )		—		—		N/A
Earned income on derivatives	128		—		755		160		( 120 )		—		—
Embedded derivatives (2)	N/A		N/A		716		—		N/A		N/A		N/A
Total	$	150	$	32	$	( 2,032 )	$	( 131 )	$	( 120 )	$	3	$	196

__________________

(1) Excludes earned income on derivatives.

(2) The valuation of guaranteed minimum benefits includes a nonperformanc e risk adjustment. The amounts included in net derivative gains (losses) in connection with this adjustment were $ 39 million and $ 43 million for the three months and nine months ended September 30, 2022, respectively, and $ 3 million and ($ 48 ) million for the three months and nine months ended September 30, 2021, respectively.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Derivat ives (continued)

Fair Value Hedges

The Company designates and accounts for the following as fair value hedges when they have met the requirements of fair value hedging: (i) interest rate swaps to convert fixed rate assets and liabilities to floating rate assets and liabilities, (ii) foreign currency swaps to hedge the foreign currency fair value exposure of foreign currency denominated assets and liabilities, and (iii) foreign currency forwards to hedge the foreign currency fair value exposure of foreign currency denominated investments.

The following table presents the balance sheet classification, carrying amount and cumulative fair value hedging adjustments for items designated and qualifying as hedged items in fair value hedges:


Balance Sheet Line Item	Carrying Amount of the Hedged Assets/(Liabilities)				Cumulative Amount of Fair Value Hedging Adjustments Included in the Carrying Amount of Hedged Assets/(Liabilities) (1)
	September 30, 2022		December 31, 2021		September 30, 2022		December 31, 2021
	(In millions)
Fixed maturity securities AFS	$	1,607	$	2,164	$	1	$	( 1 )
Mortgage loans	$	286	$	634	$	( 20 )	$	3
Future policy benefits	$	( 3,681 )	$	( 4,735 )	$	237	$	( 877 )
Policyholder account balances	$	( 1,074 )	$	—	$	24	$	—

__________________

(1) Includ es ($ 142 ) million and ($ 161 ) million of hedging adjustments on discontinued hedging relationships at September 30, 2022 and December 31, 2021, respectively.

For the Company’s foreign currency forwards, the change in the estimated fair value of the derivative related to the changes in the difference between the spot price and the forward price is excluded from the assessment of hedge effectiveness. The Company has elected to record changes in estimated fair value of excluded components in earnings. For all other derivatives, all components of each derivative’s gain or loss were included in the assessment of hedge effectiveness.

Cash Flow Hedges

The Company designates and accounts for the following as cash flow hedges when they have met the requirements of cash flow hedging: (i) interest rate swaps to convert floating rate assets and liabilities to fixed rate assets and liabilities, (ii) foreign currency swaps to hedge the foreign currency cash flow exposure of foreign currency denominated assets and liabilities, (iii) interest rate forwards and credit forwards to lock in the price to be paid for forward purchases of investments, and (iv) interest rate swaps and interest rate forwards to hedge the forecasted purchases of fixed-rate investments.

In certain instances, the Company discontinued cash flow hedge accounting because the forecasted transactions were no longer probable of occurring. Because certain of the forecasted transactions also were not probable of occurring within two months of the anticipated date, the Company reclassified amounts from AOCI into income. These amounts were $ 19 million and $ 21 million for the three months and nine months ended September 30, 2022, respectively, and $ 6 million and $ 5 million for the three months and nine months ended September 30, 2021, respectively.

At both September 30, 2022 and December 31, 2021, the maximum length of time over which the Company was hedging its exposure to variability in future cash flows for forecasted transactions did not exceed seven years .

At September 30, 2022 and December 31, 2021, the balance in AOCI associated with cash flow hedges was $ 3.9 billion and $ 2.1 billion, respectively.

All components of each derivative’s gain or loss were included in the assessment of hedge effectiveness.

At September 30, 2022, the Company expected to reclassify $ 372 million of deferred net gains (losses) on derivatives in AOCI to earnings within the next 12 months.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Derivat ives (continued)

NIFO Hedges

The Company uses foreign currency exchange rate derivatives, which may include foreign currency forwards and currency options, to hedge portions of its net investments in foreign operations against adverse movements in exchange rates. The Company also designates a portion of its foreign-denominated debt as a non-derivative hedging instrument of its net investments in foreign operations. The Company assesses hedge effectiveness of its derivatives based upon the change in forward rates and assesses its non-derivative hedging instruments based upon the change in spot rates. All components of ea ch derivative’s gain or loss were included in the assessment of hedge effectiveness.

When net investments in foreign operations are sold or substantially liquidated, the amounts in AOCI are reclassified to the statement of operations.

At September 30, 2022 and December 31, 2021, the cumulative foreign currency translation gain (loss) recorded in AOCI related to NIFO hedges was $ 618 million and $ 303 million, respectively. At September 30, 2022 and December 31, 2021, the carrying amount of debt designated as a non-deriva tive hedging instrument was $ 290 million a nd $ 365 million, respectively.

Credit Derivatives

In connection with synthetically created credit investment transactions, the Company writes credit default swaps for which it receives a premium to insure credit risk. Such credit derivatives are included within the effects of derivatives on the interim condensed consolidated statements of operations and comprehensive income (loss) table. If a credit event occurs, as defined by the contract, the contract may be cash settled or it may be settled gross by the Company paying the counterparty the specified swap notional amount in exchange for the delivery of par quantities of the referenced credit obligation. The Company can terminate these contracts at any time through cash settlement with the counterparty at an amount equal to the then current estimated fair value of the credit default swaps.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Derivat ives (continued)

The following table presents the estimated fair value, maximum amount of future payments and weighted average years to maturity of written credit default swaps at:


	September 30, 2022					December 31, 2021
Rating Agency Designation of Referenced Credit Obligations (1)	Estimated Fair Value of Credit Default Swaps		Maximum Amount of Future Payments under Credit Default Swaps		Weighted Average Years to Maturity (2)	Estimated Fair Value of Credit Default Swaps		Maximum Amount of Future Payments under Credit Default Swaps		Weighted Average Years to Maturity (2)
	(Dollars in millions)
Aaa/Aa/A
Single name credit default swaps (3)	$	2	$	158	2.4	$	4	$	159	3.1
Credit default swaps referencing indices	51		4,404		3.5	17		1,191		2.5
Subtotal	53		4,562		3.5	21		1,350		2.6
Baa
Single name credit default swaps (3)	1		81		2.7	2		101		3.4
Credit default swaps referencing indices	( 55 )		8,207		5.3	146		6,988		5.0
Subtotal	( 54 )		8,288		5.2	148		7,089		5.0
Ba
Single name credit default swaps (3)	1		62		1.6	1		82		1.2
Credit default swaps referencing indices	1		25		4.2	( 1 )		20		5.0
Subtotal	2		87		2.4	—		102		2.0
B

Credit default swaps referencing indices	—		92		3.8	5		55		4.0
Subtotal	—		92		3.8	5		55		4.0
Caa3

Credit default swaps referencing indices	( 12 )		30		3.7	( 9 )		30		4.5
Subtotal	( 12 )		30		3.7	( 9 )		30		4.5
Total	$	( 11 )	$	13,059	4.6	$	165	$	8,626	4.6

_________________

(1) The rating agency designations are based on availability and the midpoint of the applicable ratings among Moody’s Investors Service (“Moody’s”), S&P Global Ratings (“S&P”) and Fitch Ratings. If no rating is available from a rating agency, then an internally developed rating is used.

(2) The weighted average years to maturity of the credit default swaps is calculated based on weighted average gross notional amounts.

(3) Single name credit default swaps may be referenced to the credit of corporations, foreign governments, or municipals.

Credit Risk on Freestanding Derivatives

The Company may be exposed to credit-related losses in the event of nonperformance by its counterparties to derivatives. Generally, the current credit exposure of the Company’s derivatives is limited to the net positive estimated fair value of derivatives at the reporting date after taking into consideration the existence of master netting or similar agreements and any collateral received pursuant to such agreements.

Derivatives may be exchange-traded or contracted in the over-the-counter (“OTC”) market. Certain of the Company’s OTC derivatives are cleared and settled through central clearinghouses (“OTC-cleared”), while others are bilateral contracts between two counterparties (“OTC-bilateral”).

The Company manages its credit risk related to derivatives by entering into transactions with creditworthy counterparties in jurisdictions in which it understands that close-out netting should be enforceable and establishing and monitoring exposure limits. The Company’s OTC-bilateral derivative transactions are governed by International Swaps and Derivatives

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Derivat ives (continued)

Association, Inc. (“ISDA”) Master Agreements which provide for legally enforceable set-off and close-out netting of exposures to specific counterparties in the event of early termination of a transaction, which includes, but is not limited to, events of default and bankruptcy. In the event of an early termination, close-out netting permits the Company (subject to financial regulations such as the Orderly Liquidation Authority under Title II of Dodd-Frank) to set off receivables from the counterparty against payables to the same counterparty arising out of all included transactions and to apply collateral to the obligations, without application of the automatic stay, upon the counterparty’s bankruptcy. All of the Company’s ISDA Master Agreements also include Credit Support Annex provisions which require both the pledging and accepting of collateral in connection with its OTC-bilateral derivatives as required by applicable law. Additionally, effective September 1, 2021, the Company is required to pledge initial margin for certain new OTC-bilateral derivative transactions to third party custodians.

The Company’s OTC-cleared derivatives are effected through central clearing counterparties and its exchange-traded derivatives are effected through regulated exchanges. Such positions are marked to market and margined on a daily basis (both initial margin and variation margin), and the Company has minimal exposure to credit-related losses in the event of nonperformance by brokers and central clearinghouses to such derivatives.

See Note 8 for a description of the impact of credit risk on the valuation of derivatives.

The estimated fair values of the Company’s net derivative assets and net derivative liabilities after the application of master netting agreements and collateral were as follows at:


	September 30, 2022				December 31, 2021
Derivatives Subject to a Master Netting Arrangement or a Similar Arrangement	Assets		Liabilities		Assets		Liabilities
	(In millions)
Gross estimated fair value of derivatives:
OTC-bilateral (1)	$	14,315	$	7,949	$	10,132	$	3,798
OTC-cleared (1)	34		255		448		24
Exchange-traded	31		15		16		7
Total gross estimated fair value of derivatives presented on the interim condensed consolidated balance sheets (1)	14,380		8,219		10,596		3,829
Gross amounts not offset on the interim condensed consolidated balance sheets:
Gross estimated fair value of derivatives: (2)
OTC-bilateral	( 5,429 )		( 5,429 )		( 2,204 )		( 2,204 )
OTC-cleared	( 11 )		( 11 )		( 6 )		( 6 )
Exchange-traded	( 4 )		( 4 )		( 2 )		( 2 )
Cash collateral: (3), (4)
OTC-bilateral	( 7,344 )		—		( 6,948 )		—
OTC-cleared	—		( 169 )		( 421 )		( 13 )
Exchange-traded	—		( 6 )		—		( 3 )
Securities collateral: (5)
OTC-bilateral	( 1,426 )		( 2,408 )		( 891 )		( 1,473 )
OTC-cleared	—		( 75 )		—		( 5 )
Exchange-traded	—		( 5 )		—		( 2 )
Net amount after application of master netting agreements and collateral	$	166	$	112	$	124	$	121

__________________

(1) At September 30, 2022 and December 31, 2021, derivative assets included income (expense) accruals reported in accrued investment income or in other liabilities of $ 187 million an d $ 130 million , respectively, and derivative liabilities included (income) expense accruals reported in accrued investment income or in other liabilities of $ 34 million and ($ 23 ) million, respectively.

(2) Estimated fair value of derivatives is limited to the amount that is subject to set-off and includes income or expense accruals.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Derivat ives (continued)

(3) Cash collateral received by the Company for OTC-bilateral and OTC-cleared derivatives, where the centralized clearinghouse treats variation margin as collateral, is included in cash and cash equivalents, short-term investments or in fixed maturity securities AFS, and the obligation to return it is included in payables for collateral under securities loaned and other transactions on the balance sheet. For certain collateral agreements, cash collateral is pledged to the Company as initial margin on its OTC-bilateral derivatives.

(4) The receivable for the return of cash collateral provided by the Company is inclusive of initial margin on exchange-traded and OTC-cleared derivatives and is included in premiums, reinsurance and other receivables on the balance sheet. The amount of cash collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements. At September 30, 2022 and December 31, 2021, the Company received excess cash collateral of $ 950 million and $ 172 million, respectively, and provided excess cash collateral of $ 127 million and $ 126 million, respectively, which is not included in the table above due to the foregoing limitation.

(5) Securities collateral received by the Company is held in separate custodial accounts and is not recorded on the balance sheet. Subject to certain constraints, the Company is permitted by contract to sell or re-pledge this collateral, but at September 30, 2022, none of the collateral had been sold or re-pledged. Securities collateral pledged by the Company is reported in fixed maturity securities AFS on the balance sheet. Subject to certain constraints, the counterparties are permitted by contract to sell or re-pledge this collateral. The amount of securities collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements and cash collateral. At September 30, 2022 and December 31, 2021, the Company received excess securities collateral with an estimated fair value o f $ 283 million an d $ 160 million, respectively, for its OTC-bilateral derivatives, which are not included in the table above due to the foregoing limitation. At September 30, 2022 and December 31, 2021, the Company provided excess securities collateral with an estimated fair value of $ 1.4 billion and $ 243 million, respectively, for its OTC-bilateral derivatives, $ 942 million and $ 1.2 billion, respectively, for its OTC-cleared derivatives, and $ 136 million and $ 185 million, respectively, for its exchange-traded derivatives, which are not included in the table above due to the foregoing limitation.

The Company’s collateral arrangements for its OTC-bilateral derivatives generally require the counterparty in a net liability position, after considering the effect of netting agreements, to pledge collateral when the collateral amount owed by that counterparty reaches a minimum transfer amount. Substantially all of the Company’s netting agreements for derivatives contain provisions that require both the Company and the counterparty to maintain a specific investment grade credit rating from each of Moody’s and S&P. If a party’s credit or financial strength rating, as applicable, were to fall below that specific investment grade credit rating, that party would be in violation of these provisions, and the other party to the derivatives could terminate the transactions and demand immediate settlement and payment based on such party’s reasonable valuation of the derivatives. A small number of these arrangements also include credit-contingent provisions that include a threshold above which collateral must be posted. Such agreements provide for a reduction of these thresholds (on a sliding scale that converges toward zero) in the event of downgrades in the credit ratings of MetLife, Inc. and/or the counterparty. At September 30, 2022, the amount of collateral not provided by the Company due to the existence of these thresholds was $ 15 million.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Derivat ives (continued)

The following table presents the estimated fair value of the Company’s OTC-bilateral derivatives that were in a net liability position after considering the effect of netting agreements, together with the estimated fair value and balance sheet location of the collateral pledged.


	September 30, 2022						December 31, 2021
	Derivatives Subject to Credit- Contingent Provisions		Derivatives Not Subject to Credit- Contingent Provisions		Total		Derivatives Subject to Credit- Contingent Provisions		Derivatives Not Subject to Credit- Contingent Provisions		Total
	(In millions)
Estimated fair value of derivatives in a net liability position (1)	$	2,360	$	160	$	2,520	$	1,386	$	209	$	1,595
Estimated fair value of collateral provided:
Fixed maturity securities AFS	$	2,626	$	124	$	2,750	$	1,370	$	221	$	1,591

__________________

(1) After taking into consideration the existence of netting agreements.

Embedded Derivatives

The Company issues certain products or purchases certain investments that contain embedded derivatives that are required to be separated from their host contracts and accounted for as freestanding derivatives.

The following table presents the estimated fair value and balance sheet location of the Company’s embedded derivatives that have been separated from their host contracts at:


	Balance Sheet Location	September 30, 2022		December 31, 2021
		(In millions)
Embedded derivatives within asset host contracts:
Ceded guaranteed minimum benefits	Premiums, reinsurance and other receivables	$	27	$	38
Embedded derivatives within liability host contracts:
Direct guaranteed minimum benefits	Policyholder account balances	$	578	$	324
Assumed guaranteed minimum benefits	Policyholder account balances	99		98
Funds withheld and guarantees on reinsurance	Other liabilities	( 36 )		57
Fixed annuities with equity indexed returns	Policyholder account balances	126		165
Other guarantees	Policyholder account balances	—		5
Embedded derivatives within liability host contracts		$	767	$	649

8. Fair Value

Considerable judgment is often required in interpreting the market data used to develop estimates of fair value, and the use of different assumptions or valuation methodologies may have a material effect on the estimated fair value amounts.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Fair Value (continued)

Recurring Fair Value Measurements

The assets and liabilities measured at estimated fair value on a recurring basis and their corresponding placement in the fair value hierarchy, including those items for which the Company has elected the FVO, are presented below at:


	September 30, 2022
	Fair Value Hierarchy
	Level 1		Level 2		Level 3		Total Estimated Fair Value
	(In millions)
Assets
Fixed maturity securities AFS:
U.S. corporate	$	—	$	68,532	$	10,292	$	78,824
Foreign corporate	—		39,718		10,209		49,927
Foreign government	—		43,989		61		44,050
U.S. government and agency	15,493		16,069		—		31,562
RMBS	94		24,684		2,367		27,145
ABS & CLO	—		14,792		1,974		16,766
Municipals	—		12,014		—		12,014
CMBS	—		9,773		704		10,477
Total fixed maturity securities AFS	15,587		229,571		25,607		270,765
Equity securities	592		212		169		973
Unit-linked and FVO Securities (2)	6,541		1,690		723		8,954
Short-term investments (3)	4,073		735		5		4,813
Residential mortgage loans — FVO	—		—		—		—
Other investments	—		176		922		1,098
Derivative assets: (4)
Interest rate	2		4,917		—		4,919
Foreign currency exchange rate	—		7,825		26		7,851
Credit	—		41		69		110
Equity market	29		1,277		7		1,313
Total derivative assets	31		14,060		102		14,193
Embedded derivatives within asset host contracts (5)	—		—		27		27
Separate account assets (6)	56,923		77,612		1,236		135,771
Total assets (7)	$	83,747	$	324,056	$	28,791	$	436,594
Liabilities
Derivative liabilities: (4)
Interest rate	$	6	$	2,584	$	526	$	3,116
Foreign currency exchange rate	4		4,369		211		4,584
Credit	—		132		36		168
Equity market	5		312		—		317
Total derivative liabilities	15		7,397		773		8,185
Embedded derivatives within liability host contracts (5)	—		—		767		767
Separate account liabilities (6)	12		17		21		50
Total liabilities	$	27	$	7,414	$	1,561	$	9,002

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Fair Value (continued)


	December 31, 2021 (1)
	Fair Value Hierarchy
	Level 1		Level 2		Level 3		Total Estimated Fair Value
	(In millions)
Assets
Fixed maturity securities AFS:
U.S. corporate	$	—	$	81,266	$	11,768	$	93,034
Foreign corporate	—		49,973		13,667		63,640
Foreign government	—		61,518		91		61,609
U.S. government and agency	25,482		21,117		—		46,599
RMBS	7		27,270		3,127		30,404
ABS & CLO	—		16,707		1,862		18,569
Municipals	—		14,212		—		14,212
CMBS	—		11,325		882		12,207
Total fixed maturity securities AFS	25,489		283,388		31,397		340,274
Equity securities	931		187		151		1,269
Unit-linked and FVO Securities (2)	9,173		2,068		901		12,142
Short-term investments (3)	5,607		950		3		6,560

Residential mortgage loans — FVO	—		—		127		127


Other investments	—		61		898		959
Derivative assets: (4)
Interest rate	4		6,577		97		6,678
Foreign currency exchange rate	—		2,551		3		2,554
Credit	—		173		17		190
Equity market	12		1,025		7		1,044
Total derivative assets	16		10,326		124		10,466
Embedded derivatives within asset host contracts (5)	—		—		38		38
Separate account assets (6)	76,312		101,424		2,137		179,873
Total assets (7)	$	117,528	$	398,404	$	35,776	$	551,708
Liabilities
Derivative liabilities: (4)
Interest rate	$	—	$	259	$	22	$	281
Foreign currency exchange rate	2		2,676		242		2,920
Credit	—		113		12		125
Equity market	5		521		—		526
Total derivative liabilities	7		3,569		276		3,852
Embedded derivatives within liability host contracts (5)	—		—		649		649
Separate account liabilities (6)	7		12		6		25
Total liabilities	$	14	$	3,581	$	931	$	4,526

__________________

(1) Excludes amounts reclassified to assets held-for-sale or liabilities held-for-sale. Assets held-for-sale and liabilities held-for-sale are valued on a basis consistent with similar assets and liabilities described herein. See Note 3 for information on the Company’s business dispositions.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Fair Value (continued)

(2) Contractholder-directed equity securities and FVO Securities (collectively, “Unit-linked and FVO Securities”) were primarily comprised of Unit-linked investments at both September 30, 2022 and December 31, 2021.

(3) Short-term investments as presented in the tables above differ from the amounts presented on the interim condensed consolidated balance sheets because certain short-term investments are not measured at estimated fair value on a recurring basis.

(4) Derivative assets are presented within other invested assets on the interim condensed consolidated balance sheets and derivative liabilities are presented within other liabilities on the interim condensed consolidated balance sheets. The amounts are presented gross in the tables above to reflect the presentation on the interim condensed consolidated balance sheets, but are presented net for purposes of the rollforward in the Fair Value Measurements Using Significant Unobservable Inputs (Level 3) tables.

(5) Embedded derivatives within asset host contracts are presented within premiums, reinsurance and other receivables on the interim condensed consolidated balance sheets. Embedded derivatives within liability host contracts are presented within policyholder account balances and other liabilities on the interim condensed consolidated balance sheets.

(6) Investment performance related to separate account assets is fully offset by corresponding amounts credited to contractholders whose liability is reflected within separate account liabilities. Separate account liabilities are set equal to the estimated fair value of separate account assets. Separate account liabilities presented in the tables above represent derivative liabilities.

(7) Total assets included in the fair value hierarchy exclude other limited partnership interests that are measured at estimated fair value using the net asset value (“NAV”) per share (or its equivalent) practical expedient. At September 30, 2022 and December 31, 2021, the estimated fair value of such investments was $ 72 million and $ 99 million, respectively.

The following describes the valuation methodologies used to measure assets and liabilities at fair value.

Investments

Securities, Short-term Investments and Other Investments

When available, the estimated fair value of these financial instruments is based on quoted prices in active markets that are readily and regularly obtainable. Generally, these are the most liquid of the Company’s securities holdings and valuation of these securities does not involve management’s judgment.

When quoted prices in active markets are not available, the determination of estimated fair value of securities is based on market standard valuation methodologies, giving priority to observable inputs. The significant inputs to the market standard valuation methodologies for certain types of securities with reasonable levels of price transparency are inputs that are observable in the market or can be derived principally from, or corroborated by, observable market data. When observable inputs are not available, the market standard valuation methodologies rely on inputs that are significant to the estimated fair value that are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. These unobservable inputs can be based in large part on management’s judgment or estimation and cannot be supported by reference to market activity. Unobservable inputs are based on management’s assumptions about the inputs market participants would use in pricing such investments.

The estimated fair value of short-term investments and other investments is determined on a basis consistent with the methodologies described herein.

The valuation approaches and key inputs for each category of assets or liabilities that are classified within Level 2 and Level 3 of the fair value hierarchy are presented below. The primary valuation approaches are the market approach, which considers recent prices from market transactions involving identical or similar assets or liabilities, and the income approach, which converts expected future amounts (e.g. cash flows) to a single current, discounted amount. The valuation of most instruments listed below is determined using independent pricing sources, matrix pricing, discounted cash flow methodologies or other similar techniques that use either observable market inputs or unobservable inputs.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Fair Value (continued)

Instrument

Level 2

Observable Inputs

Level 3

Unobservable Inputs

Fixed maturity securities AFS

U.S. corporate and Foreign corporate securities

Valuation Approaches: Principally the market and income approaches.

Valuation Approaches: Principally the market approach.

Key Inputs:

•

quoted prices in markets that are not active

•

illiquidity premium

•

benchmark yields; spreads off benchmark yields; new issuances; issuer ratings

•

delta spread adjustments to reflect specific credit-related issues

•

trades of identical or comparable securities; duration

•

credit spreads

•

privately-placed securities are valued using the additional key inputs:

•

quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2

•

market yield curve; call provisions

•

observable prices and spreads for similar public or private securities that incorporate the credit quality and industry sector of the issuer

•

independent non-binding broker quotations

•

delta spread adjustments to reflect specific credit-related issues

Foreign government securities, U.S. government and agency securities and Municipals

Valuation Approaches: Principally the market approach.

Key Inputs:

•

quoted prices in markets that are not active

•

independent non-binding broker quotations

•

benchmark U.S. Treasury yield or other yields

•

quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2

•

the spread off the U.S. Treasury yield curve for the identical security

•

issuer ratings and issuer spreads; broker-dealer quotations

•

credit spreads

•

comparable securities that are actively traded

Structured Products

Valuation Approaches: Principally the market and income approaches.

Key Inputs:

•

quoted prices in markets that are not active

•

credit spreads

•

spreads for actively traded securities; spreads off benchmark yields

•

quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2

•

expected prepayment speeds and volumes

•

current and forecasted loss severity; ratings; geographic region

•

independent non-binding broker quotations

•

weighted average coupon and weighted average maturity

•

credit ratings

•

average delinquency rates; DSCR

•

credit ratings

•

issuance-specific information, including, but not limited to:

•

collateral type; structure of the security; vintage of the loans

•

payment terms of the underlying assets

•

payment priority within the tranche; deal performance

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Fair Value (continued)

Instrument

Level 2

Observable Inputs

Level 3

Unobservable Inputs

Equity securities

Valuation Approaches: Principally the market approach.

Valuation Approaches: Principally the market and income approaches.

Key Input:

Key Inputs:

•

quoted prices in markets that are not considered active

•

credit ratings; issuance structures

•

quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2

•

independent non-binding broker quotations

Unit-linked and FVO Securities, Short-term investments and Other investments

Valuation Approaches: Principally the market and income approaches.

Key Inputs:

•

Unit-linked and FVO Securities include mutual fund interests without readily determinable fair values given prices are not published publicly. Valuation of these mutual funds is based upon quoted prices or reported NAV provided by the fund managers, which were based on observable inputs.

•

Unit-linked and FVO Securities, short-term investments and other investments are of a similar nature and class to the fixed maturity securities AFS and equity securities described above; accordingly, the valuation approaches and unobservable inputs used in their valuation are also similar to those described above. Other investments also include certain real estate joint ventures and use the valuation approach and key inputs as described for other limited partnership interests below.

•

Short-term investments and other investments are of a similar nature and class to the fixed maturity securities AFS and equity securities described above; accordingly, the valuation approaches and observable inputs used in their valuation are also similar to those described above.

Residential mortgage loans — FVO

•

N/A

Valuation Approaches: Principally the market approach.

Valuation Techniques and Key Inputs: These investments are based primarily on matrix pricing or other similar techniques that utilize inputs from mortgage servicers that are unobservable or cannot be derived principally from, or corroborated by, observable market data.

Separate account assets and Separate account liabilities (1)

Mutual funds and hedge funds without readily determinable fair values as prices are not published publicly

Key Input:

•

N/A

•

quoted prices or reported NAV provided by the fund managers

Other limited partnership interests

•

N/A

Valued giving consideration to the underlying holdings of the partnerships and adjusting, if appropriate.

Key Inputs:

•

liquidity; bid/ask spreads; performance record of the fund manager

•

other relevant variables that may impact the exit value of the particular partnership interest

__________________

(1) Estimated fair value equals carrying value, based on the value of the underlying assets, including: mutual fund interests, fixed maturity securities, equity securities, derivatives, hedge funds, other limited partnership interests, short-term investments and cash and cash equivalents. The estimated fair value of fixed maturity securities, equity securities, derivatives, short-term investments and cash and cash equivalents is determined on a basis consistent with the assets described under “— Securities, Short-term Investments and Other Investments” and “— Derivatives — Freestanding Derivatives.”

Derivatives

The estimated fair value of derivatives is determined through the use of quoted market prices for exchange-traded derivatives, or through the use of pricing models for OTC-bilateral and OTC-cleared derivatives. The determination of estimated fair value, when quoted market values are not available, is based on market standard valuation methodologies and inputs that management believes are consistent with what other market participants would use when pricing such instruments. Derivative valuations can be affected by changes in interest rates, foreign currency exchange rates, financial indices, credit spreads, default risk, nonperformance risk, volatility, liquidity and changes in estimates and assumptions used in the pricing models.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Fair Value (continued)

The significant inputs to the pricing models for most OTC-bilateral and OTC-cleared derivatives are inputs that are observable in the market or can be derived principally from, or corroborated by, observable market data. Certain OTC-bilateral and OTC-cleared derivatives may rely on inputs that are significant to the estimated fair value that are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. These unobservable inputs may involve significant management judgment or estimation. Unobservable inputs are based on management’s assumptions about the inputs market participants would use in pricing such derivatives.

Most inputs for OTC-bilateral and OTC-cleared derivatives are mid-market inputs but, in certain cases, liquidity adjustments are made when they are deemed more representative of exit value. Market liquidity, as well as the use of different methodologies, assumptions and inputs, may have a material effect on the estimated fair values of the Company’s derivatives and could materially affect net income.

The credit risk of both the counterparty and the Company are considered in determining the estimated fair value for all OTC-bilateral and OTC-cleared derivatives, and any potential credit adjustment is based on the net exposure by counterparty after taking into account the effects of netting agreements and collateral arrangements. The Company values its OTC-bilateral and OTC-cleared derivatives using standard swap curves which may include a spread to the risk-free rate, depending upon specific collateral arrangements. This credit spread is appropriate for those parties that execute trades at pricing levels consistent with similar collateral arrangements. As the Company and its significant derivative counterparties generally execute trades at such pricing levels and hold sufficient collateral, additional credit risk adjustments are not currently required in the valuation process. The Company’s ability to consistently execute at such pricing levels is, in part, due to the netting agreements and collateral arrangements that are in place with all of its significant derivative counterparties. An evaluation of the requirement to make additional credit risk adjustments is performed by the Company each reporting period.

Freestanding Derivatives

Level 2 Valuation Approaches and Key Inputs:

This level includes all types of derivatives utilized by the Company with the exception of exchange-traded derivatives included within Level 1 and those derivatives with unobservable inputs as described in Level 3.

Level 3 Valuation Approaches and Key Inputs:

These valuation methodologies generally use the same inputs as described in the corresponding sections for Level 2 measurements of derivatives. However, these derivatives result in Level 3 classification because one or more of the significant inputs are not observable in the market or cannot be derived principally from, or corroborated by, observable market data.

Freestanding derivatives are principally valued using the income approach. Valuations of non-option-based derivatives utilize present value techniques, whereas valuations of option-based derivatives utilize option pricing models. Key inputs are as follows:

Instrument

Interest Rate

Foreign Currency
Exchange Rate

Credit

Equity Market

Inputs common to Level 2 and Level 3 by instrument type

•

swap yield curves

•

swap yield curves

•

swap yield curves

•

swap yield curves

•

basis curves

•

basis curves

•

credit curves

•

spot equity index levels

•

interest rate volatility (1)

•

currency spot rates

•

recovery rates

•

dividend yield curves

•

cross currency basis curves

•

equity volatility (1)

•

currency volatility (1)

Level 3

•

swap yield curves (2)

•

swap yield curves (2)

•

swap yield curves (2)

•

dividend yield curves (2)

•

basis curves (2)

•

basis curves (2)

•

credit curves (2)

•

equity volatility (1), (2)

•

repurchase rates

•

cross currency basis curves (2)

•

credit spreads

•

correlation between model inputs (1)

•

interest rate volatility (1), (2)

•

currency correlation

•

repurchase rates

•

currency volatility (1)

•

independent non-binding broker quotations

__________________

(1) Option-based only.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Fair Value (continued)

(2) Extrapolation beyond the observable limits of the curve(s).

Embedded Derivatives

Embedded derivatives principally include certain direct, assumed and ceded variable annuity guarantees, annuity contracts, guarantees on reinsurance, and investment risk within funds withheld related to certain reinsurance agreements. Embedded derivatives are recorded at estimated fair value with changes in estimated fair value reported in net income.

The Company issues certain variable annuity products with guaranteed minimum benefits. GMWBs, GMABs and certain GMIBs contain embedded derivatives, which are measured at estimated fair value separately from the host variable annuity contract, with changes in estimated fair value reported in net derivative gains (losses). These embedded derivatives are classified within policyholder account balances on the interim condensed consolidated balance sheets.

The Company calculates the fair value of these embedded derivatives, which is estimated as the present value of projected future benefits minus the present value of projected future fees using actuarial and capital market assumptions including expectations concerning policyholder behavior. The calculation is based on in-force business, projecting future cash flows from the embedded derivative over multiple risk neutral stochastic scenarios using observable risk-free rates.

Capital market assumptions, such as risk-free rates and implied volatilities, are based on market prices for publicly traded instruments to the extent that prices for such instruments are observable. Implied volatilities beyond the observable period are extrapolated based on observable implied volatilities and historical volatilities. Actuarial assumptions, including mortality, lapse, withdrawal and utilization, are unobservable and are reviewed at least annually based on actuarial studies of historical experience.

The valuation of these guarantee liabilities includes nonperformance risk adjustments and adjustments for a risk margin related to non-capital market inputs. The nonperformance adjustment is determined by taking into consideration publicly available information relating to spreads in the secondary market for MetLife, Inc.’s debt, including related credit default swaps. These observable spreads are then adjusted, as necessary, to reflect the priority of these liabilities and the claims paying ability of the issuing insurance subsidiaries as compared to MetLife, Inc.

Risk margins are established to capture the non-capital market risks of the instrument which represent the additional compensation a market participant would require to assume the risks related to the uncertainties of such actuarial assumptions as annuitization, premium persistency, partial withdrawal and surrenders. The establishment of risk margins requires the use of significant management judgment, including assumptions of the amount and cost of capital needed to cover the guarantees. These guarantees may be more costly than expected in volatile or declining equity markets. Market conditions including, but not limited to, changes in interest rates, equity indices, market volatility and foreign currency exchange rates; changes in nonperformance risk; and variations in actuarial assumptions regarding policyholder behavior, mortality and risk margins related to non-capital market inputs, may result in significant fluctuations in the estimated fair value of the guarantees that could materially affect net income.

The Company ceded the risk associated with certain of the GMIBs previously described. These reinsurance agreements contain embedded derivatives which are included within premiums, reinsurance and other receivables on the interim condensed consolidated balance sheets with changes in estimated fair value reported in net derivative gains (losses) or policyholder benefits and claims depending on the statement of operations classification of the direct risk. The value of the embedded derivatives on the ceded risk is determined using a methodology consistent with that described previously for the guarantees directly written by the Company with the exception of the input for nonperformance risk that reflects the credit of the reinsurer.

The estimated fair value of the embedded derivatives within funds withheld related to certain ceded reinsurance is determined based on the change in estimated fair value of the underlying assets held by the Company in a reference portfolio backing the funds withheld liability. The estimated fair value of the underlying assets is determined as described in “— Investments — Securities, Short-term Investments and Other Investments.” The estimated fair value of guarantees related to reinsurance is determined based on multiple stochastic scenarios and includes a nonperformance risk adjustment. The estimated fair value of these embedded derivatives is included, along with their underlying host contracts, in other liabilities on the interim condensed consolidated balance sheets with changes in estimated fair value recorded in net derivative gains (losses). Changes in the credit spreads on the underlying assets, interest rates and market volatility may result in significant fluctuations in the estimated fair value of these embedded derivatives that could materially affect net income.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Fair Value (continued)

The Company issues certain annuity contracts which allow the policyholder to participate in returns from equity indices. These equity indexed features are embedded derivatives which are measured at estimated fair value separately from the host fixed annuity contract, with changes in estimated fair value reported in net derivative gains (losses). These embedded derivatives are classified within policyholder account balances on the interim condensed consolidated balance sheets.

The estimated fair value of the embedded equity indexed derivatives, based on the present value of future equity returns to the policyholder using actuarial and present value assumptions including expectations concerning policyholder behavior, is calculated by the Company’s actuarial department. The calculation is based on in-force business and uses standard capital market techniques, such as Black-Scholes, to calculate the value of the portion of the embedded derivative for which the terms are set. The portion of the embedded derivative covering the period beyond where terms are set is calculated as the present value of amounts expected to be spent to provide equity indexed returns in those periods. The valuation of these embedded derivatives also includes the establishment of a risk margin, as well as changes in nonperformance risk.

Embedded Derivatives Within Asset and Liability Host Contracts

Level 3 Valuation Approaches and Key Inputs:

Direct and assumed guaranteed minimum benefits

These embedded derivatives are principally valued using the income approach. Valuations are based on option pricing techniques, which utilize significant inputs that may include swap yield curves, currency exchange rates and implied volatilities. These embedded derivatives result in Level 3 classification because one or more of the significant inputs are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. Significant unobservable inputs generally include: the extrapolation beyond observable limits of the swap yield curves and implied volatilities, actuarial assumptions for policyholder behavior and mortality and the potential variability in policyholder behavior and mortality, nonperformance risk and cost of capital for purposes of calculating the risk margin.

Reinsurance ceded on certain guaranteed minimum benefits

These embedded derivatives are principally valued using the income approach. The valuation techniques and significant market standard unobservable inputs used in their valuation are similar to those described above in “— Direct and assumed guaranteed minimum benefits” and also include counterparty credit spreads.

Transfers between Levels

Overall, transfers between levels occur when there are changes in the observability of inputs and market activity.

Transfers into or out of Level 3:

Assets and liabilities are transferred into Level 3 when a significant input cannot be corroborated with market observable data. This occurs when market activity decreases significantly and underlying inputs cannot be observed, current prices are not available, and/or when there are significant variances in quoted prices, thereby affecting transparency. Assets and liabilities are transferred out of Level 3 when circumstances change such that a significant input can be corroborated with market observable data. This may be due to a significant increase in market activity, a specific event, or one or more significant input(s) becoming observable.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Fair Value (continued)

Assets and Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)

The following table presents certain quantitative information about the significant unobservable inputs used in the fair value measurement, and the sensitivity of the estimated fair value to changes in those inputs, for the more significant asset and liability classes measured at fair value on a recurring basis using significant unobservable inputs (Level 3) at:


					September 30, 2022				December 31, 2021				Impact of Increase in Input on Estimated Fair Value (2)
	Valuation Techniques		Significant Unobservable Inputs		Range			Weighted Average (1)	Range			Weighted Average (1)
Fixed maturity securities AFS (3)
U.S. corporate and foreign corporate	•	Matrix pricing	•	Offered quotes (4)	—	-	121	84	1	-	165	109	Increase
	•	Market pricing	•	Quoted prices (4)	5	-	126	93	—	-	117	100	Increase
	•	Consensus pricing	•	Offered quotes (4)	91	-	101	97	99	-	104	100	Increase
RMBS	•	Market pricing	•	Quoted prices (4)	—	-	113	91	—	-	121	99	Increase (5)
ABS & CLO	•	Market pricing	•	Quoted prices (4)	3	-	102	91	3	-	110	102	Increase (5)

Derivatives
Interest rate	•	Present value techniques	•	Swap yield (6)	369	-	379	374	151	-	200	188	Increase (7)
			•	Volatility (8)	— %	-	— %	— %	1 %	-	1 %	1 %	Increase (7)
Foreign currency exchange rate	•	Present value techniques	•	Swap yield (6)	29	-	1,938	335	2	-	305	134	Increase (7)
Credit	•	Present value techniques	•	Credit spreads (9)	86	-	148	105	96	-	133	109	Decrease (7)
	•	Consensus pricing	•	Offered quotes (10)
Embedded derivatives
Direct, assumed and ceded guaranteed minimum benefits	•	Option pricing techniques	•	Mortality rates:
				Ages 0 - 40	0 %	-	0.17 %	0.05 %	0 %	-	0.17 %	0.08 %	Decrease (11)
				Ages 41 - 60	0.03 %	-	0.75 %	0.21 %	0.03 %	-	0.75 %	0.27 %	Decrease (11)
				Ages 61 - 115	0.12 %	-	100 %	1.45 %	0.12 %	-	100 %	2.08 %	Decrease (11)
			•	Lapse rates:
				Durations 1 - 10	0 %	-	80 %	8.84 %	0.25 %	-	100 %	6.30 %	Decrease (12)
				Durations 11 - 20	0.50 %	-	80 %	6.46 %	0.50 %	-	100 %	5.22 %	Decrease (12)
				Durations 21 - 116	0.50 %	-	80 %	2.9 %	0.50 %	-	100 %	5.22 %	Decrease (12)





			•	Utilization rates	0 %	-	22 %	0.37 %	0 %	-	22 %	0.22 %	Increase (13)
			•	Withdrawal rates	0 %	-	20 %	4.00 %	0 %	-	20 %	3.72 %	(14)
			•	Long-term equity volatilities	8.58 %	-	25 %	18.49 %	7.69 %	-	25 %	18.60 %	Increase (15)
			•	Nonperformance risk spread	0.11 %	-	1.97 %	0.75 %	0.04 %	-	1.45 %	0.35 %	Decrease (16)

__________________

(1) The weighted average for fixed maturity securities AFS and derivatives is determined based on the estimated fair value of the securities and derivatives. The weighted average for embedded derivatives is determined based on a combination of account values and experience data.

(2) The impact of a decrease in input would have resulted in the opposite impact on estimated fair value. For embedded derivatives, changes to direct and assumed guaranteed minimum benefits are based on liability positions; changes to ceded guaranteed minimum benefits are based on asset positions.

(3) Significant increases (decreases) in expected default rates in isolation would have resulted in substantially lower (higher) valuations.

(4) Range and weighted average are presented in accordance with the market convention for fixed maturity securities AFS of dollars per hundred dollars of par.

(5) Changes in the assumptions used for the probability of default would have been accompanied by a directionally similar change in the assumption used for the loss severity and a directionally opposite change in the assumptions used for prepayment rates.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Fair Value (continued)

(6) Ranges represent the rates across different yield curves and are presented in basis points. The swap yield curves are utilized among different types of derivatives to project cash flows, as well as to discount future cash flows to present value. Since this valuation methodology uses a range of inputs across a yield curve to value the derivative, presenting a range is more representative of the unobservable input used in the valuation.

(7) Changes in estimated fair value are based on long U.S. dollar net asset positions and will be inversely impacted for short U.S. dollar net asset positions.

(8) Ranges represent the underlying interest rate volatility quoted in percentage points. Since this valuation methodology uses an equivalent of LIBOR for secured overnight financing rate volatility, presenting a range is more representative of the unobservable input used in the valuation.

(9) Represents the risk quoted in basis points of a credit default event on the underlying instrument. Credit derivatives with significant unobservable inputs are primarily comprised of written credit default swaps.

(10) At both September 30, 2022 and December 31, 2021, independent non-binding broker quotations were used in the determination of less than 1% of the total net derivative estimated fair value.

(11) Mortality rates vary by age and by demographic characteristics such as gender. Mortality rate assumptions are based on company experience. A mortality improvement assumption is also applied. For any given contract, mortality rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative.

(12) Base lapse rates are adjusted at the contract level based on a comparison of the actuarially calculated guaranteed values and the current policyholder account value, as well as other factors, such as the applicability of any surrender charges. A dynamic lapse function reduces the base lapse rate when the guaranteed amount is greater than the account value as in the money contracts are less likely to lapse. Lapse rates are also generally assumed to be lower in periods when a surrender charge applies. For any given contract, lapse rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative.

(13) The utilization rate assumption estimates the percentage of contractholders with GMIBs or a lifetime withdrawal benefit who will elect to utilize the benefit upon becoming eligible. The rates may vary by the type of guarantee, the amount by which the guaranteed amount is greater than the account value, the contract’s withdrawal history and by the age of the policyholder. For any given contract, utilization rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative.

(14) The withdrawal rate represents the percentage of account balance that any given policyholder will elect to withdraw from the contract each year. The withdrawal rate assumption varies by age and duration of the contract, and also by other factors such as benefit type. For any given contract, withdrawal rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative. For GMWBs, any increase (decrease) in withdrawal rates results in an increase (decrease) in the estimated fair value of the guarantees. For GMABs and GMIBs, any increase (decrease) in withdrawal rates results in a decrease (increase) in the estimated fair value.

(15) Long-term equity volatilities represent equity volatility beyond the period for which observable equity volatilities are available. For any given contract, long-term equity volatility rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative.

(16) Nonperformance risk spread varies by duration and by currency. For any given contract, multiple nonperformance risk spreads will apply, depending on the duration of the cash flow being discounted for purposes of valuing the embedded derivative.

Generally, all other classes of assets and liabilities classified within Level 3 that are not included in the preceding table use the same valuation techniques and significant unobservable inputs as previously described for Level 3. The sensitivity of the estimated fair value to changes in the significant unobservable inputs for these other assets and liabilities is similar in nature to that described in the preceding table.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Fair Value (continued)

The following tables summarize the change of all assets (liabilities) measured at estimated fair value on a recurring basis using significant unobservable inputs (Level 3):


	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	Fixed Maturity Securities AFS
	Corporate (6)		Foreign Government		Structured Products		Municipals		Equity Securities		Unit-linked and FVO Securities
	(In millions)
Three Months Ended September 30, 2022
Balance, beginning of period	$	22,582	$	103	$	5,347	$	—	$	179	$	742
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)	2		5		5		—		( 7 )		( 27 )
Total realized/unrealized gains (losses) included in AOCI	( 2,218 )		( 1 )		( 152 )		—		—		—
Purchases (3)	1,085		—		237		—		4		14
Sales (3)	( 486 )		( 2 )		( 199 )		—		( 7 )		( 6 )
Issuances (3)	—		—		—		—		—		—
Settlements (3)	—		—		—		—		—		—
Transfers into Level 3 (4)	209		—		39		—		—		—
Transfers out of Level 3 (4)	( 673 )		( 44 )		( 232 )		—		—		—
Balance, end of period	$	20,501	$	61	$	5,045	$	—	$	169	$	723
Three Months Ended September 30, 2021
Balance, beginning of period	$	23,773	$	145	$	6,003	$	—	$	143	$	849
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)	( 22 )		—		9		—		6		( 9 )
Total realized/unrealized gains (losses) included in AOCI	( 402 )		—		36		—		—		—
Purchases (3)	1,853		12		334		34		8		9
Sales (3)	( 475 )		( 10 )		( 401 )		—		( 5 )		( 8 )
Issuances (3)	—		—		—		—		—		—
Settlements (3)	—		—		—		—		—		—
Transfers into Level 3 (4)	242		10		6		—		—		—
Transfers out of Level 3 (4)	( 233 )		( 51 )		( 407 )		—		( 1 )		( 8 )
Balance, end of period	$	24,736	$	106	$	5,580	$	34	$	151	$	833
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2022 (5)	$	2	$	5	$	1	$	—	$	( 7 )	$	( 27 )
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2021 (5)	$	( 18 )	$	—	$	9	$	—	$	6	$	( 9 )
Changes in unrealized gains (losses) included in AOCI for the instruments still held at September 30, 2022 (5)	$	( 2,217 )	$	( 1 )	$	( 146 )	$	—	$	—	$	—
Changes in unrealized gains (losses) included in AOCI for the instruments still held at September 30, 2021 (5)	$	( 387 )	$	—	$	36	$	—	$	—	$	—

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Fair Value (continued)


	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	Short-term Investments		Residential Mortgage Loans — FVO		Other Investments		Net Derivatives (7)		Net Embedded Derivatives (8)		Separate Accounts (9)
	(In millions)
Three Months Ended September 30, 2022
Balance, beginning of period	$	119	$	109	$	1,013	$	( 287 )	$	( 496 )	$	1,230
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)	—		1		8		( 201 )		( 236 )		9
Total realized/unrealized gains (losses) included in AOCI	—		—		—		( 118 )		5		—
Purchases (3)	5		—		33		54		—		62
Sales (3)	( 19 )		( 108 )		( 132 )		—		—		( 74 )
Issuances (3)	—		—		—		( 1 )		—		( 1 )
Settlements (3)	—		( 2 )		—		26		( 13 )		—
Transfers into Level 3 (4)	—		—		—		—		—		—
Transfers out of Level 3 (4)	( 100 )		—		—		( 144 )		—		( 11 )
Balance, end of period	$	5	$	—	$	922	$	( 671 )	$	( 740 )	$	1,215
Three Months Ended September 30, 2021
Balance, beginning of period	$	113	$	140	$	781	$	57	$	( 574 )	$	1,249
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)	1		—		45		( 279 )		47		12
Total realized/unrealized gains (losses) included in AOCI	( 2 )		—		—		55		—		—
Purchases (3)	2		—		116		7		—		161
Sales (3)	( 28 )		—		( 72 )		—		—		( 18 )
Issuances (3)	—		—		—		( 1 )		—		—
Settlements (3)	—		( 6 )		—		( 49 )		( 60 )		—
Transfers into Level 3 (4)	1		—		—		—		—		—
Transfers out of Level 3 (4)	( 30 )		—		( 25 )		—		—		( 5 )
Balance, end of period	$	57	$	134	$	845	$	( 210 )	$	( 587 )	$	1,399
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2022 (5)	$	—	$	—	$	9	$	( 42 )	$	( 236 )	$	—
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2021 (5)	$	—	$	( 1 )	$	40	$	( 273 )	$	44	$	—
Changes in unrealized gains (losses) included in AOCI for the instruments still held at September 30, 2022 (5)	$	—	$	—	$	—	$	( 145 )	$	6	$	—
Changes in unrealized gains (losses) included in AOCI for the instruments still held at September 30, 2021 (5)	$	—	$	—	$	—	$	25	$	1	$	—

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Fair Value (continued)


	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	Fixed Maturity Securities AFS
	Corporate (6)		Foreign Government		Structured Products		Municipals		Equity Securities		Unit-linked and FVO Securities
	(In millions)
Nine Months Ended September 30, 2022
Balance, beginning of period	$	25,435	$	91	$	5,871	$	—	$	151	$	901
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)	( 17 )		( 38 )		30		—		5		( 195 )
Total realized/unrealized gains (losses) included in AOCI	( 7,082 )		6		( 575 )		—		—		—
Purchases (3)	3,515		1		781		—		28		29
Sales (3)	( 1,241 )		( 3 )		( 850 )		—		( 13 )		( 10 )
Issuances (3)	—		—		—		—		—		—
Settlements (3)	—		—		—		—		—		—
Transfers into Level 3 (4)	352		48		228		—		—		13
Transfers out of Level 3 (4)	( 461 )		( 44 )		( 440 )		—		( 2 )		( 15 )
Balance, end of period	$	20,501	$	61	$	5,045	$	—	$	169	$	723
Nine Months Ended September 30, 2021
Balance, beginning of period	$	24,101	$	117	$	5,289	$	—	$	150	$	701
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)	( 28 )		—		36		—		16		53
Total realized/unrealized gains (losses) included in AOCI	( 1,171 )		( 1 )		9		—		—		—
Purchases (3)	3,395		13		1,333		34		10		20
Sales (3)	( 951 )		( 7 )		( 1,049 )		—		( 21 )		( 16 )
Issuances (3)	—		—		—		—		—		—
Settlements (3)	—		—		—		—		—		—
Transfers into Level 3 (4)	139		13		256		—		—		86
Transfers out of Level 3 (4)	( 749 )		( 29 )		( 294 )		—		( 4 )		( 11 )
Balance, end of period	$	24,736	$	106	$	5,580	$	34	$	151	$	833
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2022 (5)	$	( 19 )	$	( 38 )	$	23	$	—	$	—	$	( 194 )
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2021 (5)	$	( 21 )	$	—	$	33	$	—	$	11	$	53
Changes in unrealized gains (losses) included in AOCI for the instruments still held at September 30, 2022 (5)	$	( 7,056 )	$	5	$	( 554 )	$	—	$	—	$	—
Changes in unrealized gains (losses) included in AOCI for the instruments still held at September 30, 2021 (5)	$	( 1,141 )	$	( 1 )	$	11	$	—	$	—	$	—

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Fair Value (continued)


	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	Short-term Investments		Residential Mortgage Loans — FVO		Other Investments		Net Derivatives (7)		Net Embedded Derivatives (8)		Separate Accounts (9)
	(In millions)
Nine Months Ended September 30, 2022
Balance, beginning of period	$	3	$	127	$	898	$	( 152 )	$	( 611 )	$	2,131
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)	( 1 )		( 8 )		80		( 139 )		( 97 )		52
Total realized/unrealized gains (losses) included in AOCI	—		—		—		( 528 )		28		—
Purchases (3)	5		—		221		82		—		150
Sales (3)	( 2 )		( 108 )		( 178 )		—		—		( 1,107 )
Issuances (3)	—		—		—		( 3 )		—		3
Settlements (3)	—		( 11 )		—		68		( 60 )		4
Transfers into Level 3 (4)	—		—		—		—		—		—
Transfers out of Level 3 (4)	—		—		( 99 )		1		—		( 18 )
Balance, end of period	$	5	$	—	$	922	$	( 671 )	$	( 740 )	$	1,215
Nine Months Ended September 30, 2021
Balance, beginning of period	$	43	$	165	$	573	$	594	$	( 1,141 )	$	1,079
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)	1		( 3 )		70		( 490 )		716		14
Total realized/unrealized gains (losses) included in AOCI	( 2 )		—		—		( 365 )		22		—
Purchases (3)	55		—		299		14		—		336
Sales (3)	( 37 )		( 11 )		( 72 )		—		—		( 43 )
Issuances (3)	—		—		—		( 6 )		—		( 1 )
Settlements (3)	—		( 17 )		—		43		( 184 )		6
Transfers into Level 3 (4)	—		—		—		1		—		10
Transfers out of Level 3 (4)	( 3 )		—		( 25 )		( 1 )		—		( 2 )
Balance, end of period	$	57	$	134	$	845	$	( 210 )	$	( 587 )	$	1,399
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2022 (5)	$	( 1 )	$	—	$	77	$	( 133 )	$	( 97 )	$	—
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2021 (5)	$	—	$	( 7 )	$	66	$	( 392 )	$	715	$	—
Changes in unrealized gains (losses) included in AOCI for the instruments still held at September 30, 2022 (5)	$	—	$	—	$	—	$	( 474 )	$	28	$	—
Changes in unrealized gains (losses) included in AOCI for the instruments still held at September 30, 2021 (5)	$	—	$	—	$	—	$	( 206 )	$	22	$	—

__________________

(1) Amortization of premium/accretion of discount is included within net investment income. Impairments and changes in ACL charged to net income (loss) on certain securities are included in net investment gains (losses), while changes in estimated fair value of Unit-linked and FVO Securities and residential mortgage loans — FVO are included in net investment income. Lapses associated with net embedded derivatives are included in net derivative gains (losses). Substantially all realized/unrealized gains (losses) included in net income (loss) for net derivatives and net embedded derivatives are reported in net derivative gains (losses).

(2) Interest and dividend accruals, as well as cash interest coupons and dividends received, are excluded from the rollforward.

(3) Items purchased/issued and then sold/settled in the same period are excluded from the rollforward. Fees attributed to embedded derivatives are included in settlements.

(4) Items transferred into and then out of Level 3 in the same period are excluded from the rollforward.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Fair Value (continued)

(5) Changes in unrealized gains (losses) included in net income (loss) and included in AOCI relate to assets and liabilities still held at the end of the respective periods. Substantially all changes in unrealized gains (losses) included in net income (loss) for net derivatives and net embedded derivatives are reported in net derivative gains (losses).

(6) Comprised of U.S. and foreign corporate securities.

(7) Freestanding derivative assets and liabilities are presented net for purposes of the rollforward.

(8) Embedded derivative assets and liabilities are presented net for purposes of the rollforward.

(9) Investment performance related to separate account assets is fully offset by corresponding amounts credited to contractholders within separate account liabilities. Therefore, such changes in estimated fair value are not recorded in net income (loss). For the purpose of this disclosure, these changes are presented within net income (loss). Separate account assets and liabilities are presented net for the purposes of the rollforward.

Fair Value Option

The Company elects the FVO for certain residential mortgage loans that are managed on a total return basis. The following table presents information for residential mortgage loans which are accounted for under the FVO and were initially measured at fair value.


	September 30, 2022		December 31, 2021
	(In millions)
Unpaid principal balance	$	—	$	130
Difference between estimated fair value and unpaid principal balance	—		( 3 )
Carrying value at estimated fair value	$	—	$	127
Loans in nonaccrual status	$	—	$	32
Loans more than 90 days past due	$	—	$	14
Loans in nonaccrual status or more than 90 days past due, or both — difference between aggregate estimated fair value and unpaid principal balance	$	—	$	( 7 )

Fair Value of Financial Instruments Carried at Other Than Fair Value

The following tables provide fair value information for financial instruments that are carried on the balance sheet at amounts other than fair value. These tables exclude the following financial instruments: cash and cash equivalents, accrued investment income, payables for collateral under securities loaned and other transactions, short-term debt and those short-term investments that are not securities, such as time deposits, and therefore are not included in the three-level hierarchy table disclosed in the “— Recurring Fair Value Measurements” section. The Company believes that due to the short-term nature of these excluded assets, which are primarily classified in Level 2, the estimated fair value approximates carrying value. All remaining balance sheet amounts excluded from the tables below are not considered financial instruments subject to this disclosure.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Fair Value (continued)

The carrying values and estimated fair values for such financial instruments, and their corresponding placement in the fair value hierarchy, are summarized as follows at:


	September 30, 2022
			Fair Value Hierarchy
	Carrying Value		Level 1		Level 2		Level 3		Total Estimated Fair Value
	(In millions)
Assets
Mortgage loans (1)	$	82,437	$	—	$	—	$	77,970	$	77,970
Policy loans	$	8,783	$	—	$	—	$	9,603	$	9,603

Other invested assets	$	958	$	—	$	768	$	190	$	958
Premiums, reinsurance and other receivables	$	2,572	$	—	$	812	$	1,817	$	2,629
Other assets	$	250	$	—	$	88	$	154	$	242
Liabilities
Policyholder account balances	$	122,043	$	—	$	—	$	115,065	$	115,065
Long-term debt	$	14,457	$	—	$	13,826	$	—	$	13,826
Collateral financing arrangement	$	729	$	—	$	—	$	591	$	591
Junior subordinated debt securities	$	3,158	$	—	$	3,470	$	—	$	3,470
Other liabilities	$	2,491	$	—	$	937	$	1,830	$	2,767
Separate account liabilities	$	74,968	$	—	$	74,968	$	—	$	74,968


	December 31, 2021 (2)
			Fair Value Hierarchy
	Carrying Value		Level 1		Level 2		Level 3		Total Estimated Fair Value
	(In millions)
Assets
Mortgage loans (1)	$	79,226	$	—	$	—	$	82,788	$	82,788
Policy loans	$	9,111	$	—	$	—	$	10,751	$	10,751

Other invested assets	$	1,025	$	—	$	769	$	256	$	1,025
Premiums, reinsurance and other receivables	$	2,262	$	—	$	492	$	1,962	$	2,454
Other assets	$	290	$	—	$	101	$	190	$	291
Liabilities
Policyholder account balances	$	123,865	$	—	$	—	$	127,728	$	127,728
Long-term debt	$	13,852	$	—	$	16,621	$	—	$	16,621
Collateral financing arrangement	$	766	$	—	$	—	$	630	$	630
Junior subordinated debt securities	$	3,156	$	—	$	4,447	$	—	$	4,447
Other liabilities	$	2,143	$	—	$	514	$	2,321	$	2,835
Separate account liabilities	$	95,619	$	—	$	95,619	$	—	$	95,619

_________________

(1) Includes mortgage loans measured at estimated fair value on a nonrecurring basis and excludes mortgage loans measured at estimated fair value on a recurring basis.

(2) Excludes amounts reclassified to assets held-for-sale or liabilities held-for-sale. See Note 3 for information on the Company’s business dispositions.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Long Term Debt

Senior Notes

In July 2022, MetLife, Inc. issued $ 1.0 billion of senior notes due July 2052 which bear interest at a fixed rate of 5.00 %, payable semi-annually. In connection with the issuance, MetLife, Inc. incurred $ 11 million of related costs which will be amortized over the term of the senior notes.

10. Equity

Preferred Stock

Preferred stock authorized, issued and outstanding was as follows at both September 30, 2022 and December 31, 2021:


Series	Shares Authorized	Shares Issued and Outstanding
Floating Rate Non-Cumulative Preferred Stock, Series A	27,600,000	24,000,000
5.875% Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series D	500,000	500,000
5.625% Non-Cumulative Preferred Stock, Series E	32,200	32,200
4.75% Non-Cumulative Preferred Stock, Series F	40,000	40,000
3.85% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G	1,000,000	1,000,000
Series A Junior Participating Preferred Stock	10,000,000	—
Not designated	160,827,800	—
Total	200,000,000	25,572,200

The per share and aggregate dividends declared for MetLife, Inc.’s preferred stock were as follows:


	Three Months Ended September 30,								Nine Months Ended September 30,
	2022				2021				2022				2021
Series	Per Share		Aggregate		Per Share		Aggregate		Per Share		Aggregate		Per Share		Aggregate
	(In millions, except per share data)
A	$	0.256	$	6	$	0.256	$	6	$	0.762	$	18	$	0.762	$	18
C (1)	$	—	—		$	—	—		$	—	—		$	19.085	10
D	$	29.375	14		$	29.375	14		$	58.750	29		$	58.750	29
E	$	351.563	12		$	351.563	11		$	1,054.689	34		$	1,054.689	34
F	$	296.875	12		$	296.875	12		$	890.625	36		$	890.625	36
G	$	19.250	20		$	19.250	20		$	38.500	39		$	39.035	39
Total			$	64			$	63			$	156			$	166

__________________

(1) Dividends were paid through the dividend payment date of June 15, 2021, when all outstanding shares of MetLife, Inc.’s 5.25% Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series C were redeemed and eliminated. See Note 16 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report.

Common Stock

MetLife, Inc. announced that its Board of Directors authorized common stock repurchases as follows:


			Authorization Remaining at
Announcement Date	Authorization Amount		September 30, 2022
	(In millions)
May 4, 2022	$	3,000	$	1,802
August 4, 2021	$	3,000	$	—
December 11, 2020	$	3,000	$	—

Under these authorizations, MetLife, Inc. may purchase its common stock from the MetLife Policyholder Trust, in the open market (including pursuant to the terms of a pre-set trading plan meeting the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934), and in privately negotiated transactions. Common stock repurchases are subject to the

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Equity (continued)

discretion of MetLife, Inc.’s Board of Directors and will depend upon the Company’s capital position, liquidity, financial strength and credit ratings, general market conditions, the market price of MetLife, Inc.’s common stock compared to management’s assessment of the stock’s underlying value, applicable regulatory approvals, and other legal and accounting factors.

For the nine months ended September 30, 2022 and 2021, MetLife, Inc. repurchased 41,267,149 shares and 52,857,261 shares of its common stock, respectively, through open market purchases for $ 2.7 billion and $ 3.1 billion, respectively.

Stock-Based Compensation Plans

Performance Shares and Performance Units

Final Performance Shares are paid in shares of MetLife, Inc. common stock. Final Performance Units are payable in cash equal to the closing price of MetLife, Inc. common stock on a date following the last day of the three-year performance period. The performance factor for the January 1, 2019 – December 31, 2021 performance period was 141.3 %, which was determined within a possible range from 0 % to 175 %. This factor has been applied to the 1,485,512 Performance Shares and 156,090 Performance Units associated with that performance period that vested on December 31, 2021. As a result, in the first quarter of 2022, MetLife, Inc. issued 2,099,028 shares of its common stock (less withholding for taxes and other items, as applicable), excluding shares that payees choose to defer, and MetLife, Inc. or its affiliates paid the cash value of 220,555 Performance Units (less withholding for taxes and other items, as applicable).

Dividend Restrictions

Insurance Operations

For the nine months ended September 30, 2022, American Life Insurance Company paid a dividend of $ 620 million to MetLife, Inc., for which regulatory approval was obtained as required.

See Note 16 of the Notes to Consolidated Financial Statements included in the 2021 Annual Report for additional information on dividend restrictions.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Equity (continued)

Accumulated Other Comprehensive Income (Loss)

Information regarding changes in the balances of each component of AOCI attributable to MetLife, Inc. was as follows:


	Three Months Ended September 30, 2022
	Unrealized Investment Gains (Losses), Net of Related Offsets (1)		Unrealized Gains (Losses) on Derivatives		Foreign Currency Translation Adjustments		Defined Benefit Plans Adjustment		Total
	(In millions)
Balance, beginning of period	$	( 11,304 )	$	1,847	$	( 6,360 )	$	( 1,555 )	$	( 17,372 )
OCI before reclassifications	( 15,523 )		975		( 768 )		1		( 15,315 )
Deferred income tax benefit (expense)	3,521		( 211 )		( 23 )		—		3,287
AOCI before reclassifications, net of income tax	( 23,306 )		2,611		( 7,151 )		( 1,554 )		( 29,400 )
Amounts reclassified from AOCI	343		566		—		23		932
Deferred income tax benefit (expense)	( 77 )		( 145 )		—		( 5 )		( 227 )
Amounts reclassified from AOCI, net of income tax	266		421		—		18		705




Balance, end of period	$	( 23,040 )	$	3,032	$	( 7,151 )	$	( 1,536 )	$	( 28,695 )

	Three Months Ended September 30, 2021
	Unrealized Investment Gains (Losses), Net of Related Offsets (1)		Unrealized Gains (Losses) on Derivatives		Foreign Currency Translation Adjustments		Defined Benefit Plans Adjustment		Total
	(In millions)
Balance, beginning of period	$	17,535	$	1,073	$	( 4,463 )	$	( 1,836 )	$	12,309
OCI before reclassifications	( 633 )		442		( 421 )		5		( 607 )
Deferred income tax benefit (expense)	208		( 102 )		( 4 )		( 1 )		101
AOCI before reclassifications, net of income tax	17,110		1,413		( 4,888 )		( 1,832 )		11,803
Amounts reclassified from AOCI	( 91 )		236		—		30		175
Deferred income tax benefit (expense)	22		( 54 )		—		( 3 )		( 35 )
Amounts reclassified from AOCI, net of income tax	( 69 )		182		—		27		140


Sale of subsidiary, net of income tax	22		—		146		—		168
Balance, end of period	$	17,063	$	1,595	$	( 4,742 )	$	( 1,805 )	$	12,111

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Equity (continued)


	Nine Months Ended September 30, 2022
	Unrealized Investment Gains (Losses), Net of Related Offsets (1)		Unrealized Gains (Losses) on Derivatives		Foreign Currency Translation Adjustments		Defined Benefit Plans Adjustment		Total
	(In millions)
Balance, beginning of period	$	16,042	$	1,629	$	( 5,154 )	$	( 1,598 )	$	10,919
OCI before reclassifications	( 51,978 )		509		( 2,276 )		7		( 53,738 )
Deferred income tax benefit (expense)	11,866		( 116 )		( 108 )		( 1 )		11,641
AOCI before reclassifications, net of income tax	( 24,070 )		2,022		( 7,538 )		( 1,592 )		( 31,178 )
Amounts reclassified from AOCI	1,346		1,307		—		70		2,723
Deferred income tax benefit (expense)	( 307 )		( 297 )		—		( 12 )		( 616 )
Amounts reclassified from AOCI, net of income tax	1,039		1,010		—		58		2,107
Sale of subsidiaries, net of income tax (2)	( 9 )		—		387		( 2 )		376
Balance, end of period	$	( 23,040 )	$	3,032	$	( 7,151 )	$	( 1,536 )	$	( 28,695 )

	Nine Months Ended September 30, 2021
	Unrealized Investment Gains (Losses), Net of Related Offsets (1)		Unrealized Gains (Losses) on Derivatives		Foreign Currency Translation Adjustments		Defined Benefit Plans Adjustment		Total
	(In millions)
Balance, beginning of period	$	22,217	$	1,513	$	( 3,795 )	$	( 1,863 )	$	18,072
OCI before reclassifications	( 6,512 )		( 172 )		( 1,168 )		9		( 7,843 )
Deferred income tax benefit (expense)	1,584		39		( 40 )		( 2 )		1,581
AOCI before reclassifications, net of income tax	17,289		1,380		( 5,003 )		( 1,856 )		11,810
Amounts reclassified from AOCI	( 76 )		279		—		61		264
Deferred income tax benefit (expense)	18		( 64 )		—		( 10 )		( 56 )
Amounts reclassified from AOCI, net of income tax	( 58 )		215		—		51		208
Sale of subsidiaries, net of income tax	( 168 )		—		261		—		93
Balance, end of period	$	17,063	$	1,595	$	( 4,742 )	$	( 1,805 )	$	12,111

__________________

(1) See Note 6 for information on offsets to investments related to policyholder liabilities, DAC, VOBA and DSI .

(2) S ee Note 3 for information on the Company’s business dispositions .

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Equity (continued)

Information regarding amounts reclassified out of each component of AOCI was as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
AOCI Components	Amounts Reclassified from AOCI								Consolidated Statements of Operations and Comprehensive Income (Loss) Locations
	(In millions)
Net unrealized investment gains (losses):
Net unrealized investment gains (losses)	$	( 336 )	$	97	$	( 1,458 )	$	42	Net investment gains (losses)
Net unrealized investment gains (losses)	—		( 4 )		4		( 13 )		Net investment income
Net unrealized investment gains (losses)	( 7 )		( 2 )		108		47		Net derivative gains (losses)
Net unrealized investment gains (losses), before income tax	( 343 )		91		( 1,346 )		76
Income tax (expense) benefit	77		( 22 )		307		( 18 )
Net unrealized investment gains (losses), net of income tax	( 266 )		69		( 1,039 )		58
Unrealized gains (losses) on derivatives - cash flow hedges:
Interest rate derivatives	15		14		46		41		Net investment income
Interest rate derivatives	( 16 )		6		44		54		Net investment gains (losses)
Interest rate derivatives	1		1		3		2		Other expenses
Foreign currency exchange rate derivatives	1		2		4		6		Net investment income
Foreign currency exchange rate derivatives	( 567 )		( 259 )		( 1,405 )		( 383 )		Net investment gains (losses)
Foreign currency exchange rate derivatives	—		—		1		1		Other expenses

Gains (losses) on cash flow hedges, before income tax	( 566 )		( 236 )		( 1,307 )		( 279 )
Income tax (expense) benefit	145		54		297		64
Gains (losses) on cash flow hedges, net of income tax	( 421 )		( 182 )		( 1,010 )		( 215 )
Defined benefit plans adjustment: (1)
Amortization of net actuarial gains (losses)	( 25 )		( 34 )		( 78 )		( 87 )
Amortization of prior service (costs) credit	2		4		8		26
Amortization of defined benefit plan items, before income tax	( 23 )		( 30 )		( 70 )		( 61 )
Income tax (expense) benefit	5		3		12		10
Amortization of defined benefit plan items, net of income tax	( 18 )		( 27 )		( 58 )		( 51 )
Total reclassifications, net of income tax	$	( 705 )	$	( 140 )	$	( 2,107 )	$	( 208 )

__________________

(1) These AOCI components are included in the computation of net periodic benefit costs. See Note 12.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

11. Other Revenues and Other Expenses

Other Revenues

Information on other revenues, which primarily includes fees related to service contracts from customers, was as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
	(In millions)
Vision fee for service arrangements	$	135	$	135	$	427	$	410
Prepaid legal plans	118		107		356		324
Fee-based investment management	97		95		299		266
Recordkeeping and administrative services (1)	40		54		130		160
Administrative services-only contracts	59		56		177		175
Other revenue from service contracts from customers	62		69		197		210
Total revenues from service contracts from customers	511		516		1,586		1,545
Other	219		147		420		413
Total other revenues	$	730	$	663	$	2,006	$	1,958

__________________

(1) Related to products and businesses no longer actively marketed by the Company.

Receivables related to revenues from service contracts from customers were $ 222 million and $ 235 million at September 30, 2022 and December 31, 2021, respectively.

Other Expenses

Information on other expenses was as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
	(In millions)
Employee-related costs (1)	$	880	$	794	$	2,652	$	2,576
Third party staffing costs	353		353		1,111		1,001
General and administrative expenses	196		212		486		455
Pension, postretirement and postemployment benefit costs	24		43		73		94
Premium taxes, other taxes, and licenses & fees	172		144		462		480
Commissions and other variable expenses	1,268		1,323		3,899		4,147
Capitalization of DAC	( 615 )		( 635 )		( 1,887 )		( 2,052 )
Amortization of DAC and VOBA	218		816		1,371		1,943
Amortization of negative VOBA	( 12 )		( 6 )		( 31 )		( 25 )
Interest expense on debt	239		240		690		696
Total other expenses	$	2,723	$	3,284	$	8,826	$	9,315

__________________

(1) Includes $ 30 million and $ 145 million for the three months and nine months ended September 30, 2022, respectively, and ($ 15 ) million and ($ 89 ) million for the three months and nine months ended September 30, 2021, respectively, for the net change in cash surrender value of investments in certain life insurance policies, net of premiums paid.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

12. Employee Benefit Plans

Pension and Other Postretirement Benefit Plans

Certain subsidiaries of MetLife, Inc. sponsor a U.S. qualified and various U.S. and non-U.S. nonqualified defined benefit pension plans covering employees who meet specified eligibility requirements. These subsidiaries also provide certain postemployment benefits and certain postretirement medical and life insurance benefits for U.S. and non-U.S. retired employees.

The components of net periodic benefit costs, reported in other expenses, were as follows:


	Three Months Ended September 30,
	2022				2021
	Pension Benefits		Other Postretirement Benefits		Pension Benefits		Other Postretirement Benefits
	(In millions)
Service costs	$	48	$	2	$	58	$	2
Interest costs	81		8		89		9

Expected return on plan assets	( 128 )		( 13 )		( 124 )		( 14 )
Amortization of net actuarial (gains) losses	31		( 7 )		38		( 6 )
Amortization of prior service costs (credit)	( 4 )		—		( 6 )		—
Net periodic benefit costs (credit)	$	28	$	( 10 )	$	55	$	( 9 )

	Nine Months Ended September 30,
	2022				2021
	Pension Benefits		Other Postretirement Benefits		Pension Benefits		Other Postretirement Benefits
	(In millions)
Service costs	$	150	$	4	$	177	$	4
Interest costs	244		25		250		27
Curtailment (gains) losses	—		—		( 17 )		—
Expected return on plan assets	( 386 )		( 41 )		( 381 )		( 42 )
Amortization of net actuarial (gains) losses	92		( 19 )		115		( 33 )
Amortization of prior service costs (credit)	( 10 )		—		( 11 )		—
Net periodic benefit costs (credit)	$	90	$	( 31 )	$	133	$	( 44 )

13. Income Tax

For the three months and nine months ended September 30, 2022, the effective tax rate on income (loss) before provision for income tax was 5 % and ( 7 %), respectively. The Company’s effective tax rate for the three months ended September 30, 2022 differed from the U.S. statutory rate primarily due to tax benefits from foreign earnings taxed at different rates than the U.S. statutory rate and tax credits. The Company’s effective tax rate for the nine months ended September 30, 2022 reflected an income tax benefit despite having income before provision for income tax and differed from the U.S. statutory rate primarily due to tax benefits from foreign earnings taxed at different rates than the U.S. statutory rate, tax credits, the corporate tax deduction for stock compensation and non-taxable investment income.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

13. Income Tax (continued)

For the three months and nine months ended September 30, 2021, the effective tax rate on income (loss) before provision for income tax was 22 % and 21 %, respectively. The Company’s effective tax rate for the three months ended September 30, 2021 differed from the U.S. statutory rate primarily due to tax charges from foreign earnings taxed at different rates than the U.S. statutory rate and the completed sale of its wholly-owned Argentinian subsidiary, MetLife Seguros S.A. (“MetLife Seguros”), partially offset by tax benefits related to tax credits and non-taxable investment income. The Company’s effective tax rate for the nine months ended September 30, 2021 was equal to the statutory rate of 21 %, primarily due to tax charges from foreign earnings taxed at different rates than the U.S. statutory rate, the completed sales of MetLife P&C and MetLife Seguros and the pending disposition of MetLife Poland and Greece, offset by tax benefits related to tax credits, non-taxable investment income and the corporate tax deduction for stock compensation.

14. Earnings Per Common Share

The following table presents the weighted average shares, basic earnings per common share and diluted earnings per common share:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
	(In millions, except per share data)
Weighted Average Shares:
Weighted average common stock outstanding - basic	795.8		854.9		809.7		871.1
Incremental common shares from assumed exercise or issuance of stock-based awards	4.9		6.3		5.5		6.4
Weighted average common stock outstanding - diluted	800.7		861.2		815.2		877.5
Net Income (Loss):
Net income (loss)	$	400	$	1,589	$	1,212	$	5,364
Less: Net income (loss) attributable to noncontrolling interests	5		5		16		15
Less: Preferred stock dividends	64		63		156		166
Preferred stock redemption premium	—		—		—		6
Net income (loss) available to MetLife, Inc.’s common shareholders	$	331	$	1,521	$	1,040	$	5,177
Basic	$	0.42	$	1.78	$	1.28	$	5.94
Diluted	$	0.41	$	1.77	$	1.28	$	5.90

15. Contingencies, Commitments and Guarantees

Contingencies

Litigation

The Company is a defendant in a large number of litigation matters. Putative or certified class action litigation and other litigation and claims and assessments against the Company, in addition to those discussed below and those otherwise provided for in the Company’s interim condensed consolidated financial statements, have arisen in the course of the Company’s business, including, but not limited to, in connection with its activities as an insurer, mortgage lending bank, employer, investor, investment advisor, broker-dealer, and taxpayer.

The Company also receives and responds to subpoenas or other inquiries seeking a broad range of information from state regulators, including state insurance commissioners; state attorneys general or other state governmental authorities; federal regulators, including the U.S. Securities and Exchange Commission; federal governmental authorities, including congressional committees; and the Financial Industry Regulatory Authority, as well as from local and national regulators and government authorities in jurisdictions outside the United States where the Company conducts business. The issues involved in information requests and regulatory matters vary widely, but can include inquiries or investigations concerning the Company’s compliance with applicable insurance and other laws and regulations. The Company cooperates in these inquiries.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

15. Contingencies, Commitments and Guarantees (continued)

It is not possible to predict the ultimate outcome of all pending investigations and legal proceedings. The Company establishes liabilities for litigation and regulatory loss contingencies when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Liabilities have been established for a number of the matters noted below. In certain circumstances where liabilities have been established there may be coverage under one or more corporate insurance policies, pursuant to which there may be an insurance recovery. Insurance recoveries are recognized as gains when any contingencies relating to the insurance claim have been resolved, which is the earlier of when the gains are realized or realizable. It is possible that some of the matters could require the Company to pay damages or make other expenditures or establish accruals in amounts that could not be reasonably estimated at September 30, 2022. While the potential future charges could be material in the particular quarterly or annual periods in which they are recorded, based on information currently known to management, management does not believe any such charges are likely to have a material effect on the Company’s financial position. Given the large and/or indeterminate amounts sought in certain of these matters and the inherent unpredictability of litigation, it is possible that an adverse outcome in certain matters could, from time to time, have a material effect on the Company’s consolidated net income or cash flows in particular quarterly or annual periods.

Matters as to Which an Estimate Can Be Made

For some matters, the Company is able to estimate a reasonably possible range of loss. For matters where a loss is believed to be reasonably possible, but not probable, the Company has not made an accrual. As of September 30, 2022, the Company estimates the aggregate range of reasonably possible losses in excess of amounts accrued for these matters to be $ 0 to $ 125 million.

Matters as to Which an Estimate Cannot Be Made

For other matters, the Company is not currently able to estimate the reasonably possible loss or range of loss. The Company is often unable to estimate the possible loss or range of loss until developments in such matters have provided sufficient information to support an assessment of the range of possible loss, such as quantification of a damage demand from plaintiffs, discovery from other parties and investigation of factual allegations, rulings by the court on motions or appeals, analysis by experts, and the progress of settlement negotiations. On a quarterly and annual basis, the Company reviews relevant information with respect to litigation contingencies and updates its accruals, disclosures and estimates of reasonably possible losses or ranges of loss based on such reviews.

Asbestos-Related Claims

MLIC is and has been a defendant in a large number of asbestos-related suits filed primarily in state courts. These suits principally allege that the plaintiff or plaintiffs suffered personal injury resulting from exposure to asbestos and seek both actual and punitive damages. MLIC has never engaged in the business of manufacturing or selling asbestos-containing products, nor has MLIC issued liability or workers’ compensation insurance to companies in the business of manufacturing or selling asbestos-containing products. The lawsuits principally have focused on allegations with respect to certain research, publication and other activities of one or more of MLIC’s employees during the period from the 1920s through approximately the 1950s and allege that MLIC learned or should have learned of certain health risks posed by asbestos and, among other things, improperly publicized or failed to disclose those health risks. MLIC believes that it should not have legal liability in these cases. The outcome of most asbestos litigation matters, however, is uncertain and can be impacted by numerous variables, including differences in legal rulings in various jurisdictions, the nature of the alleged injury and factors unrelated to the ultimate legal merit of the claims asserted against MLIC.

MLIC’s defenses include that: (i) MLIC owed no duty to the plaintiffs; (ii) plaintiffs did not rely on any actions of MLIC; (iii) MLIC’s conduct was not the cause of the plaintiffs’ injuries; and (iv) plaintiffs’ exposure occurred after the dangers of asbestos were known. During the course of the litigation, certain trial courts have granted motions dismissing claims against MLIC, while other trial courts have denied MLIC’s motions. There can be no assurance that MLIC will receive favorable decisions on motions in the future. While most cases brought to date have settled, MLIC intends to continue to defend aggressively against claims based on asbestos exposure, including defending claims at trials.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

15. Contingencies, Commitments and Guarantees (continued)

As reported in the 2021 Annual Report, MLIC received approximately 2,824 asbestos-related claims in 2021. For the nine months ended September 30, 2022 and 2021, MLIC received approximately 1,962 and 2,156 new asbestos-related claims, respectively. See Note 21 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report for historical information concerning asbestos claims and MLIC’s update in its recorded liability at December 31, 2021. The number of asbestos cases that may be brought, the aggregate amount of any liability that MLIC may incur, and the total amount paid in settlements in any given year are uncertain and may vary significantly from year to year.

The ability of MLIC to estimate its ultimate asbestos exposure is subject to considerable uncertainty, and the conditions impacting its liability can be dynamic and subject to change. The availability of reliable data is limited and it is difficult to predict the numerous variables that can affect liability estimates, including the number of future claims, the cost to resolve claims, the disease mix and severity of disease in pending and future claims, the willingness of courts to allow plaintiffs to pursue claims against MLIC when exposure to asbestos took place after the dangers of asbestos exposure were well known, and the impact of any possible future adverse verdicts and their amounts.

The ability to make estimates regarding ultimate asbestos exposure declines significantly as the estimates relate to years further in the future. In the Company’s judgment, there is a future point after which losses cease to be probable and reasonably estimable. It is reasonably possible that the Company’s total exposure to asbestos claims may be materially greater than the asbestos liability currently accrued and that future charges to income may be necessary, but management does not believe any such charges are likely to have a material effect on the Company’s financial position.

The Company believes adequate provision has been made in its interim condensed consolidated financial statements for all probable and reasonably estimable losses for asbestos-related claims. MLIC’s recorded asbestos liability covers pending claims, claims not yet asserted, and legal defense costs and is based on estimates and includes significant assumptions underlying its analysis.

MLIC reevaluates on a quarterly and annual basis its exposure from asbestos litigation, including studying its claims experience, reviewing external literature regarding asbestos claims experience in the United States, assessing relevant trends impacting asbestos liability and considering numerous variables that can affect its asbestos liability exposure on an overall or per claim basis. Based upon its regular reevaluation of its exposure from asbestos litigation, MLIC has updated its liability analysis for asbestos-related claims through September 30, 2022.

Total Asset Recovery Services, LLC. v. MetLife, Inc., et al. (Supreme Court of the State of New York, County of New York, filed December 27, 2017)

Total Asset Recovery Services (the “Relator”) brought an action under the qui tam provision of the New York False Claims Act (the “Act”) on behalf of itself and the Sta te of New York. The Relator originally filed this action under seal in 2010, and the complaint was unsealed on December 19, 2017. The Relator alleges that MetLife, Inc., MLIC, and several other insurance companies violated the Act by filing false unclaimed property reports with the State of New York from 1986 to 2017, to avoid having to escheat the proceeds of more than 25,000 life insurance policies, including policies for which the defendants escheated funds as part of their demutualizations in the late 1990s. The Relator seeks treble damages and other relief. The Appellate Division of the New York State Supreme Court, First Department, reversed the court’s order granting MetLife, Inc. and MLIC’s motion to dismiss and remanded the case to the trial court where the Relator has filed an amended complaint. The Company intends to defend the action vigorously.

Matters Related to Group Annuity Benefits and Assumed Variable Annuity Guarantee Reserves

In 2018, the Company announced that it identified two material weaknesses in its internal control over financial reporting related to the practices and procedures for estimating reserves for certain group annuity benefits and the calculation of reserves associated with certain variable annuity guarantees assumed from the former operating joint venture in Japan. Several regulators have made inquiries into these issues and it is possible that other jurisdictions may pursue similar investigations or inquiries. The Company could be exposed to lawsuits and additional legal actions relating to these issues. These may result in payments, including damages, fines, penalties, interest and other amounts assessed or awarded by courts or regulatory authorities under applicable escheat, tax, securities, Employee Retirement Income Security Act of 1974, or other laws or regulations. The Company could incur significant costs in connection with these actions.

Table of Contents

MetLife, Inc.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

15. Contingencies, Commitments and Guarantees (continued)

Commitments

Mortgage Loan Commitments

The Company commits to lend funds under mortgage loan commitments. The amounts of these mortgage loan commitments were $ 3.4 billion and $ 4.6 billion at September 30, 2022 and December 31, 2021, respectively.

Commitments to Fund Partnership Investments, Bank Credit Facilities, Bridge Loans and Private Corporate Bond Investments

The Company commits to fund partnership investments and to lend funds under bank credit facilities, bridge loans and private corporate bond investments. The amounts of these unfunded commitments were $ 9.4 billion and $ 9.1 billion at September 30, 2022 and December 31, 2021, respectively.

Guarantees

In the normal course of its business, the Company has provided certain indemnities, guarantees and commitments to third parties such that it may be required to make payments now or in the future. In the context of acquisition, disposition, investment and other transactions, the Company has provided indemnities and guarantees, including those related to tax, environmental and other specific liabilities and other indemnities and guarantees that are triggered by, among other things, breaches of representations, warranties or covenants provided by the Company. In addition, in the normal course of business, the Company provides indemnifications to counterparties in contracts with triggers similar to the foregoing, as well as for certain other liabilities, such as third-party lawsuits. These obligations are often subject to time limitations that vary in duration, including contractual limitations and those that arise by operation of law, such as applicable statutes of limitation. In some cases, the maximum potential obligation under the indemnities and guarantees is subject to a contractual limitation ranging from less than $ 1 million to $ 329 million, with a cumulative maximum of $ 626 million, while in other cases such limitations are not specified or applicable. Since certain of these obligations are not subject to limitations, the Company does not believe that it is possible to determine the maximum potential amount that could become due under these guarantees in the future. Management believes that it is unlikely the Company will have to make any material payments under these indemnities, guarantees, or commitments.

In addition, the Company indemnifies its directors and officers as provided in its charters and by-laws. Also, the Company indemnifies its agents for liabilities incurred as a result of their representation of the Company’s interests. Since these indemnities are generally not subject to limitation with respect to duration or amount, the Company does not believe that it is possible to determine the maximum potential amount that could become due under these indemnities in the future.

The Company also has minimum fund yield requirements on certain pension funds. Since these guarantees are not subject to limitation with respect to duration or amount, the Company does not believe that it is possible to determine the maximum potential amount that could become due under these guarantees in the future.

The Company’s recorded liabilities were $ 20 million at both September 30, 2022 and December 31, 2021, for indemnities, guarantees and commitments.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Index to Management’s Discussion and Analysis of Financial Condition and Results of Operations


			Page
Forward-Looking Statements and Other Financial Information			83
Executive Summary			83
Industry Trends			86
Summary of Critical Accounting Estimates			89
Acquisitions and Dispositions			90
Results of Operations			92
Investments			117
Derivatives			129
Policyholder Liabilities			132
Liquidity and Capital Resources			139
Adopted Accounting Pronouncements			147
Future Adoption of Accounting Pronouncements			148
Non-GAAP and Other Financial Disclosures			148
Risk Management			149

Table of Contents

Forward-Looking Statements and Other Financial Information

For purposes of this discussion, “MetLife,” the “Company,” “we,” “our” and “us” refer to MetLife, Inc., a Delaware corporation incorporated in 1999, its subsidiaries and affiliates. This discussion should be read in conjunction with MetLife, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Annual Report”), the cautionary language regarding forward-looking statements included below, the “Risk Factors” set forth in Part II, Item 1A, and the additional risk factors referred to therein, “Quantitative and Qualitative Disclosures About Market Risk” and the Company’s interim condensed consolidated financial statements included elsewhere herein.

This Management’s Discussion and Analysis of Financial Condition and Results of Operations may contain or incorporate by reference information that includes or is based upon forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. See “Note Regarding Forward-Looking Statements” for cautionary language regarding forward-looking statements.

This Management’s Discussion and Analysis of Financial Condition and Results of Operations includes references to our performance measures, adjusted earnings and adjusted earnings available to common shareholders, that are not based on accounting principles generally accepted in the United States of America (“GAAP”). See “— Non-GAAP and Other Financial Disclosures” for definitions and a discussion of these and other financial measures, and “— Results of Operations” and “— Investments” for reconciliations of historical non-GAAP financial measures to the most directly comparable GAAP measures.

Executive Summary

Overview

MetLife is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management. MetLife is organized into five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa (“EMEA”); and MetLife Holdings. In addition, the Company reports certain of its results of operations in Corporate & Other. See Note 2 of the Notes to the Interim Condensed Consolidated Financial Statements for further information on the Company’s segments and Corporate & Other.

COVID-19 Pandemic

We continue to closely monitor developments relating to the COVID-19 pandemic and assess its impact on our business. The COVID-19 pandemic continues to impact the global economy and financial markets and has caused volatility in the global equity, credit and real estate markets. See “— Industry Trends — Financial and Economic Environment.” We have implemented risk management and business continuity plans and taken preventive measures and other precautions, such as employee business travel restrictions and remote work arrangements which, to date, have enabled us to maintain our critical business processes, customer service levels, relationships with key vendors, financial reporting systems, internal control over financial reporting and disclosure controls and procedures.

See “— Results of Operations — Segment Results and Corporate & Other” for further information regarding the effect of the COVID-19 pandemic on our businesses.

Current Period Highlights

During the three months ended September 30, 2022, adjusted premiums, fees and other revenues, net of foreign currency fluctuations, increased compared to the prior period driven by growth in our U.S. segment, primarily in our Retirement and Income Solutions (“RIS”) business. Equity market returns had a less favorable impact on our private equity funds and hedge funds compared to the prior period and resulted in lower investment yields, however, positive net flows drove an increase in our investment portfolio. An unfavorable change in net investment gains (losses) primarily reflects current period losses versus prior period gains on sales, partially offset by the prior period loss on the sale of our wholly-owned Argentinian subsidiary, MetLife Seguros S.A. (“MetLife Seguros”). Changes in long-term interest rates drove an unfavorable change in net derivative gains (losses). Underwriting experience was favorable and reflected an overall decline in COVID-19 related claims. Our annual actuarial assumption review resulted in a gain in the current period versus a charge in the prior period. In addition, the current period includes the favorable impact from a reinsurance recapture and the unfavorable impact from model refinements.

Table of Contents

The following represents segment level results and percentage contributions to total segment level adjusted earnings available to common shareholders for the three months ended September 30, 2022:

(1) Excludes Corporate & Other adjusted loss available to common shareholders of $265 million.

(2) Consistent with GAAP guidance for segment reporting, adjusted earnings is our GAAP measure of segment performance. For additional information, see Note 2 of the Notes to the Interim Condensed Consolidated Financial Statements.

Table of Contents

Three Months Ended September 30, 2022 Compared with the Three Months Ended September 30, 2021

Consolidated Results - Highlights

Net income (loss) available to MetLife, Inc.’s common shareholders down $1.2 billion:

•

Unfavorable change in net investment gains (losses) of $330 million ($261 million, net of income tax)

•

Unfavorable change in net derivative gains (losses) of $262 million ($207 million, net of income tax) (2)

•

Favorable change from annual actuarial assumption reviews of $356 million ($269 million, net of income tax) (3)

•

Adjusted earnings available to common shareholders down $1.1 billion

(1) See “— Results of Operations — Consolidated Results” and “— Non-GAAP and Other Financial Disclosures” for reconciliations and definitions of non-GAAP financial measures.

(2) Includes amounts relating to investment hedge adjustments, which are also included in adjusted earnings available to common shareholders. See “— Investments — Investment Portfolio Results” for additional information.

(3) Includes amounts recognized in net derivative gains (losses) and adjusted earnings available to common shareholders. See “— Results of Operations — Consolidated Results — Three Months Ended September 30, 2022 Compared with the Three Months Ended September 30, 2021 — Actuarial Assumption Review and Certain Other Insurance Adjustments” for additional information.

Consolidated Results - Adjusted Earnings Highlights

Adjusted earnings available to common shareholders was down $1.1 billion primarily due to lower investment yields as a result of the unfavorable impact of lower equity market returns on our private equity funds and hedge funds, as well as higher interest credited expense, partially offset by favorable underwriting, primarily driven by an overall decline in COVID-19 related claims, higher net investment income due to a larger average invested asset base and the favorable change from our annual actuarial assumption reviews. In addition, the current period includes the favorable impact from a reinsurance recapture in our U.S. segment and the unfavorable impact from model refinements in our MetLife Holdings segment.

For a more in-depth discussion of our consolidated results, see “— Results of Operations — Consolidated Results,” “— Results of Operations — Consolidated Results - Adjusted Earnings” and “— Results of Operations — Segment Results and Corporate & Other.”

Table of Contents

Nine Months Ended September 30, 2022 Compared with the Nine Months Ended September 30, 2021

Consolidated Results - Highlights

Net income (loss) available to MetLife, Inc.’s common shareholders down $4.1 billion:

•

Unfavorable change in net investment gains (losses) of $3.3 billion ($2.6 billion, net of income tax)

•

Unfavorable change in net derivative gains (losses) of $502 million ($397 million, net of income tax) (2)

•

Favorable change from annual actuarial assumption reviews of $356 million ($269 million, net of income tax) (3)

•

Adjusted earnings available to common shareholders down $1.8 billion

(1) See “— Results of Operations — Consolidated Results” and “— Non-GAAP and Other Financial Disclosures” for reconciliations and definitions of non-GAAP financial measures.

Consolidated Results - Adjusted Earnings Highlights

Adjusted earnings available to common shareholders was down $1.8 billion primarily due to lower investment yields as a result of the unfavorable impact of lower equity market returns on our private equity funds and hedge funds, higher interest credited expense and higher expenses, partially offset by higher net investment income due to a larger average invested asset base, favorable underwriting, primarily driven by an overall decline in COVID-19 related claims, and the favorable change from our annual actuarial assumption reviews. In addition, the current period includes the favorable impacts from a reinsurance recapture in our U.S. segment and a reinsurance settlement in our MetLife Holdings segment, as well as the unfavorable impact of model refinements in our MetLife Holdings segment and the prior period included the release of a legal reserve.

Industry Trends

We continue to be impacted by the changing global financial and economic environment that has been affecting the industry.

Financial and Economic Environment

Table of Contents

We are closely monitoring political and economic conditions that might contribute to global market volatility and impact our business operations, investment portfolio and derivatives, such as global inflation, supply chain disruptions, the Russia-Ukraine conflict and the COVID-19 pandemic. See “— Impact of Market Interest Rates — Effects of Inflation,” and “— Investments — Current Environment.” We are also monitoring the imposition of tariffs, sanctions or other barriers to international trade, changes to international trade agreements, and their potential impacts on our business, results of operations and financial condition.

Governments and central banks around the world responded to the COVID-19 pandemic with unprecedented fiscal and monetary policies, but many of these stimulus programs have concluded due to global economic recovery and rising inflation. In the United States, the Board of Governors of the Federal Reserve System (“Federal Reserve Board”) ended its asset purchase program in March 2022 and began to reduce its holdings on June 1, 2022. The Federal Open Market Committee has repeatedly raised interest rates in 2022; further increases in the target range for the federal funds rate are expected throughout 2022 to combat inflation. This has caused the gap between the two-year U.S. Treasury and the 10-year U.S. Treasury yield to invert and has contributed to a heightened level of concern about an economic downturn in the United States before the end of 2023. The European Central Bank (“ECB”) ended its pandemic asset purchase program in March 2022 and its quantitative easing program in July 2022. The ECB has repeatedly raised its policy interest rates in 2022 and is expected to continue to do so throughout 2022 to combat inflation. It also established the Transmission Protection Instrument, which aims to prevent financial fragmentation by helping more indebted periphery euro area member states, which could otherwise face a disorderly widening of government bond yield spreads over core members like Germany, as the ECB tightens policy. The Bank of England ended its quantitative easing program in 2021 and has been raising interest rates since December 2021 to combat inflation, with further increases expected throughout 2022. In September and October 2022, the Bank of England also bought government bonds as a targeted and temporary intervention to stabilize the United Kingdom (“U.K.”) bond market. Russia’s invasion of Ukraine and sanctions imposed in response represent an inflationary shock for Europe and globally, driving commodity prices up and contributing to broader inflationary pressure. Europe is particularly vulnerable given its proximity to the conflict and reliance on Russia as a primary source of its energy imports, which is aggravated by Russia largely suspending its gas supplies to Europe. Higher global food and energy prices in the wake of the conflict present additional challenges to the economic performance of net importers of these items, particularly for certain emerging market economies in Eastern Europe and the Middle East.

In Japan, the Bank of Japan (“BoJ”) has kept its monetary policy settings on hold. The BoJ has downgraded its economic assessment of the Japanese economy for fiscal years 2022 and 2023, noting downside risks from slowing global growth and rising recession risks in key exports such as Europe and the U.S. The BoJ has also strengthened its phrasing around the outlook for inflation given the expected pass-through of higher energy and commodity prices. The BoJ’s more cautious view on external growth, coupled with still below target core CPI inflation, suggests that monetary policy will remain on hold for the time being. The Japanese yen weakened to its lowest level against the U.S. dollar since the 1990s as monetary policy divergence has widened between the BoJ and the Federal Reserve and as the trade deficit has widened due to costlier commodity imports year to date. To support its currency, Japan’s government intervened in the foreign exchange market to sell U.S. dollars for the Japanese yen.

Impact of Market Interest Rates

Market interest rates are a key driver of our results. Increases and decreases in such rates, as well as extended periods of stagnation, may impact our business and investments in various ways. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Industry Trends — Impact of Market Interest Rates” and “Risk Factors — Economic Environment and Capital Markets Risks” included in the 2021 Annual Report.

Effects of Inflation

Management believes that while inflation has not had a material effect on the Company’s consolidated results of operations, except insofar as inflation may affect interest rates, both rising interest rates and inflation will have a neutral to modest impact on our business. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Industry Trends — Impact of Market Interest Rates — Impact of a Rising Interest Rate Environment,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Industry Trends — Impact of Market Interest Rates — Interest Rate Scenarios” included in the 2021 Annual Report.

Table of Contents

An increase in inflation could affect our business in several ways. In our group life and disability businesses, premiums increase as compensation levels of our customers’ employees increase. However, during inflationary periods with rising interest rates, the value of fixed income investments falls which could increase realized and unrealized losses, resulting in additional deferred tax assets that may not be realizable. Inflation also increases expenses for labor and other costs, potentially putting pressure on profitability if such costs cannot be passed through in our product prices. Prolonged and elevated inflation could adversely affect the financial markets and the economy generally, and dispelling it may require governments to pursue a restrictive fiscal and monetary policy, which could constrain overall economic activity, inhibit revenue growth and reduce the number of attractive investment opportunities.

Competitive Pressures

See “Business — Competition” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Industry Trends — Competitive Pressures” in the 2021 Annual Report for information on our competitive position.

Regulatory Developments

The following discussion on regulatory developments should be read in conjunction with “Business — Regulation” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Industry Trends — Regulatory Developments” included in the 2021 Annual Report, as amended or supplemented here.

Insurance Regulation

U.S. Federal Initiatives

U.S. federal initiatives can affect our business in a variety of ways, including regulation of financial services, securities, derivatives, pensions, health care, money laundering, foreign sanctions and corrupt practices, and taxation. The Inflation Reduction Act, signed into law by President Biden on August 16, 2022, included a number of tax-related provisions including (i) a fifteen percent alternative minimum tax rate on adjusted financial statement income and (ii) a one percent excise tax on certain corporate stock buybacks. Both provisions will be effective on January 1, 2023 and are not expected to have a material impact on our results of operations.

Surplus and Capital

Risk-Based Capital

The National Association of Insurance Commissioners (“NAIC”) adopted revisions to certain factors used to calculate Life risk-based capital (“RBC”), which is the denominator of the RBC ratios, in light of changes to U.S. tax laws in recent years. These revisions have resulted in increased RBC charges and reduced the RBC ratios of our insurance subsidiaries. The NAIC approved RBC revisions for corporate bonds, real estate equity and longevity risk that took effect at year-end 2021.These revisions had a modest net positive RBC impact on us. The NAIC has also approved an RBC update for mortality risk that will take effect at year-end 2022, and we expect this revision to have a modest net positive RBC impact on us.

Securities, Broker-Dealer and Investment Adviser Regulation

The New York State Department of Financial Services (“NYDFS”) Regulation 187 - Suitability and Best Interests in Life Insurance and Annuity Transactions incorporates the “best interest” standard for annuity transactions and sales of life insurance policies to consumers. In April 2021, the Appellate Division of the New York Supreme Court overturned the regulation for being unconstitutionally vague; however, the New York State Court of Appeals reversed this ruling on October 20, 2022.

Environmental Laws and Regulations

In furtherance of President Biden’s Executive Order on Climate-Related Financial Risk, dated May 20, 2021, the Federal Insurance Office (“FIO”) sought public comment on climate-related financial risks in the insurance industry through November 2021. The FIO’s request for information noted that it will work on assessing how the insurance sector may mitigate climate change impacts and help achieve national climate-related goals. The FIO intends to publish a report by year-end that addresses climate-related issues in the regulation of insurers and climate related disclosures by insurers.

Table of Contents

On March 21, 2022, the U.S. Securities and Exchange Commission (the “SEC”) proposed rules requiring registrants to provide additional climate-related information in their registration statements and annual reports, including in their financial statements. The proposal sets forth proposed rules for disclosure of climate-related risks, material impacts, governance, risk management, financial statement metrics, greenhouse gas emissions, attestation of emissions disclosures, and targets and goals.

On May 25, 2022, the SEC proposed rules requiring registered investment companies, business development companies, and registered and certain unregistered investment advisers to disclose in their fund prospectuses, annual reports and Form ADV information about how funds and advisers incorporate environmental, social and governance factors into their investment strategies.

Cross-Border Trade and Investments

In April 2022, we received authorization from the Central Bank of Ireland for a new entity, MetLife Investment Management Europe, under the Undertakings for the Collective Investment in Transferable Securities Directive and the Alternative Investment Fund Managers Directive with the Markets in Financial Instruments Directive top-up permissions, which allows us to continue our investment management business in the European Union (“EU”).

The U.S., the EU and the U.K., maintain and enforce a variety of economic sanctions against designated countries and their nationals around the world, which can result in disruptions in cross-border activity. In particular, U.S., EU and U.K. sanctions on Russia have expanded as a result of the war in Ukraine. These new sanctions, including a series of presidential executive orders and regulations administered by the U.S. Department of Treasury’s Office of Foreign Assets Control, have, inter alia, expanded restrictions on transactions with the Russian Central Bank and other specified Russian government entities, dealing in Russian sovereign debt, engaging in certain debt and equity transactions, and engaging in transactions related to all new investment in the Russian Federation. Trade and investment in China may also be impacted by U.S. sanctions. The Biden administration has previously issued restrictions targeting certain activity involving specified Chinese securities and technology.

London Interbank Offered Rate

In March 2022, federal legislation was enacted to address the transition from U.S. Dollar London Interbank Offered Rate (“LIBOR”) to alternative reference rates for all U.S. law governed contracts with non-existent or inadequate U.S. Dollar LIBOR fallback provisions. Except with respect to the one-week and two-month U.S. Dollar LIBOR tenors, the federal legislation supersedes all state law addressing the U.S. Dollar LIBOR transition, including legislation enacted in New York in 2021. The implementation of the federal legislation is subject to regulations to be promulgated by the Federal Reserve Board. We continue to assess current and alternative reference rates’ merits, limitations, risks and suitability for our investment and insurance processes.

Summary of Critical Accounting Estimates

The preparation of financial statements in conformity with GAAP requires management to adopt accounting policies and make estimates and assumptions that affect amounts reported on the Interim Condensed Consolidated Financial Statements. The most critical estimates include those used in determining:

(i) liabilities for future policy benefits and the accounting for reinsurance;

(ii) capitalization and amortization of deferred policy acquisition costs (“DAC”) and the establishment and amortization of value of business acquired (“VOBA”);

(iii) estimated fair values of investments in the absence of quoted market values;

(iv) investment allowance for credit loss (“ACL”) and impairments;

(v) estimated fair values of freestanding derivatives and the recognition and estimated fair value of embedded derivatives requiring bifurcation;

(vi) measurement of goodwill and related impairment;

(vii) measurement of employee benefit plan liabilities;

(viii) measurement of income taxes and the valuation of deferred tax assets; and

(ix) liabilities for litigation and regulatory matters.

Table of Contents

In addition, the application of acquisition accounting requires the use of estimation techniques in determining the estimated fair values of assets acquired and liabilities assumed — the most significant of which relate to the aforementioned critical accounting estimates. In applying these policies and estimates, management makes subjective and complex judgments that frequently require assumptions about matters that are inherently uncertain. Many of these policies, estimates and related judgments are common in the insurance and financial services industries; others are specific to our business and operations. Actual results could differ from these estimates.

The Company’s critical accounting estimates are described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Summary of Critical Accounting Estimates” and Note 1 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report.

Goodwill

Goodwill is tested for impairment at least annually or more frequently if events or circumstances, such as adverse changes in the business climate, indicate that there may be justification for conducting an interim test.

For purposes of goodwill impairment testing, if the carrying value of a reporting unit exceeds its estimated fair value, an impairment charge would be recognized for the amount by which the carrying value exceeds the reporting unit’s fair value; however, the loss recognized would not exceed the total amount of goodwill allocated to that reporting unit. Additionally, the Company will consider income tax effects from any tax deductible goodwill on the carrying value of the reporting unit when measuring the goodwill impairment loss, if applicable. The key inputs, judgments and assumptions necessary in determining estimated fair value of the reporting units include projected adjusted earnings, current book value, the level of economic capital required to support the mix of business, long-term growth rates, comparative market multiples, the account value of in-force business, projections of new and renewed business, as well as margins on such business, interest rate levels, credit spreads, equity market levels, and the discount rate that we believe is appropriate for the respective reporting unit.

We apply significant judgment when determining the estimated fair value of our reporting units and when assessing the relationship of market capitalization to the aggregate estimated fair value of our reporting units. The valuation methodologies utilized are subject to key judgments and assumptions that are sensitive to change. Estimates of fair value are inherently uncertain and represent only management’s reasonable expectation regarding future developments. These estimates and the judgments and assumptions upon which the estimates are based will, in all likelihood, differ in some respects from actual future results. Declines in the estimated fair value of our reporting units could result in goodwill impairments in future periods which could materially adversely affect our results of operations or financial position.

In the third quarter of 2022, the Company performed its annual goodwill impairment tests on all of its reporting units, using both qualitative and quantitative assessments. The quantitative assessment utilized the market multiple, embedded value and discounted cash flow valuation approaches based on best available data as of June 30, 2022. The Company concluded that the estimated fair values of all its reporting units were substantially in excess of their carrying values and, therefore, goodwill was not impaired.

Acquisitions and Dispositions

Acquisitions

Pending Acquisition of Affirmative Investment Management

In August 2022, the Company entered into a definitive agreement to acquire Affirmative Investment Management, a specialist global environmental, social and corporate governance impact fixed income investment manager. This transaction is subject to customary closing conditions, including regulatory approval.

Ownership Increase of PNB MetLife

In February 2022, the Company acquired approximately 15.0% ownership in PNB MetLife India Insurance Company Limited (“PNB MetLife”). As a result, the Company’s ownership in PNB MetLife, an operating joint venture accounted for under the equity method, increased to approximately 47.0%. This transaction supports the Company’s continued growth in India and will enable us to deliver more value for our customers, partners and shareholders.

Table of Contents

Dispositions

Disposition of MetLife Poland and Greece

For information regarding the Company's dispositions of its wholly-owned subsidiaries in Poland and Greece (collectively, “MetLife Poland and Greece”), which were reported as held-for-sale, see Notes 1 and 3 of the Notes to the Interim Condensed Consolidated Financial Statements.

Disposition of MetLife Seguros

For information regarding the Company's September 2021 disposition of MetLife Seguros, see Note 3 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report.

Disposition of MetLife P&C

For information regarding the Company's April 2021 disposition of Metropolitan Property and Casualty Insurance Company and certain of its wholly-owned subsidiaries (“MetLife P&C”), which was reported as held-for-sale, see Notes 1 and 3 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report.

Disposition of MetLife Russia

For information regarding the Company's January 2021 disposition of its wholly-owned Russian subsidiary, the Joint-stock Company MetLife Insurance Company (“MetLife Russia”), see Note 3 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report.

Table of Contents

Results of Operations

Consolidated Results


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
	(In millions)
Revenues
Premiums	$	17,547	$	9,455	$	40,039	$	28,914
Universal life and investment-type product policy fees	1,302		1,521		4,236		4,334
Net investment income	3,585		5,568		11,452		16,162
Other revenues	730		663		2,006		1,958
Net investment gains (losses)	(414)		(84)		(1,617)		1,655
Net derivative gains (losses)	(480)		(218)		(2,534)		(2,032)
Total revenues	22,270		16,905		53,582		50,991
Expenses
Policyholder benefits and claims and policyholder dividends	18,148		10,292		41,522		30,703
Interest credited to policyholder account balances	980		1,287		2,102		4,153

Capitalization of DAC	(615)		(635)		(1,887)		(2,052)
Amortization of DAC and VOBA	218		816		1,371		1,943
Amortization of negative VOBA	(12)		(6)		(31)		(25)
Interest expense on debt	239		240		690		696
Other expenses	2,893		2,869		8,683		8,753
Total expenses	21,851		14,863		52,450		44,171
Income (loss) before provision for income tax	419		2,042		1,132		6,820
Provision for income tax expense (benefit)	19		453		(80)		1,456
Net income (loss)	400		1,589		1,212		5,364
Less: Net income (loss) attributable to noncontrolling interests	5		5		16		15
Net income (loss) attributable to MetLife, Inc.	395		1,584		1,196		5,349
Less: Preferred stock dividends	64		63		156		166
Preferred stock redemption premium	—		—		—		6
Net income (loss) available to MetLife, Inc.’s common shareholders	$	331	$	1,521	$	1,040	$	5,177

Three Months Ended September 30, 2022 Compared with the Three Months Ended September 30, 2021

During the three months ended September 30, 2022, net income (loss) decreased $1.2 billion from the prior period, primarily driven by unfavorable changes in adjusted earnings, net investment gains (losses), and net derivative gains (losses), net of investment hedge adjustments, partially offset by a favorable change from our annual actuarial assumption reviews.

Management of Investment Portfolio and Hedging Market Risks with Derivatives. See “— Investments — Overview” for a discussion of the management of our investment portfolio.

We purchase investments to support our insurance liabilities and not to generate net investment gains and losses. However, net investment gains and losses are incurred and can change significantly from period to period due to changes in external influences, including changes in market factors such as interest rates, foreign currency exchange rates, credit spreads and equity markets; counterparty specific factors such as financial performance, credit rating and collateral valuation; and internal factors such as portfolio rebalancing. Changes in these factors from period to period can significantly impact the levels of provision for credit loss and impairments on our investment portfolio, as well as realized gains and losses on investments sold.

Table of Contents

We also use derivatives as an integral part of our management of the investment portfolio and insurance liabilities to hedge certain risks, including changes in interest rates, foreign currency exchange rates, credit spreads and equity market levels. We use freestanding interest rate, equity, credit and currency derivatives to hedge certain invested assets and insurance liabilities. A portion of these hedges are designated and qualify as accounting hedges, which reduce volatility in earnings. For those hedges not designated as accounting hedges, changes in market factors lead to the recognition of fair value changes in net derivative gains (losses) generally without an offsetting gain or loss recognized in earnings for the item being hedged, which creates volatility in earnings. We actively evaluate market risk hedging needs and strategies to ensure our free cash flow and capital objectives are met under a range of market conditions.

Certain variable annuity products with guaranteed minimum benefits contain embedded derivatives that are measured at estimated fair value separately from the host variable annuity contract, with changes in estimated fair value recorded in net derivative gains (losses). We use freestanding derivatives to hedge the market risks inherent in these variable annuity guarantees. The valuation of these embedded derivatives includes a nonperformance risk adjustment, which is unhedged, and can be a significant driver of net derivative gains (losses) and volatility in earnings, but does not have an economic impact on us.

We continuously review and refine our hedging strategy in light of changing economic and market conditions, evolving NAIC and NYDFS statutory requirements, and accounting rule changes. As a part of our current hedging strategy, we maintain portfolio level derivatives in our macro hedge program. These macro hedge program derivatives, which are included in the non-VA program derivatives section of the table below, mitigate the potential deterioration in our capital positions from significant adverse economic conditions.

Net Derivative Gains (Losses). The variable annuity embedded derivatives and associated freestanding derivative hedges are collectively referred to as “VA program derivatives.” All other derivatives that are economic hedges of certain invested assets and insurance liabilities are referred to as “non-VA program derivatives.” The table below presents the impact on net derivative gains (losses) from non-VA program derivatives and VA program derivatives:


	Three Months Ended September 30,
	2022		2021
	(In millions)
Non-VA program derivatives:
Interest rate	$	(333)	$	(181)
Foreign currency exchange rate	68		(147)
Credit	27		13
Equity	93		70
Non-VA embedded derivatives	(14)		45
Total non-VA program derivatives	(159)		(200)
VA program derivatives:
Market risks in embedded derivatives	91		65
Nonperformance risk adjustment on embedded derivatives	39		3
Other risks in embedded derivatives	(352)		(66)
Total embedded derivatives	(222)		2
Freestanding derivatives hedging embedded derivatives	(99)		(20)
Total VA program derivatives	(321)		(18)
Net derivative gains (losses)	$	(480)	$	(218)

Table of Contents

The favorable change in net derivative gains (losses) on non-VA program derivatives was $41 million ($32 million, net of income tax). This was primarily due to the U.S. dollar strengthening more significantly against major currencies in the current period compared to the prior period. This favorably impacted the estimated fair value of receive U.S. dollar foreign currency swaps. The favorable change was partially offset by long-term interest rates increasing more significantly in the current period compared to the prior period. This unfavorably impacted the estimated fair value of receive fixed interest rate swaps. Because certain of these hedging strategies are not designated or do not qualify as accounting hedges, the changes in the estimated fair value of these freestanding derivatives are recognized in net derivative gains (losses) without an offsetting gain or loss recognized in earnings for the items being hedged.

The unfavorable change in net derivative gains (losses) on VA program derivatives was $303 million ($239 million, net of income tax). This was due to (i) an unfavorable change of $286 million, ($226 million, net of income tax) in other risks in embedded derivatives, and (ii) an unfavorable change of $53 million ($41 million, net of income tax) in market risks in embedded derivatives, net of freestanding derivatives hedging market risks in embedded derivatives, partially offset by a favorable change of $36 million ($28 million, net of income tax) in the nonperformance risk adjustment on embedded derivatives.

The aforementioned $286 million ($226 million, net of income tax) unfavorable change in other risks in embedded derivatives reflects actuarial assumption updates and a combination of factors, such as fees deducted from accounts, changes in the benefit base, premiums, lapses, withdrawals and deaths, in addition to changes to cross-effect, basis mismatch, risk margin and fund allocation.

The aforementioned $53 million ($41 million, net of income tax) unfavorable change reflects a $79 million ($62 million, net of income tax) unfavorable change in freestanding derivatives hedging market risks in embedded derivatives, partially offset by a $26 million ($21 million, net of income tax) favorable change in market risks in embedded derivatives,

The primary changes in market factors affecting the valuation of VA program derivatives are summarized as follows:

• Long-term interest rates increased more significantly in the current period compared to the prior period, contributing to an unfavorable change in our freestanding derivatives and a favorable change in our embedded derivatives. For example, the 30-year U.S. swap rate increased 41 basis points in the current period and increased 2 basis points in the prior period.

• Key equity index levels decreased in the current period versus increased in the prior period, contributing to an unfavorable change in our embedded derivatives and a favorable change in our freestanding derivatives. For example, the S&P Global Ratings (“S&P”) 500 Index decreased 5% in the current period and increased 0.2% in the prior period.

The aforementioned $36 million ($28 million, net of income tax) favorable change in the nonperformance risk adjustment on embedded derivatives resulted from a favorable change of $35 million ($28 million, net of income tax), related to model changes and changes in capital market inputs, such as long-term interest rates and key equity index levels, on variable annuity guarantees, in addition to a slight favorable change related to changes in our own credit spread.

When equity index levels decrease in isolation, the variable annuity guarantees become more valuable to policyholders, which results in an increase in the undiscounted embedded derivative liability. Discounting this unfavorable change by the risk adjusted rate results in a smaller loss than by discounting at the risk-free rate, thus creating a gain from including an adjustment for nonperformance risk.

When the risk-free interest rate decreases in isolation, discounting the embedded derivative liability produces a higher valuation of the liability than if the risk-free interest rate had remained constant. Discounting this unfavorable change by the risk adjusted rate results in a smaller loss than by discounting at the risk-free interest rate, thus creating a gain from including an adjustment for nonperformance risk.

When our own credit spread increases in isolation, discounting the embedded derivative liability produces a lower valuation of the liability than if our own credit spread had remained constant. As a result, a gain is created from including an adjustment for nonperformance risk. For each of these primary market drivers, the opposite effect occurs when the driver moves in the opposite direction.

Net Investment Gains (Losses) . The unfavorable change in net investment gains (losses) of $330 million ($261 million, net of income tax) primarily reflects current period losses on sales of fixed maturity securities and prior period gains on sales of real estate investments. These unfavorable changes were partially offset by the prior period loss on the sale of MetLife Seguros.

Table of Contents

Taxes . For the three months ended September 30, 2022, our effective tax rate on income (loss) before provision for income tax was 5%, which differed from the U.S. statutory rate of 21% primarily due to tax benefits from foreign earnings taxed at different rates than the U.S. statutory rate and tax credits. For the three months ended September 30, 2021, our effective tax rate on income (loss) before provision for income tax was 22%, which differed from the U.S. statutory rate of 21% primarily due to tax charges from foreign earnings taxed at different rates than the U.S. statutory rate and the completed sale of MetLife Seguros, partially offset by tax benefits related to tax credits and non-taxable investment income.

Actuarial Assumption Review and Certain Other Insurance Adjustments . Results for the current period include a $75 million ($53 million, net of income tax) gain associated with our annual review of actuarial assumptions related to reserves and DAC, of which a $344 million ($273 million, net of income tax) loss was recognized in net derivative gains (losses).

Of the $75 million gain, a $315 million ($242 million, net of income tax) gain was related to DAC, and a loss of $240 million ($189 million, net of income tax) was associated with reserves. The portion of the $75 million gain that is included in adjusted earnings is $48 million ($33 million, net of income tax).

The $345 million ($273 million, net of income tax) loss recognized in net derivative gains (losses) associated with our annual review of actuarial assumptions is included within the other risks in embedded derivatives line in the table above.

As a result of our annual review of actuarial assumptions, changes were made to economic, biometric, policyholder behavior, and operational assumptions. The most significant impacts were in the MetLife Holdings and Asia segments. In the MetLife Holdings segment, significant impacts included economic assumption updates related to the projection of closed block results and updates to behavioral assumptions for variable annuities. In the Asia segment, the most significant impact was driven by economic assumption updates for interest sensitive whole life and fixed annuities. The breakdown of total current period results is summarized as follows:

• Economic assumption updates resulted in favorable impacts to reserves and DAC, for a net gain of $308 million ($234 million, net of income tax).

• Changes in biometric assumptions resulted in unfavorable impacts to reserves and favorable impacts to DAC, for a net charge of $5 million ($4 million, net of income tax).

• Changes in policyholder behavior assumptions resulted in unfavorable impacts to reserves and favorable impacts to DAC, for a net charge of $245 million ($192 million, net of income tax).

• Changes in operational assumptions resulted in favorable impacts to reserves and unfavorable impacts to DAC, for a net gain of $17 million ($15 million, net of income tax).

Results for the prior period include a $281 million ($216 million, net of income tax) charge associated with our annual review of actuarial assumptions related to reserves and DAC, of which a $2 million ($1 million, net of income tax) loss was recognized in net derivative gains (losses). Of the $281 million charge, $129 million ($96 million, net of income tax) was related to DAC and $152 million ($120 million, net of income tax) was associated with reserves. The portion of the $281 million charge that is included in adjusted earnings is $187 million ($140 million, net of income tax).

Certain other insurance adjustments recorded in the current period include a $115 million ($91 million, net of income tax) favorable reinsurance recapture in our U.S. segment and a $114 million ($90 million, net of income tax) charge related to model refinements in our MetLife Holdings segment. These adjustments are included in adjusted earnings.

Adjusted Earnings. As more fully described in “— Non-GAAP and Other Financial Disclosures,” we use adjusted earnings, which does not equate to net income (loss), as determined in accordance with GAAP, to analyze our performance, evaluate segment performance, and allocate resources. We believe that the presentation of adjusted earnings and other financial measures based on adjusted earnings, as we measure it for management purposes, enhances the understanding of our performance by highlighting the results of operations and the underlying profitability drivers of the business. Adjusted earnings and other financial measures based on adjusted earnings allow analysis of our performance relative to our business plan and facilitate comparisons to industry results. Adjusted earnings should not be viewed as a substitute for net income (loss). Adjusted earnings available to common shareholders and adjusted earnings available to common shareholders on a constant currency basis should not be viewed as substitutes for net income (loss) available to MetLife, Inc.’s common shareholders. Adjusted earnings available to common shareholders decreased $1.1 billion, net of income tax, to $966 million, net of income tax, for the three months ended September 30, 2022 from $2.1 billion, net of income tax, for the three months ended September 30, 2021.

Table of Contents

Nine Months Ended September 30, 2022 Compared with the Nine Months Ended September 30, 2021

During the nine months ended September 30, 2022, net income (loss) decreased $4.2 billion from the prior period, primarily driven by unfavorable changes in net investment gains (losses), adjusted earnings and net derivative gains (losses), net of investment hedge adjustments, partially offset by a favorable change from our annual actuarial assumption reviews.

The table below presents the impact on net derivative gains (losses) from non-VA program derivatives and VA program derivatives:


	Nine Months Ended September 30,
	2022		2021
	(In millions)
Non-VA program derivatives:
Interest rate	$	(2,424)	$	(1,206)
Foreign currency exchange rate	(102)		(356)
Credit	(95)		75
Equity	452		(612)
Non-VA embedded derivatives	33		64
Total non-VA program derivatives	(2,136)		(2,035)
VA program derivatives:
Market risks in embedded derivatives	290		803
Nonperformance risk adjustment on embedded derivatives	43		(48)
Other risks in embedded derivatives	(463)		(103)
Total embedded derivatives	(130)		652
Freestanding derivatives hedging embedded derivatives	(268)		(649)
Total VA program derivatives	(398)		3
Net derivative gains (losses)	$	(2,534)	$	(2,032)

The unfavorable change in net derivative gains (losses) on non-VA program derivatives was $101 million ($80 million, net of income tax). This was primarily due to long-term interest rates increasing more significantly in the current period compared to the prior period. This unfavorably impacted the estimated fair value of receive fixed interest rate swaps. The unfavorable change was partially offset by key equity indexes decreasing in the current period versus increasing in the prior period, favorably impacting equity options and total rate of return swaps acquired primarily as part of our macro hedge program. Because certain of these hedging strategies are not designated or do not qualify as accounting hedges, the changes in the estimated fair value of these freestanding derivatives are recognized in net derivative gains (losses) without an offsetting gain or loss recognized in earnings for the items being hedged.

The unfavorable change in net derivative gains (losses) on VA program derivatives was $401 million ($317 million, net of income tax). This was due to (i) an unfavorable change of $360 million, ($284 million, net of income tax) in other risks in embedded derivatives, and (ii) an unfavorable change of $132 million ($104 million, net of income tax) in market risks in embedded derivatives, net of freestanding derivatives hedging market risks in embedded derivatives, partially offset by a favorable change of $91 million ($71 million, net of income tax) in the nonperformance risk adjustment on embedded derivatives.

The aforementioned $360 million ($284 million, net of income tax) unfavorable change in other risks in embedded derivatives reflects actuarial assumption updates and a combination of factors, such as fees deducted from accounts, changes in the benefit base, premiums, lapses, withdrawals and deaths, in addition to changes to cross-effect, basis mismatch, risk margin and fund allocation.

The aforementioned $132 million ($104 million, net of income tax) unfavorable change reflects a $513 million ($405 million, net of income tax) unfavorable change in market risks in embedded derivatives, partially offset by a $381 million ($301 million, net of income tax) favorable change in freestanding derivatives hedging market risks in embedded derivatives.

Table of Contents

The primary changes in market factors affecting the valuation of VA program derivatives are summarized as follows:

• Key equity index levels decreased in the current period versus increased in the prior period, contributing to an unfavorable change in our embedded derivatives and a favorable change in our freestanding derivatives. For example, the S&P 500 Index decreased 25% in the current period and increased 15% in the prior period.

• Long-term interest rates increased more significantly in the current period compared to the prior period, contributing to an unfavorable change in our freestanding derivatives and a favorable change in our embedded derivatives. For example, the 30-year U.S. swap rate increased 162 basis points in the current period and increased 39 basis points in the prior period.

The aforementioned $91 million ($71 million, net of income tax) favorable change in the nonperformance risk adjustment on embedded derivatives resulted from a favorable change of $57 million ($45 million, net of income tax) related to model changes and changes in capital market inputs, such as long-term interest rates and key equity index levels, on variable annuity guarantees, in addition to a favorable change of $34 million ($26 million, net of income tax) related to changes in our own credit spread.

Net Investment Gains (Losses) . The unfavorable change in net investment gains (losses) of $3.3 billion ($2.6 billion, net of income tax) primarily reflects (i) current period losses on sales of fixed maturity securities, (ii) the prior period gain on the disposition of MetLife P&C, (iii) net foreign currency transaction losses in the current period, (iv) lower gains on sales of real estate investments, and (v) mark-to-market losses in the current period compared to market-to-market gains in the prior period on equity securities, which are measured at fair value through net income (loss). These unfavorable changes were partially offset by prior period losses on the sale of MetLife Seguros and pending disposition of MetLife Poland and Greece.

Divested Businesses. Income (loss) before provision for income tax related to divested businesses, excluding net investment gains (losses) and net derivative gains (losses), decreased $105 million ($84 million, net of income tax) to a loss of $10 million ($3 million, net of income tax) in the current period from income of $95 million ($81 million, net of income tax) in the prior period. Included in this decrease was a decline in total revenues of $938 million, before income tax, and a decrease in total expenses of $833 million, before income tax. Divested businesses primarily included activity related to the disposition of MetLife P&C in the prior period.

Taxes . For the nine months ended September 30, 2022, our effective tax rate on income (loss) before provision for income tax was (7%), which reflects an income tax benefit despite having income before provisions for income tax. Our effective tax rate differed from the U.S. statutory rate of 21% primarily due to tax benefits from foreign earnings taxed at different rates than the U.S. statutory rate, tax credits, the corporate tax deduction for stock compensation and non-taxable investment income. For the nine months ended September 30, 2021, our effective tax rate on income (loss) before provision for income tax was equal to the U.S. statutory rate of 21% as tax charges from foreign earnings taxed at different rates than the U.S. statutory rate, the completed sales of MetLife P&C and MetLife Seguros, and the pending disposition of MetLife Poland and Greece, were offset by tax benefits related to tax credits, non-taxable investment income and the corporate tax deduction for stock compensation.

Actuarial Assumption Review and Certain Other Insurance Adjustments . For the results of our 2022 and 2021 annual actuarial assumption reviews, see “— Three Months Ended September 30, 2022 Compared with the Three Months Ended September 30, 2021 — Actuarial Assumption Review and Certain Other Insurance Adjustments.”

Certain other insurance adjustments recorded in the current period include a $115 million ($91 million, net of income tax) favorable reinsurance recapture in our U.S. segment, a $97 million ($77 million, net of income tax) favorable reinsurance settlement in our MetLife Holdings segment and a $114 million ($90 million, net of income tax) charge related to model refinements in our MetLife Holdings segment. These adjustments are included in adjusted earnings.

Adjusted Earnings. Adjusted earnings available to common shareholders decreased $1.8 billion, net of income tax, to $4.3 billion, net of income tax, for the nine months ended September 30, 2022 from $6.1 billion, net of income tax, for the nine months ended September 30, 2021.

Table of Contents

Reconciliation of net income (loss) to adjusted earnings available to common shareholders and premiums, fees and other revenues to adjusted premiums, fees and other revenues

Three Months Ended September 30, 2022


		U.S.		Asia		Latin America		EMEA		MetLife Holdings		Corporate & Other		Total
		(In millions)
Net income (loss) available to MetLife, Inc.'s common shareholders		$	837	$	(421)	$	77	$	4	$	29	$	(195)	$	331
Add: Preferred stock dividends		—		—		—		—		—		64		64
Add: Preferred stock redemption premium		—		—		—		—		—		—		—
Add: Net income (loss) attributable to noncontrolling interests		—		(1)		2		1		—		3		5
Net income (loss)		837		(422)		79		5		29		(128)		400
Less: adjustments from net income (loss) to adjusted earnings available to common shareholders:
Revenues:
	Net investment gains (losses)	(71)		(386)		20		(19)		(53)		95		(414)
	Net derivative gains (losses)	284		(559)		10		7		(249)		27		(480)
	Premiums	—		—		—		—		—		—		—
	Universal life and investment-type product policy fees	—		(8)		—		1		19		—		12
	Net investment income	(93)		(82)		(63)		(269)		(70)		(1)		(578)
	Other revenues	—		—		—		1		—		39		40
Expenses:
	Policyholder benefits and claims and policyholder dividends	(2)		66		(92)		(40)		211		—		143
	Interest credited to policyholder account balances	—		53		(1)		250		—		—		302
	Capitalization of DAC	—		—		—		—		—		—		—
	Amortization of DAC and VOBA	—		8		—		1		108		—		117
	Amortization of negative VOBA	—		—		—		—		—		—		—
	Interest expense on debt	—		—		—		—		—		—		—
	Other expenses	—		—		3		(1)		—		(62)		(60)
	Goodwill impairment	—		—		—		—		—		—		—
Provision for income tax (expense) benefit		(25)		289		31		14		4		(25)		288
Adjusted earnings		$	744	$	197	$	171	$	60	$	59	(201)		1,030
Less: Preferred stock dividends												64		64
Adjusted earnings available to common shareholders												$	(265)	$	966

Premiums, fees and other revenues		$	14,966	$	1,781	$	1,123	$	547	$	1,035	$	127	$	19,579
Less: adjustments to premiums, fees and other revenues		—		(8)		—		2		19		39		52
Adjusted premiums, fees and other revenues		$	14,966	$	1,789	$	1,123	$	545	$	1,016	$	88	$	19,527

Table of Contents

Three Months Ended September 30, 2021


		U.S.		Asia		Latin America		EMEA		MetLife Holdings		Corporate & Other		Total
		(In millions)
Net income (loss) available to MetLife, Inc.'s common shareholders		$	978	$	610	$	(402)	$	74	$	501	$	(240)	$	1,521
Add: Preferred stock dividends		—		—		—		—		—		63		63
Add: Preferred stock redemption premium		—		—		—		—		—		—		—
Add: Net income (loss) attributable to noncontrolling interests		—		—		1		1		—		3		5
Net income (loss)		978		610		(401)		75		501		(174)		1,589
Less: adjustments from net income (loss) to adjusted earnings available to common shareholders:
Revenues:
	Net investment gains (losses)	115		122		(199)		(13)		48		(157)		(84)
	Net derivative gains (losses)	86		(34)		(299)		(9)		(3)		41		(218)
	Premiums	—		—		—		57		—		—		57
	Universal life and investment-type product policy fees	—		46		—		18		20		—		84
	Net investment income	(89)		16		(9)		61		(74)		(5)		(100)
	Other revenues	—		—		—		6		—		73		79
Expenses:
	Policyholder benefits and claims and policyholder dividends	(8)		(21)		—		(43)		(108)		(1)		(181)
	Interest credited to policyholder account balances	1		(55)		(8)		(58)		—		—		(120)
	Capitalization of DAC	—		—		—		15		—		—		15
	Amortization of DAC and VOBA	—		(30)		—		(13)		(15)		—		(58)
	Amortization of negative VOBA	—		—		—		—		—		—		—
	Interest expense on debt	—		—		—		—		—		—		—
	Other expenses	—		—		1		(36)		—		(74)		(109)
	Goodwill impairment	—		—		—		—		—		—		—
Provision for income tax (expense) benefit		(22)		(3)		84		(4)		27		17		99
Adjusted earnings		$	895	$	569	$	29	$	94	$	606	(68)		2,125
Less: Preferred stock dividends												63		63
Adjusted earnings available to common shareholders												$	(131)	$	2,062

Adjusted earnings available to common shareholders on a constant currency basis (1)		$	895	$	555	$	19	$	75	$	606	$	(131)	$	2,019

Premiums, fees and other revenues		$	6,408	$	2,134	$	988	$	751	$	1,161	$	197	$	11,639
Less: adjustments to premiums, fees and other revenues		—		46		—		81		20		73		220
Adjusted premiums, fees and other revenues		$	6,408	$	2,088	$	988	$	670	$	1,141	$	124	$	11,419

Adjusted premiums, fees and other revenues on a constant currency basis (1)		$	6,408	$	1,762	$	930	$	583	$	1,141	$	124	$	10,948

__________________

(1) Amounts for U.S., MetLife Holdings and Corporate & Other are shown on a reported basis, as constant currency impact is not significant.

Table of Contents

Nine Months Ended September 30, 2022


		U.S.		Asia		Latin America		EMEA		MetLife Holdings		Corporate & Other		Total
		(In millions)
Net income (loss) available to MetLife, Inc.'s common shareholders		$	1,941	$	(1,250)	$	318	$	11	$	319	$	(299)	$	1,040
Add: Preferred stock dividends		—		—		—		—		—		156		156
Add: Preferred stock redemption premium		—		—		—		—		—		—		—
Add: Net income (loss) attributable to noncontrolling interests		—		—		6		4		—		6		16
Net income (loss)		1,941		(1,250)		324		15		319		(137)		1,212
Less: adjustments from net income (loss) to adjusted earnings available to common shareholders:
Revenues:
	Net investment gains (losses)	(677)		(1,043)		58		(122)		(200)		367		(1,617)
	Net derivative gains (losses)	532		(2,468)		72		(16)		(771)		117		(2,534)
	Premiums	—		—		—		41		—		—		41
	Universal life and investment-type product policy fees	—		(27)		—		19		57		—		49
	Net investment income	(226)		(344)		(219)		(1,213)		(208)		3		(2,207)
	Other revenues	—		—		—		6		—		132		138
Expenses:
	Policyholder benefits and claims and policyholder dividends	12		88		(309)		(120)		438		—		109
	Interest credited to policyholder account balances	—		252		43		1,204		—		—		1,499
	Capitalization of DAC	—		—		—		11		—		—		11
	Amortization of DAC and VOBA	—		35		—		(8)		79		—		106
	Amortization of negative VOBA	—		—		—		—		—		—		—
	Interest expense on debt	—		—		—		—		—		—		—
	Other expenses	—		—		7		(26)		—		(187)		(206)
	Goodwill impairment	—		—		—		—		—		—		—
	Provision for income tax (expense) benefit	75		1,094		92		63		124		(100)		1,348
Adjusted earnings		$	2,225	$	1,163	$	580	$	176	$	800	(469)		4,475
Less: Preferred stock dividends												156		156
Adjusted earnings available to common shareholders												$	(625)	$	4,319

Premiums, fees and other revenues		$	31,796	$	5,701	$	3,286	$	1,803	$	3,284	$	411	$	46,281
Less: adjustments to premiums, fees and other revenues		—		(27)		—		66		57		132		228
Adjusted premiums, fees and other revenues		$	31,796	$	5,728	$	3,286	$	1,737	$	3,227	$	279	$	46,053

100

Table of Contents

Nine Months Ended September 30, 2021


		U.S.		Asia		Latin America		EMEA		MetLife Holdings		Corporate & Other		Total
		(In millions)
Net income (loss) available to MetLife, Inc.'s common shareholders		$	2,905	$	1,171	$	(319)	$	34	$	746	$	640	$	5,177
Add: Preferred stock dividends		—		—		—		—		—		166		166
Add: Preferred stock redemption premium		—		—		—		—		—		6		6
Add: Net income (loss) attributable to noncontrolling interests		—		1		4		2		—		8		15
Net income (loss)		2,905		1,172		(315)		36		746		820		5,364
Less: adjustments from net income (loss) to adjusted earnings available to common shareholders:
Revenues:
	Net investment gains (losses)	473		62		(195)		(200)		94		1,421		1,655
	Net derivative gains (losses)	127		(737)		(412)		6		(964)		(52)		(2,032)
	Premiums	865		—		—		57		—		—		922
	Universal life and investment-type product policy fees	—		59		—		26		60		—		145
	Net investment income	(236)		77		(27)		479		(216)		6		83
	Other revenues	11		—		—		6		—		168		185
Expenses:
	Policyholder benefits and claims and policyholder dividends	(603)		(59)		91		(92)		(257)		(1)		(921)
	Interest credited to policyholder account balances	2		(194)		(33)		(470)		—		—		(695)
	Capitalization of DAC	89		—		—		15		—		—		104
	Amortization of DAC and VOBA	(98)		(27)		—		(12)		—		—		(137)
	Amortization of negative VOBA	—		—		—		—		—		—		—
	Interest expense on debt	—		—		—		—		—		(1)		(1)
	Other expenses	(222)		1		3		(40)		—		(181)		(439)
	Goodwill impairment	—		—		—		—		—		—		—
	Provision for income tax (expense) benefit	(84)		278		92		2		269		(344)		213
Adjusted earnings		$	2,581	$	1,712	$	166	$	259	$	1,760	(196)		6,282
Less: Preferred stock dividends												166		166
Adjusted earnings available to common shareholders												$	(362)	$	6,116

Adjusted earnings available to common shareholders on a constant currency basis (1)		$	2,581	$	1,658	$	134	$	212	$	1,760	$	(362)	$	5,983

Premiums, fees and other revenues		$	19,812	$	6,345	$	2,797	$	2,181	$	3,545	$	526	$	35,206
Less: adjustments to premiums, fees and other revenues		876		59		—		89		60		168		1,252
Adjusted premiums, fees and other revenues		$	18,936	$	6,286	$	2,797	$	2,092	$	3,485	$	358	$	33,954

Adjusted premiums, fees and other revenues on a constant currency basis (1)		$	18,936	$	5,551	$	2,678	$	1,880	$	3,485	$	358	$	32,888

__________________

(1) Amounts for U.S., MetLife Holdings and Corporate & Other are shown on a reported basis, as constant currency impact is not significant.

101

Table of Contents

Consolidated Results - Adjusted Earnings

Business Overview. Adjusted premiums, fees and other revenues for the three months ended September 30, 2022 increased $8.1 billion, or 71%, compared to the prior period. Adjusted premiums, fees and other revenues, net of foreign currency fluctuations, increased $8.6 billion, or 78%, compared to the prior period primarily due to higher premiums in our RIS business and growth in our Group Benefits business, both in our U.S. segment. Strong sales and solid persistency in our Latin America segment also contributed to the improvement in adjusted premiums, fees and other revenues. In our Asia segment, increases in Japan and Australia were partially offset by the impact of our actuarial assumption review in both periods. A decrease in adjusted premiums, fees and other revenues in our EMEA segment was primarily due to refinements to unearned revenue reserves in both periods. In our MetLife Holdings segment, we anticipate an annual decline in adjusted premiums, fees and other revenues of approximately 6% to 8% per year from expected business run-off.

Three Months Ended September 30, 2022 Compared with the Three Months Ended September 30, 2021

Unless otherwise stated, all amounts discussed below are net of income tax.

Overview. The primary drivers of the decrease in adjusted earnings were lower investment yields due to the unfavorable impact of lower equity market returns on our private equity funds and hedge funds, as well as higher interest credited expense, partially offset by favorable underwriting, primarily driven by an overall decline in COVID-19 related claims, higher net investment income due to a larger average invested asset base and the favorable change from our annual actuarial assumption reviews. In addition, the current period includes the favorable impact from a reinsurance recapture in our U.S. segment and the unfavorable impact from model refinements in our MetLife Holdings segment.

Foreign Currency. Changes in foreign currency exchange rates had a $43 million negative impact on adjusted earnings for the third quarter of 2022 compared to the prior period. Unless otherwise stated, all amounts discussed below are net of foreign currency fluctuations. Foreign currency fluctuations can result in significant variances in the financial statement line items.

Business Growth . We benefited from positive net flows from most of our businesses, which increased our average invested asset base and resulted in higher net investment income. However, consistent with the growth in average invested assets, interest credited expenses on certain insurance-related liabilities increased. Higher premiums, fees and other revenues, net of corresponding changes in policyholder benefits, improved adjusted earnings, primarily from growth in our Asia and Latin America segments, partially offset by a decline in our MetLife Holdings segment. Higher commissions were offset by higher DAC capitalization. In our U.S. segment, higher variable expenses, coupled with higher direct expenses, including certain employee-related costs, exceeded the corresponding increase in premiums, fees and other revenues. The combined impact of the items affecting our business growth, as well as higher DAC amortization, resulted in a $62 million decrease in adjusted earnings.

Market Factors . Market factors, including interest rate levels, variability in equity market returns, and foreign currency fluctuations, continued to impact our results; however, certain impacts were mitigated by derivatives used to hedge these risks. Excluding the impact of changes in foreign currency exchange rates on net investment income in our non-U.S. segments and changes in inflation rates on our inflation-indexed investments, investment yields decreased. The decrease in investment yields was primarily driven by the unfavorable impact of lower equity market returns on our private equity and hedge funds, lower prepayment fees and lower real estate market returns on our real estate investments, primarily real estate funds. These decreases were partially offset by the favorable impact of higher yields on our fixed income securities. The changes in market factors discussed above resulted in a $1.4 billion decrease in adjusted earnings.

Underwriting, Actuarial Assumption Review and Other Insurance Adjustments. Favorable underwriting resulted in a $286 million increase in adjusted earnings and reflected overall lower impacts from the COVID-19 pandemic. This was primarily driven by favorable mortality in our U.S. and Latin America segments, partially offset by unfavorable claims experience in our Asia segment. The favorable change from our annual actuarial assumption reviews resulted in a net increase of $173 million in adjusted earnings. Refinements to certain insurance and other liabilities in both periods resulted in a $42 million increase in adjusted earnings, which includes the favorable impact from a reinsurance recapture in our U.S. segment mostly offset by model refinements in our MetLife Holdings segment, all in the current period.

Expenses. Adjusted earnings decreased $67 million primarily due to increases in corporate-related expenses and employee-related costs.

102

Table of Contents

Taxes . For the three months ended September 30, 2022, our effective tax rate on adjusted earnings was 23%, which differed from the U.S. statutory rate of 21% primarily due to tax charges from foreign earnings taxed at different rates than the U.S. statutory rate, partially offset by tax benefits from tax credits. For the three months ended September 30, 2021, our effective tax rate on adjusted earnings was equal to the U.S. statutory rate of 21% as benefits from tax credits and non-taxable investment income were offset by tax charges from foreign earnings taxed at different rates than the U.S. statutory rate.

Nine Months Ended September 30, 2022 Compared with the Nine Months Ended September 30, 2021

Unless otherwise stated, all amounts discussed below are net of income tax.

Overview. The primary drivers of the decrease in adjusted earnings were lower investment yields due to the unfavorable impact of lower equity market returns on our private equity funds and hedge funds, higher interest credited expense and higher expenses, partially offset by higher net investment income due to a larger average invested asset base, favorable underwriting, primarily driven by an overall decline in COVID-19 related claims, and the favorable change from our annual actuarial assumption reviews. In addition, the current period includes the favorable impacts from a reinsurance recapture in our U.S. segment and a reinsurance settlement in our MetLife Holdings segment, as well as the unfavorable impact from model refinements in our MetLife Holdings segment and the prior period included the release of a legal reserve.

Foreign Currency. Changes in foreign currency exchange rates had a $134 million negative impact on adjusted earnings for the first nine months of 2022 compared to the prior period. Unless otherwise stated, all amounts discussed below are net of foreign currency fluctuations. Foreign currency fluctuations can result in significant variances in the financial statement line items.

Business Growth . We benefited from positive net flows from most of our businesses, which increased our average invested asset base and resulted in higher net investment income. However, consistent with the growth in average invested assets, interest credited expenses on certain insurance-related liabilities increased. Higher premiums, fees and other revenues, net of corresponding changes in policyholder benefits, improved adjusted earnings, primarily from growth in our Asia, Latin America and EMEA segments, partially offset by a decline in our MetLife Holdings segment. Higher commissions were offset by higher DAC capitalization. The combined impact of the items affecting our business growth, partially offset by higher DAC amortization, resulted in a $430 million increase in adjusted earnings.

Market Factors . Market factors, including interest rate levels, variability in equity market returns, and foreign currency fluctuations, continued to impact our results; however, certain impacts were mitigated by derivatives used to hedge these risks. Excluding the impact of changes in foreign currency exchange rates on net investment income in our non-U.S. segments and changes in inflation rates on our inflation-indexed investments, investment yields decreased. The decrease in investment yields was primarily driven by the unfavorable impact of lower equity market returns on our private equity funds, hedge funds, and fair value option securities (“FVO Securities”), as well as lower prepayment fees. These decreases were partially offset by higher yields on our fixed income securities, as well as the favorable impact of higher real estate market returns on our real estate investments. The changes in market factors discussed above resulted in a $2.7 billion decrease in adjusted earnings.

Underwriting, Actuarial Assumption Review and Other Insurance Adjustments. Favorable underwriting resulted in a $563 million increase in adjusted earnings and reflected overall lower impacts from the COVID-19 pandemic. This was primarily driven by favorable mortality in our U.S. and Latin America segments, partially offset by unfavorable claims experience in our Asia segment. The favorable change from our annual actuarial assumption reviews resulted in a net increase of $173 million in adjusted earnings. Refinements to certain insurance and other liabilities in both periods resulted in a $127 million increase in adjusted earnings, which includes the favorable impacts from a reinsurance recapture in our U.S. segment and a reinsurance settlement in our MetLife Holdings segment, mostly offset by model refinements in our MetLife Holdings segment, all in the current period.

Expenses. Adjusted earnings decreased $273 million primarily due to increases in corporate-related expenses and employee-related costs, as well as the release of a legal reserve in the prior period.

103

Table of Contents

Taxes . For the nine months ended September 30, 2022, our effective tax rate on adjusted earnings was 22%, which differed from the U.S. statutory rate of 21% primarily due to tax charges from foreign earnings taxed at different rates than the U.S. statutory rate offset by tax benefits from tax credits, the corporate tax deduction for stock compensation and non-taxable investment income. For the nine months ended September 30, 2021, our effective tax rate on adjusted earnings was equal to the U.S. statutory rate of 21% as tax benefits from tax credits, non-taxable investment income and the corporate tax deduction for stock compensation were offset by tax charges from foreign earnings taxed at different rates than the U.S. statutory rate.

104

Table of Contents

Segment Results and Corporate & Other

U.S.

Business Overview. Adjusted premiums, fees and other revenues for the three months ended September 30, 2022 increased $8.6 billion, or 134%, compared to the prior period. This was primarily due to higher premiums in our RIS business, as well as growth in our Group Benefits business. The increase in premiums in RIS was mainly driven by a large pension risk transfer transaction in the current period. Changes in RIS premiums are mostly offset by a corresponding change in policyholder benefits. The increase in our Group Benefits business was primarily due to growth from our voluntary products, group disability, dental and group life businesses.


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
	(In millions)
Adjusted revenues
Premiums	$	14,164	$	5,746	$	29,582	$	16,919
Universal life and investment-type product policy fees	286		279		867		858
Net investment income	1,716		2,098		5,300		6,106
Other revenues	516		383		1,347		1,159
Total adjusted revenues	16,682		8,506		37,096		25,042
Adjusted expenses
Policyholder benefits and claims and policyholder dividends	14,265		6,118		30,151		17,999
Interest credited to policyholder account balances	478		362		1,212		1,080
Capitalization of DAC	(23)		(17)		(60)		(48)
Amortization of DAC and VOBA	15		26		43		50
Interest expense on debt	3		1		6		4
Other expenses	1,003		886		2,931		2,695
Total adjusted expenses	15,741		7,376		34,283		21,780
Provision for income tax expense (benefit)	197		235		588		681
Adjusted earnings	$	744	$	895	$	2,225	$	2,581

Adjusted premiums, fees and other revenues	$	14,966	$	6,408	$	31,796	$	18,936

Three Months Ended September 30, 2022 Compared with the Three Months Ended September 30, 2021

Unless otherwise stated, all amounts discussed below are net of income tax.

Business Growth . The impact of positive flows from pension risk transfer transactions and funding agreement issuances resulted in higher average invested assets, improving net investment income. However, this was partially offset by a corresponding increase in interest credited expenses on long duration insurance and investment-type products. Higher variable expenses, coupled with higher direct expenses, including certain employee-related costs, exceeded the corresponding increase in premiums, fees and other revenues. The combined impact of the items affecting our business growth decreased adjusted earnings by $8 million.

Market Factors. Market factors, including interest rate levels, variability in equity market returns and foreign currency fluctuations, continued to impact our results; however, certain impacts were mitigated by derivatives used to hedge these risks. Investment yields decreased primarily driven by the unfavorable impact of lower equity market returns on our private equity funds and lower real estate market returns on our real estate investments, primarily real estate funds. This was partially offset by higher yields on fixed income securities and mortgage loans. The impact of interest rate fluctuations resulted in an increase in our average interest credited rates on long duration insurance and investment-type products, which drove an increase in interest credited expenses. The changes in market factors discussed above resulted in a $537 million decrease in adjusted earnings.

105

Table of Contents

Underwriting and Other Insurance Adjustments . Favorable mortality in our Group Benefits business resulted in an increase in adjusted earnings of $343 million. This was driven by decreases in both incidence and severity of COVID-19 and non-COVID-19 claims. Less favorable mortality in our RIS business resulted in a decrease in adjusted earnings of $51 million, driven by our structured settlement, pension risk transfer and institutional income annuity businesses. Unfavorable claims experience in our group disability, individual disability and dental businesses, partially offset by favorable claims experience in our vision business and growth in our accident & health business resulted in a $38 million decrease in adjusted earnings. Refinements to certain insurance and other liabilities in both periods resulted in a $138 million increase in adjusted earnings, which includes the favorable impact from a reinsurance recapture in the current period.

Nine Months Ended September 30, 2022 Compared with the Nine Months Ended September 30, 2021

Unless otherwise stated, all amounts discussed below are net of income tax.

Business Growth . The impact of positive flows from pension risk transfer transactions and funding agreement issuances resulted in higher average invested assets, improving net investment income. However, this was partially offset by a corresponding increase in interest credited expenses on long duration insurance and investment-type products. Higher direct expenses, including certain employee-related costs, coupled with an increase in variable expenses, exceeded the corresponding increase in premiums, fees and other revenues. The combined impact of the items affecting our business growth increased adjusted earnings by $204 million.

Market Factors . Market factors, including interest rate levels, variability in equity market returns and foreign currency fluctuations, continued to impact our results; however, certain impacts were mitigated by derivatives used to hedge these risks. Investment yields decreased primarily driven by the unfavorable impact of lower equity market returns on our private equity funds and hedge funds, partially offset by higher yields on fixed income securities and mortgage loans, as well as the favorable impact of higher real estate market returns on our real estate investments. The impact of interest rate fluctuations resulted in an increase in our average interest credited rates on long duration insurance and investment-type products, which drove an increase in interest credited expenses. The changes in market factors discussed above resulted in a $1.1 billion decrease in adjusted earnings.

Underwriting and Other Insurance Adjustments . Favorable mortality in our Group Benefits business resulted in an increase in adjusted earnings of $510 million. This was driven by decreases in both incidence and severity of COVID-19 and non-COVID-19 claims. Less favorable mortality in our RIS business resulted in a decrease in adjusted earnings of $62 million, primarily driven by our structured settlement and pension risk transfer businesses. Unfavorable claims experience in our group disability and individual disability businesses, partially offset by growth in our accident & health business and favorable claims experience in our vision and dental businesses, resulted in a $25 million decrease in adjusted earnings. Refinements to certain insurance and other liabilities in both periods resulted in a $158 million increase in adjusted earnings, which includes the favorable impact from a reinsurance recapture in the current period.

106

Table of Contents

Asia

Business Overview . Adjusted premiums, fees and other revenues for the three months ended September 30, 2022 decreased $299 million, or 14%, compared to the prior period. Adjusted premiums, fees and other revenues, net of foreign currency fluctuations, increased $27 million, or 2%, compared to the prior period, mainly due to increases in Japan and Australia, partially offset by the impact of our annual actuarial assumption review in both periods. In Japan, higher fees from foreign currency-denominated life and fixed annuity products were partially offset by a decrease in premiums from yen-denominated life products. The increase in Australia was primarily due to higher group sales.


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
	(In millions)
Adjusted revenues
Premiums	$	1,347	$	1,594	$	4,295	$	4,861
Universal life and investment-type product policy fees	421		477		1,367		1,371
Net investment income	827		1,354		3,081		3,776
Other revenues	21		17		66		54
Total adjusted revenues	2,616		3,442		8,809		10,062
Adjusted expenses
Policyholder benefits and claims and policyholder dividends	1,257		1,220		3,670		3,750
Interest credited to policyholder account balances	497		513		1,488		1,498
Capitalization of DAC	(358)		(373)		(1,120)		(1,203)
Amortization of DAC and VOBA	190		470		799		1,080
Amortization of negative VOBA	(11)		(5)		(27)		(20)
Other expenses	749		811		2,349		2,542
Total adjusted expenses	2,324		2,636		7,159		7,647
Provision for income tax expense (benefit)	95		237		487		703
Adjusted earnings	$	197	$	569	$	1,163	$	1,712

Adjusted earnings on a constant currency basis	$	197	$	555	$	1,163	$	1,658

Adjusted premiums, fees and other revenues	$	1,789	$	2,088	$	5,728	$	6,286
Adjusted premiums, fees and other revenues on a constant currency basis	$	1,789	$	1,762	$	5,728	$	5,551

Three Months Ended September 30, 2022 Compared with the Three Months Ended September 30, 2021

Unless otherwise stated, all amounts discussed below are net of income tax.

Foreign Currency . Changes in foreign currency exchange rates decreased adjusted earnings by $14 million for the third quarter of 2022 compared to the prior period, primarily due to the weakening of the Korean won and Japanese yen against the U.S. dollar. Unless otherwise stated, all amounts discussed below are net of foreign currency fluctuations. Foreign currency fluctuations can result in significant variances in the financial statement line items.

Business Growth . Increased premiums, fees and other revenues, partially offset by higher policyholder benefits, contributed to Asia’s business growth. Consistent with this business growth, commissions increased, but were offset by DAC capitalization. Positive net flows in Japan and Korea resulted in higher average invested assets, which improved net investment income. The increase in net investment income was offset by a corresponding increase in interest credited expenses on certain insurance liabilities. The combined impact of the items affecting our business growth, partially offset by higher DAC amortization, improved adjusted earnings by $19 million.

107

Table of Contents

Market Factors . Market factors, including interest rate levels and variability in equity market returns, continued to impact our results; however, certain impacts were mitigated by derivatives used to hedge these risks. Investment yields decreased, driven by the unfavorable impact of lower equity market returns on our private equity funds, as well as lower real estate market returns on our real estate investments, primarily real estate funds. These unfavorable impacts were partially offset by higher yields on fixed income securities supporting products sold in Japan denominated in U.S. dollars and Japanese yen. A decrease in interest credited expenses on certain insurance liabilities also improved adjusted earnings. The changes in market factors discussed above decreased adjusted earnings by $353 million.

Underwriting, Actuarial Assumption Review and Other Insurance Adjustments . Unfavorable underwriting, mainly driven by COVID-19-related claims in Japan, decreased adjusted earnings by $116 million. The favorable change from our annual actuarial assumption reviews resulted in a net increase of $102 million in adjusted earnings. Refinements to certain insurance liabilities and other liabilities in both periods resulted in an $8 million increase in adjusted earnings.

Expenses . Higher expenses, primarily driven by other operating expenses, as well as an increase in corporate overhead costs, decreased adjusted earnings by $19 million.

Nine Months Ended September 30, 2022 Compared with the Nine Months Ended September 30, 2021

Unless otherwise stated, all amounts discussed below are net of income tax.

Foreign Currency . Changes in foreign currency exchange rates decreased adjusted earnings by $54 million for the first nine months of 2022 compared to the prior period, primarily due to the weakening of the Japanese yen, Korean won and Australian dollar against the U.S. dollar. Unless otherwise stated, all amounts discussed below are net of foreign currency fluctuations. Foreign currency fluctuations can result in significant variances in the financial statement line items.

Business Growth . Increased premiums, fees and other revenues, as well as lower variable expenses, were partially offset by higher policyholder benefits and commissions, net of DAC capitalization, which contributed to Asia’s business growth. Positive net flows in Japan and Korea resulted in higher average invested assets, which improved net investment income. The increase in net investment income was largely offset by a corresponding increase in interest credited expenses on certain insurance liabilities. The combined impact of the items affecting our business growth, partially offset by higher DAC amortization, improved adjusted earnings by $98 million.

Market Factors . Market factors, including interest rate levels and variability in equity market returns, continued to impact our results; however, certain impacts were mitigated by derivatives used to hedge these risks. Investment yields decreased, driven by the unfavorable impact of lower equity market returns on our private equity and hedge funds, and lower net investment income on derivatives. These unfavorable impacts were partially offset by the favorable impact of higher real estate market returns on our real estate investments, primarily real estate funds, as well as higher yields on fixed income securities supporting products sold in Japan denominated in U.S. dollars and Japanese yen. In addition, there were higher earnings from our operating joint ventures in China and India. In addition, a decrease in interest credited expenses on certain insurance liabilities improved adjusted earnings. The changes in market factors discussed above decreased adjusted earnings by $488 million.

Underwriting, Actuarial Assumption Review and Other Insurance Adjustments . Unfavorable underwriting, mainly driven by COVID-19-related claims in Japan, decreased adjusted earnings by $176 million. The favorable change from our annual actuarial assumption reviews resulted in a net increase of $102 million in adjusted earnings. Refinements to certain insurance liabilities and other liabilities in both periods resulted in an $11 million increase in adjusted earnings.

Expenses . Higher expenses, primarily driven by higher employee-related and other operating expenses, as well as an increase in corporate overhead costs, decreased adjusted earnings by $44 million.

108

Table of Contents

Latin America

Business Overview. Adjusted premiums, fees and other revenues for the three months ended September 30, 2022 increased $135 million, or 14%, compared to the prior period. Adjusted premiums, fees and other revenues, net of foreign currency fluctuations, increased $193 million, or 21%, compared to the prior period, mainly driven by strong sales and solid persistency across the region.


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
	(In millions)
Adjusted revenues
Premiums	$	823	$	705	$	2,381	$	1,936
Universal life and investment-type product policy fees	290		274		876		831
Net investment income	399		306		1,180		913
Other revenues	10		9		29		30
Total adjusted revenues	1,522		1,294		4,466		3,710
Adjusted expenses
Policyholder benefits and claims and policyholder dividends	874		885		2,454		2,370
Interest credited to policyholder account balances	89		63		241		182
Capitalization of DAC	(130)		(109)		(363)		(304)
Amortization of DAC and VOBA	68		62		238		205

Interest expense on debt	3		2		10		4
Other expenses	398		363		1,122		1,041
Total adjusted expenses	1,302		1,266		3,702		3,498
Provision for income tax expense (benefit)	49		(1)		184		46
Adjusted earnings	$	171	$	29	$	580	$	166

Adjusted earnings on a constant currency basis	$	171	$	19	$	580	$	134

Adjusted premiums, fees and other revenues	$	1,123	$	988	$	3,286	$	2,797
Adjusted premiums, fees and other revenues on a constant currency basis	$	1,123	$	930	$	3,286	$	2,678

Three Months Ended September 30, 2022 Compared with the Three Months Ended September 30, 2021

Unless otherwise stated, all amounts discussed below are net of income tax.

Foreign Currency. Changes in foreign currency exchange rates decreased adjusted earnings by $10 million for the third quarter of 2022 compared to the prior period, mainly due to the weakening of foreign currencies against the U.S. dollar, primarily the Chilean peso. Unless otherwise stated, all amounts discussed below are net of foreign currency fluctuations. Foreign currency fluctuations can result in significant variances in the financial statement line items.

Business Growth . Latin America experienced premium and fee growth across the region, primarily in Chile and Mexico. The increase in premiums and fees was partially offset by related changes in policyholder benefits. An increase in average invested assets, primarily in Chile and Mexico, generated higher net investment income. The increase in net investment income was partially offset by a corresponding increase in interest credited expenses on certain insurance liabilities. Business growth in the region drove an increase in commissions and other variable expenses, which was offset by higher DAC capitalization. The combined impact of the items affecting business growth, partially offset by higher DAC amortization, increased adjusted earnings by $25 million.

109

Table of Contents

Market Factors. Market factors, including interest rate levels and variability in equity market returns, continued to impact our results; however, certain impacts were mitigated by derivatives used to hedge these risks. Investment yields increased, driven by higher yields on fixed maturity securities and mortgage loans in Chile and Mexico, and higher earnings from a joint venture investment in Chile, partially offset by lower equity market returns on private equity funds. An increase in interest credited expenses on certain insurance liabilities also decreased adjusted earnings. The changes in market factors discussed above, as well as the net impact of inflation, resulted in a slight decrease in adjusted earnings.

Underwriting, Actuarial Assumption Review and Other Insurance Adjustments. Favorable underwriting drove a $118 million increase in adjusted earnings. This increase includes a decline in COVID-19-related claims, primarily in Mexico and Brazil. The favorable change from our annual actuarial assumption reviews resulted in a net increase of $9 million in adjusted earnings. Refinements to certain insurance liabilities and other liabilities in both periods resulted in a $6 million increase in adjusted earnings.

Expenses and Taxes . Adjusted earnings decreased $14 million due to higher employee-related costs and the region’s continued investment in technology. Tax-related adjustments in both periods resulted in a $10 million increase in adjusted earnings, primarily driven by a recurring tax item related to inflation in Chile.

Nine Months Ended September 30, 2022 Compared with the Nine Months Ended September 30, 2021

Unless otherwise stated, all amounts discussed below are net of income tax.

Foreign Currency. Changes in foreign currency exchange rates decreased adjusted earnings by $32 million for the first nine months of 2022 compared to the prior period, mainly due to the weakening of foreign currencies against the U.S. dollar, primarily the Chilean peso. Unless otherwise stated, all amounts discussed below are net of foreign currency fluctuations. Foreign currency fluctuations can result in significant variances in the financial statement line items.

Market Factors . Market factors, including interest rate levels and variability in equity market returns, continued to impact our results; however, certain impacts were mitigated by derivatives used to hedge these risks. Investment yields increased, driven by higher yields on fixed maturity securities and mortgage loans in Chile and Mexico, and higher earnings from a joint venture investment in Chile, partially offset by lower equity market returns on private equity funds. An increase in interest credited expenses on certain insurance liabilities also decreased adjusted earnings. The changes in market factors discussed above, as well as the net impact of inflation, resulted in a $38 million increase in adjusted earnings.

Underwriting, Actuarial Assumption Review and Other Insurance Adjustments. Favorable underwriting drove a $340 million increase in adjusted earnings. This increase includes a decline in COVID-19-related claims, primarily in Mexico and Brazil, as well as a reduction to the IBNR reserve that was established in the prior year. The favorable change from our annual actuarial assumption reviews resulted in a net increase of $9 million in adjusted earnings. Refinements to certain insurance liabilities and other liabilities in both periods resulted in a $12 million increase in adjusted earnings.

Expenses and Taxes . Adjusted earnings decreased $32 million due to higher employee-related costs and the region’s continued investment in technology, partially offset by the impact of continued expense discipline. Tax-related adjustments in both periods resulted in a $34 million increase in adjusted earnings, primarily driven by a recurring tax item related to inflation in Chile.

110

Table of Contents

EMEA

Business Overview. Adjusted premiums, fees and other revenues for the three months ended September 30, 2022 decreased $125 million, or 19%, compared to the prior period. Adjusted premiums, fees and other revenues, net of foreign currency fluctuations, decreased $38 million, or 7%, compared to the prior period primarily due to (i) a prior period favorable refinement to an unearned revenue reserve in Czech Republic and Slovakia, (ii) a current period unfavorable refinement to an unearned revenue reserve in the Gulf, and (iii) decreases in our corporate solutions and variable life businesses in the Gulf, as well as our pension business in Romania, partially offset by growth in our (i) accident & health business across the region, (ii) corporate solutions business in Egypt and (iii) credit life business in Turkey and Romania.


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
	(In millions)
Adjusted revenues
Premiums	$	475	$	532	$	1,476	$	1,751
Universal life and investment-type product policy fees	62		128		236		302
Net investment income	40		46		119		171
Other revenues	8		10		25		39
Total adjusted revenues	585		716		1,856		2,263
Adjusted expenses
Policyholder benefits and claims and policyholder dividends	239		268		758		944
Interest credited to policyholder account balances	16		17		53		66
Capitalization of DAC	(96)		(110)		(305)		(359)
Amortization of DAC and VOBA	79		118		260		274
Amortization of negative VOBA	(1)		(1)		(4)		(5)

Other expenses	269		308		863		1,006
Total adjusted expenses	506		600		1,625		1,926
Provision for income tax expense (benefit)	19		22		55		78
Adjusted earnings	$	60	$	94	$	176	$	259

Adjusted earnings on a constant currency basis	$	60	$	75	$	176	$	212

Adjusted premiums, fees and other revenues	$	545	$	670	$	1,737	$	2,092
Adjusted premiums, fees and other revenues on a constant currency basis	$	545	$	583	$	1,737	$	1,880

Three Months Ended September 30, 2022 Compared with the Three Months Ended September 30, 2021

Unless otherwise stated, all amounts discussed below are net of income tax.

Foreign Currency. Changes in foreign currency exchange rates decreased adjusted earnings by $19 million for the third quarter of 2022 as compared to the prior period, primarily driven by the strengthening of the U.S. dollar against the Turkish lira, euro and British pound. Unless otherwise stated, all amounts discussed below are net of foreign currency fluctuations. Foreign currency fluctuations can result in significant variances in the financial statement line items.

Business Growth. Decreases in our (i) corporate solutions and variable life businesses in the Gulf, and (ii) pension business in Romania, partially offset by growth in our (i) accident & health business across the region, (ii) credit life business in Turkey, and (iii) corporate solutions business in Egypt, resulted in a $2 million decrease in adjusted earnings.

Market Factors. Market factors, including interest rate levels and variability in equity market returns increased adjusted earnings by $4 million. This was primarily due to a decrease in DAC amortization in our variable life business as a result of equity market movements.

111

Table of Contents

Underwriting, Actuarial Assumption Review and Other Insurance Adjustments. Adjusted earnings decreased $8 million as a result of unfavorable underwriting experience in our (i) corporate solutions business in the U.K., (ii) ordinary life business in Portugal and France, and (iii) accident & health business across the region, partially offset by favorable underwriting experience in our (i) corporate solutions business in Egypt, (ii) ordinary life business in the Gulf, and (iii) credit life business in Turkey and Romania. The favorable change from our annual actuarial assumption reviews resulted in a net increase of $10 million in adjusted earnings. Refinements to certain insurance-related assets and liabilities in both periods resulted in a $20 million decrease in adjusted earnings.

Nine Months Ended September 30, 2022 Compared with the Nine Months Ended September 30, 2021

Unless otherwise stated, all amounts discussed below are net of income tax.

Foreign Currency. Changes in foreign currency exchange rates decreased adjusted earnings by $47 million for the first nine months of 2022 as compared to the prior period, primarily driven by the strengthening of the U.S. dollar against the Turkish lira, euro, British pound and Egyptian pound. Unless otherwise stated, all amounts discussed below are net of foreign currency fluctuations. Foreign currency fluctuations can result in significant variances in the financial statement line items.

Business Growth. Growth in our (i) accident & health business across the region, (ii) credit life business in Turkey, (iii) corporate solutions business in Egypt and (iv) ordinary life business in Europe, partially offset by decreases in our corporate solutions and variable life businesses in the Gulf, as well as our pension business in Romania, resulted in a $5 million increase in adjusted earnings.

Market Factors. Market factors, including interest rate levels and variability in equity market returns decreased adjusted earnings by $7 million. This was primarily due to an increase in DAC amortization in our variable life business as a result of equity market movements.

Underwriting, Actuarial Assumption Review and Other Insurance Adjustments. Adjusted earnings increased $21 million as a result of favorable underwriting experience, primarily due to the impact of the COVID-19 pandemic, which resulted in lower utilization in the first nine months of 2022 and higher claims in the prior period. Favorable underwriting experience in our (i) corporate solutions business in Egypt and the Gulf, (ii) variable life business in Lebanon and Czech Republic, and (iii) credit life business in Turkey and Romania were partially offset by unfavorable underwriting experience in our (i) ordinary life business in France, (ii) corporate solutions business in the U.K., and (iii) accident & health business across the region. The favorable change from our annual actuarial assumption reviews resulted in a net increase of $10 million in adjusted earnings. Refinements to certain insurance-related assets and liabilities in both periods resulted in a $41 million decrease in adjusted earnings.

Expenses . Higher expenses resulted in a $13 million decrease in adjusted earnings mainly due to various operating expenses across the region.

Other. In addition to the items discussed above, adjusted earnings decreased by $11 million due to the disposition of MetLife Poland and Greece.

112

Table of Contents

MetLife Holdings

Business Overview. Our MetLife Holdings segment consists of operations relating to products and businesses, previously included in our former retail business, that we no longer actively market in the United States. We anticipate an average decline in adjusted premiums, fees and other revenues of approximately 6% to 8% per year from expected business run-off. A significant portion of our adjusted earnings is driven by separate account balances. Most directly, these balances determine asset-based fee income but they also impact DAC amortization and asset-based commissions. Separate account balances are driven by movements in the market, surrenders, deposits, withdrawals, benefit payments, transfers and policy charges. Although we have discontinued selling our long-term care product, we continue to collect premiums and administer the existing block of business, which contributed to asset growth in the segment, and we expect the related reserves to grow as this block matures.


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
	(In millions)
Adjusted revenues
Premiums	$	745	$	805	$	2,281	$	2,471
Universal life and investment-type product policy fees	232		279		840		826
Net investment income	1,118		1,771		3,807		4,960
Other revenues	39		57		106		188
Total adjusted revenues	2,134		2,912		7,034		8,445
Adjusted expenses
Policyholder benefits and claims and policyholder dividends	1,659		1,611		4,610		4,683
Interest credited to policyholder account balances	202		212		607		632
Capitalization of DAC	(6)		(8)		(21)		(25)
Amortization of DAC and VOBA	(20)		80		130		190
Interest expense on debt	2		1		5		4
Other expenses	228		255		706		752
Total adjusted expenses	2,065		2,151		6,037		6,236
Provision for income tax expense (benefit)	10		155		197		449
Adjusted earnings	$	59	$	606	$	800	$	1,760

Adjusted premiums, fees and other revenues	$	1,016	$	1,141	$	3,227	$	3,485

Three Months Ended September 30, 2022 Compared with the Three Months Ended September 30, 2021

Unless otherwise stated, all amounts discussed below are net of income tax.

Business Growth . A decrease in average invested assets resulted in lower net investment income, decreasing adjusted earnings. In our deferred annuity business, negative net flows resulted in lower asset-based fee income. In addition, premiums declined due to business run-off and the impact of dividend scale reductions in both periods. The combined impact of the items affecting our business growth resulted in a $78 million decrease in adjusted earnings.

113

Table of Contents

Underwriting, Actuarial Assumption Review and Other Insurance Adjustments . Favorable underwriting, mainly in our life business resulted in a $32 million increase in adjusted earnings. The favorable change from our annual actuarial assumption reviews resulted in a net increase of $52 million in adjusted earnings. Refinements to certain insurance-related liabilities in the current period resulted in a $90 million decrease in adjusted earnings, which include the unfavorable impact from model refinements. Dividend scale reductions, as well as run-off in the Metropolitan Life Insurance Company’s (“MLIC”) closed block, contributed to lower dividend expense, net of DAC amortization, and resulted in a $16 million increase in adjusted earnings.

Expenses . Adjusted earnings increased by $16 million mainly due to lower corporate-related expenses.

Nine Months Ended September 30, 2022 Compared with the Nine Months Ended September 30, 2021

Unless otherwise stated, all amounts discussed below are net of income tax.

Business Growth . In our deferred annuity business, negative net flows resulted in lower asset-based fee income. In addition, premiums declined due to business run-off and the impact of dividend scale reductions in both periods. The combined impact of the items affecting our business growth, partially offset by lower DAC amortization, resulted in a $47 million decrease in adjusted earnings.

Underwriting, Actuarial Assumption Review and Other Insurance Adjustments. Less favorable underwriting, mainly in our long-term care business, reflecting a smaller impact from the COVID-19 pandemic in the current period, partially offset by favorable underwriting in our life business, resulted in a $46 million decrease in adjusted earnings. The favorable change from our annual actuarial assumption reviews resulted in a net increase of $52 million in adjusted earnings. Refinements to certain insurance-related liabilities, which include the unfavorable impact from model refinements, partially offset by a reinsurance settlement, all in the current period, resulted in a $13 million decrease in adjusted earnings. Dividend scale reductions, as well as run-off in the MLIC closed block, contributed to lower dividend expense, net of DAC amortization, and resulted in a $58 million increase in adjusted earnings.

Expenses . Adjusted earnings increased by $27 million mainly due to lower corporate-related expenses.

114

Table of Contents

Corporate & Other


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
	(In millions)
Adjusted revenues
Premiums	$	(7)	$	16	$	(17)	$	54
Universal life and investment-type product policy fees	(1)		—		1		1
Net investment income	63		93		172		153
Other revenues	96		108		295		303
Total adjusted revenues	151		217		451		511
Adjusted expenses
Policyholder benefits and claims and policyholder dividends	(3)		9		(12)		36

Capitalization of DAC	(2)		(3)		(7)		(9)
Amortization of DAC and VOBA	3		2		7		7
Interest expense on debt	231		236		669		683
Other expenses	186		137		506		278
Total adjusted expenses	415		381		1,163		995
Provision for income tax expense (benefit)	(63)		(96)		(243)		(288)
Adjusted earnings	(201)		(68)		(469)		(196)
Less: Preferred stock dividends	64		63		156		166
Adjusted earnings available to common shareholders	$	(265)	$	(131)	$	(625)	$	(362)

Adjusted premiums, fees and other revenues	$	88	$	124	$	279	$	358

The table below presents adjusted earnings available to common shareholders by source:


	Three Months Ended September 30,			Nine Months Ended September 30,
		2022		2021		2022		2021
		(In millions)
Business activities		$	36	$	41	$	106	$	98
Net investment income		60		95		170		159
Interest expense on debt		(240)		(247)		(693)		(716)
Corporate initiatives and projects		(15)		(25)		(48)		(74)
Other		(105)		(28)		(247)		49
Provision for income tax (expense) benefit and other tax-related items		63		96		243		288
Preferred stock dividends		(64)		(63)		(156)		(166)
Adjusted earnings available to common shareholders		$	(265)	$	(131)	$	(625)	$	(362)

Three Months Ended September 30, 2022 Compared with the Three Months Ended September 30, 2021

Unless otherwise stated, all amounts discussed below are net of income tax.

Business Activities . Adjusted earnings from business activities decreased $4 million. This was primarily related to lower results from certain of our businesses.

Net Investment Income. Net investment income decreased $28 million, primarily due to lower returns on our equity market sensitive investments, including private equity funds, and lower yields on our mortgage loans. These decreases were partially offset by higher income on our real estate investments.

115

Table of Contents

Interest Expense on Debt. Interest expense on debt decreased by $6 million, primarily due to a senior note redemption in July 2021, partially offset by a senior note issuance in July 2022.

Corporate Initiatives and Projects & Other. Adjusted earnings decreased $53 million, primarily as a result of increases in certain corporate-related expenses and employee-related costs.

Provision for Income Tax (Expense) Benefit and Other Tax-Related Items. An unfavorable change in Corporate & Other’s taxes was primarily due to lower utilization of tax preferenced items, which include non-taxable investment income, tax credits and foreign earnings taxed at different rates than the U.S. statutory rate.

Nine Months Ended September 30, 2022 Compared with the Nine Months Ended September 30, 2021

Unless otherwise stated, all amounts discussed below are net of income tax.

Business Activities . Adjusted earnings from business activities increased $6 million. This was primarily related to improved results from certain of our businesses.

Net Investment Income. Net investment income increased $9 million, primarily due to a higher average invested asset base, as well as increased income on real estate investments. These increases were partially offset by lower returns on our equity market sensitive investments, including private equity funds and FVO Securities, as well as lower yields on our mortgage loans.

Interest Expense on Debt. Interest expense on debt decreased by $18 million, primarily due to a senior note redemption in July 2021, partially offset by a senior note issuance in July 2022.

Corporate Initiatives and Projects & Other . Adjusted earnings decreased $214 million, primarily as a result of an increase in corporate-related expenses, the release of a legal reserve in the prior period and higher interest expense on tax positions due to audit settlements in both periods.

Preferred Stock Dividends. Adjusted earnings available to common shareholders increased $10 million primarily as a result of the redemption and cancellation of the Series C preferred stock, in June 2021.

116

Table of Contents

Investments

Overview

We manage our investment portfolio using disciplined asset/liability management (“ALM”) principles, focusing on cash flow and duration to support our current and future liabilities. Our intent is to match the timing and amount of liability cash outflows with invested assets that have cash inflows of comparable timing and amount, while optimizing risk-adjusted investment income and risk-adjusted total return. Our investment portfolio is heavily weighted toward fixed income investments, with the vast majority of our portfolio invested in fixed maturity securities available-for-sale (“AFS”) and mortgage loans. These securities and loans have varying maturities and other characteristics which cause them to be generally well suited for matching the cash flow and duration of insurance liabilities.

Current Environment

As a global insurance company, we continue to be impacted by the changing global financial and economic environment, the fiscal and monetary policy of governments and central banks around the world and other governmental measures. The COVID-19 pandemic continues to impact the global economy and financial markets and has caused volatility in the global equity, credit and real estate markets. See “— Industry Trends — Financial and Economic Environment.” Uncertainty created by the COVID-19 pandemic may persist for some time and may continue to impact pricing levels of risk-bearing investments, as well as our business operations, investment portfolio and derivatives. Rising market interest rates have impacted our investment portfolio and derivatives. See “— Industry Trends,” as well as “— Results of Operations — Consolidated Results,” and “— Results of Operations — Consolidated Results - Adjusted Earnings” for impacts on our derivatives and analysis of the period over period changes in investment portfolio results. See also “Investments — Fixed Maturity Securities Available-for-Sale — Evaluation of Fixed Maturity Securities AFS in an Unrealized Loss Position” in Note 6 of the Notes to the Interim Condensed Consolidated Financial Statements for impacts on the net unrealized gain (loss) on our fixed maturity securities AFS.

Selected Country and Sector Investments

Selected Country: We have a market presence in numerous countries and, therefore, our investment portfolio, which supports our insurance operations and related policyholder liabilities, as well as our global portfolio diversification objectives, is exposed to risks posed by local political and economic conditions. The countries included in the following table have been the most affected by these risks. The table below presents a summary of selected country fixed maturity securities AFS, at estimated fair value, on a “country of risk basis” (e.g. where the issuer primarily conducts business).


	Selected Country Fixed Maturity Securities AFS at September 30, 2022
Country	Sovereign (1)			Financial Services			Non-Financial Services			Total (2)
	(Dollars in millions)
Italy	15			52			511			578
Colombia	312			54			133			499
Peru	110			20			197			327
Ukraine (3)	54			—			2			56
Russian Federation (3)	43			—			3			46
Turkey	34			—			9			43
Total	$	568		$	126		$	855		$	1,549
Investment grade %	31.4		%	55.9		%	64.8		%	51.8		%

__________________

(1) Sovereign includes government and agency.

(2) The par value, amortized cost net of ACL and estimated fair value, net of purchased and written credit default swaps, of these securities wer e $1.9 billion, $1.8 billion and $1.5 billion, respectively, at September 30, 2022. The notional value and estimated fair value of the net purchased and written credit default swaps were $76 million and $11 million, respectively, at September 30, 2022.

117

Table of Contents

(3) As of September 30, 2022, the amortized cost, ACL and amortized cost, net of ACL of our Russian Federation sovereign securities were $120 million , $79 million and $41 million , respectively; and the amortized cost, ACL and amortized cost, net of ACL of our Russian Federation corporate securities were $7 million, $4 million and $3 million , respectively. As of September 30, 2022, the amortized cost, ACL and amortized cost, net of ACL of our Ukraine sovereign securities were $91 million, $37 million and $54 million, r espectively; and the amortized cost, ACL and amortized cost, net of ACL of our Ukraine corporate securities were $3 million, $1 million and $1 million, respectively.

Selected Sector: See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Investments — Current Environment —Selected Country and Sector Investments” included in the 2021 Annual Report for information on our Selected Sector investments as of December 31, 2021.

We manage direct and indirect investment exposure in the selected countries and sectors through fundamental analysis and we continually monitor and adjust our level of investment exposure.

Investment Portfolio Results

The reconciliation of net investment income under GAAP to adjusted net investment income is presented below.


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2022		2021		2022		2021
	(In millions)
Net investment income — GAAP	$	3,585	$	5,568	$	11,452	$	16,162
Investment hedge adjustments	252		228		699		660
Unit-linked investment income	321		(114)		1,507		(699)
Other	5		(14)		1		(44)
Adjusted net investment income (1)	$	4,163	$	5,668	$	13,659	$	16,079

__________________

(1) See “Financial Measures and Segment Accounting Policies” in Note 2 of the Notes to the Interim Condensed Consolidated Financial Statements for a discussion of the adjustments made to net investment income under GAAP in calculating adjusted net investment income.

The following yield table presentation is consistent with how we measure our investment performance for management purposes, and we believe it enhances understanding of our investment portfolio results.


	For the Three Months Ended September 30,								For the Nine Months Ended September 30,
	2022				2021				2022				2021
Asset Class	Yield % (1)		Amount		Yield % (1)		Amount		Yield % (1)		Amount		Yield % (1)		Amount
	(Dollars in millions)
Fixed maturity securities AFS (2), (3)	3.81	%	$	2,773	3.71	%	$	2,761	3.66	%	$	8,120	3.73	%	$	8,330
Mortgage loans (3)	4.37		898		4.12		837		4.20		2,553		4.18		$	2,583
Real estate and real estate joint ventures	5.75		179		6.00		181		7.51		697		4.28		$	385
Policy loans	5.18		114		5.09		118		5.13		344		5.14		$	359
Equity securities	6.40		14		4.85		8		4.14		26		4.69		$	28
Other limited partnership interests	(5.35)		(194)		48.43		1,542		8.26		903		45.04		$	3,877
Cash and short-term investments	2.54		78		0.70		20		1.74		151		0.76		$	62
Other invested assets	—		426		—		342		—		1,274		—		$	906
Investment income	3.98	%	4,288		5.36	%	5,809		4.33	%	14,068		5.09	%	$	16,530
Investment fees and expenses	(0.12)		(125)		(0.12)		(125)		(0.12)		(398)		(0.12)		$	(399)
Net investment income including divested businesses (4)	3.86	%	4,163		5.24	%	5,684		4.21	%	13,670		4.97	%	$	16,131
Less: net investment income from divested businesses (4)			—				16				11				$	52
Adjusted net investment income			$	4,163			$	5,668			$	13,659			$	16,079

__________________

118

Table of Contents

(1) We calculate yields using adjusted net investment income as a percent of average quarterly asset carrying values. Adjusted net investment income excludes realized gains (losses) from sales and disposals, and includes the impact of changes in foreign currency exchange rates. Average quarterly asset carrying values exclude unrealized gains (losses), collateral received in connection with our securities lending program, annuities funding structured settlement claims, freestanding derivative assets, collateral received from derivative counterparties and contractholder-directed equity securities. In addition, average quarterly asset carrying values include invested assets reclassified to held-for-sale, while ending carrying values exclude invested assets reclassified to held-for-sale. A yield is not presented for other invested assets, as it is not considered a meaningful measure of performance for this asset class.

(2) Investment income (loss) from fixed maturity securities includes amounts from FVO Securities of ($43) million and ($197) million for the three months and nine months ended September 30, 2022, respectively, and $6 million and $92 million for the three months and nine months ended September 30, 2021, respectively.

(3) Investment income from fixed maturity securities AFS and mortgage loans includes prepayment fees.

(4) See “Financial Measures and Segment Accounting Policies” in Note 2 of the Notes to the Interim Condensed Consolidated Financial Statements for discussion of divested businesses.

See “— Results of Operations — Consolidated Results - Adjusted Earnings” for an analysis of the period over period changes in investment portfolio results.

Fixed Maturity Securities AFS and Equity Securities

The following table presents fixed maturity securities AFS and equity securities by type (public or private) and information about perpetual and redeemable securities held at:


	September 30, 2022					December 31, 2021
Securities by Type	Estimated Fair Value			% of Total		Estimated Fair Value			% of Total
	(Dollars in millions)
Fixed maturity securities AFS
Publicly-traded	$	208,818		77.1	%	$	267,040		78.5	%
Privately-placed	61,947			22.9		73,234			21.5
Total fixed maturity securities AFS	$	270,765		100.0	%	$	340,274		100.0	%
Percentage of cash and invested assets	60.4		%			66.1		%
Equity securities
Publicly-traded	$	761		78.2	%	$	1,118		88.1	%
Privately-held	212			21.8		151			11.9
Total equity securities	$	973		100.0	%	$	1,269		100.0	%
Percentage of cash and invested assets	0.2		%			0.2		%
Perpetual and redeemable securities
Perpetual securities included within fixed maturity securities AFS and equity securities	$	282				$	321
Redeemable preferred stock with a stated maturity included within fixed maturity securities AFS	$	834				$	864

See Note 6 of the Notes to the Interim Condensed Consolidated Financial Statements for information about fixed maturity securities AFS by sector, contractual maturities, continuous gross unrealized losses and equity securities by security type and the related cost, net unrealized gains (losses) and estimated fair value of these securities; as well as realized gains (losses) on sales and disposals and unrealized net gains (losses) recognized in earnings.

Included within fixed maturity securities AFS are structured securities, including residential mortgage-backed securities (“RMBS”), asset-backed securities and collateralized loan obligations (“ABS & CLO”), previously disclosed as ABS in the 2021 Annual Report, and commercial mortgage-backed securities (“CMBS”) (collectively, “Structured Products”). See “— Structured Products” for further information.

119

Table of Contents

Perpetual securities are included within fixed maturity securities AFS and equity securities. Upon acquisition, we classify perpetual securities that have attributes of both debt and equity as fixed maturity securities AFS if the securities have an interest rate step-up feature which, when combined with other qualitative factors, indicates that the securities have more debt-like characteristics; while those with more equity-like characteristics are classified as equity securities. Many of such securities, commonly referred to as “perpetual hybrid securities,” have been issued by non-U.S. financial institutions that are accorded the highest two capital treatment categories by their respective regulatory bodies (i.e. core capital, or “Tier 1 capital” and perpetual deferrable securities, or “Upper Tier 2 capital”).

Redeemable preferred stock with a stated maturity is included within fixed maturity securities AFS. These securities, which are commonly referred to as “capital securities,” primarily have cumulative interest deferral features and are primarily issued by U.S. financial institutions.

See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Investments — Fixed Maturity Securities AFS and Equity Securities — Valuation of Securities” included in the 2021 Annual Report for further information on the processes used to value securities and the related controls.

Fair Value of Fixed Maturity Securities AFS and Equity Securities

Fixed maturity securities AFS and equity securities measured at estimated fair value on a recurring basis and their corresponding fair value pricing sources were as follows:


	September 30, 2022
Level	Fixed Maturity Securities AFS				Equity Securities
	(Dollars in millions)
Level 1
Quoted prices in active markets for identical assets	$	15,587	5.8	%	$	592	60.8	%
Level 2
Independent pricing sources	229,008		84.6		167		17.2
Internal matrix pricing or discounted cash flow techniques	563		0.2		45		4.6
Significant other observable inputs	229,571		84.8		212		21.8
Level 3
Independent pricing sources	19,803		7.3		19		2.0
Internal matrix pricing or discounted cash flow techniques	5,483		2.0		147		15.1
Independent broker quotations	321		0.1		3		0.3
Significant unobservable inputs	25,607		9.4		169		17.4
Total estimated fair value	$	270,765	100.0	%	$	973	100.0	%

See Note 8 of the Notes to the Interim Condensed Consolidated Financial Statements for the fixed maturity securities AFS and equity securities fair value hierarchy; a rollforward of the fair value measurements for securities measured at estimated fair value on a recurring basis using significant unobservable (Level 3) inputs; transfers into and/or out of Level 3; and further information about the valuation approaches and inputs by level by major classes of invested assets that affect the amounts reported above.

The majority of the Level 3 fixed maturity securities AFS and equity securities were concentrated in three sectors at September 30, 2022: U.S. corporate securities, foreign corporate securities and RMBS. During the three months ended September 30, 2022, Level 3 fixed maturity securities AFS decreased by $2.4 billion, or 9%. The decrease was driven by a decrease in estimated fair value recognized in other comprehensive income (loss) and by transfers out of Level 3 in excess of transfers into Level 3, partially offset by purchases in excess of sales. During the nine months ended September 30, 2022, Level 3 fixed maturity securities AFS decreased by $5.8 billion, or 18%. The decrease was driven by a decrease in estimated fair value recognized in other comprehensive income (loss) and by transfers out of Level 3 in excess of transfers into Level 3, partially offset by purchases in excess of sales.

See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Investments — Fixed Maturity Securities AFS and Equity Securities — Valuation of Securities” included in the 2021 Annual Report for further information on the estimates and assumptions that affect the amounts reported above.

120

Table of Contents

Fixed Maturity Securities AFS

See Notes 1 and 6 of the Notes to the Interim Condensed Consolidated Financial Statements for information about fixed maturity securities AFS by sector, contractual maturities and continuous gross unrealized losses.

Fixed Maturity Securities AFS Credit Quality — Ratings

See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Investments — Fixed Maturity Securities AFS and Equity Securities — Fixed Maturity Securities AFS Credit Quality — Ratings” included in the 2021 Annual Report for a discussion of the credit quality ratings assigned by Nationally Recognized Statistical Rating Organizations (“NRSRO”), credit quality designations and designation categories assigned by the Securities Valuation Office of the NAIC for fixed maturity securities AFS and modeling methodologies adopted by the NAIC for non-agency RMBS and CMBS that estimate security level expected losses under a variety of economic scenarios.

NRSRO ratings and NAIC designations are as of the dates shown below. Over time, credit ratings and designations can migrate, up or down, through the NRSRO’s and NAIC’s continuous monitoring process. NRSRO ratings are based on availability of applicable ratings. If no NRSRO rating is available, then an internally developed rating is used. If no NAIC designation is available, then, as permitted by the NAIC, an internally developed designation is used. NAIC designations are generally similar to the credit quality ratings of the NRSRO, except for (i) non-agency RMBS and CMBS and (ii) securities rated Ca or C by NRSROs, included within Caa and lower, that are designated NAIC 6; accordingly, NAIC designations may not correspond to NRSRO ratings.

The following table presents total fixed maturity securities AFS by NRSRO rating, except for non-agency RMBS and CMBS, which are presented using NAIC designations for modeled securities. In addition, in the following table, the applicable NAIC designation from the NAIC published comparison of NRSRO ratings to NAIC designations is provided.


		September 30, 2022								December 31, 2021
NRSRO Rating	NAIC Designation	Amortized Cost net of ACL		Unrealized Gains (Losses)		Estimated Fair Value		% of Total		Amortized Cost net of ACL		Unrealized Gains (Losses) (1)		Estimated Fair Value		% of Total
		(Dollars in millions)
Aaa/Aa/A	1	$	205,583	$	(19,803)	$	185,780	68.6	%	$	217,886	$	21,508	$	239,394	70.4	%
Baa	2	81,544		(10,268)		71,276		26.3		77,739		7,470		85,209		25.0
Subtotal investment grade		287,127		(30,071)		257,056		94.9		295,625		28,978		324,603		95.4
Ba	3	11,725		(1,073)		10,652		4.0		11,439		534		11,973		3.5
B	4	2,909		(291)		2,618		1.0		3,152		(2)		3,150		0.9
Caa and lower	5	336		(30)		306		0.1		563		(37)		526		0.2
In or near default	6	162		(29)		133		—		14		8		22		—
Subtotal below investment grade		15,132		(1,423)		13,709		5.1		15,168		503		15,671		4.6
Total fixed maturity securities AFS		$	302,259	$	(31,494)	$	270,765	100.0	%	$	310,793	$	29,481	$	340,274	100.0	%

__________________

(1) Excludes gross unrealized gains (losses) related to assets held-for-sale. See Note 3 of the Notes to the Interim Condensed Consolidated Financial Statements for information on the Company’s business dispositions.

121

Table of Contents

The following tables present total fixed maturity securities AFS, at estimated fair value, by sector and by NRSRO rating, except for non-agency RMBS and CMBS, which are presented using NAIC designations for modeled securities. In addition, in the following table, the applicable NAIC designation from the NAIC published comparison of the NRSRO ratings to NAIC designations is provided.


	Fixed Maturity Securities AFS — by Sector & Credit Quality Rating
NRSRO Rating	Aaa/Aa/A			Baa			Ba			B			Caa and Lower			In or Near Default			Total Estimated Fair Value
NAIC Designation	1			2			3			4			5			6
	(Dollars in millions)
September 30, 2022
U.S. corporate	$	39,166		$	33,404		$	4,399		$	1,649		$	146		$	60		$	78,824
Foreign corporate	17,598			28,767			3,068			453			40			1			49,927
Foreign government	36,234			4,872			2,545			291			63			45			44,050
U.S. government and agency	31,108			454			—			—						—			31,562
RMBS	26,341			663			71			51			5			14			27,145
ABS & CLO	13,880			2,408			366			73			26			13			16,766
Municipals	11,798			192			24			—			—			—			12,014
CMBS	9,655			516			179			101			26			—			10,477
Total fixed maturity securities AFS	$	185,780		$	71,276		$	10,652		$	2,618		$	306		$	133		$	270,765
Percentage of total	68.6		%	26.3		%	4.0		%	1.0		%	0.1		%	—		%	100.0		%

December 31, 2021
U.S. corporate	$	47,377		$	39,094		$	4,523		$	1,796		$	244		$	—		$	93,034
Foreign corporate	23,228			35,893			3,731			577			210			1			63,640
Foreign government	52,316			5,739			3,032			506			14			2			61,609
U.S. government and agency	46,065			534			—			—			—			—			46,599
RMBS	29,529			634			150			67			5			19			30,404
ABS & CLO	15,920			2,221			316			85			27			—			18,569
Municipals	13,737			457			18			—			—			—			14,212
CMBS	11,222			637			203			119			26			—			12,207
Total fixed maturity securities AFS	$	239,394		$	85,209		$	11,973		$	3,150		$	526		$	22		$	340,274
Percentage of total	70.4		%	25.0		%	3.5		%	0.9		%	0.2		%	—		%	100.0		%

U.S. and Foreign Corporate Fixed Maturity Securities AFS

We maintain a diversified portfolio of corporate fixed maturity securities AFS across industries and issuers. This portfolio did not have any exposure to any single issuer in excess of 1% of total investments at September 30, 2022. The top 10 holdings comprised 1% and 2% of total investments at September 30, 2022 and December 31, 2021, respectively. The table below presents our U.S. and foreign corporate securities holdings by industry at:


	September 30, 2022				December 31, 2021
Industry	Estimated Fair Value		% of Total		Estimated Fair Value		% of Total
	(Dollars in millions)
Industrial	$	38,048	29.6	%	$	45,732	29.2	%
Finance	29,766		23.1		35,676		22.7
Consumer	26,002		20.2		31,142		19.9
Utility	22,145		17.2		28,961		18.5
Communications	9,930		7.7		12,346		7.9
Other	2,860		2.2		2,817		1.8
Total	$	128,751	100.0	%	$	156,674	100.0	%

122

Table of Contents

Structured Products

Structured Products are comprised of investments in securities that are collateralized by residential mortgages, commercial mortgages, bank loans and other assets. Our investment selection criteria and monitoring includes the reviews of credit ratings, characteristics of the assets underlying the securities, borrower characteristics and the level of credit enhancement. We held $54.4 billion and $61.2 billion of Structured Products, at estimated fair value, at September 30, 2022 and December 31, 2021, respectively, as presented in the RMBS, ABS & CLO and CMBS sections below.

RMBS

Our RMBS portfolio is diversified by security type and risk profile. The following table presents our RMBS portfolio by security type, risk profile and ratings profile at:


	September 30, 2022						December 31, 2021
	Estimated Fair Value		% of Total		Net Unrealized Gains (Losses)		Estimated Fair Value		% of Total		Net Unrealized Gains (Losses) (1)
	(Dollars in millions)
Security type
Collateralized mortgage obligations	$	15,978	58.9	%	$	(1,655)	$	17,646	58.0	%	$	1,092
Pass-through mortgage-backed securities	11,167		41.1		(1,617)		12,758		42.0		160
Total RMBS	$	27,145	100.0	%	$	(3,272)	$	30,404	100.0	%	$	1,252
Risk profile
Agency	$	16,884	62.2	%	$	(2,324)	$	19,487	64.1	%	$	671
Non Agency
Prime	2,554		9.4		(454)		3,018		9.9		13
Alt-A	4,827		17.8		(328)		3,887		12.8		267
Sub-prime	2,880		10.6		(166)		4,012		13.2		301
Subtotal Non Agency	10,261		37.8	%	(948)		10,917		35.9	%	581
Total RMBS	$	27,145	100.0	%	$	(3,272)	$	30,404	100.0	%	$	1,252
Ratings profile
Rated Aaa and Aa	$	22,415	82.6	%			$	24,190	79.6	%
Designated NAIC 1	$	26,345	97.1	%			$	29,529	97.1	%

__________________

See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Investments — Fixed Maturity Securities AFS and Equity Securities — Structured Products — RMBS” included in the 2021 Annual Report for further information about collateralized mortgage obligations and pass-through mortgage-backed securities, as well as agency, prime, alternative residential mortgage loans (“Alt-A”) and sub-prime RMBS.

Historically, we have managed our exposure to sub-prime RMBS holdings by focusing primarily on senior tranche securities, stress testing the portfolio with severe loss assumptions and closely monitoring the performance of the portfolio. Our sub-prime RMBS portfolio consists predominantly of securities that were purchased at significant discounts to par value and discounts to the expected principal recovery value of these securities. The vast majority of these securities are investment grade under the NAIC designations (e.g., NAIC 1 and NAIC 2).

123

Table of Contents

ABS & CLO

Our non-mortgage loan-backed structured securities are comprised of two broad categories of securitizations: ABS & CLO. These portfolios are diversified by collateral type and issuer. The following table presents these portfolios by collateral type and ratings profile at:


	September 30, 2022						December 31, 2021
	Estimated Fair Value		% of Total		Net Unrealized Gains (Losses)		Estimated Fair Value		% of Total		Net Unrealized Gains (Losses) (1)
	(Dollars in millions)
ABS
Collateral type
Vehicle and equipment loans	$	1,438	8.6	%	$	(61)	$	1,864	10.0	%	$	10
Consumer Loans	1,326		7.9		(96)		1,653		8.9		48
Student loans	861		5.1		(79)		1,143		6.2		15
Foreign residential loans	652		3.9		(43)		922		5.0		2
Credit card	1,031		6.1		(15)		900		4.8		9
Other (2)	3,955		23.6		(481)		3,646		19.6		45
Total ABS	9,263		55.2	%	(775)		10,128		54.5	%	129
CLO (3)	7,503		44.8		(466)		8,441		45.5		(3)
Total ABS & CLO	$	16,766	100.0	%	$	(1,241)	$	18,569	100.0	%	$	126

ABS ratings profile
Rated Aaa and Aa	$	4,407	47.6	%			$	5,289	52.2	%
Designated NAIC 1	$	7,058	76.2	%			$	8,105	80.0	%
CLO ratings profile
Rated Aaa and Aa	$	5,660	75.4	%			$	6,749	80.0	%
Designated NAIC 1	$	6,814	90.8	%			$	7,815	92.6	%
ABS & CLO ratings profile
Rated Aaa and Aa	$	10,067	60.0	%			$	12,038	64.8	%
Designated NAIC 1	$	13,872	82.7	%			$	15,920	85.7	%

__________________

(2) Other ABS are broadly diversified across several subsectors and issuers, including securities with the following collateral types: digital infrastructure, franchise, transportation equipment, and renewable energy.

(3) Includes primarily securities collateralized by broadly syndicated bank loans.

124

Table of Contents

CMBS

Our CMBS portfolio is comprised primarily of securities collateralized by multiple commercial mortgage loans and is diversified by property type, borrower and geography. The following tables present our CMBS portfolio by collateral type and ratings profile at.


	September 30, 2022						December 31, 2021
	Estimated Fair Value		% of Total		Net Unrealized Gains (Losses)		Estimated Fair Value		% of Total		Net Unrealized Gains (Losses) (1)
	(Dollars in millions)
Collateral type
Conduit	$	7,054	67.3	%	$	(604)	$	8,282	67.8	%	$	341
Single asset and single borrower	1,981		18.9		(162)		2,269		18.6		32
Commercial real estate collateralized loan obligations	513		4.9		(6)		653		5.4		2
Agency	606		5.8		(87)		610		5.0		50
Other	323		3.1		(25)		393		3.2		2
Total CMBS	$	10,477	100.0	%	$	(884)	$	12,207	100	%	$	427
Ratings profile
Rated Aaa and Aa	$	8,255	78.8	%			$	9,614	78.8	%
Designated NAIC 1	$	9,654	92.1	%			$	11,222	91.9	%

__________________

Evaluation of Fixed Maturity Securities AFS for Credit Loss, Rollforward of Allowance for Credit Loss and Credit Loss on Fixed Maturity Securities AFS Recognized in Earnings

See Note 6 of the Notes to the Interim Condensed Consolidated Financial Statements for information about the evaluation of fixed maturity securities AFS for credit loss, rollforward of the ACL, net credit loss provision (release), and impairment loss, as well as realized gross gains and gross losses on sales and disposals of fixed maturity securities AFS at and for the nine months ended September 30, 2022.

Contractholder-Directed Equity Securities and Fair Value Option Securities

The estimated fair value of these investments, which are primarily comprised of contractholder-directed investments supporting unit-linked variable annuity type liabilities (“Unit-linked investments”), was $9.0 billion and $12.1 billion, or 2% and 2.4% of cash and invested assets, at September 30, 2022 and December 31, 2021, respectively. See Notes 6 and 8 of the Notes to the Interim Condensed Consolidated Financial Statements for a description of this portfolio, investments by asset type and the related cost or amortized cost, net unrealized gains (losses) and estimated fair value of these securities, the fair value hierarchy and a rollforward of the fair value measurements for these investments measured at estimated fair value on a recurring basis using significant unobservable (Level 3) inputs.

Securities Lending Transactions, Repurchase Agreements and Third-Party Custodian Administered Programs

We participate in securities lending transactions, repurchase agreements and third-party custodian administered programs with unaffiliated financial institutions in the normal course of business for the purpose of enhancing the total return on our investment portfolio.

Securities lending transactions and repurchase agreements: We account for these arrangements as secured borrowings and record a liability in the amount of the cash received. We obtain collateral, usually cash, from the borrower, which must be returned to the borrower when the securities are returned to us. Through these arrangements, we were liable for cash collateral under our control of $16.6 billion and $24.4 billion at September 30, 2022 and December 31, 2021, respectively, including a portion that may require the immediate return of cash collateral we hold. See Note 6 of the Notes to the Interim Condensed Consolidated Financial Statements, as well as “Summary of Significant Accounting Policies — Investments — Securities Lending Transactions and Repurchase Agreements” in Note 1 of the Notes of the Consolidated Financial Statements included in the 2021 Annual Report for further information about the secured borrowings accounting and the classification of revenues and expenses.

125

Table of Contents

Third-party custodian administered programs: The estimated fair value of securities we own which are loaned in connection with these programs was $475 million and $273 million at September 30, 2022 and December 31, 2021, respectively. The estimated fair value of the related non-cash collateral on deposit with third-party custodians on our behalf, which is not reflected in our interim condensed consolidated financial statements and cannot be sold or re-pledged, was $493 million and $282 million at September 30, 2022 and December 31, 2021, respectively.

Mortgage Loans

Our mortgage loans held-for-investment are principally collateralized by commercial, agricultural and residential properties. Mortgage loans carried at amortized cost and the related ACL are summarized as follows at:


	September 30, 2022									December 31, 2021
Portfolio Segment		Amortized Cost		% of Total		ACL		% of Amortized Cost		Amortized Cost		% of Total		ACL		% of Amortized Cost
		(Dollars in millions)
Commercial		$	52,273	63.1	%	$	209	0.4	%	$	50,553	63.3	%	$	340	0.7	%
Agricultural		18,923		22.8		118		0.6	%	18,111		22.7		88		0.5	%
Residential		11,708		14.1		140		1.2	%	11,196		14.0		206		1.8	%
Total		$	82,904	100.0	%	$	467	0.6	%	$	79,860	100.0	%	$	634	0.8	%

The carrying value of all mortgage loans, net of ACL, was 18.4% and 15.4% o f cash and invested assets at September 30, 2022 and December 31, 2021, respectively.

We diversify our mortgage loan portfolio by both geographic region and property type to reduce the risk of concentration. Of our commercial and agricultural mortgage loan held-for-investment portfolios, 86% are collateralized by properties located in the United States, with the remaining 14% collateralized by properties located primarily in Mexico, U.K. and Australia at September 30, 2022. The carrying values of our commercial and agricultural mortgage loans held-for-investment located in California, New York and Texas were 17%, 9% and 7%, respectively, of total commercial and agricultural mortgage loans held-for-investment at September 30, 2022. Additionally, we manage risk when originating commercial and agricultural mortgage loans by generally lending up to 75% of the estimated fair value of the underlying real estate collateral.

We manage our residential mortgage loan held-for-investment portfolio in a similar manner to reduce risk of concentration, with 92% collateralized by properties located in the United States, and the remaining 8% collateralized by properties located primarily in Chile at September 30, 2022. The carrying values of our residential mortgage loans located in California, Florida, and New York were 32%, 10%, and 8%, respectively, of total residential mortgage loans at September 30, 2022.

126

Table of Contents

Commercial Mortgage Loans by Geographic Region and Property Type. Commercial mortgage loans are the largest mortgage loan portfolio segment. The tables below present the diversification across geographic regions and property types of commercial mortgage loans held-for-investment at:


	September 30, 2022				December 31, 2021
	Amount		% of Total		Amount		% of Total
	(Dollars in millions)
Region
Non-U.S.	$	8,977	17.2	%	$	9,969	19.7	%
Pacific	9,805		18.7		9,676		19.1
Middle Atlantic	7,748		14.8		7,537		14.9
South Atlantic	6,691		12.8		6,800		13.5
West South Central	4,005		7.7		3,492		6.9
New England	2,754		5.3		2,748		5.4
East North Central	1,596		3.1		2,129		4.2
Mountain	2,269		4.3		1,993		4.0
East South Central	635		1.2		759		1.5
West North Central	471		0.9		663		1.3
Multi-Region and Other	7,322		14.0		4,787		9.5
Total amortized cost	52,273		100.0	%	50,553		100.0	%
Less: ACL	209				340
Carrying value, net of ACL	$	52,064			$	50,213
Property Type
Office	$	21,144	40.5	%	$	22,388	44.3	%
Apartment	10,793		20.6		9,121		18.0
Retail	8,305		15.9		8,548		16.9
Industrial	5,068		9.7		5,096		10.1
Hotel	3,261		6.2		3,201		6.3
Other	3,702		7.1		2,199		4.4
Total amortized cost	52,273		100.0	%	50,553		100.0	%
Less: ACL	209				340
Carrying value, net of ACL	$	52,064			$	50,213

Our commercial mortgage loan portfolio is well positioned with exposures concentrated in high quality underlying properties located in primary markets typically with institutional investors who are better positioned to manage their assets during periods of market volatility. Our portfolio is comprised primarily of lower risk loans with higher debt service coverage ratios (“DSCR”) and lower loan-to-value (“LTV”) ratios. See “— Mortgage Loan Credit Quality — Monitoring Process” for further information and Note 6 of the Notes to the Interim Condensed Consolidated Financial Statements for a distribution of our commercial mortgage loans by DSCR and LTV ratios.

Mortgage Loan Credit Quality - Monitoring Process. We monitor our mortgage loan investments on an ongoing basis, including a review of loans by credit quality indicator and loans that are current, past due, restructured and under foreclosure. See Note 6 of the Notes to the Interim Condensed Consolidated Financial Statements for further information regarding mortgage loans by credit quality indicator, past due and nonaccrual mortgage loans.

We review our commercial mortgage loans on an ongoing basis. These reviews may include an analysis of the property financial statements and rent roll, lease rollover analysis, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios, DSCR and tenant creditworthiness. The monitoring process focuses on higher risk loans, which include those that are classified as restructured, delinquent or in foreclosure, as well as loans with higher LTV ratios and lower DSCR. The monitoring process for agricultural mortgage loans is generally similar, with a focus on higher risk loans, such as loans with higher LTV ratios. Agricultural mortgage loans are reviewed on an ongoing basis which include, but are not limited to, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios and borrower creditworthiness, including reviews on a geographic and property-type basis. We review our residential mortgage loans on an ongoing basis, with a focus on higher risk loans, such as nonperforming loans. See Notes 1 and 6 of the Notes to the Interim Condensed Consolidated Financial Statements for information on our evaluation of residential mortgage loans and related ACL methodology.

127

Table of Contents

LTV ratios and DSCR are common measures in the assessment of the quality of commercial mortgage loans. LTV ratios are a common measure in the assessment of the quality of agricultural mortgage loans. LTV ratios compare the amount of the loan to the estimated fair value of the underlying collateral. An LTV ratio greater than 100% indicates that the loan amount is greater than the collateral value. An LTV ratio of less than 100% indicates an excess of collateral value over the loan amount. Generally, the higher the LTV ratio, the higher the risk of experiencing a credit loss. The DSCR compares a property’s net operating income to amounts needed to service the principal and interest due under the loan. Generally, the lower the DSCR, the higher the risk of experiencing a credit loss. For our commercial mortgage loans, our average LTV ratio was 57% and 56% at September 30, 2022 and December 31, 2021, respectively, and our average DSCR was 2.5x at both September 30, 2022 and December 31, 2021. The DSCR and the values utilized in calculating the ratio are updated routinely. In addition, the LTV ratio is routinely updated for all but the lowest risk loans as part of our ongoing review of our commercial mortgage loan portfolio. For our agricultural mortgage loans, our average LTV ratio was 48% and 49% at September 30, 2022 and December 31, 2021, respectively. The values utilized in calculating our agricultural mortgage loan LTV ratio are developed in connection with the ongoing review of our agricultural loan portfolio and are routinely updated.

Mortgage Loan Allowance for Credit Loss. Our ACL is established for both pools of loans with similar risk characteristics and for mortgage loans with dissimilar risk characteristics, collateral dependent loans and reasonably expected troubled debt restructurings, individually on a loan specific basis. We record an allowance for expected lifetime credit loss in earnings within net investment gains (losses) in an amount that represents the portion of the amortized cost basis of mortgage loans that the Company does not expect to collect, resulting in mortgage loans being presented at the net amount expected to be collected.

In determining our ACL, management (i) pools mortgage loans that share similar risk characteristics, (ii) considers expected lifetime credit loss over the contractual term of our mortgage loans, as adjusted for expected prepayments and any extensions, and (iii) considers past events and current and forecasted economic conditions. Actual credit loss realized could be different from the amount of the ACL recorded. These evaluations and assessments are revised as conditions change and new information becomes available, which can cause the ACL to increase or decrease over time as such evaluations are revised. Negative credit migration, including an actual or expected increase in the level of problem loans, will result in an increase in the ACL. Positive credit migration, including an actual or expected decrease in the level of problem loans, will result in a decrease in the ACL. See Note 6 of the Notes to the Interim Condensed Consolidated Financial Statements for information on how the ACL is established and monitored, and activity in and balances of the ACL.

Real Estate and Real Estate Joint Ventures

Real estate and real estate joint ventures is comprised of wholly-owned real estate and joint ventures with interests in single property income-producing real estate and, to a lesser extent, joint ventures with interests in multi-property projects with varying strategies ranging from the development of properties to the operation of income-producing properties, as well as real estate funds. The carrying value of real estate and real estate joint ventures was $12.5 billion and $12.2 billion, or 2.8% and 2.4% of cash and invested assets, at September 30, 2022 and December 31, 2021, respectively.

Our real estate investments are typically stabilized properties that we intend to hold for the longer-term for portfolio diversification and long-term appreciation. Our real estate investment portfolio has significantly appreciated to a $7.5 billion and $6.3 billion unrealized gain position at September 30, 2022 and September 30, 2021, respectively. We continuously monitor expected future cash flows of each of our real estate investments and incorporate them into our periodic impairment analyses. There were no impairments recognized in earnings within net investment gains (losses) on real estate and real estate joint ventures for either the nine months ended September 30, 2022 or 2021.

We diversify our real estate investments by both geographic region and property type to reduce risk of concentration. See Note 6 of the Notes to the Interim Condensed Consolidated Financial Statements for a summary of real estate investments, by income type, as well as income earned.

Other Limited Partnership Interests

Other limited partnership interests are comprised of investments in private funds, including private equity funds and hedge funds. At September 30, 2022 and December 31, 2021, the carrying value of other limited partnership interests was $14.4 billion and $14.6 billion, which included $532 million and $663 million of hedge funds, respectively. Other limited partnership interests were 3.2% and 2.8% of cash and invested assets at September 30, 2022 and December 31, 2021, respectively. Cash distributions on these investments are generated from investment gains, operating income from the underlying investments of the funds and liquidation of the underlying investments of the funds.

128

Table of Contents

We use the equity method of accounting for most of our private equity funds. We generally recognize our share of a private equity fund’s earnings in net investment income on a three-month lag when the information is reported to us. Accordingly, changes in equity market levels, which can impact the underlying results of these private equity funds, are recognized in earnings within our net investment income on a three-month lag.

Other Invested Assets

The following table presents the carrying value of our other invested assets by type at:


	September 30, 2022					December 31, 2021
Asset Type	Carrying Value			% of Total		Carrying Value			% of Total
	(Dollars in millions)
Freestanding derivatives with positive estimated fair values	$	14,193		63.6	%	$	10,466		56.1	%
Tax credit and renewable energy partnerships	1,391			6.2		1,564			8.4
Annuities funding structured settlement claims	1,237			5.5		1,251			6.7
Direct financing leases	1,006			4.5		1,143			6.1
Operating joint ventures	1,139			5.1		901			4.8
Leveraged leases	795			3.6		787			4.2
FHLB common stock	768			3.4		769			4.1
Funds withheld	426			1.9		525			2.8
Other	1,344			6.2		1,249			6.8
Total	$	22,299		100.0	%	$	18,655		100.0	%

Percentage of cash and invested assets	5.0		%			3.6		%

Investment Commitments

We enter into the following commitments in the normal course of business for the purpose of enhancing the total return on our investment portfolio: mortgage loan commitments and commitments to fund partnerships, bank credit facilities, bridge loans and private corporate bond investments. See Note 15 of the Notes to the Interim Condensed Consolidated Financial Statements for the amount of our unfunded investment commitments at September 30, 2022 and December 31, 2021. See “Net Investment Income” and “Net Investment Gains (Losses)” in Note 6 of the Notes to the Interim Condensed Consolidated Financial Statements for information on the investment income, investment expense, gains and losses from such investments and the liability for credit loss for unfunded mortgage loan commitments. See also “— Fixed Maturity Securities AFS and Equity Securities,” “— Mortgage Loans,” “— Real Estate and Real Estate Joint Ventures” and “— Other Limited Partnership Interests.”

Derivatives

Overview

We are exposed to various risks relating to our ongoing business operations, including interest rate, foreign currency exchange rate, credit and equity market. We use a variety of strategies to manage these risks, including the use of derivatives such as market standard purchased and written credit default swap contracts. See Note 7 of the Notes to the Interim Condensed Consolidated Financial Statements for:

• A comprehensive description of the nature of our derivatives, including the strategies for which derivatives are used in managing various risks.

• Information about the primary underlying risk exposure, gross notional amount, and estimated fair value of our derivatives by type of hedge designation, excluding embedded derivatives held at September 30, 2022 and December 31, 2021.

• The statement of operations effects of derivatives in net investments in foreign operations, cash flow, fair value, or nonqualifying hedge relationships for the three months and nine months ended September 30, 2022 and 2021.

129

Table of Contents

We enter into market standard purchased and written credit default swap contracts. Payout under such contracts is triggered by certain credit events experienced by the referenced entities. For credit default swaps covering North American corporate issuers, credit events typically include bankruptcy and failure to pay on borrowed money. For European corporate issuers, credit events typically also include involuntary restructuring. With respect to credit default contracts on sovereign debt, credit events typically include failure to pay debt obligations, repudiation, moratorium, or involuntary restructuring. In each case, payout on a credit default swap is triggered only after the relevant third party, Credit Derivatives Determinations Committee, determines that a credit event has occurred.

We use purchased credit default swaps to mitigate credit risk in our investment portfolio. Generally, we purchase credit protection by entering into credit default swaps referencing the issuers of specific assets we own. In certain cases, basis risk exists between these credit default swaps and the specific assets we own. For example, we may purchase credit protection on a macro basis to reduce exposure to specific industries or other portfolio concentrations. In such instances, the referenced entities and obligations under the credit default swaps may not be identical to the individual obligors or securities in our investment portfolio. In addition, our purchased credit default swaps may have shorter tenors than the underlying investments they are hedging, which gives us more flexibility in managing our credit exposures. We believe that our purchased credit default swaps serve as effective economic hedges of our credit exposure.

See “Quantitative and Qualitative Disclosures About Market Risk — Management of Market Risk Exposures — Hedging Activities” included in the 2021 Annual Report for more information about our use of derivatives by major hedge program.

Fair Value Hierarchy

See Note 8 of the Notes to the Interim Condensed Consolidated Financial Statements for derivatives measured at estimated fair value on a recurring basis and their corresponding fair value hierarchy.

The valuation of Level 3 derivatives involves the use of significant unobservable inputs and generally requires a higher degree of management judgment or estimation than the valuations of Level 1 and Level 2 derivatives. Although Level 3 inputs are unobservable, management believes they are consistent with what other market participants would use when pricing such instruments and are considered appropriate given the circumstances. The use of different inputs or methodologies could have a material effect on the estimated fair value of Level 3 derivatives and could materially affect net income.

Derivatives categorized as Level 3 at September 30, 2022 include: interest rate forwards with maturities which extend beyond the observable portion of the yield curve; interest rate caps with unobservable volatility inputs; foreign currency swaps and forwards with certain unobservable inputs, including the unobservable portion of the yield curve; and credit default swaps priced using unobservable credit spreads, or that are priced through independent broker quotations. At September 30, 2022, less than 1% of the estimated fair value of our derivatives was priced through independent broker quotations.

See Note 8 of the Notes to the Interim Condensed Consolidated Financial Statements for a rollforward of the fair value measurements for derivatives measured at estimated fair value on a recurring basis using significant unobservable (Level 3) inputs.

See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Summary of Critical Accounting Estimates — Derivatives” included in the 2021 Annual Report for further information on the estimates and assumptions that affect derivatives.

Credit Risk

See Note 7 of the Notes to the Interim Condensed Consolidated Financial Statements for information about how we manage credit risk related to derivatives and for the estimated fair value of our net derivative assets and net derivative liabilities after the application of master netting agreements and collateral.

Our policy is not to offset the fair value amounts recognized for derivatives executed with the same counterparty under the same master netting agreement. This policy applies to the recognition of derivatives on the consolidated balance sheets, and does not affect our legal right of offset.

130

Table of Contents

Credit Derivatives

The following table presents the gross notional amount and estimated fair value of credit default swaps at:


	September 30, 2022				December 31, 2021
Credit Default Swaps	Gross Notional Amount		Estimated Fair Value		Gross Notional Amount		Estimated Fair Value
	(In millions)
Purchased	$	2,993	$	(47)	$	3,042	$	(100)
Written	13,059		(11)		8,626		165
Total	$	16,052	$	(58)	$	11,668	$	65

The following table presents the gross gains, gross losses and net gains (losses) recognized in net derivative gains (losses) for credit default swaps as follows:


	Three Months Ended September 30,												Nine Months Ended September 30,
	2022						2021						2022						2021
Credit Default Swaps	Gross Gains		Gross Losses		Net Gains (Losses)		Gross Gains		Gross Losses		Net Gains (Losses)		Gross Gains		Gross Losses		Net Gains (Losses)		Gross Gains		Gross Losses		Net Gains (Losses)
	(In millions)
Purchased (1)	$	7	$	—	$	7	$	5	$	(1)	$	4	$	101	$	(2)	$	99	$	21	$	(5)	$	16
Written (1)	1		—		1		2		(4)		(2)		3		(247)		(244)		44		(11)		33
Total	$	8	$	—	$	8	$	7	$	(5)	$	2	$	104	$	(249)	$	(145)	$	65	$	(16)	$	49

__________________

(1) Gains (losses) do not include earned income (expense) on credit default swaps.

The unfavorable change in net gains (losses) on written credit default swaps of $277 million for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 was due to certain credit spreads on certain credit default swaps used as replications widening in the current period as compared to narrowing in the prior period. The favorable change in net gains (losses) on purchased credit defaults swaps of $83 million for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 was due to certain credit spreads on certain credit default swaps widening in the current period as compared to narrowing in the prior period.

The maximum amount at risk related to our written credit default swaps is equal to the corresponding gross notional amount. In a replication transaction, we pair an asset on our balance sheet with a written credit default swap to synthetically replicate a corporate bond, a core asset holding of life insurance companies. Replications are entered into in accordance with the guidelines approved by state insurance regulators and the NAIC and are an important tool in managing the overall corporate credit risk within the Company. In order to match our long-dated insurance liabilities, we seek to buy long-dated corporate bonds. In some instances, these may not be readily available in the market, or they may be issued by corporations to which we already have significant corporate credit exposure. For example, by purchasing Treasury bonds (or other high-quality assets) and associating them with written credit default swaps on the desired corporate credit name, we can replicate the desired bond exposures and meet our ALM needs. In addition, given the shorter tenor of the credit default swaps (generally five-year tenors) versus a long dated corporate bond, we have more flexibility in managing our credit exposures.

Collateral for Derivatives

We enter into derivatives to manage various risks relating to our ongoing business operations. We receive non-cash collateral from counterparties for derivatives, which can be sold or re-pledged subject to certain constraints, and which is not reflected on our interim condensed consolidated balance sheets. The amounts of this non-cash collateral were $1.7 billion and $1.1 billion, at estimated fair value, at September 30, 2022 and December 31, 2021, respectively. See “— Liquidity and Capital Resources — The Company — Liquidity and Capital Uses — Pledged Collateral” and Note 7 of the Notes to the Interim Condensed Consolidated Financial Statements for information regarding the earned income on and the gross notional amount, estimated fair value of assets and liabilities and primary underlying risk exposure of our derivatives.

131

Table of Contents

Embedded Derivatives

See Note 8 of the Notes to the Interim Condensed Consolidated Financial Statements for information about embedded derivatives measured at estimated fair value on a recurring basis and their corresponding fair value hierarchy and a rollforward of the fair value measurements for embedded derivatives measured at estimated fair value on a recurring basis using significant unobservable (Level 3) inputs.

See Note 7 of the Notes to the Interim Condensed Consolidated Financial Statements for information about the nonperformance risk adjustment included in the valuation of guaranteed minimum benefits accounted for as embedded derivatives.

Policyholder Liabilities

We establish, and carry as liabilities, actuarially determined amounts that are calculated to meet policy obligations or to provide for future annuity payments. Amounts for actuarial liabilities are computed and reported on the interim condensed consolidated financial statements in conformity with GAAP. For more details on Policyholder Liabilities, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Summary of Critical Accounting Estimates” included in the 2021 Annual Report.

We periodically review our estimates of actuarial liabilities for future benefits and compare them with our actual experience. We revise estimates, to the extent permitted or required under GAAP, if we determine that future expected experience differs from assumptions used in the development of actuarial liabilities. We charge or credit changes in our liabilities to expenses in the period the liabilities are established or re-estimated. If the liabilities originally established for future benefit payments prove inadequate, we must increase them. Such an increase could adversely affect our earnings and have a material adverse effect on our business, results of operations and financial condition.

See “Business — Regulation — Insurance Regulation — Policy and Contract Reserve Adequacy Analysis” and “Risk Factors — Business Risks” included in the 2021 Annual Report for further information regarding required analyses of the adequacy of statutory reserves of our insurance operations.

The following discussions on future policy benefits and policyholder account balances should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Industry Trends — Impact of Market Interest Rates” included in the 2021 Annual Report, as amended or supplemented in our subsequently filed Quarterly Reports on Form 10-Q and “— Variable Annuity Guarantees.” See also Notes 1 and 4 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report for additional information.

Future Policy Benefits

We establish liabilities for amounts payable under insurance policies. A discussion of future policy benefits by segment (as well as Corporate & Other) follows.

U.S.

Amounts payable under insurance policies for this segment are comprised of group insurance and annuities. For group insurance, future policyholder benefits are comprised mainly of liabilities for disabled lives under disability waiver of premium policy provisions, liabilities for survivor income benefit insurance, active life policies and premium stabilization and other contingency liabilities held under life insurance contracts. For group annuity contracts, future policyholder benefits are primarily related to payout annuities, including pension risk transfers, structured settlement annuities and institutional income annuities. There is no interest rate crediting flexibility on these liabilities.

Asia

Future policy benefits for this segment are held primarily for traditional life, endowment, annuity and accident & health contracts. They are also held for total return pass-through provisions included in certain universal life and savings products. They include certain liabilities for variable annuity and variable life guarantees of minimum death benefits, and longevity guarantees. Factors impacting these liabilities include sustained periods of lower than expected yields, lower than expected asset reinvestment rates, market volatility, actual lapses resulting in lower than expected income, and actual mortality or morbidity resulting in higher than expected benefit payments.

132

Table of Contents

Latin America

Future policy benefit liabilities for this segment are held primarily for immediate annuities, traditional life contracts and total return pass-through provisions included in certain universal life and savings products. There is no interest rate crediting flexibility on the immediate annuity and traditional life liabilities. Other factors impacting these liabilities are actual mortality resulting in higher than expected benefit payments and actual lapses resulting in lower than expected income.

EMEA

Future policy benefits for this segment include unearned premium reserves for group life and medical and credit insurance contracts. Future policy benefits are also held for traditional life, endowment and annuity contracts with significant mortality risk and accident & health contracts. Factors impacting these liabilities include lower than expected asset reinvestment rates, market volatility, actual lapses resulting in lower than expected income, and actual mortality or morbidity resulting in higher than expected benefit payments.

MetLife Holdings

Future policy benefits for the life insurance business are comprised mainly of liabilities for traditional life insurance contracts. For the annuities business, future policy benefits are comprised mainly of liabilities for life-contingent income annuities and liabilities for the variable annuity guaranteed minimum benefits that are accounted for as insurance. For the long-term care business, future policyholder benefits are comprised mainly of liabilities for disabled lives under disability waiver of premium policy provisions, and active life policies. In addition, for our other products, future policyholder benefits related to the reinsurance of our former Japan joint venture are comprised of liabilities for the variable annuity guaranteed minimum benefits that are accounted for as insurance.

Corporate & Other

Future policy benefits primarily include liabilities for other reinsurance business.

Policyholder Account Balances

Policyholder account balances are generally equal to the account value, which includes accrued interest credited, but excludes the impact of any applicable charge that may be incurred upon surrender. A discussion of policyholder account balances by segment follows.

U.S.

Policyholder account balances in this segment are comprised of funding agreements, retained asset accounts, universal life policies, the fixed account of variable life insurance policies and specialized life insurance products for benefit programs.

Group Benefits

Policyholder account balances in this business are held for retained asset accounts, universal life policies, the fixed account of variable life insurance policies and specialized life insurance products for benefit programs. Policyholder account balances are credited interest at a rate we determine, which is influenced by current market rates. Most of these policyholder account balances have minimum credited rate guarantees.

The table below presents the breakdown of account value subject to minimum guaranteed crediting rates for Group Benefits:


	September 30, 2022
Guaranteed Minimum Crediting Rate	Account Value		Account Value at Guarantee
	(In millions)
Greater than 0% but less than 2%	$	5,589	$	5,406
Equal to or greater than 2% but less than 4%	$	1,513	$	1,470
Equal to or greater than 4%	$	818	$	786

133

Table of Contents

Retirement and Income Solutions

Policyholder account balances in this business are held largely for investment-type products, mainly funding agreements, as well as postretirement benefits and corporate-owned life insurance to fund non-qualified benefit programs for executives. Interest crediting rates vary by type of contract and can be fixed or variable. Variable interest crediting rates are generally tied to an external index, most commonly (1-month or 3-month) LIBOR or Secured Overnight Financing Rate. We guarantee payment of interest and return of principal at the contractual maturity date.

The table below presents the breakdown of account value subject to minimum guaranteed crediting rates for RIS:


	September 30, 2022
Guaranteed Minimum Crediting Rate	Account Value		Account Value at Guarantee
	(In millions)
Greater than 0% but less than 2%	$	1,280	$	—
Equal to or greater than 2% but less than 4%	$	812	$	232
Equal to or greater than 4%	$	4,584	$	4,402

Asia

Policyholder account balances in this segment are held largely for fixed income retirement and savings plans, fixed deferred annuities, interest sensitive whole life products, universal life and, to a lesser degree, liability amounts for Unit-linked investments that do not meet the GAAP definition of separate accounts. Also included are certain liabilities for retirement and savings products sold in certain countries in Asia that generally are sold with minimum credited rate guarantees. Liabilities for guarantees on certain variable annuities in Asia are accounted for as embedded derivatives and recorded at estimated fair value and are also included within policyholder account balances. Most of these policyholder account balances have minimum credited rate guarantees. Liabilities for Unit-linked investments are impacted by changes in the fair value of the associated underlying investments, as the return on assets is generally passed directly to the policyholder.

The table below presents the breakdown of account value subject to minimum guaranteed crediting rates for Asia:


	September 30, 2022
Guaranteed Minimum Crediting Rate	Account Value		Account Value at Guarantee
	(In millions)
Annuities:
Greater than 0% but less than 2%	$	30,240	$	1,643
Equal to or greater than 2% but less than 4%	$	831	$	377
Equal to or greater than 4%	$	1	$	1
Life & Other:
Greater than 0% but less than 2%	$	10,938	$	10,212
Equal to or greater than 2% but less than 4%	$	34,189	$	20,967
Equal to or greater than 4%	$	273	$	273

Latin America

Policyholder account balances in this segment are held largely for investment-type products, universal life products, deferred annuities and Unit-linked investments that do not meet the GAAP definition of separate accounts. Liabilities for Unit-linked investments are impacted by changes in the fair value of the associated investments, as the return on assets is generally passed directly to the policyholder. Many of the other liabilities have minimum credited rate guarantees.

EMEA

Policyholder account balances in this segment are held mostly for universal life, deferred annuities, pension products, and Unit-linked investments that do not meet the GAAP definition of separate accounts. They are also held for endowment products without significant mortality risk. Most of these policyholder account balances have minimum credited rate guarantees. Liabilities for Unit-linked investments are impacted by changes in the fair value of the associated investments, as the return on assets is generally passed directly to the policyholder.

134

Table of Contents

MetLife Holdings

Life policyholder account balances in this segment are held for retained asset accounts, universal life policies, the fixed account of variable life insurance policies, and funding agreements. For annuities, policyholder account balances are held for fixed deferred annuities, the fixed account portion of variable annuities, non-life contingent income annuities, and embedded derivatives related to variable annuity guarantees. Interest is credited to the policyholder’s account at interest rates we determine which are influenced by current market rates, subject to specified minimums. Most of these policyholder account balances have minimum credited rate guarantees. Additionally, for our other products, policyholder account balances are held for variable annuity guarantees assumed from a former operating joint venture in Japan that are accounted for as embedded derivatives.

The table below presents the breakdown of account value subject to minimum guaranteed crediting rates for the MetLife Holdings segment:


	September 30, 2022
Guaranteed Minimum Crediting Rate	Account Value		Account Value at Guarantee
	(In millions)
Greater than 0% but less than 2%	$	1,075	$	1,048
Equal to or greater than 2% but less than 4%	$	16,889	$	15,499
Equal to or greater than 4%	$	7,199	$	6,589

Variable Annuity Guarantees

We issue, directly and through assumed business, certain variable annuity products with guaranteed minimum benefits that provide the policyholder a minimum return based on their initial deposit (i.e., the benefit base) less withdrawals. In some cases, the benefit base may be increased by additional deposits, bonus amounts, accruals or optional market value resets. See Note 4 of the Notes to the Interim Condensed Consolidated Financial Statements, as well as Notes 1 and 4 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report for additional information.

Certain guarantees, including portions thereof, have insurance liabilities established that are included in future policy benefits. Guarantees accounted for in this manner include GMDBs, the life-contingent portion of guaranteed minimum withdrawal benefits (“GMWBs”), elective guaranteed minimum income benefit (“GMIB”) annuitizations, and the life contingent portion of GMIBs that require annuitization when the account balance goes to zero. These liabilities are accrued over the life of the contract in proportion to actual and future expected policy assessments based on the level of guaranteed minimum benefits generated using multiple scenarios of separate account returns. The scenarios are based on best estimate assumptions consistent with those used to amortize DAC. When current estimates of future benefits exceed those previously projected or when current estimates of future assessments are lower than those previously projected, liabilities will increase, resulting in a current period charge to net income. The opposite result occurs when the current estimates of future benefits are lower than those previously projected or when current estimates of future assessments exceed those previously projected. At the end of each reporting period, we update the actual amount of business remaining in-force, which impacts expected future assessments and the projection of estimated future benefits resulting in a current period charge or increase to earnings.

Certain guarantees, including portions thereof, accounted for as embedded derivatives, are recorded at estimated fair value and included in policyholder account balances. Guarantees accounted for as embedded derivatives include guaranteed minimum accumulation benefits (“GMABs”), the non-life contingent portion of GMWBs and certain non-life contingent portions of GMIBs. The estimated fair values of guarantees accounted for as embedded derivatives are determined based on the present value of projected future benefits minus the present value of projected future fees. The projections of future benefits and future fees require capital market and actuarial assumptions including expectations concerning policyholder behavior. A risk-neutral valuation methodology is used to project the cash flows from the guarantees under multiple capital market scenarios to determine an economic liability. The reported estimated fair value is then determined by taking the present value of these risk-free generated cash flows using a discount rate that incorporates a spread over the risk-free rate to reflect our nonperformance risk and adding a risk margin. For more information on the determination of estimated fair value, see Note 8 of the Notes to the Interim Condensed Consolidated Financial Statements.

135

Table of Contents

The table below presents the carrying value for guarantees at:


	Future Policy Benefits				Policyholder Account Balances
	September 30, 2022		December 31, 2021		September 30, 2022		December 31, 2021
	(In millions)
Asia
GMDB	$	4	$	4	$	—	$	—
GMAB	—		—		10		14
GMWB	25		32		58		107
EMEA
GMDB	4		3		—		—
GMAB	—		—		10		6
GMWB	25		19		(36)		(58)
MetLife Holdings
GMDB	763		561		—		—
GMIB	906		1,029		476		180
GMAB	—		—		(1)		—
GMWB	180		174		160		173
Total	$	1,907	$	1,822	$	677	$	422

The carrying amounts for guarantees included in policyholder account balances above include nonperformance risk adjustments of $164 million and $120 million at September 30, 2022 and December 31, 2021, respectively. These nonperformance risk adjustments represent the impact of including a credit spread when discounting the underlying risk-neutral cash flows to determine the estimated fair values. The nonperformance risk adjustment does not have an economic impact on us as it cannot be monetized given the nature of these policyholder liabilities. The change in valuation arising from the nonperformance risk adjustment is not hedged.

The carrying values of these guarantees can change significantly during periods of sizable and sustained shifts in equity market performance, equity volatility, interest rates or foreign currency exchange rates. Carrying values are also impacted by our assumptions around mortality, separate account returns and policyholder behavior, including lapse rates.

As discussed below, we use a combination of product design, hedging strategies, reinsurance, and other risk management actions to mitigate the risks related to these benefits. Within each type of guarantee, there is a range of product offerings reflecting the changing nature of these products over time. Changes in product features and terms are in part driven by customer demand but, more importantly, reflect our risk management practices of continuously evaluating the guaranteed benefits and their associated asset-liability matching. We continue to diversify the concentration of income benefits in our portfolio by focusing on withdrawal benefits, variable annuities without living benefits and index-linked annuities.

The sections below provide further detail by total account value for certain of our most popular guarantees. Total account values include amounts not reported on the interim condensed consolidated balance sheets from assumed business, Unit-linked investments that do not qualify for presentation as separate account assets, and amounts included in our general account. The total account values and the net amounts at risk include direct and assumed business, but exclude offsets from hedging or ceded reinsurance, if any.

GMDBs

We offer a range of GMDBs to our contractholders. The table below presents GMDBs, by benefit type, at September 30, 2022:


	Total Account Value (1)
	Asia & EMEA		MetLife Holdings
	(In millions)
Return of premium or five to seven year step-up	$	5,093	$	34,007
Annual step-up	—		2,244
Roll-up and step-up combination	—		3,811
Total	$	5,093	$	40,062

__________________

136

Table of Contents

(1) Total account value excludes $496 million for contracts with no GMDBs. The Company’s annuity contracts with guarantees may offer more than one type of guarantee in each contract. Therefore, the amounts listed for GMDBs and for living benefit guarantees are not mutually exclusive.

Based on total account value, less than 17% of our GMDBs included enhanced death benefits such as the annual step-up or roll-up and step-up combination products at September 30, 2022.

Living Benefit Guarantees

The table below presents our living benefit guarantees based on total account values at September 30, 2022:


	Total Account Value (1)
	Asia & EMEA		MetLife Holdings
	(In millions)
GMIB	$	—	$	14,185
GMWB - non-life contingent (2)	649		1,390
GMWB - life-contingent	1,991		5,877
GMAB	984		96
Total	$	3,624	$	21,548

__________________

(1) Total account value excludes $20.5 billion for contracts with no living benefit guarantees. The Company’s annuity contracts with guarantees may offer more than one type of guarantee in each contract. Therefore, the amounts listed for GMDBs and for living benefit guarantee amounts are not mutually exclusive.

(2) The Asia and EMEA segments include the non-life contingent portion of the GMWB total account value of $649 million with a guarantee at annuitization.

In terms of total account value, GMIBs are our most significant living benefit guarantee. Our primary risk management strategy for our GMIB products is our derivatives hedging program as discussed below. Additionally, we have engaged in certain reinsurance agreements covering some of our GMIB business. As part of our overall risk management approach for living benefit guarantees, we continually monitor the reinsurance markets for the right opportunity to purchase additional coverage for our GMIB business. We stopped selling GMIBs in February 2016.

The table below presents our GMIB associated total account values, by their guaranteed payout basis, at September 30, 2022:


	Total Account Value
	(In millions)
7-year setback, 2.5% interest rate	$	4,299
7-year setback, 1.5% interest rate	870
10-year setback, 1.5% interest rate	2,854
10-year mortality projection, 10-year setback, 1.0% interest rate	5,229
10-year mortality projection, 10-year setback, 0.5% interest rate	933
	$	14,185

The annuitization interest rates on GMIBs have been decreased from 2.5% to 0.5% over time, partially in response to the low interest rate environment in effect at the time the GMIBs were sold, accompanied by an increase in the setback period from seven years to 10 years and the introduction of a 10-year mortality projection.

Additionally, 34% of the $14.2 billion of GMIB total account value has been invested in managed volatility funds as of September 30, 2022. These funds seek to manage volatility by adjusting the fund holdings within certain guidelines based on capital market movements. Such activity reduces the overall risk of the underlying funds while maintaining their growth opportunities. These risk mitigation techniques reduce or eliminate the need for us to manage the funds’ volatility through hedging or reinsurance.

Our GMIB products typically have a waiting period of 10 years to be eligible for annuitization. As of September 30, 2022, only 44% of our contracts with GMIBs were eligible for annuitization. The remaining contracts are not eligible for annuitization for an average of three years.

137

Table of Contents

Once eligible for annuitization, contractholders would be expected to annuitize only if their contracts were in-the-money. We calculate in-the-moneyness with respect to GMIBs consistent with net amount at risk as discussed in Note 4 of the Notes to the Interim Condensed Consolidated Financial Statements, by comparing the contractholders’ income benefits based on total account values and current annuity rates versus the guaranteed income benefits. The net amount at risk was $685 million at September 30, 2022, of which $638 million was related to GMIBs. For those contracts with GMIB, the table below presents details of contracts that are in-the-money and out-of-the-money at September 30, 2022:


	In-the- Moneyness	Total Account Value		% of Total
		(In millions)
In-the-money	30% or greater	$	586	4	%
	20% to less than 30%	365		3	%
	10% to less than 20%	729		5	%
	0% to less than 10%	1,642		12	%
		3,322
Out-of-the-money	-10% to 0%	2,960		21	%
	-20% to less than -10%	3,037		21	%
	Greater than -20%	4,866		34	%
		10,863
Total GMIBs		$	14,185

Derivatives Hedging Variable Annuity Guarantees

Our risk mitigating hedging strategy uses various over-the-counter and exchange traded derivatives. The table below presents the gross notional amount, estimated fair value and primary underlying risk exposure of the derivatives hedging our variable annuity guarantees:


	Instrument Type	September 30, 2022						December 31, 2021
Primary Underlying Risk Exposure		Gross Notional Amount		Estimated Fair Value				Gross Notional Amount		Estimated Fair Value
				Assets		Liabilities				Assets		Liabilities
		(In millions)
Interest rate	Interest rate swaps	$	7,371	$	36	$	728	$	8,663	$	52	$	75
	Interest rate futures	1,367		2		6		1,087		3		—
	Interest rate options	50		6		—		100		1		—
Foreign currency exchange rate	Foreign currency forwards	858		8		33		1,149		4		13


Equity market	Equity futures	2,498		25		4		3,641		11		5
	Equity index options	3,709		198		252		4,161		513		362
	Equity variance swaps	692		18		13		699		17		13
	Equity total return swaps	2,723		169		—		2,763		11		44
	Total	$	19,268	$	462	$	1,036	$	22,263	$	612	$	512

The change in estimated fair values of our derivatives is recorded in policyholder benefits and claims if such derivatives are hedging guarantees included in future policy benefits, and in net derivative gains (losses) if such derivatives are hedging guarantees included in policyholder account balances.

Our hedging strategy involves the significant use of static longer-term derivative instruments to avoid the need to execute transactions during periods of market disruption or higher volatility. We continually monitor the capital markets for opportunities to adjust our liability coverage, as appropriate. Futures are also used to dynamically adjust the daily coverage levels as markets and liability exposures fluctuate.

138

Table of Contents

We remain liable for the guaranteed benefits in the event that reinsurers or derivative counterparties are unable or unwilling to pay. Certain of our reinsurance agreements and all derivative positions are collateralized and derivatives positions are subject to master netting agreements, both of which significantly reduce the exposure to counterparty risk. In addition, we are subject to the risk that hedging and other risk management actions prove ineffective or that unanticipated policyholder behavior or mortality, combined with adverse market events, produces economic losses beyond the scope of the risk management techniques employed.

Liquidity and Capital Resources

Overview

Our business and results of operations are materially affected by conditions in the global capital markets and the economy generally due to our market presence in numerous countries, large investment portfolio and the sensitivity of our insurance liabilities and derivatives to changing market factors. Changing conditions in the global capital markets and the economy may affect our financing costs and market interest for our debt or equity securities. For further information regarding market factors that could affect our ability to meet liquidity and capital needs, see “— Industry Trends” and “— Investments — Current Environment.”

Liquidity Management

Based upon the strength of our franchise, diversification of our businesses, strong financial fundamentals and the substantial funding sources available to us as described herein, we continue to believe we have access to ample liquidity to meet business requirements under current market conditions and reasonably possible stress scenarios. We continuously monitor and adjust our liquidity and capital plans for MetLife, Inc. and its subsidiaries in light of market conditions, as well as changing needs and opportunities.

Short-term Liquidity

We maintain a substantial short-term liquidity position, which was $15.4 billion and $12.4 billion at September 30, 2022 and December 31, 2021, respectively. Short-term liquidity includes cash and cash equivalents and short-term investments, excluding assets that are pledged or otherwise committed, including amounts received in connection with securities lending, repurchase agreements, derivatives, and secured borrowings, as well as amounts held in the closed block.

Liquid Assets

An integral part of our liquidity management includes managing our level of liquid assets, which was $174.1 billion and $223.0 billion at September 30, 2022 and December 31, 2021, respectively. Liquid assets include cash and cash equivalents, short-term investments and publicly-traded securities, excluding assets that are pledged or otherwise committed. Assets pledged or otherwise committed include amounts received in connection with securities lending, repurchase agreements, derivatives, regulatory deposits, the collateral financing arrangement, funding agreements and secured borrowings, as well as amounts held in the closed block.

Capital Management

We have established several senior management committees as part of our capital management process. These committees, including the Capital Management Committee and the Enterprise Risk Committee (“ERC”), regularly review actual and projected capital levels (under a variety of scenarios including stress scenarios) and our annual capital plan in accordance with our capital policy. The Capital Management Committee is comprised of members of senior management, including MetLife, Inc.’s Chief Financial Officer (“CFO”), Treasurer, and Chief Risk Officer (“CRO”). The ERC is also comprised of members of senior management, including MetLife, Inc.’s CFO, CRO and Chief Investment Officer.

MetLife, Inc.’s Board of Directors (“Board of Directors”) and senior management are directly involved in the development and maintenance of our capital policy. The capital policy sets forth, among other things, minimum and target capital levels and the governance of the capital management process. All capital actions, including proposed changes to the annual capital plan, capital targets or capital policy, are reviewed by the Finance and Risk Committee of the Board of Directors prior to obtaining full Board of Directors approval. The Board of Directors approves the capital policy and the annual capital plan and authorizes capital actions, as required.

139

Table of Contents

See “Risk Factors — Capital Risks — We May Not be Able to Pay Dividends or Repurchase Our Stock Due to Legal and Regulatory Restrictions or Cash Buffer Needs” and Note 16 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report for information regarding restrictions on payment of dividends and stock repurchases. See also “— The Company — Liquidity and Capital Uses — Common Stock Repurchases” for information regarding MetLife, Inc.’s common stock repurchase authorizations.

The Company

Liquidity

Liquidity refers to the ability to generate adequate amounts of cash to meet our needs. In the event of significant cash requirements beyond anticipated liquidity needs, we have various alternatives available depending on market conditions and the amount and timing of the liquidity need. These available alternatives include cash flows from operations, sales of liquid assets, global funding sources including commercial paper and various credit and committed facilities. See “Management’s Discussion and Analysis of Financial Condition — Liquidity and Capital Resources — The Company — Liquidity” included in the 2021 Annual Report.

Capital

We manage our capital position to maintain our financial strength and credit ratings. Our capital position is supported by our ability to generate strong cash flows within our operating companies and borrow funds at competitive rates, as well as by our demonstrated ability to raise additional capital to meet operating and growth needs despite adverse market and economic conditions.

Summary of the Company’s Primary Sources and Uses of Liquidity and Capital

Our primary sources and uses of liquidity and capital are summarized as follows:


	Nine Months Ended September 30,
	2022		2021
	(In millions)
Sources:
Operating activities, net	$	10,670	$	7,256
Net change in policyholder account balances	4,593		4,041
Net change in payables for collateral under securities loaned and other transactions	—		1,279
Long-term debt issued	1,013		29
Financing element on certain derivative instruments and other derivative related transactions, net	—		305
Other, net	—		20
Total sources	16,276		12,930
Uses:
Investing activities, net	2,423		8,325
Net change in payables for collateral under securities loaned and other transactions	6,602		—
Cash paid for other transactions with tenors greater than three months	—		100
Long-term debt repaid	77		540
Collateral financing arrangement repaid	37		39
Treasury stock acquired in connection with share repurchases	2,730		3,127
Redemption of preferred stock	—		494
Preferred stock redemption premium	—		6
Dividends on preferred stock	156		166
Dividends on common stock	1,205		1,242
Other, net	206		—
Effect of change in foreign currency exchange rates on cash and cash equivalents	756		392
Total uses	14,192		14,431
Net increase (decrease) in cash and cash equivalents	$	2,084	$	(1,501)

140

Table of Contents

Cash Flows from Operations

The principal cash inflows from our insurance activities come from insurance premiums, net investment income, annuity considerations and deposit funds. The principal cash outflows are the result of various life insurance, annuity and pension products, operating expenses and income tax, as well as interest expense.

Cash Flows from Investments

The principal cash inflows from our investment activities come from repayments of principal, proceeds from maturities and sales of investments and settlements of freestanding derivatives. The principal cash outflows relate to purchases of investments, issuances of policy loans and settlements of freestanding derivatives. In addition, cash inflows and outflows relate to sales and purchases of businesses. We typically have a net cash outflow from investing activities because cash inflows from insurance operations are reinvested in accordance with our ALM discipline to fund insurance liabilities. We closely monitor and manage these risks through our comprehensive investment risk management process.

Cash Flows from Financing

The principal cash inflows from our financing activities come from issuances of debt and other securities, deposits of funds associated with policyholder account balances and lending of securities. The principal cash outflows come from repayments of debt and the collateral financing arrangement, payments of dividends on and repurchases or redemptions of MetLife, Inc.’s securities, withdrawals associated with policyholder account balances and the return of securities on loan.

Liquidity and Capital Sources

In addition to the general description of liquidity and capital sources in “— Summary of the Company’s Primary Sources and Uses of Liquidity and Capital,” the Company’s primary sources of liquidity and capital are set forth below.

Global Funding Sources

Liquidity is provided by a variety of global funding sources, including funding agreements, credit and committed facilities and commercial paper. Capital is provided by a variety of global funding sources, including short-term and long-term debt, the collateral financing arrangement, junior subordinated debt securities, preferred securities, equity securities and equity-linked securities. MetLife, Inc. maintains a shelf registration statement with the SEC that permits the issuance of public debt, equity and hybrid securities. As a “Well-Known Seasoned Issuer” under SEC rules, MetLife, Inc.’s shelf registration statement provides for automatic effectiveness upon filing and has no stated issuance capacity. The diversity of our global funding sources enhances our funding flexibility, limits dependence on any one market or source of funds and generally lowers the cost of funds. Our primary global funding sources include:

Preferred Stock

See Note 16 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report.

Common Stock

For the nine months ended September 30, 2022 and 2021, MetLife, Inc. issued 3,067,435 and 4,478,479 new shares of its common stock, respectively, for $148 million and $180 million, respectively, to satisfy various stock option exercises and other stock-based awards.

Commercial Paper, Reported in Short-term Debt

MetLife, Inc. and MetLife Funding, Inc. (“MetLife Funding”), a subsidiary of MLIC, each have a commercial paper program that is supported by our unsecured revolving credit facility (see “— Credit and Committed Facilities”). MetLife Funding raises cash from its commercial paper program and uses the proceeds to extend loans through MetLife Credit Corp., another subsidiary of MLIC, to affiliates in order to enhance the financial flexibility and liquidity of these companies.

Policyholder Account Balances

See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Liquidity and Capital Resources — The Company — Liquidity and Capital Sources — Global Funding Sources — Policyholder Account Balances” included in the 2021 Annual Report for information regarding the Company’s contractual obligations related to future policy benefits and policyholder account balances.

141

Table of Contents

Federal Home Loan Bank Funding Agreements, Reported in Policyholder Account Balances

Certain of our U.S. insurance subsidiaries are members of a regional Federal Home Loan Bank (“FHLB”). For the nine months ended September 30, 2022 and 2021, we issued $25.9 billion and $27.4 billion, respectively, and repaid $25.9 billion and $27.4 billion, respectively, of funding agreements with certain regional FHLBs. At both September 30, 2022 and December 31, 2021, total obligations outstanding under these funding agreements were $15.8 billion. See Note 4 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report.

Special Purpose Entity Funding Agreements, Reported in Policyholder Account Balances

We issue fixed and floating rate funding agreements, which are denominated in either U.S. dollars or foreign currencies, to certain unconsolidated special purpose entities that have issued either debt securities or commercial paper for which payment of interest and principal is secured by such funding agreements. For the nine months ended September 30, 2022 and 2021, we issued $39.7 billion and $32.1 billion, respectively, and repaid $38.3 billion and $31.1 billion, respectively, under such funding agreements. At September 30, 2022 and December 31, 2021, total obligations outstanding under these funding agreements were $39.7 billion and $39.5 billion, respectively. See Note 4 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report.

Federal Agricultural Mortgage Corporation Funding Agreements, Reported in Policyholder Account Balances

We have issued funding agreements to a subsidiary of the Federal Agricultural Mortgage Corporation which are secured by a pledge of certain eligible agricultural mortgage loans. For the nine months ended September 30, 2022 and 2021, we issued $625 million and $425 million, respectively, and repaid $625 million and $750 million, respectively, under such funding agreements. At both September 30, 2022 and December 31, 2021, total obligations outstanding under these funding agreements were $2.1 billion. See Note 4 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report.

Debt Issuances

See Note 9 of the Notes to the Interim Condensed Consolidated Financial Statements for information about senior notes issued by MetLife, Inc.

Credit and Committed Facilities

At September 30, 2022, we maintained a $3.0 billion unsecured revolving credit facility and certain committed facilities aggregating $3.2 billion, to which MetLife, Inc. is a party and/or guarantor. When drawn upon, these facilities bear interest at varying rates in accordance with the respective agreements.

The unsecured revolving credit facility is used for general corporate purposes, to support the borrowers’ commercial paper programs and for the issuance of letters of credit. At September 30, 2022, we had outstanding $263 million in letters of credit and no drawdowns against this facility. Remaining availability was $2.7 billion at September 30, 2022.

The committed facilities are used as collateral for certain of our affiliated reinsurance liabilities. At September 30, 2022, we had outstanding $2.8 billion in letters of credit and no drawdowns against these facilities. Remaining availability was $408 million at September 30, 2022.

See Note 13 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report for further information on credit and committed facilities.

We have no reason to believe that our lending counterparties will be unable to fulfill their respective contractual obligations under these facilities. As commitments under our credit and committed facilities may expire unused, these amounts do not necessarily reflect our actual future cash funding requirements.

142

Table of Contents

Outstanding Debt Under Global Funding Sources

The following table summarizes our outstanding debt at:


	September 30, 2022		December 31, 2021
	(In millions)
Short-term debt (1)	$	183	$	341
Long-term debt (2)	$	14,520	$	13,933
Collateral financing arrangement	$	729	$	766
Junior subordinated debt securities	$	3,158	$	3,156

__________________

(1) Includes $84 million and $241 million of debt that is non-recourse to MetLife, Inc. and MLIC, subject to customary exceptions, at September 30, 2022 and December 31, 2021, respectively. Certain subsidiaries have pledged assets to secure this debt.

(2) Includes $447 million and $482 million of debt that is non-recourse to MetLife, Inc. and MLIC, subject to customary exceptions, at September 30, 2022 and December 31, 2021, respectively. Certain investment subsidiaries have pledged assets to secure this debt.

Debt and Facility Covenants

Certain of our debt instruments and committed facilities, as well as our unsecured revolving credit facility, contain various administrative, reporting, legal and financial covenants. We believe we were in compliance with all applicable financial covenants at September 30, 2022.

Dispositions

For information regarding the Company’s dispositions, see Note 3 of the Notes to the Interim Condensed Consolidated Financial Statements.

Liquidity and Capital Uses

In addition to the general description of liquidity and capital uses in “— Summary of the Company’s Primary Sources and Uses of Liquidity and Capital,” the Company’s primary uses of liquidity and capital are set forth below.

Preferred Stock Redemption

See Note 16 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report.

Common Stock Repurchases

See Note 10 of the Notes to the Interim Condensed Consolidated Financial Statements for information relating to authorizations by the Board of Directors to repurchase MetLife, Inc. common stock, amounts of common stock repurchased pursuant to such authorizations for the nine months ended September 30, 2022 and 2021, and the amount remaining under such authorizations at September 30, 2022.

Common stock repurchases are subject to the discretion of our Board of Directors and will depend upon our capital position, liquidity, financial strength and credit ratings, general market conditions, the market price of MetLife, Inc.’s common stock compared to management’s assessment of the stock’s underlying value, applicable regulatory approvals, and other legal and accounting factors. Restrictions on the payment of dividends that may arise under so-called “Dividend Stopper” provisions would also restrict MetLife, Inc.’s ability to repurchase common stock. See “— Dividends,” as well as “Business — Regulation,” “Risk Factors — Capital Risks — We May Not be Able to Pay Dividends or Repurchase Our Stock Due to Legal and Regulatory Restrictions or Cash Buffer Needs” and Note 16 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report.

Dividends

For the nine months ended September 30, 2022 and 2021, MetLife, Inc. paid dividends on its preferred stock of $156 million and $166 million, respectively. For each of the nine months ended September 30, 2022 and 2021, MetLife, Inc. paid dividends on its common stock of $1.2 billion. See Note 10 of the Notes to the Interim Condensed Consolidated Financial Statements, as well as Note 16 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report for information regarding the calculation and timing of these dividend payments.

143

Table of Contents

The declaration and payment of common stock dividends are subject to the discretion of our Board of Directors, and will depend on MetLife, Inc.’s financial condition, results of operations, cash requirements, future prospects, regulatory restrictions on the payment of dividends by MetLife, Inc.’s insurance subsidiaries and other factors deemed relevant by the Board of Directors. See Note 16 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report for additional information.

Dividend Restrictions

The payment of dividends is also subject to restrictions under the terms of our preferred stock and junior subordinated debentures in situations where we may be experiencing financial stress. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Liquidity and Capital Resources — The Company — Liquidity and Capital Uses — Dividends — ‘Dividend Stopper’ Provisions in MetLife’s Preferred Stock and Junior Subordinated Debentures,” “Risk Factors — Capital Risks — We May Not be Able to Pay Dividends or Repurchase Our Stock Due to Legal and Regulatory Restrictions or Cash Buffer Needs” and Note 16 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report.

Debt Repayments

For the nine months ended September 30, 2022 and 2021, following regulatory approval, MetLife Reinsurance Company of Charleston, a wholly-owned subsidiary of MetLife, Inc., repurchased and canceled $37 million and $39 million, respectively, in aggregate principal amount of its surplus notes, which were reported in collateral financing arrangement on the interim condensed consolidated balance sheets.

Debt Repurchases, Redemptions and Exchanges

We may from time to time seek to retire or purchase our outstanding debt through cash purchases, redemptions and/or exchanges for other securities, in open market purchases, privately negotiated transactions or otherwise. Any such repurchases, redemptions, or exchanges will be dependent upon several factors, including our liquidity requirements, contractual restrictions, general market conditions, and applicable regulatory, legal and accounting factors. Whether or not to repurchase or redeem any debt and the size and timing of any such repurchases or redemptions will be determined at our discretion.

Support Agreements

MetLife, Inc. and several of its subsidiaries (each, an “Obligor”) are parties to various capital support commitments and guarantees with subsidiaries. Under these arrangements, each Obligor has agreed to cause the applicable entity to meet specified capital and surplus levels or has guaranteed certain contractual obligations. We anticipate that in the event these arrangements place demands upon us, there will be sufficient liquidity and capital to enable us to meet such demands. See Note 5 of the Notes to the MetLife, Inc. (Parent Company Only) Condensed Financial Information included in the 2021 Annual Report.

Insurance Liabilities

Liabilities arising from our insurance activities primarily relate to benefit payments under various life insurance, annuity and group pension products, as well as payments for policy surrenders, withdrawals and loans. For annuity or deposit type products, surrender or lapse behavior differs somewhat by segment. In the MetLife Holdings segment, which includes individual annuities, lapses and surrenders tend to occur in the normal course of business. For the nine months ended September 30, 2022 and 2021, general account surrenders and withdrawals from annuity products were $998 million and $971 million, respectively. In the RIS business within the U.S. segment, which includes pension risk transfers, bank-owned life insurance and other fixed annuity contracts, as well as funding agreements and other capital market products, most of the products offered have fixed maturities or fairly predictable surrenders or withdrawals. With regard to the RIS business products that provide customers with limited rights to accelerate payments, at September 30, 2022 there were funding agreements totaling $126 million that could be put back to the Company. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Liquidity and Capital Resources — The Company — Liquidity and Capital Uses — Insurance Liabilities” included in the 2021 Annual Report for additional information.

144

Table of Contents

Pledged Collateral

We pledge collateral to, and have collateral pledged to us by, counterparties in connection with our derivatives. At September 30, 2022 and December 31, 2021, we had received pledged cash collateral from counterparties of $8.3 billion and $7.5 billion, respectively. At September 30, 2022 and December 31, 2021, we had pledged cash collateral to counterparties of $302 million and $142 million, respectively. See Note 7 of the Notes to the Interim Condensed Consolidated Financial Statements for additional information about collateral pledged to us, collateral we pledge and derivatives subject to credit contingent provisions.

We pledge collateral and have had collateral pledged to us, and may be required from time to time to pledge additional collateral or be entitled to have additional collateral pledged to us, in connection with the collateral financing arrangement related to the reinsurance of closed block liabilities.

We pledge collateral from time to time in connection with funding agreements and advance agreements. See Note 6 of the Notes to the Interim Condensed Consolidated Financial Statements, as well as Note 4 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report.

Securities Lending Transactions, Repurchase Agreements and Third-Party Custodian Administered Programs

See “— Investments — Securities Lending Transactions, Repurchase Agreements and Third-Party Custodian Administered Programs.”

Litigation

We establish liabilities for litigation and regulatory loss contingencies when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. For material matters where a loss is believed to be reasonably possible but not probable, no accrual is made but we disclose the nature of the contingency and an aggregate estimate of the reasonably possible range of loss in excess of amounts accrued, when such an estimate can be made. It is not possible to predict the ultimate outcome of all pending investigations and legal proceedings. In some of the matters referred to herein, very large and/or indeterminate amounts, including punitive and treble damages, are sought. Given the large and/or indeterminate amounts sought in certain of these matters and the inherent unpredictability of litigation, it is possible that an adverse outcome in certain matters could, from time to time, have a material adverse effect on our consolidated net income or cash flows in particular quarterly or annual periods. See Note 15 of the Notes to the Interim Condensed Consolidated Financial Statements.

MetLife, Inc.

Liquidity and Capital Management

Liquidity and capital are managed to preserve stable, reliable and cost-effective sources of cash to meet all current and future financial obligations and are provided by a variety of sources, including a portfolio of liquid assets, a diversified mix of short- and long-term funding sources from the wholesale financial markets and the ability to borrow through credit and committed facilities. Liquidity is monitored through the use of internal liquidity risk metrics, including the composition and level of the liquid asset portfolio, timing differences in short-term cash flow obligations, access to the financial markets for capital and debt transactions and exposure to contingent draws on MetLife, Inc.’s liquidity. MetLife, Inc. is an active participant in the global financial markets through which it obtains a significant amount of funding. These markets, which serve as cost-effective sources of funds, are critical components of MetLife, Inc.’s liquidity and capital management. Decisions to access these markets are based upon relative costs, prospective views of balance sheet growth and a targeted liquidity profile and capital structure. A disruption in the financial markets could limit MetLife, Inc.’s access to liquidity.

MetLife, Inc.’s ability to maintain regular access to competitively priced wholesale funds is fostered by its current credit ratings from the major credit rating agencies. We view our capital ratios, credit quality, stable and diverse earnings streams, diversity of liquidity sources and our liquidity monitoring procedures as critical to retaining such credit ratings. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Liquidity and Capital Resources — The Company — Rating Agencies” included in the 2021 Annual Report.

Liquidity

For a summary of MetLife, Inc.’s liquidity, see “— The Company — Liquidity.”

Capital

For a summary of MetLife, Inc.’s capital, see “— The Company — Capital.” See also “— The Company — Liquidity and Capital Uses — Common Stock Repurchases” for information regarding MetLife, Inc.’s common stock repurchases.

145

Table of Contents

Liquid Assets

At September 30, 2022 and December 31, 2021, MetLife, Inc., collectively with other MetLife holding companies, had $5.2 billion and $5.4 billion, respectively, in liquid assets. Of these amounts, $4.0 billion and $4.2 billion were held by MetLife, Inc. and $1.2 billion and $1.2 billion were held by other MetLife holding companies at September 30, 2022 and December 31, 2021, respectively. Liquid assets include cash and cash equivalents, short-term investments and publicly-traded securities, excluding assets that are pledged or otherwise committed. Assets pledged or otherwise committed include amounts received in connection with derivatives and a collateral financing arrangement.

See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Liquidity and Capital Resources — MetLife, Inc. — Liquid Assets” included in the 2021 Annual Report for additional information on the sources and uses of liquid assets, as well as sources and uses of liquid assets included in free cash flow for MetLife, Inc. and other MetLife holding companies.

Liquidity and Capital Sources

In addition to the description of liquidity and capital sources in “— The Company — Summary of the Company’s Primary Sources and Uses of Liquidity and Capital” and “— The Company — Liquidity and Capital Sources,” MetLife, Inc.’s primary sources of liquidity and capital are set forth below.

Dividends from Subsidiaries

MetLife, Inc. relies, in part, on dividends from its subsidiaries to meet its cash requirements. MetLife, Inc.’s insurance subsidiaries are subject to regulatory restrictions on the payment of dividends imposed by the regulators of their respective domiciles. The dividend limitation for U.S. insurance subsidiaries is generally based on the surplus to policyholders at the end of the immediately preceding calendar year and statutory net gain from operations for the immediately preceding calendar year. Statutory accounting practices, as prescribed by insurance regulators of various states in which we conduct business, differ in certain respects from accounting principles used in financial statements prepared in conformity with GAAP. The significant differences relate to the treatment of DAC, certain deferred income tax, required investment liabilities, statutory reserve calculation assumptions, goodwill and surplus notes.

The table below sets forth the dividends permitted to be paid in 2022 by MetLife, Inc.’s primary U.S. insurance subsidiaries without insurance regulatory approval and the actual dividends paid for the nine months ended September 30, 2022:


Company	Paid (1)		Permitted Without Approval (2)
	(In millions)
Metropolitan Life Insurance Company	$	2,539	$	3,539
American Life Insurance Company	$	620	$	554
Metropolitan Tower Life Insurance Company	$	—	$	163

__________________

(1) Reflects all amounts paid, including those where regulatory approval was obtained as required.

(2) Reflects dividend amounts that may be paid during 2022 without prior regulatory approval. However, because dividend tests may be based on dividends previously paid over rolling 12-month periods, if paid before a specified date during 2022, some or all of such dividends may require regulatory approval.

In addition to the amounts presented in the table above, for the nine months ended September 30, 2022, MetLife, Inc. also received from certain other subsidiaries cash dividends of $64 million, as well as cash returns of capital of $8 million.

The dividend capacity of our non-U.S. operations is subject to similar restrictions established by the local regulators. The non-U.S. regulatory regimes also commonly limit dividend payments to the parent company to a portion of the subsidiary’s prior year statutory income, as determined by the local accounting principles. The regulators of our non-U.S. operations, including Japan’s Financial Services Agency, may also limit or not permit profit repatriations or other transfers of funds to the U.S. if such transfers are deemed to be detrimental to the solvency or financial strength of the non-U.S. operations, or for other reasons. Most of our non-U.S. subsidiaries are second tier subsidiaries which are owned by various non-U.S. holding companies. The capital and rating considerations applicable to our first tier subsidiaries may also impact the dividend flow into MetLife, Inc.

146

Table of Contents

We proactively manage target and excess capital levels and dividend flows and forecast local capital positions as part of the financial planning cycle. The dividend capacity of certain U.S. and non-U.S. subsidiaries is also subject to business targets in excess of the minimum capital necessary to maintain the desired rating or level of financial strength in the relevant market. See “Risk Factors — Capital Risks — Our Subsidiaries May be Unable to Pay Dividends, a Major Component of Holding Company Free Cash Flow” and Note 16 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report.

Credit and Committed Facilities

See “— The Company — Liquidity and Capital Sources — Global Funding Sources — Credit and Committed Facilities” for further information regarding the Company’s unsecured revolving credit facility and certain committed facilities.

Long-term Debt Outstanding

The following table summarizes the outstanding long-term debt of MetLife, Inc. at:


	September 30, 2022		December 31, 2021
	(In millions)
Long-term debt — unaffiliated	$	13,454	$	12,814
Long-term debt — affiliated	$	1,550	$	1,884
Junior subordinated debt securities	$	2,465	$	2,463

Debt and Facility Covenants

Certain of MetLife, Inc.’s debt instruments and committed facilities, as well as its unsecured revolving credit facility, contain various administrative, reporting, legal and financial covenants. MetLife, Inc. believes it was in compliance with all applicable financial covenants at September 30, 2022.

Liquidity and Capital Uses

The primary uses of liquidity of MetLife, Inc. include debt service, cash dividends on common and preferred stock, capital contributions to subsidiaries, common stock, preferred stock and debt repurchases and/or redemptions, payment of general operating expenses and acquisitions. Based on our analysis and comparison of our current and future cash inflows from the dividends we receive from subsidiaries that are permitted to be paid without prior insurance regulatory approval, our investment portfolio and other cash flows and anticipated access to the capital markets, we believe there will be sufficient liquidity and capital to enable MetLife, Inc. to make payments on debt, pay cash dividends on its common and preferred stock, contribute capital to its subsidiaries, repurchase its common stock and certain of its other securities, pay all general operating expenses and meet its cash needs under current market conditions and reasonably possible stress scenarios.

In addition to the description of liquidity and capital uses in “— The Company — Liquidity and Capital Uses,” MetLife, Inc.’s primary uses of liquidity and capital are set forth below.

Affiliated Capital and Debt Transactions

For the nine months ended September 30, 2022 and 2021, MetLife, Inc. invested a net amount of $12 million and $118 million, respectively, in various subsidiaries.

MetLife, Inc. lends funds, as necessary, through credit agreements or otherwise to its subsidiaries and affiliates, some of which are regulated, to meet their capital requirements or to provide liquidity. MetLife, Inc. had loans to subsidiaries outstanding of $35 million at both September 30, 2022 and December 31, 2021.

Support Agreements

MetLife, Inc. is party to various capital support commitments and guarantees with certain of its subsidiaries. Under these arrangements, MetLife, Inc. has agreed to cause each such entity to meet specified capital and surplus levels or has guaranteed certain contractual obligations. See “— The Company — Liquidity and Capital Uses — Support Agreements.”

Adopted Accounting Pronouncements

See Note 1 of the Notes to the Interim Condensed Consolidated Financial Statements.

147

Table of Contents

Future Adoption of Accounting Pronouncements

See Note 1 of the Notes to the Interim Condensed Consolidated Financial Statements.

Non-GAAP and Other Financial Disclosures

In this report, the Company presents certain measures of its performance on a consolidated and segment basis that are not calculated in accordance with GAAP. We believe that these non-GAAP financial measures enhance the understanding for the Company and our investors of our performance by highlighting the results of operations and the underlying profitability drivers of our business. Segment-specific financial measures are calculated using only the portion of consolidated results attributable to that specific segment.

The following non-GAAP financial measures should not be viewed as substitutes for the most directly comparable financial measures calculated in accordance with GAAP:


Non-GAAP financial measures:		Comparable GAAP financial measures:
(i)	adjusted premiums, fees and other revenues	(i)	premiums, fees and other revenues
(ii)	adjusted earnings	(ii)	net income (loss)
(iii)	adjusted earnings available to common shareholders	(iii)	net income (loss) available to MetLife, Inc.’s common shareholders
(iv)	adjusted net investment income	(iv)	net investment income

Any of these financial measures shown on a constant currency basis reflect the impact of changes in foreign currency exchange rates and are calculated using the average foreign currency exchange rates for the most recent period and applied to the comparable prior period (“constant currency basis”).

Reconciliations of these non-GAAP financial measures to the most directly comparable historical GAAP financial measures are included in “— Results of Operations” and “— Investments.” Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are not accessible on a forward-looking basis because we believe it is not possible without unreasonable effort to provide other than a range of net investment gains and losses and net derivative gains and losses, which can fluctuate significantly within or outside the range and from period to period and may have a material impact on net income.

Our definitions of non-GAAP and other financial measures discussed in this report may differ from those used by other companies.

Adjusted earnings and related measures:

• adjusted earnings;

• adjusted earnings available to common shareholders; and

• adjusted earnings available to common shareholders on a constant currency basis.

These measures are used by management to evaluate performance and allocate resources. Consistent with GAAP guidance for segment reporting, adjusted earnings and components of, or other financial measures based on, adjusted earnings are also our GAAP measures of segment performance. Adjusted earnings and other financial measures based on adjusted earnings are also the measures by which senior management’s and many other employees’ performance is evaluated for the purposes of determining their compensation under applicable compensation plans. Adjusted earnings and other financial measures based on adjusted earnings allow analysis of our performance relative to our business plan and facilitate comparisons to industry results.

Adjusted earnings is defined as adjusted revenues less adjusted expenses, net of income tax. Adjusted loss is defined as negative adjusted earnings. Adjusted earnings available to common shareholders is defined as adjusted earnings less preferred stock dividends. For information relating to adjusted revenues and adjusted expenses, see “Financial Measures and Segment Accounting Policies” in Note 2 of the Notes to the Interim Condensed Consolidated Financial Statements.

In addition, adjusted earnings available to common shareholders excludes the impact of preferred stock redemption premium, which is reported as a reduction to net income (loss) available to MetLife, Inc.’s common shareholders.

148

Table of Contents

Return on equity, allocated equity and related measures:

• Total MetLife, Inc.’s common stockholders’ equity, excluding accumulated other comprehensive income (“AOCI”) other than foreign currency translation adjustments (“FCTA”), is defined as total MetLife, Inc.’s common stockholders’ equity, excluding the net unrealized investment gains (losses) and defined benefit plans adjustment components of AOCI, net of income tax.

• Adjusted return on MetLife, Inc.’s common stockholders’ equity is defined as adjusted earnings available to common shareholders divided by MetLife, Inc.’s average common stockholders’ equity.

• Adjusted return on MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA, is defined as adjusted earnings available to common shareholders divided by MetLife, Inc.’s average common stockholders’ equity, excluding AOCI other than FCTA.

• Allocated equity is the portion of MetLife, Inc.’s common stockholders’ equity that management allocates to each of its segments and sub-segments based on local capital requirements and economic capital. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Risk Management — Economic Capital” in the 2021 Annual Report. Allocated equity excludes the impact of AOCI other than FCTA.

The above measures represent a level of equity consistent with the view that, in the ordinary course of business, we do not plan to sell most investments for the sole purpose of realizing gains or losses.

Expense ratio and direct expense ratio:

• Expense ratio: other expenses, net of capitalization of DAC, divided by premiums, fees and other revenues.

• Direct expense ratio: adjusted direct expenses divided by adjusted premiums, fees and other revenues. Direct expenses are comprised of employee-related costs, third party staffing costs, and general and administrative expenses.

• Direct expense ratio, excluding total notable items related to direct expenses and pension risk transfers: adjusted direct expenses excluding total notable items related to direct expenses, divided by adjusted premiums, fees and other revenues, excluding pension risk transfers.

The following additional information is relevant to an understanding of our performance results and outlook:

• We sometimes refer to sales activity for various products. These sales statistics do not correspond to revenues under GAAP, but are used as relevant measures of business activity. Further, sales statistics for our Latin America, Asia and EMEA segments are on a constant currency basis.

• Near-term represents one to three years.

• Notable items reflect the unexpected impact of events that affect the Company’s results, but that were unknown and that the Company could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife’s results and to evaluate and forecast those results. Notable items represent a positive (negative) impact to adjusted earnings available to common shareholders.

• The Company uses a measure of free cash flow to facilitate an understanding of its ability to generate cash for reinvestment into its businesses or use in non-mandatory capital actions. The Company defines free cash flow as the sum of cash available at MetLife’s holding companies from dividends from operating subsidiaries, expenses and other net flows of the holding companies (including capital contributions to subsidiaries), and net contributions from debt to be at or below target leverage ratios. This measure of free cash flow is prior to capital actions, such as common stock dividends and repurchases, debt reduction and mergers and acquisitions. Free cash flow should not be viewed as a substitute for net cash provided by (used in) operating activities calculated in accordance with GAAP. The free cash flow ratio is typically expressed as a percentage of annual adjusted earnings available to common shareholders.

Risk Management

See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Risk Management” in the 2021 Annual Report for information on our risk management.

149

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We regularly analyze our exposure to interest rate, equity market price and foreign currency exchange rate risks. As a result of that analysis, we have determined that the estimated fair values of certain assets and liabilities are materially exposed to changes in interest rates, foreign currency exchange rates and changes in the equity markets. We have exposure to such market risks through our insurance operations and investment activities. We use a variety of strategies to manage these risks, including the use of derivatives. A description of our market risk exposures may be found under “Quantitative and Qualitative Disclosures About Market Risk” included in the 2021 Annual Report. Further, our exposure to these market risks is expected to remain elevated due to the COVID-19 pandemic. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Executive Summary — COVID-19 Pandemic.”

150

Table of Contents

Item 4. Controls and Procedures

Management, with the participation of the Chief Executive Officer (“CEO”) and CFO, has evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (“Exchange Act”), as of the end of the period covered by this report. Based on that evaluation, the CEO and CFO have concluded that these disclosure controls and procedures are effective.

There were no changes to the Company’s internal control over financial reporting as defined in Exchange Act Rule 13a-15(f) during the quarter ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

151

Table of Contents

Part II — Other Information

Item 1. Legal Proceedings

See Note 15 of the Notes to the Interim Condensed Consolidated Financial Statements.

Item 1A. Risk Factors

Certain factors that may affect the Company’s business or operations are described under “Risk Factors” in Part I, Item 1A, of the 2021 Annual Report. There have been no material changes to our risk factors from the risk factors previously disclosed in the 2021 Annual Report.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

Purchases of MetLife, Inc. common stock made by or on behalf of MetLife, Inc. or its affiliates during the quarter ended September 30, 2022 are set forth below:


Period	Total Number of Shares Purchased (1)	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs (2)
July 1 — July 31, 2022	—	$	—	—	$	2,475,053,649
August 1 — August 31, 2022	4,207,063	$	66.12	4,207,063	$	2,196,884,590
September 1 — September 30, 2022	6,120,545	$	64.60	6,120,545	$	1,801,514,554
Total	10,327,608			10,327,608

__________________

(1) During the periods July 1 — July 31, 2022, August 1 — August 31, 2022 and September 1 — September 30, 2022, there were no purchases by separate account index funds of MetLife, Inc. common stock on the open market in non-discretionary transactions.

(2) In May 2022, MetLife, Inc. announced that its Board of Directors authorized $3.0 billion of common stock repurchases. At September 30, 2022, MetLife, Inc. had $1.8 billion of common stock repurchases remaining under the authorization. For more information on common stock repurchases, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Liquidity and Capital Resources — The Company — Liquidity and Capital Uses — Common Stock Repurchases” and Note 10 of the Notes to the Interim Condensed Consolidated Financial Statements. See also “Risk Factors — Capital Risks — We May Not be Able to Pay Dividends or Repurchase Our Stock Due to Legal and Regulatory Restrictions or Cash Buffer Needs” included in the 2021 Annual Report.

152

Table of Contents

Item 6. Exhibits

(Note Regarding Reliance on Statements in Our Contracts: In reviewing the agreements included as exhibits to this Quarterly Report on Form 10-Q, please remember that they are included to provide you with information regarding their terms and are not intended to provide any other factual or disclosure information about MetLife, Inc., its subsidiaries or affiliates, or the other parties to the agreements. The agreements contain representations and warranties by each of the parties to the applicable agreement. These representations and warranties have been made solely for the benefit of the other parties to the applicable agreement and (i) should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate; (ii) have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement; (iii) may apply standards of materiality in a way that is different from what may be viewed as material to investors; and (iv) were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments. Accordingly, these representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time. Additional information about MetLife, Inc., its subsidiaries and affiliates may be found elsewhere in this Quarterly Report on Form 10-Q and MetLife, Inc.’s other public filings, which are available without charge through the U.S. Securities and Exchange Commission website at www.sec.gov.)

Incorporated by Reference

Exhibit No.

Description

Form

File Number

Exhibit

Filing Date

Filed or Furnished Herewith

4.1

Certain instruments defining the rights of holders of long-term debt of MetLife, Inc. and its consolidated subsidiaries are omitted pursuant to Item 601(b)(4)(iii) of Regulation S-K. MetLife, Inc. hereby agrees to furnish to the Securities and Exchange Commission, upon request, copies of such instruments.

31.1

Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2

Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.SCH

Inline XBRL Taxonomy Extension Schema Document.

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

101.INS

XBRL Instance Document - the instance document does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline XBRL document.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).

153

Table of Contents

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


METLIFE, INC.

By:						/s/ Tamara L. Schock
						Name: Tamara L. Schock Title: Executive Vice President and Chief Accounting Officer (Authorized Signatory and Principal Accounting Officer)

Date: November 3, 2022

154

TABLE OF CONTENTS

Part I Financial Information Item 1. Financial Statements Item 2. Management S Discussion and Analysis Of Financial Condition and Results Of Operations Item 3. Quantitative and Qualitative Disclosures About Market Risk Item 4. Controls and Procedures Part II Other Information Item 1. Legal Proceedings Item 1A. Risk Factors Item 2. Unregistered Sales Of Equity Securities and Use Of Proceeds Item 6. Exhibits

Exhibits

31.1 Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2 Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1 Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 32.2 Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Customer name	Ticker
American Axle & Manufacturing Holdings, Inc.	AXL
Aon Plc	AON
Marsh & McLennan Companies, Inc.	MMC
Unum Group	UNM

Supplier name	Ticker
Johnson & Johnson	JNJ
Toyota Motor Corporation	TM
Abbott Laboratories	ABT
Tesla, Inc.	TSLA
AbbVie Inc.	ABBV
The Blackstone Group Inc.	BX
Merck & Co., Inc.	MRK
Pfizer Inc.	PFE

MET 10-Q Quarter ended Sept. 30, 2022

Exhibits